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SUMMARY
Improvements have taken place in recent years, In the treatment of 
acute myeloid leukaemia(AML) with a steady Increase in the 
proportion of patients entering complete remission. There has been 
less progress in devising appropriate post-remission therapy, with 
the result that there is a continuous risk of disease recurrence 
with most patients dying from their disease within five years. For 
a minority of patients a combination of chemotherapy and total body 
irradiation, designed to be ablative to the bone marrow, supported 
by bone marrow transplantation from an HLA matched sibling donor has 
proved effective, being capable of curing half the patients, but 
having the probability of eradicating leukaemia in approximately 80$£ 
of patients.
Allogeneic Bone Marrow Transplantation, however, can only make a 
limited impact overall on AML because its successful use can only be 
applied to younger patients for whom a donor is available, and even 
then Is usually associated with procedural related death in a third 
of patients, and a few long-term survivors suffer important 
morbidity. This Thesis discusses the role of Autologous Bone Marrow 
Transplantation to support ablative chemo-radiotherapy as a strategy 
of treatment for acute myeloblastic leukaemia in first remission. 
The discussions are based on the first twenty-five patients treated 
in Glasgow, with follow-up of one to six and a half years. These 
patients constitute the largest single series with the longest 
median follow-up in the international experience. This Thesis 
discusses the rationale for introducing, in 1981, such an approach 
to treatment.
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The current status of conventional chemotherapy and the impact of 
allogeneic bone marrow transplantation are outlined initially, but 
the limitations of allograft are examined in detail with particular 
attention being given to hbw the reasons for failure may be affected 
in an autograft setting, and how best to design an autograft 
protocol to minimise potential toxicity.
Alternative sources of haemopoietic stem cells such as partially 
matched or matched ^unrelated donors have been explored by some 
centres, but such options were not available in 1981. Recent 
results of these approaches are reviewed in the context of a 
detailed discussion of the advantages and disadvantages of 
autologous bone marrow transplantation. The major conceptual 
disadvantages of this approach are the possibility that the 
autologous marrow, although collected In morphological remission, 
may be contaminated by residual leukaemic cells, and that there 
would be loss of a "graft-versus-leukaemia" effect which may, to an 
unknown extent, contribute to the cure rate seen in the allograft 
results.
The concept of graft-versus-leukaemia is examined in some detail 
including a review of the original rodent experimental data. 
Evidence for such an effect in allogeneic transplantation for AML in 
man is reviewed, including the outcome of an updated analysis of the 
largest series of syngeneic transplants for AML, so far documented.
An important precept of the autograft approach has been that the 
technique should have minimum procedural related death. In this 
respect, attention is next given to designing the protocol of the
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ablative treatment and of supportive care. In the former respect, 
thoughts concerning the safer use of total body irradiation and the 
radiobiological principles of fractionation are discussed. The 
protocols of supportive care which have been employed were 
conditioned by personal experience over several years of looking 
after neutropenic and transplant patients.
Considerable effort has been made in our laboratory in recent years 
to develop and refine techniques of bone marrow procurement, 
processing and storage. This has to be achieved without detriment 
to the donor and contamination or damage to the bone marrow itself. 
This aspect is dealt with in Chapter 5 which constitutes one of the 
most extensive experiences in this area. In particular, it contains 
the original data confirming that marrow can be stored in the liquid 
state for up to 54 hours at 4°C while still retaining repopulative 
ability in patients given ablative chemoradiotherapy.
For a number of reasons cryopreservation has superceded liquid 
storage in our requirements, and the principles related to the 
technique of cryopreservation are illustrated. Of increasing 
interest in recent years is concentration of bone marrow into a stem 
cell fraction, either as a prelude to cryopreservation or 
manipulation in vitro. Our experience of the technique of bone 
marrow concentration drawn from over 300 procedures is discussed in 
depth.
All the data relating to procurement, processing and storage of bone 
marrow is validated by in vitro bone marrow culture techniques and 
repopulation of patients following ablative chemoradiotherapy.
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The clinical results achieved in this series have resulted in a 
projected survival of 50$ at 6 years with a prospect of remaining 
free of leukaemia of 54$. This result has a number of implications:
(a) there is a very low procedural mortality and morbidity with the 
major reason for failure being leukaemic relapse; (b) no relapses 
have been seen beyond 12 months after autograft with a plateau 
forming between one to six years; (c) these results are 
indistinguishable from that seen in syngeneic transplantation for 
AML in first remission, implying that the theoretical risk posed by 
contamination of the autograft by minimal residual leukaemia, is not 
of significance at a clinical level; (d) these results are not worse 
in terms of overall survival than the international results of 
allogeneic transplantation, thus substantiating the original 
arguments that the predictable increase in relapse rate would be 
offset by a minimal procedural related mortality and (e) this 
treatment is well tolerated in older patients and this can be 
confidently offered to a larger proportion of patients with AML.
An important consideration for the more general introduction of this 
approach to treatment is the implication for supportive care. In 
terms of bacterial and viral infection and bed occupancy these 
patients have been broadly similar to what one might expect with 
modern chemotherapy protocols. In the course of these studies we 
have been able to suggest improvements to supportive care with 
particular reference to reducing catheter related sepsis and the use 
of CMV negative blood products for CMV seronegative recipients in 
allografts and autografts. The duration of cellular
immunosuppression is well known following allograft, but a direct 
comparison between our autograft and allograft patients without
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graft-versus-host disease does not highlight any substantial 
differences in the kinetics of recovery in the autograft group. 
Similarly, long-term defects in pulmonary function have been 
reported following allograft, but it is not clear to what extent 
this might be attributable to the effects on the lung of the 
ablative chemo-radiotherapy or a subclinical manifestation of 
graft-versus-host disease. Serial pulmonary function tests have 
provided reassuring evidence that the relatively minor changes seen 
after autograft are reversed in most autograft patients* within a 
year, with no long-term consequences.
Despite the originality and prolonged follow-up of this series of 
patients, it cannot be guaranteed that they are not a selected 
patient group or indeed that other approaches to aspects of ablative 
protocol and timing of autograft would not be more appropriate. For 
this reason an analysis of 324 cases of AML autografted in first or 
second remission in other centres has been performed. This analysis 
for the most part confirms that the rationale on which this series 
was based was largely correct, but that there may be alternative 
ways to achieve equivalent results. The international analysis 
reflects many of the features of the Glasgow series, in particular, 
the low procedural related mortality, the lack of late relapses and 
the probability of survival in half the patients.
As previously stated, the ability of autograft protocols to achieve 
results identical to that achieved in twin transplants is perhaps 
the strongest evidence to support the view that techniques aimed at 
eradicating residual disease from the marrow ex vivo ("purging”) may 
be unnecessary. Such a stance would be premature. The major
techniques of 'purging* are reviewed, and, illustration that such 
techniques can modify clinical outcome is illustrated by our 
experience of using immunologically mediated techniques to remove 
T cells from allogeneic marrow to prevent graft-versus-host 
disease. This technique has proved remarkably effective in our
experience in preventing significant graft-versus-host disease, but
(
has brought with it unanticipated problems related to engraftment 
which we appear to have overcome.
Preliminary data on our studies of autologous transplantation for 
high risk acute lymphoblastic leukaemia (ALL) are also cited to 
illustrate that such an approach can be applied in a leukaemia 
context where appropriate monoclonal antibodies are at present 
available. Although the results from these studies are also 
encouraging, they cannot be used as definitive evidence to support 
the use of purging techniques per se, because insufficient 
information is yet available on the expected outcome for patients 
who receive ablative treatment supported by unpurged bone marrow in 
ALL.
Due to the lack of a specifically leukaemic phenotype on 
myeloblasts, no obvious immunological approach to purging in AML 
exists. The use of pharmacological agents, particularly 
Cyclophosphamide derivatives, has been advocated by some 
investigators but our pre-clinical studies presented here do not 
suggest that such an approach is technically logical based on our 
finding of interpatient variation in responsiveness in vitro, and 
the lack of suitable technology to measure the effectiveness in 
vitro of such techniques.
It is not my feeling that purging techniques for nonlymphoid 
leukaemia should be ignored completely. To this end, I describe a 
completely original autologous bone marrow transplant model in the 
rat which has the strong dual attributes of being capable on the one 
hand of detecting damage to the repopulative ability of treated bone 
marrow, and on the other, the sensitivity to detect less than ten, 
and probably as few as one, contaminating leukaemic cell.
This model will be useful in devising and comparing different 
purging techniques or the relative efficacy of putative agents for 
purging. Some studies using two pharmacological agents, 4-hydro- 
peroxycyclophosphamide (ASTA-Z-7557) and VP-16 (Etoposide), are 
presented, indicating the utility of the system. The potential for 
further exploitation of the model is substantial.
While the clinical results presented here will represent, to those 
familiar with the usual outcome of chemotherapy in AML, an 
apparently important improvement in control of this disease, I have 
tried to be careful in in interpreting these data. Many questions 
remain to be answered in this area,, particularly in relation to 
improving the ablative protocol, detecting patients who are destined 
to relapse early, the most appropriate timing of the autograft, and 
its relationship to prior cytoreductive chemotherapy.
This Thesis is completed at the time when a major clinical trial is 
about to commence under the auspices of the Medical Research Council 
which is designed to address several of these questions in an 
appropriately randomised manner.
CHAPTER 1
CURRENT STATUS of THE TREATMENT of ACUTE MYELOID LEUKAEMIA
1,1 INTRODUCTION
Acute Myeloid Leukaemia(AML) occurs with a frequency of thirty per 
million of the population per annum and will, if untreated, be fatal 
within two or three months of diagnosis. The clinical 
manifestations are essentially those of marrow failure so the 
reasons for death are predominantly haemorrhage or infection. It is 
only in the last 25 years that any impact on the outcome of the 
disease has been made. Progress has been at times undetectable such 
that some have periodically questioned the point of therapeutic 
intervention 1,2).
Traditionally treatment has been, somewhat artificially, divided 
into three phases. A prerequisite for any prolongation of survival 
is the attainment of remission of disease, followed by consolidation 
of this position with additional treatment, which may be at reduced 
doses, but is intensive enough to cause cytopenia and necessitate 
in-patient administration. Maintenance treatment, continuing for 
months or even years, usually with a few days treatment per month as 
an outpatient represents the final phase of treatment.
It would be an error to regard these traditional phases of treatment 
as separate, and as will regularly be alluded to, the effectiveness 
of treatment in one area may have major impact on the outcome of 
another and this, in turn, leads to difficulties in interpreting 
clinical studies which purport to show an improvement in one phase 
of treatment.
1.2 STRATEGY OF TREATMENT
The concepts of chemotherapy largely derive from the observations 
initially made by Skipper in the mouse L1210 leukaiemia model(3). 
These data and subsequent histopathological findings suggest that 
clinically apparent disease is equivalent to a tumour burden of 10^2 
cells. Cytoreductive treatment- may reduce the tumour load to 
1o9-io8 cells which is sufficient to render the disease undetectable 
by general clinical criteria, however eradication of the disease has 
not been achieved and sooner or later repopulation by leukaemic 
cells occurs manifesting as clinical relapse. Acceptance of this 
principle has led to the use of post-remission treatment which is 
initially intended to effect further cytoreduction (consolidation) 
and thereafter by continuation (maintenance) to prevent the 
development of recurrence.
These phases of treatment are represented diagramatically in 
Figure 1.1. It is a matter of semantics whether treatment given 
early is "induction" or "consolidation" treatment. The optimum out­
come overall is the theoretical elimination of the last tumour cell 
- whether this is a prerequisite for cure will be discussed later 
(Chapter 3). Although this concept of treatment strategy is still 
widely accepted by therapists, it is arguable that other mechanisms 
may have a role to play, which should be taken into account when 
designing therapeutic protocols. An example of such a mechanism may 
be the possibility that immune regulation may be able to contain 
minimal residual disease and this may be compromised by continuous 
immunosuppressive chemotherapy.
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1.3 INDUCTION OF REMISSION
Achievement of remission of disease is a requirement for any 
meaningful prolongation of life and progress has been slow but 
steady over the last 25 years. Complete remission is conventionally 
defined on morphological criteria, as the achievement of normal 
peripheral blood counts with less than 5? myeloblasts in the bone 
marrow(i|, 5). Drugs which had been used with some success as single 
agents for acute lymphoblastic leukaemia (ALL) made little impact in 
AML in terms of achievement of complete remissions.
Prednisolone, Vincristine and 6-Mercaptopurine were capable of 
inducing occasional remissions(6,7) but the objective methods now 
available to distinguish myeloid from lymphoid leukaemias were not 
available at that time, and the diagnostic precision of cases who 
responded to such treatment could be questioned.
The introduction of Cytosine-Arabinoside in the late sixties and 
early seventies was a prelude to an important decade of sustained 
improvement. This drug had already been demonstrated to have an 
anti-leukaemic effect in experimental systems(8,9). As a single 
agent it could induce remission in 25? of cases and its 
effectiveness is dose and schedule dependent but it is not yet clear 
what is the ideal standard dosage or duration, or whether it is more 
effective if given by continuous infusion or by intravenous 
bolus(10,11,12,13) with the initial evidence favouring the former 
route despite its greater inconvenience. Its combination with 
relatively ineffective single agents was again accompanied by .better 
results (Table 1.1). More recent experience in high dose may offer
a further dimension to its use, and will be discussed below, but low 
dose Cytosine probably has little role to play in remission 
induction(18,19) although it has been of benefit in myelodysplastic 
syndromes where its effect might be related to induction of 
differentiation. Where remissions of AML have been achieved they 
have followed a hypoplastic phase suggesting a cytotoxic mechanism.
Table 1.1 Remission induction with Cytosine Arabinoside and other 
Non-Anthracycline Drugs
Protocol
Ara-C/Vincristine
Cyclophosphamide
CR(?)
46
Reference
14
Ara-C/6 Thioguanine 56 15
Ara-C/6 Thioguanine 41 16
Ara-C/Vincristine/
Cyclophosphamide/Prednisolone 48 17
Shortly after the studies of Cytosine were initiated Daunorubicin 
became available and represented further major advance in AML. This 
anthracycline antibiotic intercalates into the base pairs of 
replicating DNA and initial studies established it as probably the 
most effective single agent capable of achieving remission rates of 
35-50? if given daily for three days(20,21,22,23). Much optimism 
accompanied the addition of the two most potent single agents 
(Daunorubicin + Cytosine) or the addition of Daunorubicin to the 
hopeful combination of Cytosine and Thioguanine. The. early
seventies were extensively devoted to the evaluation of such 
combinations usually as five day courses of Cytosine with or without 
Thioguanine and one to three days of Daunorubicin. It resulted in 
regular achievement of remission rates of the order of 50? 
plus(20,21,22,23), but it was disappointing to note this was not 
substantially better than Cytosine/Thioguanine or Daunorubicin alone 
had achieved(20,21,22,24,25).
From the mid-seventies some changes have taken place which have 
resulted in the regular achievement of remission in 60-80? of
patients without the introduction of any new agents. Over this
period supportive care has made a major impact, by permitting much 
more intensive combinations to be given safely. Improved anti­
biotics and blood product support together with greater awareness of 
the problems of the pancytopenic patient by medical and nursing 
attendants have permitted prolongation of the treatment pulses from 
five to seven or ten days(26,27). Such approaches seem to be 
capable of producing much higher remission rates but it is not clear 
that there is a major difference between a seven day schedule and a 
ten day schedule, at least in terms of remission rate(28,29). A
five day schedule may be inferior(30) or may produce an equivalent
remission rate but requires more pulses of therapy(31).
There is little evidence to suggest that it is necessary in these 
intensive regimens to give Cytosine by continuous infusion or by 
twice daily bolus. Similarly, the use of Daunorubicin early or late 
in the pulse is not of crucial importance, in that the initial pilot 
studies of both approaches produced very encouraging remission rates 
of greater than 80?, which typically have not been matched when
evaluated in a large multicentre trial (C.R.=67?)(31). Although the 
recent MRC Study, which used a five day schedule with a single 
Daunorubicin dose produced a respectable remission rate (67? 
overall: 74? in the under 60s) an average of 3 pulses was required 
with a remission induction time of, on average, 2 months. In the 
more recent trial where remission induction is more intensive (10 
day schedule including 3 Daunorubicin doses) half of the patients 
achieved remission after one pulse, thus reducing the period of 
exposure to risk of infection or bleeding(32).
Recently high dose Cytosine, which has been shown to be effective in 
relapsed AML, has been used as first line treatment either alone or 
in combination with Etoposide with very encouraging rates of 
remission in younger patients(33).
In summary, it should be possible to achieve complete remission in 
70-80? of patients who present with AML. Most experience centres 
around the use of a 7-10 day schedule of Cytosine and Thioguanine 
with two or three doses of Daunorubicin either at the beginning or 
end of the pulse. In general, an aggressive approach with more 
intensive treatment aimed at attaining remission as quickly as 
possible to avoid protracted risk of haemorrhage or infection seems 
to be paying dividends.
With this substantial improvement over the last 15 years, substit­
ution of new drugs into first-line treatment will be harder to 
justify but it appears that drugs such as Asmsacrine or possibly new 
agents such as Mitoxantrone are effective and worthy of evaluation, 
while the contribution of Thioguanine remains unclear. A number of
anthracyclines are available but there seems little incentive to 
displace Daunorubicin, which may be associated with less mucositis.
1.4 CONSOLIDATION THERAPY
There is no doubt that the achievement of remission is, in itself, 
insufficient to produce sustained remission and further treatment is 
required in the post-remission phase(34,21), This "consolidating" 
treatment has varied substantially over the years but it usually 
means giving drugs at doses that cause cytopenia but which are lower 
than used for induction. In accordance with the concept, that 
repeated exposure to the same drugs may permit the emergence of 
resistance, drugs not used in the induction phase have often been 
used. The most recently published MRC study [MRC AML VIII]compared 
the outcome of two versus six consolidation pulses of the same drug 
protocol (DAT) used for remission induction, and could find no 
significant advantage to be gained by giving the prolonged 
treatment(31). Although in excess of 600 hundred patients were in 
the randomisation, by chance more poor prognosis and elderly 
patients received the six course treatment, thus complicating the 
analysis.
A number of similar studies have been reported(35,36), some 
including a variety of alternative drugs not used in remission 
induction, without any particular approach producing outstanding 
results and obvious advantage emerging for prolonged schedules. The 
beneficial influence of one consolidation pulse compared with no 
consolidation has been reported(34,14). In general terms, • it is 
accepted that consolidation treatment with the same drugs used in
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remission induction at similar doses, or non-cross resistant drugs 
will improve the median duration of remission(37,38,39). There is 
no obvious advantage in giving several pulses of consolidation 
therapy of this type. While the median durations of survival may 
have improved, few of these studies demonstrate more than 20$ of 
patients remaining in remission at 5 years.
Apparent exceptions to these depressing results are the studies from 
Boston and results of the co-operative German BFM group.
The Boston group designed a prolonged intensive post-remission 
schedule aimed at producing maximum cytoreduction and reducing drug 
resistance by varying the agents used(40).
The initial protocol used Daunorubicin, Vincristine, Cytosine and 
Prednisolone over 7 days for the first pulse - which achieved 
remission in *10 of 83 patients treated, and an additional 5 day 
pulse which produced a further 18 remissions, giving an overall 
remission rate of 70$.
Remitters then entered a prolonged intensification schedule given 
over 1*1 months which involved four sequences of approximately 3 
months duration using different drugs which were selected to avoid 
the emergence of drug resistance and given in doses which produced 
significant cytopenia. The study was given the acronym VAPA.
In a total of 75 remission patients (45 0-17 yrs: 30 18-50 yrs)
entered into this consolidation study, 20/45 children and- 15/46 
adults relapsed and 2 adults died from non-leukaemic causes. It was
noteworthy that 8/20 relapses in children were in the CNS compared 
with 1/15 of the adult relapses. This appears to be accounted for 
by the preponderance of cases of the FAB M5 subgroup (see below)in 
the younger patients, and this morphological subgroup was the only 
prognostic factor which affected outcome, having a negative effect. 
The probability of being in continuous complete remission at 5 years 
is 50$ for children and 29$ for adults. The average duration of 
hospitalisation during remission was 80 days(4l).
In view of the high CNS relapse rate, a modified protocol - 
designated 80-035 - was introduced which differed from the VAPA 
protocol in that younger patients received intrathecal prophylaxis. 
There was some reduction in anthracycline dosage and reduction of 
the number of cycles of sequenced therapy which reduced the duration 
of the schedule to 12 months. So far CNS relapses have been reduced 
but there has been an increase in deaths in remission (5/39 in the 
children 0-17 years, and 9/48 in the adults 18-60 yrs). The 
probability of continuous remission at 2 years in this study with 
shortened follow-up is 54$ (children) and 31$ (adults)(42). A 
similar approach has been taken to post-remission treatment by the 
German Co-operative Study Group(43). Modifying a previous ALL 
schedule, remission induction comprised a 28 day course of 
6-Thioguanine, Prednisolone, Cytosine 4 days per week; and weekly 
Adriamycin and Vincristine. A subsequent 28 day phase includes CNS 
irradiation, Methotrexate (weekly) Cyclophosphamide (x 3) Cytosine 
as before, Adriamycin (x 2) and continuous 6-Thioguanine. Patients 
subsequently received 4 weekly maintenance of 4 days Cytosine and 
6-Thioguanine with some additional Adriamycin doses, for a further 2 
years. This protocol was designated BFM-78.
Of 151 children entering the study 119 (79$) achieved complete 
remission. Of these children 47 have relapsed, (7 in the CNS) and 6 
died in remission. The probability of survival at 5 years for those 
who achieved remission is 52$ with a median follow-up of 36 months 
and no relapses observed beyond 30 months. The most recent update 
on this study indicates little or no deterioration in these results 
with longer follow-up.
In an effort to improve outcome, a subsequent protocol (BFM-83) was 
introduced which differed mainly in that patients received an 8-day 
induction pulse comprising Cytosine, Daunorubicin and VP-16 before 
entering the BFM-78 protocol(44). The remission rate is 79$ and of 
129 patients who achieved remission the projected survival is 66$ 
after 36 months but the follow-up is relatively short at the present 
time. One of the aims of this modification was to reduce the 
proportion of FAB-M5 patients who relapsed. In the event, the 
improvement which is apparent at present,has been derived within the 
other subtypes rather than in the M5 subgroup. Since a higher 
proportion of children - particularly younger children - have the M5 
morphology (10-21$) treatment failure in this group is an important 
issue in paediatric practice.
In childhood AML these two studies represent the best results. The 
VAPA protocol is intensive over several months necessitating a 
considerable number of days in hospital and must represent the 
maximum tolerable chemotherapy.
The introduction of CNS treatment has reduced the CNS relapse rate 
but has not resulted in an improved survival probably because of an
increase in toxic deaths. The BFM studies are perhaps less 
intensive overall for the patients after the first 3-4 months but 
include CNS prophylaxis without paying a substantial price in toxic 
deaths. It is not clearjwhat the role of maintenance is in the BFM 
studies.
1.5 MAINTENANCE THERAPY
In the earlier studies in AML, maintenance treatment was usually 
used, most probably in the expectation that in due course an optimum 
schedule would evolve as had happened in ALL where there is little 
doubt about the value of maintenance treatment. The usual pattern 
of treatment is a few days of treatment monthly, at doses that 
result in no or mild haemopoietic suppression, continued for 1-2 
years, usually given on an outpatient basis. The inherent differ­
ences in sensitivity between ALL and AML referred to earlier,suggest 
that treatment which does not result in cytopenia in AML is unlikely 
to make a major impact on leukaemic cells, and therefore raise 
serious doubts about the concept of maintenance chemotherapy in AML. 
There is little evidence from the various studies using maintenance 
that more than the usual 20-25$ of patients will remain 
leukaemia-free. Since this can be achieved with consolidation 
alone(34,35,39,45,46), additional maintenance seems to offer little 
advantage. A number of studies have addressed the question of 
maintenance in a randomised way and either showed no advantage or 
the advantage demonstrated over the control arm was more 
attributable to a poorer than usual outcome for the control 
patients(47,48,49,50). The contribution of maintenance is. still 
controversial but it seems justified to conclude that, if effective
remission induction and consolidation treatment is given, there will 
be nothing further to be gained by maintenance. If consolidation is 
not intensive it is possible - but not convincingly demonstrated - 
that continued treatment may be beneficial.
1.6 IMMUNOTHERAPY
Immunotherapy is an alternative method of eradicating leukaemic 
cells with the major potential advantage that it is independent of 
cell-cycle considerations on which some of the chemotherapeutic 
agents depend, and its therapeutic ratio or selectivity is superior 
to cell-cycle non-specific drugs like the anthracyclines. To work, 
this form of treatment relies on there being - on the one hand - a 
specific leukaemia cell-specific antigen, and - on the other - the 
host’s immune system capable of mounting a response to it, which it 
clearly failed to do during disease evolution. It is deduced from 
experimental studies that immunotherapy can only cope with a low 
tumour burden, e.g. 1 x 10^ cells, and therefore its use has been 
confined to remission maintenance. There is, as will be discussed 
later, no clear evidence that leukaemia-specific antigens can be 
detected in AML, but there may be some evidence to support 
immunological mechanisms of control following allogeneic bone marrow 
transplant.
Several studies have been undertaken involving immunotherapy with or 
without chemotherapy as maintenance in AML(51,52,53>54). The immune 
stimulation was generally attempted by either Bacillus 
Calmette-Guerin (BCG) or Methanol extraction residue of BCG (MER) or 
Levamisole with or without specific immunisation with irradiated
allogeneic or autologous blasts. Some groups have reported improved 
durations of remission(54,55) without necessarily producing more 
.long-term survivors(5 6), but on the whole confirmation of 
effectiveness has not been obtained. Many of these studies were 
carried out following chemotherapy that by current standards would 
be considered inadequate, and it may be that many of these patients 
were insufficiently cytoreduced to allow immunotherapy a real chance 
of being effective.
1.7 INTER-RELATIONSHIPS BETWEEN PHASES OF TREATMENT
As previously mentioned, the individual phases of treatment cannot 
sensibly be assessed separately. Based on the concept of treatment 
illustrated in Figure 1.1 it is readily seen that two different 
treatment protocols, perhaps of different intensity may produce a 
similar remission rate but because the definition of remission is 
relatively crude, there may be major differences in what has been 
achieved in terms of cytoreduction between the treatments. If a 
comparison is then made between two consolidation protocols which 
shows important differences in median durations of remission, it 
should not immediately be assumed that the benefit was attributable 
to differences in consolidation. The difference may be explained 
purely by the intensity of remission induction. Such an effect will 
only come out of large trials and it is of interest to note that in 
the current MRC Study (MRC AML IX) there is no significant 
difference in remission rate between DAT 5+2 and DAT 10+3 but there 
is a later improvement in leukaemia-free survival wfcjich is 
attributable to the heavier induction protocol rather than the 
effect of the consolidation randomisation (R G Gray,1987, personal 
communication).
It is important also to ensure that any comparisons of 
post-remission approaches are conducted where there has been a good 
remission rate. Where the remission rate is poor it is conceivable 
that the cases with the most resistant disease do not enter 
remission and an overestimate of the effectiveness of subsequent 
treatment is made because it is only treating less resistant, or 
"biologically benign" disease. Similarly, where the remission rate 
is high, there will be a larger proportion of "biological 
aggressive" cases exposed to the consolidation treatment presenting 
a greater challenge. These cases will tend to make subsequent 
therapy look worse. The fact that in recent years the absolute 
number of cases entering remission has increased, and the number of 
long term survivors has stayed constant may not therefore 
necessarily mean that no progress is being made with post-induction 
treatment.
The apparent failure of consolidation therapy to increase the number 
of cures does not mean that it would not have a major influence on 
the outcome of another form of treatment, for example, autologous 
bone marrow transplantation or indeed immunotherapy.
The fact that it has been so difficult to demonstrate any benefit of 
maintenance therapy over many years, probably means that there is 
none. It is well known that patients who relapse on chemotherapy 
have a low second remission rate compared with patients who relapse 
off treatment (3^ 1). This could constitute an argument for avoiding 
unnecessary treatment, but it has so far lacked wide appeal because 
important survival after relapse is exceptional. This may not 
necessarily remain the case, as will be suggested later.
1.8 PREDICTIVE FACTORS
In the majority of studies over the last 20 years, efforts have been 
made to identify variables which arie predictive, either of likelihood 
of entering remission or of experiencing prolonged remissions. The 
list is long (Table 1.2) and the effect is not consistent in all 
studies. It is generally true that prognostic factors are derived 
within the context of one therapeutic approach and do not 
necessarily retain their importance if applied to other studies, and 
may become less relevant as treatment becomes more effective.
Table 1.2. Predictive Factors in AML
Predictive Factor Reference
- Age 31
- Cell Cycle Responses to Chemotherapy *1,57-62
- In Vitro Growth Patterns 63-68
- Secondary Leukaemia or
Antecedent Dysplasias 69-72
- Level of Blast Cells at Diagnosis 35,73
Several factors, such as hepatosplenomegaly and performance status, 
simply reflect the condition of the patient and the extent of tumour 
burden at time of diagnosis. This may clearly be related to cell 
cycle characteristics and so on. Once again, although significant 
correlations can be found within certain studies with overall 
outcome, and significant differences demonstrated, in very ^ew
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circumstances is there a good outlook. In most circumstances it is 
poor or very poor. There is, at present, little evidence to suggest 
that subgroups of patients should be specifically removed from a 
particular study because they have an inherently good or t?ad 
outlook, based on prognostic factors. An exception to that 
generalisation is that elderly patients will probably do less well 
with continuous intensive treatments. An antecedent
dyserthyropoietic state is often an exclusion criteria; but these 
tend to occur in the elderly and do badly with chemotherapy.
Non random chromosome abnormalities should be detectable in at least 
half of patients with AML(7^) and there are predictions that all 
cases will turn out to have demonstrable defects by improved 
techniques(75). A number of studies suggest that a normal karyotype 
predicts a better chance of entering remission and superior 
remission duration(7l}, 76,77). A specific translocation(15:17) is 
usually associated with the FAB M3 subtype (78) which has been 
reported to have the best remission duration but that has not been a 
universal observation(31). It appears that 8:21 translocations, 
which are often associated with a FAB M2 morphology, and inversions 
or deletions involving chromosome 16 may have a better outlook that 
cases with abnormalities involving chromosome 5 or 7 , which may be 
associated with antecedent dysplasias(79).
1.8.1 The FAB Classification
A morphological system of classification, of AML was introduced in 
1976 as a result of the deliberations of an international, panel
(French-American-British), to standardise differing subtypes of AML 
and, hence, to aid the comparison of patient populations in clinical 
trials(80). Some revisions have subsequently been made(8l,82) and 
the system is not without its critics. There is some clinical data 
to suggest that it is(83) or is not(8^,85) an independent prognostic 
variable. It is generally believed that the M3 subtype has a good 
prospect of prolonged survival once in remission(80), but this was 
not the case in the recent MRC Trial(31). The monocytic(M5) variant 
responds less well(86) and has poorer duration of remission(i|1).
Immunophenotyping is complicated by the fact that the antigen 
expression of leukaemic blast cells may differ from their respective 
clonogenic precursors(87), a finding which currently limits antibody 
mediated therapeutic intervention, as will be discussed later. In 
general, immunophenotyping suggests that AML is either derived from 
cells which are committed to the granulocytic lineage or from an 
earlier population equivalent to the multilineage precursor 
cell(s)(88).
Some evidence already suggests that immunophenotyping may be more 
useful prognostically(89), but relatively few clinical studies have 
been carried out where this data is available.
The concept that AML may be either lineage derived, or a disease of 
the pluripotent stem cell, has been given considerable credence by 
studies using the Glucose-6-Phosphate (G-6-PD) marker(90,91). In 
the small number of heterozygotes available for study by this 
technique it appears that clonal phenotype (isoenzyme type. A or 
type B) of the blast cells in some cases is also the phenotype
expressed by the other haemopoietic lineages suggesting that the 
disease is of stem cell origin, while in others the other lineages 
have the normal heterozygous phenotype. This important information 
together with the immunophenotype information, suggests that AML is 
of two broad types. This may have important therapeutic 
implications, but so far there is insufficient information, to be 
sure of the clinical implications.
1.9 THE IMPACT OF BONE MARROW TRANSPLANTATION
Allogeneic bone marrow transplantation(BMT) was introduced as an 
experimental form of treatment for end-stage leukaemia in the 
1970s. Almost all transplants have been between siblings who are 
matched at the major histocompatibility loci of the HLA system, and 
who are mutually non-stimulatory in mixed-lymphocyte culture (MLC). 
The rationale of its use was that the dosage limitation imposed by 
myeloid toxicity would be removed and this may allow increased 
flexibility to improve an anti-leukaemic effect. It was also 
postulated that stable engraftment of donorsT marrow might itself 
have an anti-leukaemic effect against residual leukaemia. The 
developmental work of Thomas and others in the previous 20 years had 
demonstrated that total body irradiation to a dose of around 1000 
cGy reliably resulted, in combination with cyclophosphamide, in 
stable engraftment.
Based on their initial experience of allogeneic transplantation in 
100 cases of relapsed acute leukaemia (both myeloid and lymphoid) a 
number of important observations were made by the Seattle 
Group(92). Approximately 15$ of patients became long term
survivors. While this may appear disappointing it did demonstrate
(a) that sustained haemopoietic engraftment could be achieved and
(b) that a small number of patients with e.nd-stage and probably 
resistant disease could be cured. The immunobiological problems of 
allogeneic bone marrow transplantation were defined, the 
implications of which will be discussed in more detail in Chapter 2.
While this experience demonstrated a unique effect, it was clear 
that the procedural related problems would be considerable and the 
benefit of this form of treatment at this stage of acute leukaemia 
was very limited. The important observation was made, however, that 
patients who were in better clinical condition, that is, not 
infected or unresponsive to blood product support, with perhaps less 
florid relapse, tended to tolerate the procedure better. Similarly, 
the development of graft-versus-host disease was associated with a 
poorer outcome. It was concluded that bone marrow transplantation 
would be more effectively used in younger patients where these 
problems appeared less severe, and at an earlier stage of the 
disease.
In the mid-seventies there was little evidence to suggest that 
chemotherapy was having much impact on patients achieving remission, 
so it was seen as logical to offer bone marrow transplantation as an 
alternative form of consolidation treatment, in first remission. In 
recent years several groups have pursued such a policy 
(93,94,95,96). Despite substantial heterogeneity of treatment (in 
particular, radiation technique) the results achieved have been 
remarkably similar and are illustrated in figures 1.2 and 1.3* which 
is cumulated data collected by the International Bone Marrow 
Registry(97).
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Figure 1.2 International Experience of Allogeneic BMT for Acute 
Myeloid Leukaemia (IBMTR Data)
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Figure 1.3 Prospects of remaining leukaemia free following 
Allogeneic BMT
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These data illustrate three important features.
(a) the prospects for overall survival are approximately 50$
(b) few events occur after 18 months post-transplant, so that the
development of a plateau effect suggests the possibility of
cure.
(c) the actuarial risk of relapse is around 20$. This is derived
statistically by compensating for competing causes of death.
Since the initial series of reports, there has been little change in 
outcome but the overall expectation of survival of 50$ has held up 
with time. The most optimistic chemotherapy studies recently 
reported may be equivalent in their 2 or 3 year follow-up but most 
comparisons at 5 years favour transplantation, and it is in the 
tradition of chemotherapy studies that late relapses occur. In long 
term follow-up of bone marrow transplant patients a small number of 
relapses have been noted at 5 years but this makes only minor impact 
on the position of the survival curve. Equivalent outcome could 
only be argued for chemotherapy in children, but if the transplant 
patients are stratified by age, the survival plateau for young 
people <20 years, is still superior at around 70$(98).
The important lesson of the allograft experience is the relatively 
low probability of relapse which is undoubtedly superior to any 
other approach. This supports the concept that intensive 
consolidation offers the best hope of disease eradication in AML, 
although the possibility that there may be other mechanisms 
contributing to cure will be discussed later.
The fact that approximately 30$ of patients undergoing allograft for 
AML in first remission die from causes other than leukaemia is 
important and represents a major challenge to transplant 
physicians. Clearly the objective over the next few years is to 
eliminate the procedural related deaths without compromising the 
potential antileukaemic effect. This is a complex problem which 
will be alluded to later.
Despite this impressive data, controversy still exists as to 
whether BMT is now superior to best available chemotherapy. This 
debate centres around two problems. Firstly, it usually takes time 
to identify a donor and arrange referral to a transplant centre. 
This inevitably means that the transplant can only be carried out on 
patients who have continued in remission for 2-4 months. Critics 
periodically claim that these patients are selected. In a survey of 
the database of the European Bone Marrow Transplant Group [EBMT] 
there was no evidence to suggest that patients transplanted late did 
better than those transplanted early(96).
Only a few controlled studies have been done comparing allograft 
with chemotherapy, and not all of these have been prospective 
(99, 100). In most observations the long term survival of the 
transplanted patients is superior but not always statistically so. 
Because of the mortality due to procedural related complications in 
the first year, chemotherapy often appears superior if the follow-up 
is only 1-2 years.
1.10 CONCLUSIONS
Most strategies concerning treatment of AML to date have been 
reviewed. Chemotherapy has undoubtedly undergone gradual 
improvement over the years with remission rates of 70-80$ in 
patients under 60 years, now to be expected. Post-remission 
induction treatment, given intensively, appears to have increased 
the median duration of remission but it is not clear that this 
improvement could not be attributed to improved remission induction 
therapy. Successful consolidation is currently accepted to be 
intensive treatment probably with non-cross resistant drugs. It is 
unclear what drugs are most appropriate at this stage or for how 
long consolidation should last. There is no convincing evidence 
that additional treatment, either in the form of intermittent 
maintenance chemotherapy or immunotherapy, confers further benefit 
and may indeed preclude achievement of further remissions.
Despite these improvements it remains the situation that most 
patients will die from their disease and alternative approaches are 
needed. Allogeneic bone marrow transplantation is an important 
advance for selected cases, and is at least as good as the best 
available chemotherapy with an undoubtedly superior anti-leukaemic 
effect.
While these conclusions are based on much data which has become 
available after 1980-81, they correspond to the conclusions drawn at 
that time from the evidence then available, and formed the basis 
upon which the alternative approach of autologous bone marrow 
transplantation to be described, was devised.
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CHAPTER 2
THE LIMITATIONS OF ALLOGENEIC TRANSPLANTATION
39
The use of allogeneic BMT as consolidation of first remission has 
resulted in a much improved prospect of patients remaining 
leukaemia-free. Whereas the predicted chance of relapsing, assuming 
non-intervention of competing causes of death is 70-90$ in most 
series, in practice only 50$ of patients undergoing allograft become 
long-term survivors. Approximately 30$ of patients who undergo 
allograft die from the immuno-biological complications of the 
procedure, principally graft-versus-host disease (GVHD), pneumonitis 
and the consequences of immunosuppression. Even a proportion of 
patients who eventually become long-term survivors may suffer 
significant temporary or permanent disability related to these 
complications. A small proportion of patients will develop late 
consequences predominantly related to the chemo-radiotherapy 
preparative protocol so, in order to achieve the full antileukaemic 
benefit of allograft, modifications of the treatment protocol, or 
more effective intervention treatment of the complications, will be 
required.
2.1 GRAFT-VERSUS-HOST DISEASE
Graft-versus-host disease (GVHD) is a major reason for failure 
following allogeneic transplantation, occurring to some extent in 
almost half of all cases despite HLA identity at A, B, D, Dr loci 
and non-reactivity in mixed lymphocyte reaction(1,2). It takes two 
forms which can usually be distinguished clinically and 
histologically - "acute" and "chronic". More general application of 
allograft will depend on the development of effective means of its 
prevention and treatment. Initial clinical studies indicated that 
the severity of acute GVHD increases with age, such that most units
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have limited the use of allografts to patients under forty 
years(3,5). Although most tissues express the histocompatibility 
antigen, acute GVHD usually restricts its clinical manifestation to 
skin, liver and gastrointestinal tract, usually in that order of 
clinical progression. The rash is typically maculopapular and 
sometimes difficult to distinguish from other causes - particularly 
a drug-induced rash. Typical histological changes are described but 
these are difficult to distinguish from radiation changes in the 
early post-transplant period. Provided that the area of skin 
involved is small, treatment is usually not necessary but extensive 
involvement can result in desquamation with infective risks. In 
most cases, clinical response can be obtained with steroids. Liver 
involvement is usually manifest by bilirubin and enzyme rise with 
progression to an obstructive pattern. There are usually several 
other possible causes of hepatic dysfunction, e.g. infection, drugs, 
veno-occlusive disease, parenteral nutrition, so that it is 
difficult to be confident of the cause, even in the presence of a 
typical rash. Diarrhoea is the typical manifestation of gut 
involvement often associated with abdominal pain. In its severe 
form it is extremely difficult to keep up with fluid loss. The more 
generalised the involvement with acute GVHD the poorer the 
prognosis. A clinical staging system has been widely employed 
(Stage I-IV) and can usefully be used to describe the extent of 
disease(6). Where the disease is limited to skin (stage I), or skin 
with mild liver involvement (stage II), steroids or anti-lymphocyte 
globulin(7) can result in a satisfactory response, but more severe 
involvement of liver or gut (stage III and IV) seldom responds to 
treatment. Overall? acute GVHD will be the main cause of death in 
5-10$ of transplants but in addition it makes a major contribution
to the development of opportunistic infection which may be the 
principal cause of death. Even patients who develop acute GVHD and 
respond to treatment have reduced performance status for several 
weeks. Once the patient reaches the 60-70th day post-transplartt the 
development of acute GVHD is unlikely.
Since the treatment of GVHD is unsatisfactory, most efforts have 
been directed at prophylaxis. Most of the initial clinical studies 
adopted the Seattle protocol of intermittent doses of Methotrexate 
in the first 100 days post-graft(1). Such an approach was effective 
in the canine model(8) but its benefits in man are less certain. 
Some initial reports suggested that Cyclosporin A post-transplant 
reduced the severity of GVHD(9) and this drug gained a place in 
clinical practice without a great deal of evidence to suggest that 
it improved survival. Indeed, such comparative studies of 
Cyclosporin and Methotrexate that have been performed show no 
survival advantage for either group(10,11).
Successful prevention of GVHD will be an important component in 
making allogeneic transplantation safer and therefore more 
applicable to older patients. All evidence points to the T cells in 
the infused marrow as being the prime movers in the syndrome. They 
are stimulated by antigens of the host or possible in the host (e.g. 
bacterial or viral antigens) and the cytotoxic action results in the 
clinical manifestations. The possible role played by bacterial or 
viral antigens is not clear. It is of interest to note the 
experimental data which indicates difficulty in inducing GVHD in 
mice reared in sterile conditions( 12). In man, it has been shown 
that patients managed in laminar flow conditions during transplant
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for aplastic anaemia have a lower incidence of acute GVHD with 
improved survival than those patients managed in an ’ordinary1 
environment(13).
Recently it has become clear that in vitro treatment of the graft 
with anti-T monoclonal antibody based techniques can prevent 
significant GVHD(1^,15,16,17,18,19).
As will be discussed later (Chapter 9) these techniques have brought 
new problems which at present raise questions about whether they 
will produce an overall survival advantage. The most important of 
these is graft rejection which has been reported in about 10-15$ of 
cases. A further potential disadvantage of such an approach may be 
loss of a theoretical graft-versus-leukaemia effect. Such an effect 
can be demonstrated in experimental leukaemia models(20) and are 
cited as the reason for the increased relapse rates in syngeneic 
transplants(21). Statistical evidence has been presented to 
indicate a correlation between risk of relapse and severity of 
graft-versus-host disease - but such relationship has not been 
demonstrated for AML transplanted in remission(22). There is 
conflicting evidence to suggest an increased relapse rate in 
recipients of T cell depleted marrow in all circumstances. Perhaps 
the clearest evidence for this is in chronic myeloid leukaemia. 
These aspects will be discussed in more detail later.
Apart from avoiding direct morbidity and mortality, prevention of 
acute GVHD could also be expected to have the additional benefit by 
reducing the risks of CMV pneumonitis and immunosuppression, to 
which it is a substantial contributor.
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Chronic GVHD is of later onset - the risk period being from 2-15 
months post-transplant. This manifestation will occur to some 
extent in about one third of patients and has certain well
recognised clinical manifestations in skin and buccal mucosa (most 
commonly a lichenoid reaction), liver, eyes, joints and - rarely - 
muscles leading it to be compared with connective tissue diseases 
such as systemic lupus erythematosis, scleroderma, Sjogren's 
syndrome and primary biliary cirrhosis(23) • In chronic GVHD there
is no renal or oesophageal involvement which form part of lupus or 
scleroderma. The classic manifestations are not difficult to
diagnose where skin or buccal mucosa biopsy is very useful, but 
there are several patients who probably have low-grade disease
resulting in failure to thrive and diagnosis is difficult. The 
mechanism of chronic GVHD is still poorly understood, but certain 
immune characteristics are regularly found. Most patients have 
antibody and complement component deposition on skin basement 
membrane(24). Non-specific suppressor T cell activity is usually 
demonstrable(25).
Apart from patient age, as previously mentioned, administration of 
donor buffycoat increases the incidence of GVHD(26). The outcome is 
better for patients with disease limited to skin, and possibly 
liver, and worse for more general organ involvement. Most patients 
will have had preceding acute GVHD. The prognosis for patients 
where acute GVHD is successfully curtailed but who later develop 
chronic GVHD is better than for those who progress into chronic 
disease. In these latter cases it is frequently difficult to 
distinguish acute from chronic disease. A small proportion of cases 
(20J5) arise nde novo” without previous acute GVHD. This subgroup 
are the most responsive of all.
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There is some controversy as to whether Prednisolone given for 
several months post-graft can reduce the frequency of cGVHD, but 
there seems little doubt that immunosuppressive treatment with 
Prednisolone and Azathioprine is the treatment of choice, but this 
usually requires to be continued for several months(27). Chronic 
GVHD can be a persistent and troublesome later complication of 
transplant which affects patients1 performance. Its main life 
threatening implication is its own inherent immunosuppressive effect 
which is compounded by immunosuppressive therapy. In particular, 
these patients are at risk from herpes zoster and pneumococcal 
infections and it is important to re-introduce prophylactic 
Penicillin or Septrin as part of the treatment.
2.2 PULMONARY COMPLICATIONS
Pneumonitis has been recognised as a major complication following 
allogeneic bone marrow transplantation. In addition, subclinical 
deficiencies can be detected on serial measurement of pulmonary 
function.
2.2.1 Pneumonitis in Allogeneic Transplantation - The Size of The 
Problem.
In the large series from Seattle (n=952)(28) and the multicentre 
data available through the International Bone Marrow Transplant 
Registry (n=932)(29), representing data from 69 centres, there is an 
incidence of non-bacterial pneumonitis of 332(35$) and 268(29$) 
respectively. Death occurs in *10-70$ of cases being particularly
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high(>90/O where the aetiological agent is identified as 
cytomegalovirus (CMV).
Detailed analysis of risk factors suggests that a triad of principal 
factors inter-react to result in pneumonitis. These factors are in 
turn positively and negatively influenced by numerous subsidiary
causes. The primary factors appear to be (i) lung damage (ii) 
immunosuppression and (iii) infection.
2.2.2 Damage to Lung Tissue
Chemotherapeutic agents which may have been used as part of the 
patient*s previous leukaemia treatment may subclinically damage 
lung. Pre-transplant changes, albeit minor, in pulmonary function 
have been noted in such patients(30). Cyclophosphamide and 
Melphalan have both been documented to produce lung toxicity
(31*32). Similarly, it is possible that post-graft administration 
of Methotrexate (MTX), to prevent graft-versus-host disease, may 
have been contributory. In an analysis on behalf of the European 
Bone Marrow Transplant Group(33), patients given Cyclosporin had a 
lower incidence of pneumonitis compared with those receiving
Methotrexate. However, there were important differences between 
centres in other variables such as radiation technique. It remains 
unclear whether lung tissue itself is a target for graft-versus-host 
reaction.
There is little doubt that radiation damage to the lungs is a major 
consideration. The radiobiological rationale of delivery of Total 
Body Irradiation, which will be discussed elsewhere, is equally
relevant to sparing effects on the lung. Radiotherapy experience 
related to pulmonary damage highlights two factors likely to be 
influential also in TBI protocols. Where it is proposed to 
administer the TBI as a single fraction, dose rate will tend to have 
a direct relationship to incidence of pneumonitis.
The importance of low dose rate has been advocated by the Marsden 
Group who have persisted with a single fraction TBI approach(3l|). 
In the wider experience of the IBMTR(29) where single fraction was
used, the relationship was corroborated in that a low incidence of
6%(4/69) was noted at dose rates of <6.0 cGy/min compared with 
30^(32/107) for rates >6.0 cGy/min. Based on the radiobiological 
principles described elsewhere it is unlikely that dose rate will be 
relevant where TBI is to be fractionated. At least two groups have 
regularly used rapid rate single fraction TBI without 
disproportionate increase in pneumonitis but, unlike other groups, 
the total dose was restricted to 750 cGy(35). It may be that dose 
rate only becomes decisive over that threshold, at total doses 
(900-1050 cGy) preferred by most groups. This contention is perhaps 
supported by the recent experience of one of these two groups 
attempting to increase the total dose to 800 cGy (to avoid graft
rejection) with a resultant dramatic increase in pneumonitis
(Prentice H G, personal communication).
The tissue which limits escalation of TBI dose is lung, and the 
total dose traditionally employed has been around 1000 cGy but often 
with shielding of the lung fields to 800 cGy. From the anti- 
leukaemic point of view such a dose ceiling is relatively arbitrary, 
as previously discussed, and may be amenable to further improvement, 
but the lung dose is also based on the radiotherapy observations
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from Toronto suggesting a significant escalation of incidence of
pneumonitis with increased absorbed lung dose(36).
Many centres have now moved to fractionated TBI where the relation­
ship between total dose to the lung and dose rate to the incidence 
of pneumonitis is less clear. The Seattle experience of 
fractionated versus unfractionated TBI indicated a trend in favour 
of improved survival in the fractionated group but this was not due 
to a significant difference in the incidence of pneumonitis between 
the two groups(37).
The influence of radiation protocol seems to be most pronounced in 
the subgroup of patients developing pneumonitis for which no
clinical reason can be found (so called "idiopathic" pneumonitis) 
which amounts to HO-50% of all cases in most series. It seems
probable that the major mechanism is via lung damage but it is
arguable that minor degrees of damage caused by radiation which are 
insufficient to cause pneumonitis may predispose the patient to 
opportunistic infection.
Radiation, even optimally delivered, results in increased immuno­
suppression of the patient which may in turn facilitate the 
development of pneumonitis. Perhaps the most convincing clinical 
data to support this point is the reduced incidence of pneumonitis 
in patients transplanted for severe aplastic anaemia(10%) with 
Cyclophosphamide alone as conditioning, compared with 25% when TBI 
is incorporated even at low dose (300 cGy TBI) with Cyclophos- 
phamide(29). Such ablative chemotherapy protocols which have been 
used instead of TBI (such as Busulphan and Cyclophosphamide) are not 
associated with a noticeable reduction in pneumonitis.
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2.2.3 Immunosuppression.
In general terms, it appears that patients who receive more 
immunosuppressive preparative protocols tend to have increased 
incidence of pneumonitis. This is likely to be, in whole or in 
part, the reason for increased rates in leukaemics compared with 
aplastics, but there is also a tendency for such a relationship 
within aplastic studies where additional chemotherapy was given 
pre-graft to diminish the prospect of graft rejection. 
Graft-versus-host disease is itself immunosuppressive in that it 
delays .immune reconstitution and has clearly been implicated as a 
risk factor in non-bacterial pneumonitis of probable infective 
origin but has not been shown to be contributory to "idiopathic" 
pneumonitis(38). It remains unclear whether the lung is a target 
tissue for GVHD but this is a point of interest that could be 
examined in the context of syngeneic or autologous transplants.
Post-graft immunosuppression with anti-lymphocyte globulin and the 
use of Methotrexate, rather than Cyclosporin A, to prevent GVHD have 
been shown to increase risk(29), but the Methotrexate effect only 
appears to operate when the irradiation dose to the lung exceeds 800 
cGy. It is possible that Methotrexate in association with TBI 
inflicts subclinical damage of pulmonary macrophages(39) for which 
CMV has a predilection(ilO).
2.2. $ Infective.
Bacterial pneumonias occur during the neutropenic pre-engraftment 
phase, and late after transplant in patients with chronic GVHD who
appear particularly susceptible to pneumococcal infections due to 
impaired immune reconstitution. Bacterial pneumonias are 
surprisingly uncommon, occurring in less than 5% of all transplants, 
and seldom being fatal(28). j
The major organism implicated in pneumonitis is cytomegalovirus 
(CMV). It is probable that lJ0-60£ (IBMTR Data:Seattle H455) of all 
cases of pneumonitis are due to CMV, which remains unresponsive to 
treatment and therefore is associated with a high death rate (>9055).
Graft-versus-host disease is a major risk factor, either by a 
mechanism of immunosuppression as suggested above, or possibly by a 
direct reactivating effect on latent CMV. Such a mechanism has been 
suggested by experimental studies. The Seattle Group have 
demonstrated a clear relationship between incidence of pneumonitis 
and grade of acute GVHD(38).
The mechanisms by which any individual can develop CMV pneumonia 
must either be reactivation of latent virus or primary infection 
which is almost certainly derived from donated blood products or 
possible from the bone marrow donor with the graft. It is probable 
that patients who are seronegative (titre i.e. have not had
previous exposure to the virus, are most at risk of reactivation of 
latent virus and the prospects of this happening increase with the 
degree of immunosuppression associated with the transplant resulting 
from an intensive preparative regimen or from post-graft 
immunosuppression and/or GVHD. Where patients are CMV-seronegative 
pre-graft, then the probable mode of infection is via the. blood 
product support. It remains unclear whether a seropositive donor
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represents a serious risk to a seronegative recipient. Since CMV 
pneumonitis remains intransigent to treatment, most attention in 
recent years has been directed at strategies of prevention. Passive 
immunisation with anti-CMV immunoglobulin has produced conflicting 
results since the dose and frequency of administration are not 
known(4l,42,43). For patients who are seronegative, avoidance of 
granulocyte transfusion and the use of blood products exclusively 
from donors would appear to be a logical approach. It is probable 
that seropositive patients will reactivate^4), so the provision of 
seronegative products is unlikely to influence the situation.
Serological status of the recipient pre-graft has historically been 
associated with a higher incidence of CMV pneumonitis (seropositive 
21J5: seronegative 13%)(38). The influence of conditioning protocol 
is less marked since aplastics, with Cyclophosphamide preparation 
alone, have a 10^ incidence compared with leukaemias prepared in 
addition with TBI, have an incidence of 1755(38).
Particularly relevant from the autologous point of view is the very 
low incidence of CMV pneumonitis in syngeneic transplants(45).
Infection with other viruses (herpes simplex, herpes zoster), 
aspergillosis and candidiasis are well recognised historically, 
accounting for 5-10JG of cases. More liberal use of Acyclovir to 
treat established mucocutaneous infections, or prophylactically, has 
probably reduced further pulmonary manifestations of simplex and 
zoster, while laminar flow isolation may well reduce aspergillus 
infection. Traditionally, pneumocystis carinii is associated with 
the immunosuppressed, but the practice of using Trimethoprim-
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Sulfamethoxazole (Septrin) prophylactically has virtually eradicated 
it as a problem. Sporadic cases occur. In established disease 
about a third do not respond to high dose septrin, suggesting the 
development of resistance. For patients who are allergic to the 
sulphonamide component of Septrin, protection can be provided by 
Trimethoprim alone. There has been a suspicion that the integrity 
of the graft can be affected by Septrin, but there is little hard 
evidence to sustain this point of view(46).
The clinical diagnosis of pneumonitis is not usually problematical. 
Tachypnoea, reduced PO2 , bilateral pulmonary infiltrates on x-ray 
are the key to the clinical diagnosis. International data suggests 
that 50-6056 of causes have demonstrable aetiology while the 
remainder are designated idiopathic.
Pneumonitis is essentially a diagnosis of exclusion and as such it 
is essential that adequate diagnostic efforts are made. The fgold 
standard1 in this respect is lung biopsy but bronchio-alveolar- 
lavage (BAL) has more recently been accepted as adequate for 
patients too ill or thrombocytopenic to undertake biopsy(47). 
Failure to demonstrate a causative agent by invasive techniques has 
raised the question of occult infective causes, due to more exotic 
organisms. In a study specifically to examine this possibility, 147 
cases were carefully examined and only 4 revealed additional 
information - all due to chlamydia infections(48). Similarly, 
indirect approaches such as serological demonstration of antigen 
(pneumocystis carinii)(49) or detection of cytomegalovirus RNA by 
in-situ hybridisation techniques(50) is no more frequent in patients 
with biopsy proven infections than in patients without pneumonia.
2.2.5 Conclusions on Pulmonary Complications of Transplantation and 
Implications for Autologus Transplantation.
Pneumonitis is a major cause of procedural death in allogeneic
transplantation. As discussed elsewhere, autograft must have little 
or no procedural mortality to gain a role in the management of
leukaemia.
Of major comfort is the report of a low incidence in syngeneic
transplantation. A number of factors identified as components
leading to pneumonitis may be avoided by autologous transplantation, 
namely graft-versus-host disease, post-graft immunosuppression, 
possible targeting of a graft reaction within the pulmonary tissue.
It seems relevant to incorporate the radiobiological principles 
relevant to the lung, such as dose rate, absorbed lung dose and dose 
fractionation into an autograft protocol.
Subclinical damage attributable to the radiation, uninfluenced by 
the other implicated influences operating in an allograft setting, 
such as GVHD, may be detectable in an autograft protocol. No 
information exists to suggest whether CMV reactivation and 
pneumonitis will be seen in autologous patients or whether it is 
necessary to consider supplying seronegative patients with 
seronegative blood products.
Pneumonitis has been a major cause of death in the allograft 
experience, and it would be unproductive if any alternative
treatment involving dose escalation was to have a similar result. 
The point of discussing the inter-related causes of pneumonitis in 
allogeneic transplantation is to attempt to separate the component 
causes which may be avoidable in the autograft setting. Clearly 
there are important radiobiological considerations which must be 
taken into account. The avoidance of graft-versus-host disease may 
also help to reduce the risk of pneumonitis by several mechanisms 
including reactivation of cytomegalovirus, avoidance of direct 
damage to the lung and by avoidance of the immunosuppressive 
consequences of GVHD.
The inter-relating factors in the causation of pneumonitis in 
allograft are summarised in Figure 2.1. It is hoped that many of 
these factors can be avoided or minimised by protocol design in the 
expectation that deaths from pneumonitis will be minimal in an 
autograft setting. The syngeneic experience which has now emerged 
suggests that such a hope is justified(45).
As will be mentioned below, there is potential for subclinical or 
late pulmonary damage in patients who do not develop pneumonitis in 
the few months post-transplant.
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2.3 IMMUNOSUPPRESSION
The technique of removing bone marrow from a donor and infusing it 
into this recipient is simple, but what makes bone marrow transplant­
ation complex is the degree to which these patients are necessarily 
immunosuppressed. Immunosuppression is the result of the 
preparative protocol designed to ensure consistent engraftment and 
in the case of the leukaemias eradicate residual disease. Even in 
uncomplicated cases recovery of immune function is slow and may be 
exacerbated by further complications or post-graft therapy which put 
the patient at significant risk.
2.3*1 Immune reconstitution
Despite numerical reconstitution of peripheral blood white cells, 
which is achieved in J|-5 weeks post-graft, patients remain immuno- 
deficient for a further 3-6 months period when opportunistic 
infections of a bacterial, fungal or viral nature are common. By 
one year post-graft measurable immune function is almost normal. 
This period of immuno-deficiency reflects the time taken for donor 
derived immune system to mature in a balanced fashion, but will be 
further prolonged if associated with graft-versus-host disease or 
its treatment. Several studies now indicate that repopulation of 
peripheral blood by T and B cells takes 3-J| months(51,52). T cell 
subpopulations regenerate at different rates resulting in an 
imbalance. Cells with the CD8 phenotype recover earlier with an 
absolute increase in number, whereas CD*! cells recover more slowly, 
thus during the first year the helper (CD^ 4) suppressor (CD8) ratio 
is abnormal, but by 12 months has returned to normal. An increase in
immature T cells (OKT-jq:CD38) phenotype has been reported in the 
early months post-transplant, but this population falls to normal 
levels by 9-12 months(53)•
Humoral immunity also returns at a variable rate. IgG and IgM 
levels are usually normal by 4 months but IgA remains subnormal for 
at least 12 months. The ability to produce an antibody response 
with IgM and then IgG is demonstrable at 3-4 months(54). 
Measurements of cellular immunity as indicated by delayed-type 
hypersensitivity skin testing may be subnormal for 2 years 
post-grafting, and response to recall antigen for up to 4 years 
post-grafting.
The imbalance of T cell subsets found after allograft was initially 
postulated to be related to development of graft-versus-host disease 
but both the pattern and pace of immune reconstitution is similar in 
syngeneic and autologous transplantation(55). GVHD retards recovery 
of the immune system(56). The T cells subsets imbalance persists 
and antibody responses are subnormal with limited ability to switch 
from IgM to an IgG response(57). Response to pneumococcal antibody 
is poor and perhaps explains the increased incidence of 
pneumococcal infections associated with chronic GVHD in the first 2 
years post-graft.
The pattern of immune recovery does not appear to be substantially 
different in patients receiving Methotrexate or Cyclosporin as GVHD 
prophylaxis(58). One of the hopes of T cell depletion from the 
graft, as a method of GVHD prevention, is that immune recovery may 
be more rapid and occur in a more balanced way, perhaps reducing the 
dangers of opportunistic infections.
2.4 INFECTIOUS COMPLICATIONS.
The pattern of infection following transplantation is related to the 
reconstitution of the immune system and certain pre-transplant 
characteristics of the patient. These patients are prone to the 
complete spectrum of normally pathogenic and opportunistic 
infection(59). Gram negative and positive infections are most 
likely to occur in the early neutropenic phase and the clinical 
consequences and treatment strategies for these infections are well 
known to physicians treating immunosuppressed neutropenic patients. 
The pattern of bacterial frequency and sensitivity to antibiotics 
usually varies between institutions. The standard practice in bone 
marrow transplant patients is to have an indwelling catheter 
(Hickman or Broviac) to facilitate sample collection and intravenous 
medication. This has resulted in frequent infections with staph, 
epidermidis which is usually quite resistant to antibiotics but does 
not result in rapid clinical deterioration of the patient. As 
previously implied, late infections with pneumococcus are well 
recognised and require vigilance. The use of pneumococcal vaccine 
has not been scientifically assessed but would be a rationale 
approach for patients with restored humoral immunity. An advantage 
of the current practice of transplantation in remission is that 
patients retain some neutrophils for the first few days after 
transplant. Most patients become febrile within the first 10-14 
days. The yield of positive bacteriology during these episodes is 
low but most will receive empirical broad spectrum intravenous 
antibiotics. Within a few days the pyrexia resolves, usually 
coincident with the re-appearance of neutrophils. Since the 
patients are in remission there is less likelihood of them being
infected pretransplant, but if they are there is less chance of 
clinical deterioration by delaying the transplant, which would be 
appropriate. In some circumstances, such as aplastic anaemia, 
deciding to delay might be difficult but pre-transplant infection is 
an important prognostic factor in this group of patients(60).
Fungal infections are mainly due to Candida or aspergillosis and are 
also probably less of a problem in good risk patients who engraft 
promptly. Pre-mortem diagnosis of candidal infections tends to 
indicate extensive infection probably beyond the capacity of 
anti-fungal therapy. There may be a role for earlier use of 
anti-fungal therapy, either almost empirically in neutropenic 
patients who are unresponsive to broad-spectrum antibiotic 
treatment or in patients who have evidence of candidal colonisation.
Of the important viral infections, cytomegalovirus, has already been 
discussed in relation to pneumonitis and has been an important cause 
of death. Herpes Simplex (Type 1) of the oropharynx, but rarely of 
the lung or genitals, is common in the first two weeks 
post-transplant. Patients who have had previous infections or are 
seropositive have a high probability of re-activating the 
infection(60). These infections are seldom life-threatening but may 
have a major impact on patient well-being and compliance with oral 
medication or nutrition. Acyclovir is effective prophylactically in 
these patients(6 1 ,6 2) but is also effective in established 
infections when measured by pain reduction, healing and viral 
shedding(60). There is some indication that its use prevents 
prolongation of neutropenia(62).
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Late infection with varicella zoster remains a threat for several 
months reflecting the prolonged immunosuppression. These infections 
are similarly amenable if treated promptly.
i
2.5 LATE SEQUELAE OF TRANSPLANTATION
Apart from disease recurrence and the immunobiological complications 
already discussed, attention must also be paid to other late effects 
which may be preventable by treatment modification or about which 
patients should be informed.
2.5.1 Pulmonary Function
Routine monitoring of pulmonary function tests have pointed out that 
in addition to the overt clinical problem of pneumonitis, 
restrictive or obstructive abnormalities of lung function can be 
detected(30,63). Many of these patients are asymptomatic. Not 
unexpectedly, the more pronounced measurable defects were noted in 
patients who had had pneumonitis. In general terms, restrictive 
changes did not progress but in some cases obstructive 
manifestations have increased.
2.5.2 Cataracts.
In their observation of 277 patients who received differing 
conditioning protocols the Seattle Group have noted 86 posterior 
capsule cataracts occurring from 1 year post-transplant(64). It is 
projected that 80$ of cases who received TBI as a single fraction 
would go on to develop cataract, whereas the projected risk in
patients receiving a fractionated approach is 19$. Other 
contributory factors such as drug treatment were not elucidated.
2.5.3 Endocrine Dysfunction.
Endocrine insufficiencies are known to occur in patients receiving 
conventional chemotherapy or radiotherapy and, although limited 
studies have been done, it is not surprising to find deficiencies 
after Cyclophosphamide, TBI and allograft(65). Both
Cyclophosphamide and TBI affect gonadal function and fertility. In 
the Seattle experience in Aplastic Anaemia (Cyclophosphamide alone) 
pre-pubertal children of both sexes reached puberty at the expected 
time with normal gonadotrophin levels. In adult females, menstrual 
cycles returned about six months post-transplant, with normal 
gonadotrophin levels in those patients under 26 years. Older women 
had an early menopause with elevated levels of lutenising and 
follicle stimulating hormone. In excess of 60$ of males, normal 
gonadotrophin levels and sperm counts returned - although subnormal 
counts in some patients. The remaining patients remained 
azoospermic with increased follicle stimulating and lutenising 
hormone levels.
More profound and permanent changes have been observed in leukaemic 
patients given additional TBI(6^ 1). All pre-pubertal females had 
primary ovarian failure, no menstrual periods and absence of 
secondary sex characteristics. In pre-pubertal boys a third have 
developed secondary sex characteristics at the appropriate time but 
two-thirds were delayed. In post-pubertal females, ovarian failure 
was the rule and half the patients had menopausal symptoms. Only 2
patients regained fertility at 3 and 6 years post-transplant and 
became pregnant. Similarly, azoospermia with primary gonadal 
failure is the rule in post-pubertal males although 2/*l1 recovered 
spermatogenesis about 6 years post-graft.
It is our practice recently to offer sperm bank storage facilities, 
when desired, to patients about to undergo allograft or autograft. 
Previous chemotherapy of course may itself have induced 
oligospermia.
Growth curves in children given Cyclophosphamide alone do not 
deviate from normal, but the addition of TBI appears to decrease 
growth rate although bone age is equivalent to chronological age. 
About one third of children have subnormal growth hormone levels. 
Growth hormone supplementation should be considered if these studies 
are corroborated.
2.5*11 Second Malignancy
Anxiety exists that some patients successfully treated by bone 
marrow transplantation may be at higher risk of developing 
malignancy some years later. The basis of this anxiety is the 
experimental data in dogs(66) and rhesus monkeys(69) where radiation 
was used, which indicates the risk to be about 5 times that of 
controls. Seventeen cases of second neoplasms have been reported in 
humans(6JJ). While several hundred bone marrow transplants have been 
performed, the precise incidence of neoplasia is not known. Of 
those reported cases all were in patients who had leukaemia.. In 5 
cases leukaemia recurred in donor cells, for which a number of
explanations are possible. Seven patients developed lymphomas and 5 
a variety of solid tumours. No second malignancy has yet been 
documented in patients transplanted for non-malignant disease 
prepared with chemotherapy.
2.6 LIMITED AVAILABILITY
The discussion so far has been based on data where the donor is 
almost exclusively an HLA-matched MLC non-reactive sibling, and the 
recipient usually under the age of 40. This age limit has been more 
or less adhered to by the majority of transplant units in the 
general belief that mortality and morbidity from the immuno- 
biological complications just described increase with age such that 
the survival for older patients is equivalent to the outcome with 
chemotherapy. This assumption is based on the original data 
described from Seattle in 100 consecutive patients where the 
transplant was undertaken at a later stage of the disease.
Analysis of the effect of age by the Seattle group appeared to
support the imposition of an age limit in AML(68). Patients under 
20 years had a predicted survival of 70$ whereas those aged 30-40 
years had a survival of 30$. More recent data confirms that 
patients under 20 do well, but the influence of age as an
independent risk factor, beyond that age is now less clear, although 
the bulk of allograft experience is still in under 40 year-olds. It 
is important to recognise that the poorer outlook for older patients 
is not related to a higher risk of relapse but purely to
non-leukaemic causes of death. A possible contributory factor to
this apparently increased risk with age is that it is likelier that
older patients will have been exposed to Cytomegalovirus with the 
important pulmonary consequences just described. For reasons that 
are not clearly understood, children tend to have a lower incidence 
of GVHD.
Current strategies of T cell depletion and the use of CMV Negative 
blood products for seronegative recipients may make transplantation 
safer, to the extent that the age limit presently imposed, may be 
raised.
The incidence of AML increases with age such that the majority of 
patients cannot be considered for allograft on the grounds of age, 
even if they fulfil all other criteria. The incidence of AML by age 
is shown in Figure 2.2 for the Scottish population (5,000,000) for 
the 17 years 1968-85. During this period 1,720 cases of AML 
occurred of which 341 (20$) were under 40 years old. If the
assumption is made that 70$ of this younger group achieved initial 
complete remission and about a third had a suitable sibling donor 
about 80 or (4.7$ of all cases) could be offered allograft of whom, 
the international data suggests, half currently have the prospect 
of being cured(i.e. 2.3$ of all cases). It is quite feasible to 
expect 90$ of young patients to enter remission, and assuming no 
relapses in the remission period pre-allograft and that 
non-leukaemic post-transplant causes of death are eliminated, then 
it is possible to argue that a maximum of 80, or 4.7$ of all these 
cases, could be cured. There is in fact little evidence from major 
centres who have examined their data by calendar year to suggest 
that the success rate they have been achieving has improved with the 
passage of time, i.e. results predicted in 1984-85 are not different 
for those predicted in 1979/80.
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The crucial point therefore is that, despite its outstanding 
antileukaemic effect when compared with conventional chemotherapy, 
allogeneic BMT can only cure a small proportion (2-6JO of all cases 
of Acutel Myeloid Leukaemia.
Figure 2.2 The Incidence of Acute Myeloid Leukaemia by Age*.
AGE DISTRIBUTION OF AML IN SCOTLAND 1968-85 (N-1720)
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* The author is grateful to the Information Services Division of 
the Common Services Agency, Edinburgh for the raw data.
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CHAPTER 3
ALTERNATIVES to ALLOGENEIC TRANSPLANTATION 
FROM HLA MATCHED SIBLING DONORS
3.1 INTRODUCTION
In the context of the very limited ability of chemotherapy to 
prevent relapse, allogeneic bone marrow transplantation, despite its 
limitations, is still a superior form of treatment for AML, for 
those to whom it can be made available. Currently this is, for the 
reasons just discussed, a small proportion of those with the 
disease. The antileukaemic effect apparent in allograft gives 
overwhelming incentive to strive to make such ablative treatment 
available to a higher proportion of those with the disease. At 
present, three approaches can be taken:-
1) Transplant from donors who have a degree of HLA mismatch
2) Transplant from donors who are phenotypically matched but 
are not genotypically matched (unrelated donors)
3) Autologous transplantation of stored marrow collected 
earlier in remission.
3.2 TRANSPLANTATION FROM DONORS WHO ARE NOT FULLY MATCHED
The substantial knowledge of allogeneic transplantation has been 
gained virtually exclusively within the groups of patients for whom 
a sibling HLA phenotype matched donor, (genotype matched) with a 
negative mixed lymphocyte reaction, is available. In recent years, 
preliminary clinical investigations have been undertaken to 
determine whether it may be possible to successfully transplant 
where there is a degree of non-identity. In experimental transplant 
systems, the significance of MHC incompatibility is well 
documented( 1,2) but little is known in man. In addition to the 
advantage of including a higher proportion of patients with AML,
there is the theoretical advantage - to be discussed in more detail 
below - of an additional graft-versus-leukaemia effect which may be 
amplified in this situation by immune recognition of different MHC 
determinants on the hostfs leukaemic cells, or possibly by the 
introduction of genes conferring resistance to leukaemia.
At present, the technical problems associated with such an approach 
have been clearly defined, namely non-engraftment, increased GVHD, 
infection and, in some series, the capillary leak syndrome(3,4,5). 
Mortality associated with these problems has been substantial and it 
has therefore not been possible to evaluate whether or not the 
graft-versus-leukaemia effect has been augmented. Most studies have 
included a heterogeneous group of patients, many of whom have 
advanced disease. There is some reason to hope that "mismatched” 
transplant technology will improve. Improved preparative protocols, 
including the in vivo use in the host of anti-T monoclonal antibody, 
represent some immediate optimism that initial engraftment may be 
achieved more regularly(ll). The extensive Seattle experience of 105 
mismatched transplants has defined a number of points(4,5). The 
extent and severity of GVHD appears to be related to the degree of 
mismatch. Where there is a haplotype match and three of the four 
loci on the other chromosome match, the incidence of GVHD and the 
survival differ very little from that seen in the genotypically 
fully matched transplants. It is of interest to note that it does 
not seem to matter which single locus does not match, as this does 
not influence outcome. If mismatches of this minor degree are 
routinely accepted it is still unlikely that this could be applied 
in the older patient, and of younger patients it is suggested that 
only an additional 10/5 would qualify for allograft. It may be
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possible in the future to more scientifically select donors from the 
family within categories of extended haplotype groupings which are 
more likely to give a negative MLR(7). Survivors of greater degrees 
of mismatch do occur, but these have for the most part been limited 
to younger patients (<20 yrs) where the survival has been 30  ^ for 
the small number of cases of AML in first remission(3). A small 
number of unrelated partially matched transplants have been done, 
with poor results(8).
3.3 PHENOTYPICALLY MATCHED UNRELATED DONORS
Since the first report of successful transplantation from a donor 
who was matched at the HLA loci but was not a genotypic match(8), 
interest has grown in the use of unrelated matched donors. There is 
relatively little evidence at present to suggest that this approach 
will be any more successful than mismatch transplantation since the 
problems of engraftment and GVHD have also been paramount. It 
appears that younger patients may be the ones to benefit from future 
improvements in technique.
The logistic problems involved in locating a suitable donor have 
proved considerable. It can be anticipated that more extensive 
panels will be available in the near future and that molecular 
biological probing techniques may replace serology. As it stands, 
considerable periods of time elapse between search initiation and 
donor location during which time the patient is at risk of relapse. 
It appears likely, however, that storage of DNA preparations, which 
would be part of the newer molecular biological approach from 
potential donors, may eliminate this delay(10,11).
Cautious optimism that matched unrelated transplantation may be a 
technically viable approach is encouraged by the recent results from 
the Hammersmith Group, predominantly in severe aplastic anaemia and 
chronic myeloid leukaemia(12,13) and the few phenotype matches in 
the Seattle series(5). Although graft failures and severe GVHD 
occurred in about half of all patients in the small number of 
patients evaluable, 50% receiving marrow from an unrelated matched 
donor survived compared with 29  ^ receiving marrow from mismatched 
family donors.
The preliminary clinical studies of using other then HLA 
genotypically matched donors suggest that only a few additional 
patients may benefit, almost all restricted to the younger patients, 
where the smallest proportion of the disease exists. Even if such 
approaches improve to the extent that they can be recommended with a 
significant prospect of success, the technical and logistic problems 
for the larger group of older patients. make such an option seem 
remote.
3.4 AUTOLOGOUS TRANSPLANTATION
The use of the patient fs own remission bone marrow as a source of 
haemopoietic stem cells can create an opportunity - a "therapeutic 
window" - to give high dose therapy without regard to the 
restrictions imposed by myelotoxicity. Such a concept is not new in 
the treatment of some forms of cancer.
3.4.1 History of Autologous Bone Marrow Transplantation
Stored autologous bone marrow was first used as supportive treatment 
in the late 1950s( 14,15,16,17). Over the subsequent four or five 
years, several groups embarked on tentative clinical studies of high 
dose chemotherapy or irradiation in a variety of solid tumours. An 
attempt was made to salvage relapsed leukaemia following super 
voltage irradiation(24). Almost all of these studies involved the 
use of cryopreserved bone marrow.
The clinical results achieved in these studies were poor. This was 
often due to failure of supportive measures to prevent infection or 
haemorrhage, but there was little knowledge at that time what the 
dose limits of the various agents used were. By modern standards, 
several of the protocols used would be regarded as modest, and 
certainly not requiring haemopoietic stem cell rescue. In the odd 
instance where high doses were given, it is not surprising that 
little therapeutic gain was noticed because many of the patients had 
reached the stage of having multiply resistant disease. Because the 
dose given would, in the light of present knowledge, not necessitate 
stem cell rescue, it is not possible to say that the techniques 
developed for marrow storage were effective, an aspect which will be 
discussed again in Chapter 5.
These early studies probably delayed progress in high dose treatment 
because the results were so poor, and it was not until the late 
seventies and early eighties that autografting has been approached 
with enthusiasm. Despite substantial use in solid tumours, there is 
still little evidence in the majority of cases of clinical benefit
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and improved survival. The stimulus of its use in leukaemia was of 
course the improved effectiveness of ablative treatment with 
allogeneic marrow transplantation. In the late seventies some
preliminary studies in relapsed disease were carried out - the 
contribution of which will be discussed in Chapter 4.
3.1J.2 Advantages of Autologous BMT
The potential advantages of autologous transplantation for patients 
who do not have donors are:-
a) Availability to Patients Who Lack a Matched Donor
For younger patients who are to be considered for allograft, it 
is necessary' to explain to the patient and his family that, 
despite the fact that treatment has so far been successful in 
achieving haematological remission, further treatment in the 
form of a bone marrow transplant must be considered. It is
usually at this time that the patient is made aware of the
limited chance for long-term disease-free survival with 
conventional chemotherapy. Failure to find a matched donor 
within a family group usually results in disappointment and
unease, and the development of the autograft approach as an
alternative to permit "ablative" treatment stemmed directly from 
this reaction.
b) Reduction in Transplant Related Mortality and Morbidity
As previously mentioned, Graft-versus-host disease represents an 
important cause of death and morbidity following allograft which 
would be eliminated by autologous marrow. GVHD is 
immunosuppressive because it retards the pace of immunological 
recovery. Preventative treatments (e.g. Methotrexate or
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Cyclosporin) are in themselves also immunosuppressive and 
associated with direct toxicity to the patient. The 
contributions of GVHD and immunosuppression in the aetiology of 
pneumonitis have been discussed in detail, so it is reasonable 
to expect a lower incidence of this problem in patients who have 
no GVHD and who are not immunosuppressed by GVHD or its 
preventative treatment. Comfort that these hopes may be 
realised comes from the results of syngeneic grafts where 
toxicity, pneumonitis and procedural related deaths are 
considerably less than the allograft experience(25).
c) Age.
The restriction of allogeneic transplantation to younger 
patients is primarily to avoid excessive toxicity. The 
numerical limitations of Allograft to the overall number of 
patients with AML has been illustrated. There is, on the other 
hand, no evidence to suggest that the antileukaemic effect 
should diminish with age. If autograft is associated with 
little or no procedural morbidity or mortality, as postulated 
above and as suggested by the syngeneic experience, then it 
would seem feasible to safely offer such treatment to older 
patients. An arbitrary limit of fifty-five was set for these 
initial clinical studies.
Clearly, the safe inclusion of older patients involves a greater 
proportion of all patients with AML. The Scottish based 
figures (Figure 2.2) suggest that, if J0% of patients achieve 
complete remission, J411 will be eligible for autograft (24?5 of all 
patients) compared with H.7% able to be offered allograft.
3.4.3 Disadvantages of Autologous BMT
The major conceptual reservations about this approach are (a) that a 
component in the anti-leukaemic effect of allograft is an 
immunologically mediated graft-versus-leukaemia effect; (b) there 
may be residual disease contaminating the graft, which will 
inevitably lead to relapse.
GRAFT-VERSUS-LEUKAEMIA
3.4.3 .1(a)Experimental Evidence for Graft-versus-leukaemia
Experimental data to support the concept that engrafted immuno­
competent cells have an anti-leukaemic effect against the host, is 
limited almost entirely to rodent lymphatic leukaemia model 
systems(26,27). Barnes and Loutit recognised that the ability of 
administered bone marrow cells to haematologically "rescue" mice 
from lethal irradiation might also be effective in eradicating 
leukaemia, but questioned whether isologous(autologous) or 
homologous(matched allogeneic) marrow was more effective(28). The 
latter - it was postulated - could deal with the residual cells 
remaining after irradiation. In a series of experiments to test 
this hypothesis they found that irradiated recipients of the 
autologous marrow survived irradiation without a "wasting syndrome", 
but usually suffered leukaemia recurrence whereas the recipients of 
allografts, which survived, were leukaemia free. These experiments 
were complicated by the fact that the allograft recipients developed 
the wasting syndrome - the equivalent of graft-versus-hose disease - 
which curtailed survival.
The demonstration that a LDgg* dose of irradiation was incapable of 
eradicating leukaemia in this model unless the source of marrow was 
homologous, conditioned much of the early thinking in 
transplantation in man concerning how the technique could be used to 
cure some patients with leukaemia.
In these studies and in similar studies by others it was clear that 
the major clinical limitation would be failure to survive 
graft-versus-host disease. The question arises whether the 
graft-versus-leukaemia (GVL) effect and graft-versus-host disease 
(GVHD) can be separated. The relative expression of GVH or GVL in 
the mouse is strain dependent, and is also influenced by the dose of 
allogeneic cells or their ratio to residual leukaemic cells(29,30). 
It is of interest to note that, to achieve the anti-leukaemic 
effect, engraftment of the donors immunocompetent cells is only 
required for short time.
Experimental data is convincing on this point. H-l mismatched 
grafts can eradicate residual disease but results in death from 
GVHD. However if the allogeneic graft is destroyed and replaced
with syngeneic or compatible grafts these animals can survive 
leukaemia free. Not all strains of mouse have equal GVH and GVL
reactivity. In CBA, AKR, and C57BL/6 there appears to be a direct
correlation but strain A has a greater GVH than GVL effect.
Interestingly, in AKR leukaemia DBA/2 donors have the highest GVL 
effect but less severe GVH reaction(31). Little antileukaemie 
effect was noted in syngeneic grafts or where the mice were H-2
* The dose required to kill 98? of the cell population.
matched(32). When leukaemia bearing AKR mice were transplanted with 
DBA/2 H-2 mismatched marrow, and the GVHD reaction stopped by high 
dose chemotherapy, and then rescued with H-2 matched bone marrow 
cells, increased survival was noted.
Factors of importance in the mechanism are (i) ratios of 
immunocompetent cells to target cells. A suggested minimum ratio is 
1:5 or 1:30. (i.e. clonogenic cells versus effective immunocompetent 
cells), and this ratio may vary substantially within the different 
tissues of the body; (ii) the timing of the immunological events. 
It takes, in these experimental systems, five days for the incoming 
immune cells to graft, proliferate and migrate to the target area. 
This tempo is not affected by the degree of histocompatibility but 
the cytotoxic action increases as the incompatibility of the match 
increases. For most strains no anti-leukaemic effect occurs without 
initiating the graft-versus-host effect. In elegant experiments it 
was demonstrated that the anti-leukaemic effect was completed by Day 
7 post-graft(33,34,35). In the system described(33) to exemplify 
this point, the injection of spleen cells from the test animal into 
a syngeneic host results in tumour formation. This is a reliable 
bioassay which is capable of detecting a small number (possibly one) 
of contaminating leukaemic cells. When leukaemia bearing mice were 
irradiated and given allogeneic marrow infusion, cohorts were 
sacrificed at daily intervals and recipient spleen cells injected 
into syngeneic hosts. It was noted that the cell suspensions from 
the first few days regularly produced tumour formation, but by Day 7 
no leukaemia cell transfer was observed. By Day 7 in this system it 
was not possible to abort the GVH effect by conventional treatment, 
and most animals, while by then leukaemia free, would go on to
develop fatal GVHD. If however, the graft was chemotherapeutically 
destroyed and the animal rescued with syngeneic marrow, leukaemia 
free survival was observed. Similar results have been described in 
another system(36).
Separation of a GVH and GVL reaction depends on specific antigen 
recognition on leukaemic cells. In mismatched situations such a 
reaction may be relatively insignificant compared with that mounted 
against histocompatible antigens.
Where the number of immunocompetent cells in the graft is few, the 
antileukaemic effect is transient. It appears that in the 
experimental situation potentially lethal GVH is usually an 
inevitable consequence of an immune mediated eradication of 
leukaemia(GVL).
Attempts to modify the GVH reaction by better matching, reducing the 
number of immunocompetent cells in the graft, or treatment of the 
grafted host within the fmaturingT time of the reaction, to reduce 
GVH will also reduce GVL, Intervention beyond 7 days with measures 
compatible with graft survival, are not capable in these systems of 
preventing GVHD.
Drugs given to the animals in the early post-graft period may have 
an anti-leukaemic effect, far in excess of that expected in 
leukaemic patients. In initial immunologically mediated attack 
(GVL) on leukaemic cells in resting phase may induce residual cells 
to cycle and be susceptible to anti-GVHD drugs such as methotrexate 
or even corticosteroids.
3*4.3.1(b)Evidence for a Graft-versus-Leukaemia Effect in Man
It is not possible to reproduce the rodent experience in man, so any 
evidence is necessarily circumstantial, but information can be 
derived from four sources(i) evidence for a direct anti-leukaemic 
effect attributable to the emergence of GVHD (ii) correlation 
between leukaemia relapse and the occurrence and severity of GVHD 
(iii) comparison of relapse rates between allografted and syngeneic 
transplants, and (iv) the influence of effective GVHD prevention on 
relapse rates.
(i) Evidence for a Direct Anti-leukaemic Effect of GVHD
Odom and colleagues reported(37) the cases of two boys with ALL who 
were allografted in relapse, in whom they postulate a graft-versus- 
leukaemia effect. In the first case, a multiply relapsed thirteen 
year old boy, post graft bone marrow examinations on days 21 and 27 
showed the presence of 43$ and 72$ lymphoblasts. On Day 41 the 
child developed characteristic manifestations of acute GVHD and a 
repeat bone marrow on Day 42 showed complete remission. Remission 
persisted till death at four months of pneumocystis pneumonia. At 
post mortem, marrow remission was confirmed but extensive extra- 
medullary deposits were found. The second case was also trans­
planted in relapse. Thirty days post-graft, he developed testicular 
relapse and had 90$ lymphoblasts in his marrow. On day 40 
progressive GVHD started and somewhat unexpectedly bone marrow 
examination on day 48 was in complete remission. Despite the fact 
that leukaemia recurred in multiple extramedullary (mostly 
cutaneous) sites, marrow remission persisted until 189 days 
post-graft.
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Alternative mechanisms could explain these findings. It is possible 
for example that the leukaemic cells were lethally damaged but not 
destroyed by the irradiation, but were incapable of subsequent 
division. Both patients received intermittent modest doses of 
methotrexate as post- graft GVHD prophylaxis, but the doses given 
were considerably smaller than had previously given to the patients, 
without response.
The clinical sequence of events taken together with the finding of 
donor lymphocyte cytotoxic activity against host leukaemia cells, 
led the authors to invoke a direct graft-versus-leukaemia effect 
associated with graft-versus-host disease.
(ii) Correlation Between Leukaemia Relapse and the Occurrence and 
Severity of GVHD
Demonstration of such an effect in man is difficult because of 
associated complications and treatments. Statistical manipulation 
of the Seattle results in 262 patients presented by Weiden(38) 
suggests that patients transplanted for Acute Lymphoblastic 
Leukaemia (ALL), who developed the more severe grades of acute GVHD, 
had a reduced probability of relapse. This relationship could be 
demonstrated to be obvious in relapsed disease and could not be 
demonstrated for AML in remission.
In a subsequent study taking into account chronic GVHD, Weiden(39) 
again demonstrated that patients who had both acute and chronic GVHD 
had a higher probability of remaining disease-free compared with 
those who had none. Unfortunately, ALL and AML were analysed
together in this study, so it is not possible to separate the effect 
on AML alone. Again, the apparent antileukaemic benefit is a 
statistical prediction when competing causes of death are censored, 
and no actual survival benefit was demonstrated.
Bacigalupo(*}0) recently reported relapse in 1336 of 36 of his 
patients allografted for ALL(1st and 2nd CR), AML and CML who had 
developed chronic graft-versus-host disease, compared with 73% of 21 
of those who did not develop this complication.
In European data(*!3, *11) collected from 27 centres (229 patients, 183 
in first remission) no relationship with acute GVHD was demonstrable 
but patients who developed chronic disease were shown to have fewer 
relapses. How real this effect is when only 22 patients relapsed is 
questionable, particularly in the first remission cases where only 
1*1 relapses occurred.
Since the overall relapse rate for AML transplanted in first 
remission is relatively low, and there are other competing causes of 
death, it is difficult to demonstrate an antileukaemic effect 
compared with situations where the relapse rate is higher, such as 
ALL. It still remains controversial whether the evidence presented 
in association with GVHD is real, because of the various treatments 
which these patients will have for the GVHD which may have an 
anti-leukaemic effect in these circumstances.
Given that there are major difficulties in demonstrating a GVL 
effect in AML in remission in man, the flavour of the evidence 
suggests that such an effect exists, but the extent to which it
contributes to cure is difficult to quantitate. It is clearly 
strongest where GVHD is severe, but that is not a clinical 
circumstance which is usually compatible with patient survival.
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It is of interest to note that there is so far no data to suggest 
that undertaking an HLA mismatched transplant results in lower rates 
of relapse, largely due to the substantial death rate for other 
reasons. But it is noteworthy that there is no difference in the 
actuarially predicted relapse rate as the degree of HLA disparity 
increases(5).
(iii) Comparison of the Relapse Rate in Syngeneic Transplant 
Recipients
Syngeneic transplant data of AML in first remission provides a 
unique opportunity to examine the relapse rate where no allogeneic 
effect contributes to the antileukaemic effect. In 1983 Gale(*J2) 
collected data on 31 such cases and showed that the relapse rate was 
approximately 50$ with an actuarial prediction of relapse in the 
range *10-65$ (95$ confidence limits) at 3 years, suggesting that the 
relapse rate was approximately double that seen for allogeneic 
matched grafts.
I have collected updated data(February 1987) on 3*} syngeneic grafts 
for AML in first remission, some of which were included in GaleTs 
analysis while further cases were obtained from the European 
Transplant Group Database. The survival and disease free survival 
is shown in figure'3.1.
Figure 3.1 Survival of Patients Transplanted in First Remission of 
AML from an Identical Twin
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There are some reservations about the solidity of this data, which 
will be discussed later in the context of the results of autologous 
BMT, but, if taken at face value, the twin data is perhaps the 
strongest evidence to suggest that there is an allogeneic effect 
which contributes to cure in allograft. This has crucial 
implications for the potential role of autologous transplantation. 
First, it is difficult to see how an autograft could result in less 
than a 50% relapse rate. Second, if the autograft has important 
contamination with residual leukaemic cells then the relapse rate 
will be higher.
Two further observations concerning the twin data can be made at 
this point. Patients who failed to become long term survivors did 
so largely because of leukaemic relapse. Toxicity and procedural 
related jmortality was therefore unusual, supporting the contention 
expressed earlier, that it may be safer to apply autograft to older 
patients with AML and balance the anticipated increased relapse rate 
with minimal procedural related morbidity and mortality. A second 
observation to make that may be relevant when examining the 
autograft data, is that most of the relapses which have occurred 
have taken place in the first year post-graft.
The twin experience is useful baseline data which may help to answer 
the question of whether there is an allogeneic GVL effect occurring 
in man which is not associated with GVHD. The data available 
suggests that this effect is only marginal since the predicted 
relapse rate is the same in twins as in allografts with no GVHD in 
Weiden's study(38). This evidence is not strong, given the 
heterogeneous group of patients, but it tends to lead to the same 
conclusion that can be made from the experimental systems, namely 
that useful antileukaemic effect is associated only with significant 
GVHD which in turn is an important threat to survival.
(iv) Consequences of Effective Prevention of GVHD by T-Depletion in 
Vitro
As will be discussed later, graft-versus-host disease can now be 
prevented by removal of T cells from the marrow donation before it 
is given. An unexpected consequence of this has been the emergence 
of graft rejection which formerly was an unusual occurrence.
Precisely why this occurs is not clear, but a probable explanation 
is that the T cells in the graft have a cytotoxic effect on host 
lymphoid tissue, adding to the therapeutic immunosuppression, thus 
permitting engraftment. It is similarly possible that a residual 
leukaemia in the host in some way mediates the postulated graft- 
versus-leukaemia effect so that a further consequence of T depletion 
may be an increased rate of relapse; such is already apparent in the 
chronic myeloid leukaemia experience(US). It is tantalising to note 
that in CML recipients of syngeneic grafts (presumably lacking a GVL 
effect) the relapse rate is around 20% which is similar to the 
allograft. In AML the data at present is equivocal with evidence 
for and against an increased rate of relapse. In our own 
experience, which corresponds very closely to that of the Royal Free 
Hospital, London (Prentice H G, 1987, personal communication) who 
have used the same monoclonal antibody technique of T depletion (see 
Chapter 9), we have not observed an increased relapse rate in AML in 
first remission, greater than the international norm.
It seems too early to draw conclusions about the effect of T 
depletion on relapse rate in AML, far less to use such evidence to 
support the contention that there is an important GVL effect.
3.^.3.1(c) Summary Of The Evidence For A Graft Versus Leukaemia 
Effect
In summary, therefore, from experimental systems four points emerge:
i) an anti-leukaemic effect in the immediate post-transplant period 
is clearly demonstrable but only in mismatched grafts; ii) the 
strength of the anti-leukaemic effect is directly correlated with
the severity of the inevitable subsequent GVHD (except uniquely in 
the DBA/2 mouse); iii) efforts to abort the GVHD effect must be 
undertaken in the early post-graft period, but if successful also 
result in reciirrent leukaemia; iv) there is no rodent data to 
support a GVL effect in non-lymphoid malignancies.
In man (i) syngeneic transplants for AML in first remission may 
result in a higher relapse rate; (ii) actuarial statistical evidence 
suggests that the development of GVHD results in less relapses in 
ALL but similar evidence in AML in remission is less clear; (iii) so 
far the evidence to suggest the effective prevention of GVHD, by T 
cell depletion of the graft, results in higher relapse rates is 
equivocal; (iv) so far HLA mismatched transplants are not associated 
with reduction in relapse rate in AML but this data is scarce due to 
the low overall survival.
3. *1.3.2 Alternative Explanation for the Association of GVHD and GVL 
In Man
If it is accepted, as seems likely, that the occurrence of GVHD, in 
particular chronic GVHD, is associated with reduced relapse rate in 
man, then this causes serious doubts about the likely success of 
autologous transplantation which will presumably not have an immune 
component in its antileukaemic effect. The data, however, may be 
interpreted differently.
In patients transplanted for severe aplastic anaemia a proportion of 
patients have been noted to be stable mixed chimeras of host and
donor cells(i|4). These mixed chimera patients were noted to be less 
likely to develop GVHD. The aplastic patients were conditioned for 
transplant with high dose chemotherapy but not with TBI, so survival 
of host haemopoiesis is not surprising. In leujcaemic patients who 
have had TBI, mixed chimerism is being increasingly recognised 
(^5,46,47) but no association with GVHD has been looked for. The 
fact that some host cells can survive "ablative" treatment suggests 
that it is not truly ablative. Since the radiobiological 
characteristics of leukaemia cells and haemopoietic precursors are 
usually accepted as being the same, there is a possibility that the 
mixed chimerism may be the major reason for persistent leukaemic 
cells. Since mixed chimerism mitigates against GVHD (M) the 
observed association of lack of GVHD with relapse could be explained 
by inadequate ablation of the patient. This is not to ignore the 
experimental data of an apparently clear GVL effect - but this was
restricted to the early post-graft period and may be an alternative
mechanism which is not demonstrable in man.
A summary of this alternative explanation is shown in figure 3.2. 
Just as the relationship between the mixed chimeras observed in
patients after TBI, and the development of GVHD is not at present 
documented, so there is limited knowledge of whether there is a 
relationship between the degree of chimerism and the risk of
relapse. Finding such a relationship would be necessary to support 
this alternative explanation. It would be equally important from 
the autograft perspective, if it were demonstrated that mixed 
chimerism did not mean an increased likelihood of relapse. Such an 
observation would suggest that it may be possible for leukaemic 
cells to persist, but be compatible with clinical relapse-free
survival. These fascinating questions remain to be answered by new 
technology. To date only cytogenetic techniques have been useful in 
this respect between sex mismatched transplants. But this 
technique, as well as being limited to a proportion of transplants, 
is also limited to assessment of lymphoid chimerism because the 
mitoses examined result from mitogen stimulated cells. Chimerism of 
haemopoiesis can be examined by DNA fingerprinting techniques such 
as use of minisatellite gene probe analysis(48). This work is 
underway in a number of laboratories including my own at the present 
time, with a view to tackling the questions raised above.
Figure 3.2 An Alternative Explanation for the Apparent Association 
of Graft-versus-Host Disease and Reduced Relapse Rate
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3.^.3«3 Contamination of Remission Marrow by Residual Disease
It is, at present, assumed that since relapse of disease is 
inevitable for most patients with AML who enter remission then the 
"remission” marrow must be 1contaminated* with residual leukaemia, 
which if autografted will result in recurrent disease. That there 
is occult residual leukaemia is implicit in the concepts derived 
from the L1210 leukaemia model system propounded by Skipper(49,50) 
and displayed in figure 1.1 in Chapter 1. This concept is 
compatible with the observed facts and principles but it is possible 
that remission could require a secondary event to result in relapse, 
rather like that with which we are familiar in the blast 
transformation of CML.
The arguments to support the autograft approach for prolonging 
remission in AML are those of cytoreduction. Conceptually 
conventional chemotherapy fails because it is unable to eradicate 
residual disease either because of inherent ineffectiveness or 
because of dosage constraints imposed by non-myeloid toxicity. With 
time it is more likely that resistant leukaemic subpopulations will 
emerge.
Cure may result either because (i) the treatment has been capable of 
eradicating the last leukaemic cell or (ii) reducing the total 
tumour mass to such a small amount that it is either compatible with 
long term remission, or that the hosts immune mechanisms can 
re-assert themselves and contain residual disease. In experimental 
systems evidence can be produced to support both concepts, -namely 
that a single cell is capable of leading to recurrence or that it is
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possible to exist in remission when detection of residual leukaemia 
can be demonstrated by transfer of spleen cells to susceptible hosts 
as a bioassay for residual leukaemia(51).
Allogeneic bone marrow transplantation for AML may be unique either 
because the TBI is alone capable of either eradicating fthe last 
cell1 or reducing the burden below the minimum threshold compatible 
with operational cure. These mechanisms may - to a greater or 
lesser extent - be assisted by a GVL effect.
If remission is arbitrarily set at a leukaemic cell burden of 1 0 ^ 
ceils then the components of allograft may be capable of achieving 
the rest. As mentioned previously, allograft in relapse - i.e. with 
a residual cell burden of >1 x 10^ - is less effective. This may 
be due to cell resistance or it may indicate that TBI has limited 
effect of a higher cell load.
If we assume, for the sake of argument, that bone marrow harvest is 
to be attempted at a time when the body load is 1 x 10? cells it is 
probable that only of bone marrow cells are removed. Assuming an 
even distribution of contamination within the marrow, 1 x 10^ 
leukaemic cells will be harvested of which 1-2£ may be clonogeneic 
cells, i.e. 1-2 x 1C)3 cells. During the subsequent processing, 
freezing and thawing a further proportion may be lost so it is 
possible that as few as 1 x 10^-1 x 103 clonogeneic cells may be 
reinfused to the patient.
If in the meantime adequate ablative treatment has been given to the 
patient, the total tumour burden after the autograft will be small
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and may be beneath the theoretical threshold mentioned above.
The accuracy in man of these figures is quite unknown. It is 
conceivable that it may be possible that when the harvest is taken 
the total body burden is greater or less than 1 x 10?. Whether this 
is the case will be influenced by previous chemotherapy and, as will 
be discussed later, the role of cytoreduction prior to the harvest 
and the autograft may have a crucial effect on outcome. For similar 
mathematical reasons the number of cells harvested may be important.
It is conceivable that the few clonogenic leukaemic cells which may 
be infused with the autograft, may not be capable of seeding into 
the haemopoietic environment. How such events are controlled is 
unknown. It is possible that leukaemic cells cannot adhere with the 
same efficiency as normal haemopoietic precursors, a concept for 
which there is some experimental in vitro evidence(52). 
Alternatively, there may have been sufficient damage to the marrow 
microenvironment which does not favour leukaemic haemopoiesis. 
Since the bone marrow will be hypocellular at the time of marrow 
infusion, there may be a crucial lack of cell mediated growth 
factors necessary to maintain leukaemic haemopoiesis, but which may 
be less crucial for normal cells.
3.^.3.^ Summary of the Disadvantages of Autograft in AML
Loss of a graft-versus-leukaemia effect, and the possibility of 
contamination of the autograft with residual leukaemia are the 
conceptual disadvantages which could limit the success of autologous 
bone marrow transplantation in AML.
The evidence to suggest that these will negate any potential benefit 
has been fully discussed, and the counter arguments reviewed. At 
the time of initiation of my clinical studies the potential
advantages seemed to outweigh the disadvantages. The practicality 
of attempting to remove residual leukaemic cells to improve the 
quality of the autograft will be reviewed later, but since no method
existed in 1981 all my clinical studies in AML have been conducted
without any effort being made to "purge" the marrow of contaminating 
leukaemia cells.
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CHAPTER i|
PROTOCOL DESIGN
Three major components are required for success of autologous 
transplantation. First, the opportunity to administer high dose 
treatment must be maximised; second, supportive care must be 
adequate to protect patients from any intended or unintended toxic 
complications and third, the conditions of collection, preparation 
and storage of the autologous marrow must be rigorously evaluated.
1». 1 CYTOREDUCTIVE TREATMENT
The effectiveness of the treatment modality in an attempt to 
eradicate leukaemia will be determined by two major considerations: 
(a) when in the natural history of the disease the therapy is given, 
and (b) the choice of particular cytoreductive modalities. At the 
initiation of these clinical studies in 1981, extrapolation from the 
then currently available data, mostly from allograft experience, 
largely dictated the approach taken. More clinical information has 
emerged over the intervening five years as other groups have 
initiated autograft programmes, but that will be referred to in 
Chapter 8.
4.2 TIMING OF AUTOLOGOUS TRANSPLANT
4.2.1 Transplantation of Acute Leukaemia in Relapse
Dicke and co-workers initiated autograft studies in acute 
leukaemia. In their series, 24 patients with acute leukaemia 
(myeloid and lymphoid) were autografted in relapse with marrow 
collected earlier in remission(1). Further remissions were obtained 
but these were short-lived and there was a disappointing impact on
survival. All patients were treated with TBI but had 
Piperazinedione instead of Cyclophosphamide, and it is therefore 
difficult to know whether they were optimally treated. It was 
concluded by the authors that the lack of success of this approach 
could largely be attributed to the probability that the autograft 
was contaminated by residual disease but in the crucial early series 
of patients allografted in relapse(2) in Seattle, the predicted 
relapse rate was high (in excess of 60-7035). This high relapse rate 
is relevant because it occurred in these patients despite the fact 
that the graft was uncontaminated by possible residual disease, and, 
although not detected, a graft-versus-leukaemia effect may have been 
operating (50 of 93 patients at risk developed moderate to severe 
GVHD). In addition, these patients received post-graft Methotrexate 
which may have had a minor anti-leukaemic effect. If an allograft 
with its subsidiary antileukaemic mechanisms resulted in such high 
relapse rate, it is scarcely surprising that autologous 
transplantation at this stage should be unsuccessful. The major 
conclusion to be drawn from this data is that ablative treatment is 
unlikely to produce important benefits in relapsed disease either 
due to tumour bulk or tumour resistance or both.
4.2.2 Autograft in Second Remission
The initial results of allograft in AML in second remission, now 
confirmed by the larger registry data (IBMTR and EBMT), predicted 
that the relapse rate would be around fifty per cent. While a more 
advantageous prospect for an autograft than relapsed disease, it 
still appeared that only a small number of long term survivors could 
be expected from this strategy. The results of second remission
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autografts will be discussed more fully later. The initial decision 
not to set the protocol in second remission was also influenced by 
the predominant fashion in the late 1970s to administer maintenance 
chemotherapy. |As previously discussed, this has little influence in 
leukaemia-free survival but many patients relapsed on treatment. In 
general terms, the prospects of achieving a second remission are 
strongly influenced by whether or not the patient relapses on or off 
treatment. The more recent trend has been to discontinue treatment 
earlier, and while patients continue to relapse, the fact that they 
are off treatment is likely to mean that reinduction will be more 
successful and a higher proportion of patients could be available 
for a second remission study. This change in clinical practice may 
have important implications for the timing of autograft which will 
be discussed later.
4.2.3 Autograft in First Remission
Available data from the initial studies of allograft in first 
remission AML indicated that the prospects of remaining 
leukaemia-free were 75—9055 with all but a few relapses occurring in 
the first 18-24 months post-graft. The syngeneic results as 
illustrated previously suggest a 5055 chance of leukaemia-free 
survival. Reservations about the firmness of the twin data have 
been expressed and will be discussed later, but if it is accepted at 
face value, then it would represent the maximum achievable target of 
autograft in first remission, assuming contamination of the graft 
was not a major issue. Such a result would nevertheless be an 
important improvement in disease-free survival in AML, particularly 
if older patients can be included.
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While there may be reservations about the comparative results 
achieved by autografting in first remission, which can only be 
resolved by a controlled trial, this stage of disease offers the 
prospect of producing the highest proportion of survivors, than if 
autograft was delayed to a later stage of the disease.
4.3 CYTOREDUCTIVE PROTOCOL
4.3.1 Chemotherapy
The choice of chemotherapy alone will depend on pharmacological 
considerations. Clearly the objective is to exploit maximally the 
"therapeutic window" created by the removal of myelotoxicity as the 
dose-limiting factor. While non-myeloid toxicity associated with 
increased dose can in part be predicted from experimental data, 
cross-species interpretation may be unreliable, and the toxicity of 
combinations used in high dose may be unpredictable. The 
pharmacokinetics of certain drugs also limits their usefulness in 
high dose. For example, increased antitumour effect with 
antifolates is better achieved by prolonged exposure rather than by 
increased dose, this being partly due to the limitations of cell 
uptake dictated by membrane transport mechanisms as well as to the 
number of cells in cell cycle over the period of drug 
administration. Other drugs, e.g. cyclophosphamide, depend on 
metabolic activation by the liver. Some alkylating agents and 
nitrosoureas are not limited by such considerations and are widely 
used in ABMT regimens.
In general terms, the restrictions imposed by non-myeloid toxicity
[e.g. gut - Melphalan, heart - Doxorubicin (Adriamycin), bladder and 
lung - Cyclophosphamide] are the more practical dose-limiting 
factors. A dose escalation of a single agent of 3-5 fold is often 
possible(3) Such an increase may have a beneficial antileukaemic 
effect, particularly for drugs in which a steep dose response can be 
demonstrated in vitro. This will, however, be insufficient to 
eradicate any population of cells which have become resistant to 
that drug. In vitro studies, at least for certain solid tumours, 
suggest that a 10,000 fold increase would be required to kill 
resistant cells in these circumstances(4).
4.3.2 Total Body Irradiation
Total Body Irradiation(TBI) has been used in association with 
transplantation of bone marrow since the early experiments of Lorenz 
and Jacobson(5,6). In experimental situations chemotherapeutic 
agents have not been consistent or predictable in permitting 
engraftment. In the developmental days of allogeneic 
transplantation in man, Graw reported(7) unsuccessful attempts to 
achieve engraftment with a multiple drug regimen. As will be 
discussed later it is still an undecided issue as to whether 
cytoreduction with TBI is superior to chemotherapy in the autograft 
setting. The arguments supporting TBI for allogeneic 
transplantation were that it was advantageous to administer to the 
patients treatment within a matter of hours rather than over a 
number of days, as the initial patients were generally in fairly 
poor clinical condition. This would not be such a compelling reason 
nowadays since the aim is to transplant in remission of disease. 
TBI may have the advantage of reaching sanctuary sites of disease,
e.g. CNS or testicle, which are less efficiently treated by 
chemotherapy. The most compelling reason for adopting this approach 
in these studies was that TBI is the anti-leukaemic modality that 
has proved so effective in the allograft and in the syngeneic 
setting, and as such represents the yardstick of antileukaemic 
treatment, against which alternatives must be measured.
The conditioning protocol has three aspirations in the allograft, 
setting not all of which are required for autograft. In allograft, 
sufficient immunosuppression must take place to permit engraftment, 
there must be maximum leukaemic cell kill, and the toxicity to 
non-myeloid tissues must be minimised. In autograft only maximum 
antileukaemia effect and minimal toxicity are required but other 
factors may be operating in the allograft and not in autograft which 
affect the outcome, such as a graft-versus-leukaemia effect of 
graft-versus-host disease, as already discussed.
The use of total body irradiation is not without risk of short and 
long term effects, which may affect the patients who are expected to 
become long-term survivors. The toxicity and antileukaemic 
effectiveness are a balance, but consideration of some principles of 
radiobiology and previous experimental data may maximise benefit to 
the patient.
4.3.2.1 Dose of Radiation
Many centres have used single fraction irradiation to a total 
exposure of around 1000 cGy, but practice varies between centres, 
partly due to physical differences in facilities (Review 8). This
relatively standard approach was derived largely from the experience 
of Thomas and his co-workers in Seattle. Previously they had found 
in dogs that consistent engraftment required a minimum of 800 rads 
(800 cGy)(9110). In his initial experience in CooperstoWn, patients 
given 100-600 rads either did not engraft or engrafted poorly. In a 
later group of patients receiving 300-700 cGy graft failure was 
again the main cause of death(11). In subsequent clinical 
experience with doses in excess of 1000 cGy consistent engraftment 
was achieved(12). During this evolution they postulated that an 
interval of 2-3 days should elapse post irradiation, before the 
infusion of bone marrow, to improve engraftment - a suggestion not 
subsequently adopted by themselves or others in the light of 
consistent engraftment at the higher dose. Titration of the 
irradiation dose, therefore, eventually resulted in a widely 
accepted schedule that almost invariably ensured successful 
engraftment. Cyclophosphamide was included in this protocol because 
of its additional immunosuppressive effect, but there was some soft 
evidence, from the preliminary Seattle experience in man, that its 
introduction - following the first ten unsuccessful cases - 
resulted in a small number of long-term survivors(13). While 
Cyclophosphamide alone is sufficient to secure engraftment in a 
proportion of aplastics, it has regularly fallen short of securing 
engraftment in all patients. On its own it is unlikely to have a 
useful antileukaemic effect.
Even during the early developmental period of this traditional 
conditioning protocol it was apparent that the anti-leukaemic effect 
was dependent on its application at an appropriate stage of the 
disease. In his developmental studies Thomas reported 5 cases with
relapsed disease given between 1.4 and 2.0 Gy TBI(14). All these 
cases subsequently relapsed, so it was recognised that hopes of 
curing the leukaemia by radiation alone stood little chance of 
success at the chosen dose of 1.0 Gy. A major intention of the 
initial studies in human leukaemia was to use sufficient 
conditioning to reliably secure engraftment and rely on a 
graft-versus-leukaemia effect to eradicate residual disease. As 
previously discussed, such an approach to relapsed disease largely 
failed and the existence of a G-V-L effect in AML in remission 
remains debatable.
The priority, then, of the traditional TBI protocol devised for 
allograft was to ensure engraftment. Less information is available 
to indicate whether the anti-leukaemic effect could have been 
improved, which would be of prime importance to the autograft 
approach, which in turn would be expected to be associated with less 
non-radiation induced toxicity. Consideration of the principles of 
radiation biology, with particular attention to the effect of 
fractionation, may be one approach to improve the anti-leukaemic 
effect, while minimising non-myeloid toxicity.
4,3.2.2 Rationale of Fractionation
Reduction in tumour mass following exposure to irradiation is the 
nett result of cell kill, cell repair and repopulation. The extent 
to which a tissue (or tumour) recovers from irradiation will depend 
on the contribution from cell repair and repopulation. It is 
conceivable that even in tissues with limited ability to repair, 
sufficient repopulation may take place to restore the status quo.
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It is believed, for example, that gastrointestinal epithelial cells 
have this characteristic. The relative sensitivity of tissues to 
'radiation will in part depend on their individual characteristics of 
repair and repopulation(15,16). i
Sensitivity of a cell population is represented by the slope on a 
semi-log survival curve (Fig 4.1), the steeper the slope the more 
sensitive the tissue. This dose- response effect may not be
initially linear. At lower doses of irradiation the tissue can
recover by the mechanisms of repair or repopulation so a nshoulder” 
effect will appear on the curve initially. Thereafter, as the
fdosef increases, the curve will become linear because the
contributions from repair and repopulation become relatively less as 
a higher proportion of cells are destroyed. The dose required to 
kill 63% of the cells is designated D0 and is the measure of 
sensitivity of that particular tissue.
Figure 4.1 Cytoreductive Effect of Radiation: Tissue Sensitivity
Radiation Dose (cGy)
)0  8 0 0
0.001
AsShoulder
'o
Dq: Dose required to kill 6 3 %  of cells
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The sensitivity (D0) of individual tissues differs. In part these 
differences will be due to the size of the shoulder on the survival 
curve representing the capacity for repair and repopulation. If 
tissue A has a very narrow shoulder (limited ability to repair! or 
repopulate), then little therapeutic effect will be lost by 
fractionating the total dose (line A, Fig 4.2). On the other hand, 
if a broader shoulder is apparent, then substantial tissue recovery 
may be possible between fractions. ‘ There will be a shoulder of 
recovery following each dose with a nett survival curve similar to 
line B (Fig 4.2).
There will be little lost in fractionating the total dose for 
tissue A since between fractions there is little capacity for repair
Figure 4.2 The Effect of Fractionation of Radiation Dose on Tissues 
with the Same Sentitivity (D0 ) but Different 
Shouldering (Dq)
200
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V
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Tissues A  and B  have a similar C^but different D|q
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or repopulation. However, for tissue B with good capacity in this 
respect, there will be some tissue recovery between each fraction. 
The result will be substantial nett tissue destruction in tissue A 
but relatively little for tissue B.
Within the context of TBI applied to leukaemia the most advantageous 
circumstance would be that the radiobiological characteristics of 
leukaemic cells were similar to tissue A and that the next most 
vulnerable normal tissue had characteristics of tissue B. The need 
for bone marrow as a source of stem cells is required because normal 
bone marrow has radiobiological characteristics similar to leukaemic 
cells, so eradication of haemopoietic stem cells is hopefully 
synonymous with eradication of residual leukaemia. The other 
candidate tissues to which toxicity should be minimal are gut and
lung. Fortunately, the substantial repopulative capacity of
intestinal epithelial cells eliminates them as the radiation 
limiting tissue at presently employed doses, although some short 
term early toxicity is usual. The lung is the dose limiting tissue 
and therefore the one most likely to benefit from the postulated 
tissue sparing effects which fractionation would bring.
*1.3.3 Radiobiological Characteristics of Normal Haematological, 
Leukaemic and Lung Cells
McCulloch and Till used their mouse stem cell assay (CFU-S) to 
demonstrate that there was little difference between the radio­
biological characteristics of mouse stem cells in vitro or in vivo 
to the extent that the D0 in vitro was 105 £ 13 cGy and in vivo was
95 i 9 cGy(17). There was a significant difference in
extrapolation number (2.5 in vitro, 1.5 in vivo) but there was 
little evidence of a "shoulder” effect suggesting that 
haematological stem cells had characteristics similar to tissue A. 
Guerney(l8) I produced some evidence to suggest that erythropoietin 
responsive marrows stem in a polycythaemic mouse model system 
behaved in a similar fashion with D0 110 cGy and an extrapolation 
number of 1.2. It is therefore generally accepted that marrow stem 
cells had limited capacity of repair and repopulation and therefore 
are quite radiosensitive. Some doubt was thrown on this by the 
finding of different sensitivity in mouse (Do=160 cGy) and human 
(D0=137 cGy) myeloid committed precursor cell (CFU-GM)(19). It 
should be noted that these are now clearly recognised as a cell 
population different from multipotent stem cells. Also, in order to 
achieve a visible endpoint in the CFU-GM assay, the starting cell 
population only requires 6-8 divisions in the agar technique 
compared with 40-50 to produce a spleen colony assay (CFU-S), so a 
radiation effect in that system is more difficult to measure.
Such as is known, therefore, about the radiobiological character­
istics of normal haemopoietic and leukaemic cells (20,21,22,23,24) 
suggests (i) there is little difference between these tissues - 
implying that eradication of leukaemia equals eradication of normal 
haemopoiesis; (ii) that they are radiosensitive as judged by the 
slope of the dose response curve (D0) and the minimal shouldering 
effect (Dq) and (iii) fractionation of the radiation dose is 
unlikely to reduce the antileukaemic effect provided an "equivalent” 
fractionated dose is given. In figure 4.3, if a single fraction 
dose(A) of 1000 cGy results in a 3 log kill the equivalent 
fractionated dose is 1200 cGy(B).
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Figure $ .3 Relationship Between Tumour Cell Log Kill and Radiation 
Dose Fractionation
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4•3.3•1 Radiobiological Characteristics of Non-Haemopoietic
Tissues: Lung.
The most important dose limiting tissue for TBI is lung. The 
clinical consequences of TBI at the "standard" (1000 cGy) dose are 
well known from allograft series and have been discussed (Chapter 2) 
and it is now possible to make some general deductions which, if 
implemented, should reduce the scale of the problem seen to date in 
allogeneic transplantation.
Clearly, if pulmonary tissue had the radiobiological characteristics 
of tissue B, then there would be a compelling argument to .adopt a 
fractionated protocol of TBI, perhaps thereby permitting escalation 
of the dose of TBI to improve its anti-leukaemic effect.
There is evidence to suggest that lung tissue is similar to tissue
B. In a series of experiments on mice using an endpoint of LD
50/160, much higher total doses of irradiation could be given before 
respiratory deaths occurred, if the dose was fractionated. Up to 
175^ as much radiation could be given with as few as four 
fractions(25).
A more complex factor influencing the dose response curve is that of 
dose rate. It is generally accepted, and supported by in vitro and 
in vivo evidence, that reduction in dose rate leads to a reduction 
in Dq and an increase in D0(26,27). This implies that tissue 
sensitivity is somehow altered at lower dose rates. This effect 
could be understood better if low dose rate is regarded as multiple 
fractionation, where each micro-dose is not quite big enough to 
completely overcome the initial shoulder (Dq) and commence on 
tumour/tissue cell reduction so that the observed effect will tend 
to be that illustrated by line B (figure i|.2).
A third factor, which can be influenced by protocol design is the
total dose of radiation absorbed by the lung. The most substantial 
evidence originates from the Toronto group who have shown a direct 
relationship between absorbed lung dose and pneumonitis (28). It is 
noteworthy that there is a substantial difference in the incidence 
of pneumonitis between 800 and 1000 cGy of absorbed dose. It seems 
likely, from subsequent clinical results of TBI, that this 
relationship is considerably modified if fractionation or low dose 
rate is employed. In units where rapid dose rate has been adopted 
then 750-800 cGy does appear to be the maximum tolerable dose(29).
It is quite feasible to give larger doses and restrict the absorbed 
lung dose by shielding techniques. Such an approach requires 
considerable expertise in radiation design and appropriate technical 
resources, which may explain why it has not been more widely 
employed. Although lung shielding would also protect rib bone 
marrow, the benefits of allowing increased doses to other sites of 
residual disease are worth considering.
The radiobiological evidence clearly suggests advantages in either 
giving the TBI as a single fraction at low dose rate (<6 cGy/min) or 
as a series of fractions, in both cases with or without lung 
shielding, because of the protective effects.
3.3.2 Effect of Fractionation or Low Dose Rate on Haemopoietic 
Tissues
Because the Dq of haemopoietic tissues is, as illustrated 
previously, so small it would seem theoretically that fractionation 
was unlikely to reduce the ablative effect. Experimental evidence 
supports this contention in that no alteration of D0 was 
demonstrable in BALB/c mice when the dose rate was reduced from 274 
to *1.5 cGy/min(26). Other data suggests at reduction of 12£ at 
lower dose rates (8 cGy/min) in dose ratios when compared with 
higher dose rates (25 or i}7 cGy/min) (30). When, in addition, these 
different dose rates were fractionated, loss of effect (measured as 
LD50/30) at the higher dose rates was 21% but at the lower dose rate 
the loss was 1*1$. It therefore appears that fractionation is more 
effective at high dose rates, but has only a minor influence on a 
low dose rate protocol. Both fractionation or low dose rate can be
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shown to reduce haemopoietic cell kill by 12-21?, but this is 
relatively insignificant compared to the sparing effect of 175%» 
even with only four fractions, which can be achieved for the 
lung(25). Increased duration of the radiation treatment involving 
more fractions is a well known therapeutic strategy for other 
malignancies but are not acceptable because they will delay the 
administration of the bone marrow. Since fractionated doses of, say 
200 cGy, achieve cell kill by a "single-hit" mechanism(31), then 
dose rate is not relevant, so it is quite permissible to use rapid 
dose rate which minimise patient discomfort and consumption of 
machine time.
Fractionated or low dose rate approaches have been justifiable 
because of the sparing effects. The conventional dogma that this is 
unlikely to be detrimental to leukaemia cell or normal haemopoietic 
cell kill is not universally accepted. Conflicting evidence has 
been presented to suggest that these cells do indeed have capacity 
to repair and the D0 and Dq may differ from the values quoted 
above. Much of the data to support both points of view is derived 
from clonal assays in agar or experimental endpoints such as T50/30 
for normal haemopoietic precursors, and response curves of 
experimental leukaemia/lymphoma cell lines, all of which may be 
quite artificial. Some groups have designed radiation protocols 
incorporating these alternative views and intentionally seek to give 
single fraction high dose rate TBI, without producing substantially 
differences in clinical outcome from the more established 
approaches. It must be recognised on the one hand that the 
theoretical and experimental data may not be completely solid, and 
that, on the other hand, the major clinical endpoints in allogeneic
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transplantation, namely pneumonitis and relapse, are heavily 
influenced by other factors such as prior chemotherapy, 
immunosuppression, graft-versus-host disease and degree of HLA 
identity. i
#•3.3.3 Other Non-Haemopoietic Toxicity
While the dominant limiting toxicity has been the development of 
pneumonitis other long term toxicities such as progressive late lung 
disease, infertility, cataract formation, growth retardation and 
possibly second neoplasms have to be taken into account. While 
there is clear evidence to show a reduction in cataract formation in 
patients receiving fractionated irradiation, it is not clear the 
other effects can be modified by fractionation. Similarly, there is 
insufficient data on the long-term consequences of other 
chemotherapy based fablative* approaches, to suggest that they may 
not be associated with long-term effects.
Acute gastrointestinal toxicity is unlikely to be dose limiting for 
TBI because these cells are reputed to have substantial capacity for 
repair and repopulation giving them a substantial *shoulder* on the 
dose response curve. Nausea, vomiting and diarrhoea are to be 
expected around the time of the irradiation, and it would seem 
likely that fractionation of TBI would have an important 
gastrointestinal sparing effect with reduced toxicity. This benefit 
may translate into reduced or minimal irradiation interruption, 
commonly seen with single fraction treatment.
1| • 3• 4 The Role of Cyclophosphamide
In conventional doses, Cyclophosphamide would not be regarded as an 
effective single agent in acute myeloid leukaemia. Its more recent 
use in high dose (up to 1 i|G) for solid tumours is not ablative to 
haemopoietic tissue(32). Some evidence will be produced later to 
indicate that haematological recovery after such doses is not 
influenced by infusion of autologous bone marrow. In the 
developmental period, Thomas transplanted 10 patients using TBI 
alone with resulting high relapse rates, but reports that the 
introduction of two cyclophosphamide 60 mgs/kg doses before the 
irradiation resulted in a "striking" decrease in the rate of 
recurrence(13). There may be an, as yet, undefined synergy between 
Cyclophosphamide and TBI, or it may equally well be that alternative 
chemotherapeutic agents could be substituted for cyclophosphamide. 
At the initiation of these clinical studies it was felt important to 
adopt the standard conditioning treatment employed for allogeneic 
transplantation on the grounds that (a) the toxicity and 
side-effects were generally known, (b) the anti-leukaemic record was 
well known and impressive, and (c) these studies would provide 
useful baseline information to compare autologous and allogeneic 
transplantation in terms of toxicity and anti-leukaemic effect and 
thereby dissect important elements in the mechanisms whereby 
allograft cures AML,such as a graft-versus-leukaemia effect.
4.3.4.1 Modification of the Urotoxicity of Cyclophosphamide
At increased dosage, Cyclophosphamide causes haemorrhagic cystitis 
which can be severe. This effect is mediated by a metabolite,
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isophosphamide, excreted in urine and can be ameliorated by 
hydration of the patient and intensive bladder irrigation. As an 
alternative or additional preventative measure 2-mercaptoethanol 
sulphonate-sodium (mesnum) can be given immediately before dnd for 
several hours after the cyclophosphamide. This effectively binds 
the metabolite and prevents urotoxicity(33). There is no evidence 
to suggest that the cytotoxic effect of Cyclophosphamide will be 
compromised but it has recently been pointed out that it might 
confer a radiosensitising effect(34) and should be discontinued 
before the commencement of the TBI. This effect has been disputed, 
but in our practice a discrete time interval of at least 12-18 hours 
always occurred between the discontinuation of mesnum and TBI.
4.4 SUMMARY OF CYTOREDUCTIVE PROTOCOL
In devising this approach, several factors have been taken into 
account based on relevant data available until 1981. The deductions 
made will be evaluated later in the light of the results and the 
international data which has emerged in the intervening period. The 
protocol is outlined in Table 4.1, but the important factors can be 
summarised.
(i) Optimum results of autograft are going to be achieved in first 
remission of disease.
(ii) Autograft in second remission or relapse would be associated 
with a high rate of recurrent disease.
(iii) The cytoreductive approach will be Cyclophosphamide and Total 
Body Irradiation rather than a high dose chemotherapy because 
of its known record in terms of toxicity and antileukaemic 
effect.
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(iv) Total Body Irradiation would be given initially as a single 
fraction 950 cGy at low dose rate 5 .5 cGy/min with posterior 
lung shielding to limit the lung dose to 800 cGy [Designated 
Protocol A], A Cobalt 60 source would be used.
(v) In 1984, for reasons to be discussed later, the cytoreductive 
protocol was modified. Melphalan was substituted for the 
Cyclophosphamide at a dose of 110 mgs/m2 given intravenously 
on the day before irradiation. TBI would be fractionated over 
3 days comprising six 200 cGy fractions from the Cobalt 60 
source given at least 6- hours apart. The lung dose was 
limited to 1100 cGy by posterior lung shielding [Designated 
Protocol B].
(Vi) Based on data to be presented in Chapter 5, the autologous
bone marrow would be stored in liquid phase at 4°C for 54 
hours for the single fraction TBI approach, but would be 
cryopreserved for patients receiving fractionated TBI.
(vii) In the light of the cytoreductive arguments made in Chapter 3, 
and in the absence of available techniques, no effort was made 
to manipulate the marrow ex-vivo to remove possible 
contamination with residual leukaemia.
Table 4.1 Outline Protocols for Autologous Bone Marrow
Transplantation
Eligible Patients: Acute Myeloid Leukaemia in first complete
remission aged 55 years or less
Manipulation of Bone Marrow Ex Vivo: Unpurged Marrow
Ablative Protocol:
Protocol A:
- Bone Marrow Harvest under general anaesthetic.
(time 0 hrs)
- Cyclophosphamide 60 mgs/kg I.V. at +2 and +26 hours 
with Mesnum cover 3-hourly and an hydration regimen
- Total Body Irradiation to a midline dose of 1000 cGy, 
with posterior lung shielding to 800 cGy, given as a 
single fraction at 5.5 cGy/min from a Cobalt 60 Source 
(Mobaltron MS 80). Radiotherapy commenced at +4H 
hours, completed at +52 hours.
- Bone Marrow stored as bulk marrow at 4°C, and 
re-infused at 54 hours.
Protocol B:
- Bone marrow harvest about l|-6 weeks pre-autograft
- Melphalan 110 mgs/m2 I.V. with an hydration regimen 
given day -4
- Total Body Irradiation fractionated to 6 x 200 cGy 
over 3 days (days -2,-1 and 0) at a dost rate of 16 
cGy/min, with posterior lung shielding to a total of 
1100 cGy, from a Cobalt 60 source (Mobaltron MS 80)
- Bone Marrow Cryopreserved as a Mononuclear Cell 
Fraction (MNC) given 3 hours after completion of 
radiotherapy
4.5 INFECTION CONTROL
The proposed cytoreductive protocol will predictably result in 
severe immunosuppression. All patients are likely to be severely 
neutropenic for three or four weeks, when they will be highly 
vulnerable to bacterial and fungal infections. Allogeneic 
transplant experience is associated with slow recovery of humoral 
and cellular mechanisms of the immune response resulting in a 
continued susceptibility to viral and protozoal infection for 
several weeks or months(35,36), with a very characteristic pattern 
of infective organisms, e.g. herpes I infections early, followed by 
Cytomegalovirus and later by Herpes Zoster. My studies are in part 
intended to define whether the infective problems of autologous 
transplantation are as great as those of the allografted patient who 
has, in addition, the potential for protracted immune-paresis due to 
graft-versus-host disease.
The problems of the neutropenic patient have become better 
understood in the last fifteen years. Severity and duration of 
neutropenia are well known to correlate with infection(37). Since 
most neutropenia is associated with chemotherapy, there is probably 
a major contribution to the risk contributed by the associated 
tissue damage and breakdown of muco-cutaneous barriers.
A major element in the rationale for undertaking autologous 
transplantation is the argument that this would be a safe procedure, 
and other than optimum provision for infection control could 
contribute to procedural morbidity and mortality. It was therefore 
decided that these patients justified extensive measures towards 
infection control.
4.5.1 Protected Environment
It has long been recognised that about half the infective organisms 
isolated from neutropenic patients are from exogenous sources(38).
All patients were nursed in laminar air flow(LAF), either in a LAF 
bed (Microflow Ltd) or, more recently, in an LAF Room (Microflow 
Dent and Hellier Ltd) which filters air to a 99.97$ efficiency of 
removal of particles of 0.3 pm, with laminar flow being maintained 
by an airspeed of 30-90 feet/min. Such conditions have been shown 
to reduce potential pathogens to near zero(39). To maintain such 
conditions, all items entering the patients1 environment require to 
be sterilised. Dry materials, e.g dry foods, books, newspapers etc, 
were double wrapped and irradiated. Sterilisation of food is not 
practical but food such as cheeses and fresh fruit or salads were 
avoided. Tinned food, which was extensively used, was opened, 
dispensed and portioned in a laminar flow cabinet and, either 
thoroughly cooked or double-wrapped and microwaved before giving to 
the patient.
4.5.2 Oral Non-Absorbable Antibiotics
Since the gastro-intestinal tract is an important source of 
potential pathogens in the neutropenic patients(38), it seems 
illogical to take extensive environmental measures without also 
considering suppression of gut flora. Reduction of infection rates 
with protected environment has been shown(40) but not universally. 
Even the introduction of gut decontamination alone has been found to 
be beneficial(41), although this also is not universal(42). Many
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studies of these approaches involve small numbers, but it appears 
that gut decontamination and protected environment together is more 
beneficial than either alone(43,44), despite the fact that 
compliance is al problem.
The profound and protracted neutropenia observed in BMT patients has 
been associated with twice the incidence of autopsy proven fungal 
infection(36). In addition, suppression of the bacterial flora of 
the gut will increase the susceptibility to fungal colonisation, so 
fungal prophylaxis was considered an essential component. 
Initially, the patients received oral Nystatin as well as Nystatin 
lozenges to deal with the oro-pharynx but, since the demonstration 
of the imidazole,(ketoconazole), as an effect agent at high dose 
(400 mgs) (45) this was added to the regimen.
4.5.3 Prevention of Viral Infection
Patients who are seropositive to Herpes Simplex virus (HSVI) are 
highly likely to reactivate infection in oropharynx within the first 
three weeks post-transplant. Acyclovir has been shown to be 
effective in dealing with such infections(46,47) and its 
prophylactic use effective in prevention(48). Such infections are 
seldom life threatening and it was not clear to what extent 
reactivation would occur, or cause symptoms in the autograft 
population.
Patient discomfort is usually the main problem associated with HSVI 
infection, but, in one of the studies of prophylaxis, there was a 
reduction in febrile days suggesting that curtailment or prevention
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of damage to the oropharynx can prevent entry of pathogenic
bacteria. It was also shown that the patient group receiving
Acyclovir had reduced durations of neutropenia, suggesting that 
these apparently local infections may be myelosuppressive. Despite 
that, it was decided that the prophylactic use of Acyclovir was not 
cost-effective, when the extent of the problem in the autograft
patients was not known.
Cytomegalovirus pneumonitis has been predicted to be much less of a 
problem in the autograft patients than it has been in allograft
patients(iJ9) • Viral reactivation cannot be avoided, but transfer .of 
infection via blood products to seronegative recipients by the 
selection of seronegative donors is theoretically possible, but will 
be discussed in more detail below in relation to blood product 
policy.
11.5.2! Nursing Care
All protective measures are futile in the absence of impeccable 
nursing care and familiarity with the problems of neutropenic 
patients. In particular, nursing attention to mouth care and skin 
sepsis can be crucial. Most patients, in addition, have an 
indwelling catheter which is a potential source of sepsis which 
requires meticulous aseptic care during the neutropenic period. The 
approach to venous access and minimising catheter related sepsis is 
discussed below.
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*1.5.5 Bacterial and Viral Surveillance
The preventative measures just enumerated will fail to prevent the 
development of pyrexia (infection) in many patients. Significant 
pyrexial incidents cannot await microbiological results and require 
empirical antibiotic treatment. Similarly, relevant infections, 
particularly viral excretion, may occur without symptoms or 
pyrexia. Clinical decisions may be aided by information collected 
by limited bacterial and viral surveillance cultures. Such measures 
are standard practice in all our leukaemia and transplant patients, 
and are shown in Table *1.2.
Table *1.2 Routine Surveillance Cultures.
Bacteriology Virology
a) Screening:
Monday Throat Swab 
MSSU
Throat Swab 
MSSU
Thursday Throat Swab 
MSSU
Weekly Faeces 
Hickman Site
Faeces
b) On Development of Pyrexia:
C-reactive protein Buffycoat (CMV)
Hickman Blood 
Venous Blood 
MSSU
Morning Urine
Infected Site
4.5.6 Empirical Treatment of Infection
Significant pyrexias (i.e. temperatures greater than 39°C on one 
reading, or 38.5°C on two occasions two hours apart), require the 
introduction of broad spectrum intravenous antibiotics in the 
neutropenic patient (neutrophils <1 x 10^/1). The aim is to provide 
a spectrum of activity to cover all likely infective agents. The 
particular choice of agents may depend on local circumstances, such 
as the prevalence of pseudomonas within the ward etc. During the 
period under consideration, 1981-1987, our unit has remained largely 
free of endemic infective organisms such as pseudomonas, and, while 
the antibiotics have changed, the overall policy is unaltered. It 
has, throughout, been the policy to treat febrile episodes in the 
neutropenic patients with a combination of an aminoglycoside 
(Gentamicin, Tobramicin, Netilmicin or Amikacin) and a 
uridopenicillin (Ticarallin, Mezlocillin or Pipercillin). Where 
there is obvious evidence of catheter sepsis, Vancomycin may be used 
initially, but this is usually reserved for the patients who have 
not shown a clinical response or temperature reduction within 48 
hours, or where positive blood cultures have become available. 
Where surveillance samples (i.e. throat and faeces) indicate fungal 
colonisation, intravenous Amphotericin may be introduced at 48 hours 
in unresponsive patients. In the occasional patient whose pyrexia 
persists beyond the introduction of Vancomycin at 48 hours, the 
empirical use of Amphotericin at 96 hours is initiated. Antibiotics 
are usually continued for 5-7 apyrexial days. When a clinically 
significant pyrexia develops, cultures are taken to provide 
additional information to the surveillance cultures (Table 4.2)-.
4.5.7 Summary of Infection Control Measures
The prophylactic measures taken to prevent infection in these 
patients is summarised in Table 4.3. Special studies were made of 
the relevance of giving Vancomycin prophylactically at the time of 
venous catheter insertion and the provision of cytomegalovirus 
negative blood products.
Table 4.3 Infection Control for Neutropenia (<1 x 1()9/1)
1) Reverse Barrier Nursing/Aseptic Technique.
2) Laminar Flow.
3) Oral Non-Absorbable Antibiotics
Framycetin 500 mgs qid 
Colistin 1.5 mega units qid
4) Fungal Prophylaxis
Nystatin 1.5 mega units qid 
or
Ketoconazole 400 mgs 
and
Nystatin Mouth Irrigation 1.5 mega units qid
5) Sterile Food
6) Anti-Protozoal Prophylaxis
Cotrimoxazole 1 tab x 3/week 
from 3-4 weeks post-graft
An equally important component in infection control is the response 
made to pyrexia in the neutropenic patients. the broad principles 
have been discussed and the actual policy is summarised in 
Table 4.4.
Table l}.l| Response to Pyrexia during Neutropenia
Pyrexia of >39°C on one occasion or >38®C 
for 2 hours with <1 x 109 neutrophils
Bacteriology + Virology 
Samplesi
Intravenous Antibiotics 
Aminoglycoside 
+
Uridopenicillin
/
No response at 
48 hours
\
Add Vancomycin 
or Amphotericin
/ \
No response at Response — ►  Stop after 5-7 apyrexial
96 hours daysj
Add Amphotericin
4.6 VENOUS ACCESS
Ready venous access is required for patient monitoring and the 
administration of drugs, fluids, intravenous nutrition and blood 
products. This was achieved by the surgical insertion, usually 
under local anaesthetic, of a right atrial (Hickman) catheter.* More 
recently, double lumen catheters were used(50). The line is
\
Response
i
IcJb
tunnelled subcutaneously from the anterior chest wall, and 
introduced via a neck incision to the external jugular and adjusted 
such that the tip is in the atrium. To minimise line infection, a 
cuff - which is an integral part of the line - is positioned just 
under the skin insertion point with the expectation that it will 
fhealf into the subcutaneous tissues and present a barrier to
ascending infection. To minimise the possibility of introducing 
infection with the catheter, the upper chest was prepared with two 
or three applications in the previous 2*1 hours of povidine iodine in 
alcohol (Betadine). More recent patients have been given 
intravenous Vancomycin around the time of catheter insertion, to
reduce catheter sepsis. The result of this approach will be
discussed. When not in use, the central line is kept patent by
heparinised saline, which is flushed through every 48 hours.
4.7 BLOOD PRODUCT POLICY
Blood products, including coagulation factors, will be given to 
these patients as indicated in normal practice, but three special 
provisions were made:
(i) all cellular products would be irradiated. In the optimally 
prepared patients, it is possible to achieve transient engraftment, 
which, since the donors are random, could initiate an important 
graft-versus-host reaction. At the time of bone marrow harvest it 
is usual to remove 700-900 mis of marrow blood, and to replace this 
with community donor blood. These blood donations should be 
irradiated, also since if given during the harvest procedure itself 
may find the way into the autograft itself and therefore iqto the 
patient. Blood product irradiation was achieved with an irradiation
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dose of 2500 cGy in a treatment machine, or latterly in a cell 
irradiator at ward level (Gammacell 2000).
(ii) Platelets would be given prophylactically daily when the 
patientfs peripheral count was <20 x 1()9/1. Random community donor 
platelets would be used routinely, one donation comprising the 
platelet rich fraction from five or six donors. If - in the 
presence of a haemorrhagic problem - a platelet increment could not 
be achieved, or the patient exhibited a significant allergic 
reaction, single donor donations would be given from donors matched 
at the HLA A and B locus.
(iii) CMV Negative Blood Products. Approximately a quarter of all 
cases undergoing allogeneic bone marrow transplantation (BMT) 
develop pneumonitis. In approximately half of these cases, 
cytomegalovirus is the implicated cause (51,52) but is so seldom 
responsive to treatment (53,54), that current hopes of reducing this 
complication depend on strategies of prevention. Graft-versus-host 
disease is an important risk factor (55) and its more effective 
prevention may also reduce the incidence of CMV pneumonitis, in 
allografted patients, and its complete avoidance should reduce this 
risk in the autografted patients.
Infection with CMV in these immunosuppressed patients may arise by
(a) reactivation of latent virus in the host who can be identified 
as seropositive on pretransplant examination; (b) transmission of 
virus through blood products from community donors, or (c) in the 
bone marrow donation itself. It would seem logical for patients who 
have not previously been exposed to the virus (i.e. seronegative) to 
receive blood products which were least likely to represent a risk 
of transferring the virus (i.e. seronegative donors). Transfusion-
acquired cytomegalovirus infections in newborn infants can be 
prevented by exclusive use of seronegative blood donors(56).
Since 1983, the transplant recipients in Glasgow - with the 
invaluable help of the West of Scotland Blood Transfusion Service - 
were among the first to receive, where appropriate, exclusively CMV 
Negative blood products as a routine part of their supportive care.
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CHAPTER 5
PROCUREMENT PREPARATION and STORAGE of HAEMOPOIETIC
STEM CELLS
146
5.1 INTRODUCTION
Based on the arguments set out previously it is clear that the 
cytoreductive protocol is intended to be ablative to the recipient's 
bone marrow and satisfactory conditions for procurement, 
manipulation and storage of the autologous bone marrow are a major 
requirement of this chosen investigative approach to therapy. A 
number of considerations in this respect have been considered:
(a) the relevance of the proposition that the bone marrow may 
contain residual clonogenic leukaemic cells has already been 
discussed in Chapter 3.
(b) can bone marrow, which has been subjected to prior chemotherapy, 
adequately repopulate the host and will it be possible to obtain 
adequate amounts of marrow to make a viable graft?
(c) does the technique of removal of bone marrow under general 
anaesthetic represent any hazard to the patient?
(d) what would be the most suitable way to prepare bone marrow for 
storage?
(e) what conditions of storage are required to ensure viability of 
the marrow?
(f) what techniques can be used in vitro to assess viability of bone 
marrow and therefore monitor manipulation and storage?
5.2 HISTORICAL NOTE
The origin of bone marrow transplantation lies in the experiments of 
Leon Jacobson at The University of Chicago. His major interest was 
the physiology of erythropoiesis but in 19*19 he demonstrated that 
shielding of the spleen in mice, which had received irradiation in a
dose lethal to the bone marrow, restored haemopoietic function( 1). 
The initial interpretation of this observation was that the spleen 
produced a humoral "protective factor". Two years later Jacobson 
showed that splenic intraperitoneal implants or the intravenous 
infusion of bone marrow were also protective(2). It had become 
clear that the protective effect was mediated not by a humoral, but 
by a cellular mechanism(3). It is, however, of interest that the 
more recent studies of Millar(*J), where he has been able to protect 
mice against fatal aplasia by the prior administration of a small 
dose of a cytotoxic agent, suggest that other mechanisms of possibly 
humoral protection, may indeed play a role.
Nevertheless, the experiments of the early 1950s clarified that it 
was possible with the transfer cellular elements to restore 
long-term bone marrow function, thus laying the foundations of 
modern clinical bone marrow transplantation. The current concept 
that haemopoiesis originates from a pluripotent stem cell pool with 
the unique ability of self-renewal evolved from these observations 
and is fundamental to what is currently understood to be happening 
during successful transplantation of bone marrow in man.
5.3 PHYSIOLOGY OF HAEMOPOIESIS: RELEVANCE TO MARROW TRANSPLANTATION
It has progressively become clear in recent years that haemopoiesis 
is organised in an hierarchical manner(5,6) outlined in Figure 5.1. 
There is no direct evidence in man of the existence of a pluripotent 
stem cell which can, under suitable environmental conditions, 
differentiate into compartments of clonogenic stem cells "committed" 
to a particular cell lineage. The pluripotent stem cell has the
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Figure 5.1 Physiology of Haemopoiesis
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further crucial characteristic of being able to reproduce itself. 
Committed stem cells have limited ability of self-renewal and are 
assumed not to be able to divert to another lineage. The evidence 
for this concept of j cellular organisation has evolved from an 
amalgam of observations in rodents and pathological states in man.
Multi-potency is suggested by the presence of cells of the different 
lineages within the spleen nodules of mice which have received 
intravenous bone marrow following ablative irradiation. These cells 
are assumed to originate from an injected stem cell - the so called 
CFU-S(6) (Colony Forming Unit - Spleen). No techniques exist to 
demonstrate an equivalent cell in man but pathological states in 
humans, most notably chronic myeloid leukaemia, serve as indirect 
evidence that all cell lineages are descended from a single cell. 
The demonstration of the marker Philadelphia Chromosome in all 
haematological cell lines in this condition strongly suggests a 
common ancestral cell. Extensive analysis of human haematological 
malignancies in recent years with monoclonal antibodies directed 
against antigens thought to be lineage specific, have been extremely 
useful in the classification of disease. As this experience has 
grown so has it become increasingly apparent that some 
haematological malignancies believed to be clonal are capable of 
phenotypic expression of more than one lineage(7 ). This so-called 
"lineage-infidelity" could be interpreted to be inconsistent with 
the stem cell organisation just described but these observations 
could be interpreted as further evidence of common ancestry, the 
malignant cells manifesting disordered expression of antigens which 
in normal circumstances are useful markers of lineage.
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While a cell equivalent to CFU-S can be assumed to be the important 
cell in human transplantation it cannot be measured by current 
technology in humans. No suitable unique marker antigens are
expressed to permit its recognition or positive or negative
isolation by monoclonal antibody techniques. The ability to
recognise the pluripotent stem cell in humans would have a major
importance in clinical bone marrow transplantation, for example,
permitting development of techniques which either positively select 
for stem cells or aim to eliminate unwanted cells such as 
immunocompetent allogeneic cells or residual malignant cells, the 
relevance of which will be discussed later. Techniques for 
recognition of the "committed" stem cells (Colony Forming Units) for 
most cell lineages are available in man and can be used in 
transplantation work to reflect the presence of the CFU-S. While 
such assays are useful they act as a guide only.
In humans, as will be described in more detail elsewhere, in vitro 
treatment of bone marrow which eliminates Committed1 colony forming 
units [CFU-GM, BFU-E and CFU-Mix], even in ablated patients, does 
not prevent haematological reconstitution. Similarly, the
relationship between the numbers of committed colonies reinfused 
into patients and kinetics of haematological recovery is equivocal.
Techniques of long-term culture of human marrow have recently become 
available, may be more representative of the multipotent stem 
cell(8).
5.4 PROCUREMENT of STEM CELLS
For practical purposes stem cells are most readily obtained from 
bone marrow. Foetal liver cells - and as has more recently been 
recognised - peripheral blood stem cells are also sources, the 
potential of which has not yet been fully evaluated. The 
repopulative stem cells only constitute a small fraction of all bone 
marrow cells and their relative preponderance may vary between 
individuals. The minimum number of cells required to ensure 
sustained engraftment in man is not known precisely. Animal model 
systems indicate that progressively increased numbers of nucleated 
marrow cells are required for autograft, HLA matched allograft and 
non-identical grafts. In humans the likelihood of rejection in 
previously transfused severe aplastic anaemia patients was reduced 
if the nucleated cell dose was in excess of 3 x 10® cells per kg of 
recipient weight(9). But this disease setting represents a special 
circumstance. Firstly the pathogenesis of the disease itself may be 
hostile to engraftment. Secondly, these patients receive less 
immunosuppression (no irradiation) than leukaemic patients who have 
a very low incidence of rejection. Even in transfused aplastics 
engraftment can be consistently achieved if conditioning protocols 
incorporate irradiation, and cell dose given becomes less crucial.
The cell dose required for autograft in man is not known, although 
in our studies an arbitrary target of 1 x 10® nucleated cells/kg 
body weight was set. Some workers, in addition, express the cell 
dose as a result of the number of cells harvested less the number of 
nucleated cells in an equivalent volume of patientfs peripheral
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blood per kilogram. Where the recipient is particularly obese it is 
usual to calculate the ideal body mass.
Correlation between the kinetics of regeneration and the number of 
committed stem cell precursors infused has been demonstrated by 
some(10), but this has not been the general experience. This 
relationship has little practical relevance in allografts since the 
assay result is not available for several days, but its relevance to 
regeneration will be in the context of marrow manipulation which 
will be discussed further later.
5.4.1 Collection of Bone Marrow Stem Cells
Thomas has described the Seattle technique of harvesting bone 
marrow(11), during which the patient may be offered the option of 
regional (spinal) or general anaesthesia(12). I have made local 
modifications to his original methods.
In all but one case in a consecutive series of in excess of 230 
harvests we have used a general anaesthetic, thus leaving the 
option of using the sternum if required. In practice, sufficient 
marrow is almost always obtained from the posterior iliac crests, 
with the anaesthetised patient in the prone position during the 
entire procedure which lasts 30-50 mins. Modified trephine needles 
are used (Figure 5.2) which allow deep penetration and aspiration at 
several levels. The needle is rotated at each level through 90° 
between aspirations at each level. It is probably most effective to 
limit the volume of each aspirate to 5 mis to prevent significant 
contamination with peripheral blood nucleated cells. The volume
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obtained is noted and the marrow is then injected into a sterile 
bag(500 mis) which contains 70 mis of CPD (Citrate Phosphate 
Dextrose)[Tuta], without sieving of bone spicules. The bag is 
regularly kneaded to prevent clotting. The syringe is then flushed 
through with heparinised tissue culture medium [TC199» Flow 
Laboratories, containing 100u preservative free heparin per 100 ml] 
and re-used. Heparinisation of the donor, as routinely done in some 
units, is not necessary. A nucleated cell count is made on an
aliquot from the bag in theatre such that the required volume is 
obtained to ensure an adequate dose. [2-3 x 10® cells/kg for 
allogeneic grafts and 1 x 10®/kg for autologous grafts]. As has 
been stated, these doses are arbitrary and are probably in excess of 
what is required. However, in the autologous marrow, allowance 
should be made for some loss during storage.
The donor may receive one unit of irradiated packed red cells after 
the harvest, which is usually less than the volume removed. If the 
harvest has been difficult necessitating removal of large volumes 
(>1000 mis) or the donor is anaemic a larger volume is considered.
For normal donors, there is therefore the small potential risk of
transfusion related complications which could be avoided by 
autotransfusion, but this has not been our practice. The blood 
given to the donor is routinely irradiated to eliminate the
possibility of viable non-HLA matched stem cells from the blood 
donor reaching the harvested donation. This policy holds, even if 
the transfusion is withheld, till after the harvest since a 
reharvest of the donor may be planned or occasionally necessary, 
should an allograft fail to engraft.
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5.4.2 Consequences for the Marrow Donor
In my experience of 230 harvest procedures no sequelae to the 
detriment of!the donor has occurred. The patients are admitted the 
day prior to the harvest, subjected to a full medical examination 
including full blood count, ECG and chest x-ray. They leave 
hospital the morning after the procedure (less than 24 hours later), 
sometimes with some local tenderness, easily controlled with mild 
analgesia. No patient has developed wound site infection or 
thrombosis at sites of venous access. We are therefore confident of 
the safety of the procedure.
In a review of the complications of bone marrow harvests from the 
International Bone Marrow Transplant Registry, Bortin and 
Buckner(13) reported on 3290 donors. In less than 0.5$ the site was 
painful for more than 7 days. Nine potentially life-threatening 
incidents occurred (0 .27$) although no deaths or lasting sequelae 
were reported.
5.4.3 Peripheral Blood Stem Cells
The theoretical possibility exists that peripheral blood may be a 
source of haematological stem cells. At present there appears to be 
limited incentive to pursue such an option but potential advantages 
would be the avoidance of a general anaesthetic, which may be 
desirable in particular patients, or in the context of unrelated 
donors in whom there could be a reluctance to submit to a general 
anaesthetic. There may be the additional potential benefit of 
avoiding residual clonogenic tumour (leukaemia) cells which may be 
present in bone marrow.
Committed stem cells (CFU-C) have been demonstrated in peripheral 
blood in rodents(14,15), dogs(l6) and man(17,l8), but justifiable 
concern exists that the presence of these committed stem cells may 
not indicate the availability of pluripotent stem cells. There is 
some indication that these CFU-Cs are qualitatively different from 
bone marrow CFU-Cs in terms, for example, of density, and 
susceptibility to lysis with la and complement (19,20,21,22,23,24).
Ontogenically, BFU-E or the CFU-GEMM may be a better indicator of 
the presence of a pluripotent stem cell. Although these have been 
demonstrated in the peripheral blood in man, observation of similar 
cell types in rodents indicate differences between these cells and 
the measurable CFU-S.
Experimental systems have clearly indicated, however, from para­
biosis experiments that peripheral blood cells can reconstitute in 
vivo following ablative therapy. Goodman(15) demonstrated 
repopulation of irradiated D2 mice with peripheral blood cells from 
B6D2F strain. Malinin(25) demonstrated similar effectiveness in 
guinea-pigs while Storb demonstrated the effect in dogs(26). Storb 
was able to rescue larger mammals (baboons) by cross circulation 
experiments(27). The numbers of cells which would have to be given 
is generally assumed to be related to recipient body weight, so 
StorbTs demonstration of effectiveness in baboons(27), and the 
general use of leucopheresis with continuous cell separators 
indicate that such an approach for stem cell procurement is feasible 
in man.
The effectiveness of such techniques with appropriate cryo-
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preservation has been adequately demonstrated in vitro or in animal 
models in vivo(28,29,30,31,32,33).
Expansion jof the circulating stem cell pool before cytopheresis 
would be advantageous. Exercise^), hydrocortisone(35), ACTH(3i|), 
Endotoxin(36) and even leucopheresis have this effect. Polyvinyl- 
pyrolidone is effective but, till recently, has been associated with 
significant allergic responses. Hydroxyethyl starch which is 
effective would perhaps be more acceptable to patients(2 8 ). 
Richman(37) demonstrated a substantial rise ( x 10) following 
chemotherapy - this expansion being temporary but predictable 
following the neutrophil nadir. She calculated that a total of 17 
leucophereses could obtain a similar number of CFO-Cs obtained in an 
acceptable bone marrow harvest, but a similar number in unstimulated 
patients would require pheresis of HH2 litres. Abrams(38) confirmed 
that a considerable augmentation (x 8) of stem cells occurred 
following chemotherapy.
The major clinical experience of autografting with peripheral blood 
mononuclear cells is that of Goldman(39, *10) and subsequently 
Korbling(lJ1) in Chronic Myeloid Leukaemia. In this disease patients 
at diagnosis have a large number of CFD-GMs circulating as part of 
the very high presenting white count. It is not difficult to 
procure large numbers of these cells in one or two cytopheresis 
sessions. These have been cryopreserved and used to reconstitute 
patients following ablative treatment at a later stage of the 
disease. This experience, although of limited therapeutic value, 
provides the initial evidence in man to support peripheral, blood 
stem cell use. However, CML may be a special case. Being a stem
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cell disease it is conceivable that pluripotent stem cells may 
circulate as part of the proliferative process and extrapolations 
based on the presence of large numbers of CFU-GMs obtainable may not 
be justified in the normal state. It is not anticipated that 
cytopheresis of non-CML patients would be able to obtain equivalent 
numbers of CFU-GMs.
Experience of procuring stem cells from peripheral blood in 
conditions other than CML in humans is preliminary, but the early 
experience was not encouraging. Hershko(i}2) attempted 
haematological reconstitution of a patient with the aplastic phase 
of Paroxysmal Nocturnal Haemoglobinuria with peripheral blood 
mononuclear cells from a syngeneic donor. Donations were given over 
several days and the recipient was not conditioned. Engraftment was 
not achieved, but the patient was subsequently successfully 
reconstituted by syngeneic bone marrow. Abrams(il3) was similarly 
unsuccessful with a patient with Ewings sarcoma but accelerated 
lymphoid recovery was noted. In both cases there were reasons for 
failure, although both appeared to be given doses of CFU-GM 
equivalent to an fadequate1 marrow dose. This experience again 
suggests caution in equating CFU-C number with repopulating ability.
More recent experience of RieffesCM) in France and Juttner(45) in 
Australia is more optimistic with demonstration of prompt 
reconstitution in leukaemic patients receiving ablative treatment. 
This has stimulated new interest in this approach since some have 
speculated that this source of stem cells may be free of clonogenic 
leukaemic (or tumour) cells, a controversial proposition for. which 
little evidence exists. As will be argued later, the need for any
form of cleansing of marrow is at present debatable. It is probably 
a more practicable proposition to continue to use bone marrow for 
logistic reasons.
I
Peripheral blood cells in the form of buffycoat have been 
successfully employed to overcome the problems of allograft 
rejection in severe aplastic anaemia(46). In multiply transfused 
patients rejection of the graft has been historically a major 
problem. Additional immunosuppression in the conditioning protocol 
(with irradiation, cytotoxic agents or cyclosporin) has now reduced 
this problem, but in Seattle the use of donor buffycoat as the only 
addition to the protocol substantially reduced rejection rates, but 
the mechanism is unclear. It may be too simplistic to assume the 
effect is due simply to additional stem cells. Although marrow cell 
dose is a risk factor for rejection in this context, it seems the 
number provided from buffycoat would be rather small compared with 
those from bone marrow. T cells can be demonstrated in vitro to 
provide haemopoietic growth factors(47»48) but the role of T cells 
in engraftment will be discussed in a later section in relation to 
T cell depletion. While T cells may be the important cellular 
contributor to the augmentation of engraftment in sensitised 
patients, the effect may be related to an immunosuppressive action 
of these cells which has been demonstrated in rodent models(49).
In Juttner's initial two patients some encouraging evidence of 
marrow recovery was obtained(45). The first patient received 
Melphalan 200 mg/m2, which however is probably not ablative, and 
neutrophil recovered to 780 x 10^/1 by day 14. The second case 
received ablation with TBI. Neither patient substantially increased
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their neutrophil count further or achieved a normal platelet count 
but this may have been related to the occurrence of relapse at 3 and 
12 weeks respectively. Neither case convincingly demonstrates 
capacity for sustained engraftment. The neutrophil peak may reflect 
CFU-GM only and not be indicative of CFU-S equivalent population.
Bell and colleagues(50) report full haemopoietic regeneration in a 
lymphoma patient receiving intensive high dose (but arguably not 
ablative) chemotherapy protocol fBEAMf* which was sustained for 12 
weeks at the time of the report.
Reiffers recently reported surprisingly prompt regeneration in two 
of three leukaemic patients who received ablation including TBI. 
One patient subsequently relapsed as did the patient who failed to 
regenerate. The neutrophil rise reported is earlier than seen in 
leukaemic marrow autografts but that may simply reflect the higher 
CFU-GM numbers given which would be expected to contribute an early 
neutrophil increment. There can be little doubt that the sustained 
counts in these patients must have originated from the graft.
These anecdotal reports offer some encouragement to those who 
believe that advantage can be gained from the use of peripheral 
blood cells, but little is known about longevity of haemopoiesis. 
The sequential leucophereses required are time consuming and 
expensive and arguably no safer for the donor (a small number of 
fatalities are recorded in patients undergoing pheresis). Whether 
peripheral blood stem cells may be less liable to contamination with 
leukaemic cells even during remission seems doubtful. I t . is of 
interest to note a recent report of detectable leukaemia cells
* BEAM Protocol:- BCNU 300 mg/m2 day 1
VP-16 200 mg/m2 days 3-5
Cytosine Arabinsode 100 mg/m2 12-hrly days 3-5 
Melphalan 140 mg/m2 day 7
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present in the peripheral blood during remission(51). The
justification for, and necessity to attempt to remove residual 
' leukaemic cells from marrow as a pre-requisite for successful 
autograft will be discussed later. Peripheral blood is perhaps the 
only source of stem cells in patients where there is obvious marrow 
infiltration, but in such circumstances, the procedure is likely to 
fail due to inability to eradicate this disease from the patient.
5.5 PROCESSING OF BONE MARROW
The harvested marrow requires little further preparation if it is 
being given to the recipient (allograft) within a few hours. It is 
prepared in a laminar flow cabinet, as a single pack donation by 
transfer, by a sealed technique, to a litre dry pack which is then 
heat sealed. Excess fat can be removed prior to transfer by 
allowing the bag to stand at room temperature till the fat layer 
forms. This can be transferred to a waste pack as part of the
transfer process. Two or three mis of residual marrow suspension
are retained for cell count and bacteriological culture. We have
experienced no significant bacterial contamination. The marrow is 
given through a blood giving set so any residual fat or particulate 
matter is removed.
Since mid-1982 all our marrows have undergone further processing to 
prepare a Mononuclear Cell Fraction (MNC). This fraction contains 
the stem cell component and greatly facilitates storage or in vitro 
manipulation of the marrow.
5.5.1 Stem Cell Enriched Mononuclear Concentrate [MNC]
A proportion of the mononuclear fraction of bone marrow comprises 
the pluripotent and committed stem-cell fraction. Red cell and 
differentiated granulocyte fractions can be separated and 
discarded. Achieving this has a number of advantages. In 
allogeneic graft where there is ABO blood group incompatibility such 
that recipient antibody may lyse donor and cells, removal of 
antibody by plasmapheresis is effective but red cell depletion is 
equally convenient(52). Mature granulocytes do not survive 
cryopreservation and may contribute to cell clumping which can be 
awkward in the post-thaw phase. Reduction of marrow bulk will save 
considerable storage space and may permit more effective freezing. 
A homogeneous cell population with minimal red cell contamination is 
a pre-requisite for successful in vitro purging techniques.
Although a certain amount of separation and concentration can be 
achieved by manual manipulation or the use of continuous cell 
separators, routine processing of bulk marrow can best be achieved 
using an IBM 2991 Blood Cell Processor which was originally intended 
to wash red cells in a closed system(Figure 5.3). This can be 
conveniently adapted, first to obtain a buffycoat from bulk marrow, 
and as a second step, with the introduction of density gradient 
medium, a further stem cell rich fraction which is referred to the 
"mononuclear concentrate"[MNC].
The technique was originally described by Gilmore et al(53). Bulk 
marrow from theatre is transferred under sterile conditions into a 
disc shaped bag which fits into the centrifuge chamber. Separation
is carried out in three stages.
Stage 1. Buffycoat Preparation:-
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The first stage of the procedure is to obtain a buffycoat. Up to 
600 mis of bulk marrow is allowed to run into the centrifuge bag 
which is then spun at 1000 g (3000 rpm) for 10 mins. The centrifuge 
bag is then compressed within the fixed volume chamber and the 
plasma transferred into a supernatant bag at 100 ml/min. As the 
buffycoat layer appears the clamp adjustment diverts this fraction 
into a separate collection bag. Approximately 60 secs is allocated 
to this stage in which residual plasma, complete buffycoat and the 
top of the red cell layer will be collected. The centrifuge bag is 
then refilled with the balance of the whole marrow, and the 
procedure repeated. The final plasma and residual red cells are 
discarded and the first stage of separation is complete.
Stage 2. Preparation of Mononuclear Fraction:-
The important difference in this step is the introduction of 
Ficoll-Metrizoate (FM) at a specific gravity of 1.077 g/ml [Nyegaard 
& Co, Oslo], 150 mis of FM, pooled buffycoat and 500 mis of 0.9? 
(w/v) sodium chloride solution are attached to the harness. The FM 
enters the centrifuge bag first. The saline is allowed to pass 
through to the empty FM bag, purging the line of air in the process, 
and the buffycoat transferred to the empty saline bag and small 
amounts of saline used to rinse the buffycoat bag. The volume 
containing the buffycoat is restricted to l|50 mis maximum.
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The rotor is started at 3000 rpm and the buffycoat volume is layered 
on at a rate of HO mls/min, controlled by the roller pump. Periodic 
delays, where the pump is switched off, are introduced to allow an 
obvious layer to form at the interface, before more cells are 
introduced. The centrifugation continues for 25 mins, then the 
supernatant is transferred to waste, the monolayer directed to a 
collecting bag until red cells begin to appear at the inlet at which 
time the machine is switched off. The plasma and residual red cells 
are discarded. The MNC must now be washed to remove ficoll.
Stage 3 . Washing the MNC:-
A solution of 2056 autologous plasma (from the plasma discard bag) in 
sterile 0.9% saline in a new harness is used for three washes. The 
cell suspension remaining after the final supernatant removal is 
transferred into the final pack as the Mononuclear Cell Fraction 
(and is available for (a) direct administration to the patient as an 
allograft, (b) for storage in liquid state or by cryopreservation 
for autologous use, or (c) for immunological or pharmacological 
purging with or without subsequent preservation for alio- or 
auto-graft.
5.5.2 In Vitro Assessment of Marrow Processing Technique
In vitro assessments of the marrow processing technique described, 
are shown in tables 5 .1-5 .H, based on data obtained from 116 
consecutive procedures.
Volume reduction to 10-1256 of the original bulk marrow was easily
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achieved (Table 5.1). While such a degree of reduction is of 
importance when it comes to storage of bone marrow it is of little 
clinical importance. It would indeed be possible to further reduce 
bulk if desired. Nucleated cell numbers were reduced on average to 
23^ of those in bulk marrow(Table 5.2). In addition, there is 
almost complete red cell removal (MNC haematocrit < 2 % ) . Elimination 
of red cells by this technique is convenient in ABO blood group 
incompatible allogeneic grafts, but is also relevant to some of the 
techniques of in vitro treatment which will be referred to later. 
The nucleated cell loss is primarily of differentiated myeloid 
lineage cells which have no repopulative ability. The remaining 
cells are mononuclear cells which are assumed to contain the stem 
cells but these are not morphologically or phenotypically 
distinguishable by currently available methods. Figure 5.1| shows an 
example of the cellular components of the fractions obtained by the 
processing. w
The doses (i.e. the nucleated cell count/kg) which are obtained 
during the harvests are assessed by a manual count in theatre and 
the amount of marrow taken calculated taking into consideration the 
patient*s weight. Table 5.3 shows the cell doses which were 
obtained in 103 harvests which result in an average dose of 0.71 * 
0.70 x 10®/kg in the mononuclear fraction. What was aimed at for an 
autograft was less than that which we wished to obtain for 
allografts.
The crucial factor is whether or not the MNC contains the stem 
cells. As previously discussed, current techniques only, allow 
measurement "committed** stem cells in short term culture techniques,
Table 5.1. IBM Cell Washer Runs: Volume Reduction
No Initial Vol 
(mis)
I
Buffy Coat Vol %
(mis)
MNC Vol %
(ml)
116 866.1 
1 252.0
301.7 
± 90.4
101.5
143.1
Mean 1 S.D.
Table 5.2 IBM Cell Washer Runs: Cell Numbers
No Initial No 
x 10^/1
Buffy Coat No % 
x 109/1
MNC No % 
x 109/1
116 14.22 
1 6.89
13.49 95.8 
1 6.71 1 8.5
3.21 23.1 
1 1.96 1 9.2
Mean ± S.D.
Table 5.3 Cell Doses per Kilogram Recipient Body Weight
Whole Marrow 
x 10^/kg
MNC
x 10®/kg
Total
(n=103)
3.13 t  2.48 0.71 1 0.70
allograft
(n=44)
3.9 - 2.18 0.86 1 0.73
autograft
(n=59)
2.31 ± 1.74 0.63 1 0.77
Mean 1  S.D.
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Figure 5.4 Cellular Components of Whole Marrow and Mononuclear Cell 
Fraction
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which is an indirect measurement only of the pluripotent cells which 
will be responsible for sustained haemopoiesis in the recipient. In 
vitro assessments of the recovery of CFU-GM and BFU-E representing 
myeloid and erythroid lineages were used as our means of assessing 
the technique in vitro. A description of these in vitro assays is 
given at the end of this section. The results, shown in table 5.4, 
indicate the colony forming units recovered from the MNC expressed 
as a percentage available in total in the initial bulk marrow. The 
absolute number of colonies varied considerably from patient to 
patient but the total numbers available in the starting marrow and 
the MNC can be roughly calculated from a small aliquot of each 
fraction. This is not a precise measurement, but the finding that 
126? of CFU-GM and 97?S of BFU-E are present in the MNC, together 
with the failure to demonstrate colonies in the discarded fractions 
indicates the reliability of the Technique.
Table 5.4 Yield of Committed Stem Cell Precursors in Mononuclear 
Cell Fraction.
CFU-GM
(n=36)
BFU-E
(n=27)
% Bulk Marrow 126.1 i 68.2 
(range 17-280)
97.1 t 60.6  
(range 14-328)
mean ± S.D.
5.5.3 In Vivo Assessment of Marrow Processing Technique
The in vitro data is not the acid test of the technique. What is 
crucial is whether the MNC fraction results in as adequate 
haematological reconstitution as unmanipulated marrow in the ablated 
patient.
This was assessed in 10 patients given fresh MNC and compared with 
12 similar patients given fresh unmanipulated marrow. All these 
patients received allogeneic transplants following ablative 
treatment(Cyclophosphamide and TBI). All the fresh MNC group 
received Cyclosporin to prevent graft-versus-host reaction, whereas 
5 received Methotrexate and 7 Cyclosporin in the unmanipulated 
marrow group. On analysis of individual patterns of recovery there 
was little difference between patients who received Methotrexate or 
Cyclosporin. The kinetics of neutrophil regeneration to 500 and 
1000 x 10^/1 is indistinguishable from the control group given whole 
marrow(Figure 5.5).
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Fig 5.5 Regeneration of Neutrophils in Patients given Bone Marrow 
Prepared as MNC Following Ablative Treatment.
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5.5.4 Conclusion on Marrow Processing Technique
This technique of preparing marrow successfully prepares a stem cell 
concentrate which contains almost all the lineage committed colony 
forming cells, and pluripotent stem cells. It has the advantage of 
reducing marrow bulk which is relevant to cryopreservation 
techniques - not only in terms of storage space occupation but 
possibly also in respect of quality of cryopreservation.
The elimination of unnecessary red cells is convenient in ABO 
incompatible allografts, making plasmapheresis of the recipient 
redundant. A small volume stem cell rich fraction probably permits 
better quality in vitro purging as well as saving valuable reagents.
5.6 STORAGE OF BONE MARROW
All autograft protocols will require bone marrow to be stored for 
variable periods of time. It may be possible to administer the 
desired cytoreductive therapy within a matter of a few hours during 
which time there may be little loss of viability. Prolonged storage 
may be required either because the cytoreductive treatment is 
prolonged or a definite interval between harvest and cytoreductive 
treatment is planned. This will require cryopreservation of the 
bone marrow to preserve function. There is no in vivo data to 
indicate how long marrow can be safely stored without 
cryopreservation.
5.6.1 Cryopreservation
Barnes and Loutit demonstrated in 1955(54) that the "protective 
factor" against lethal irradiation in the mouse retained its 
effectiveness following cryopreservation. Preservation of cells at 
low temperature in a viable state dates from the pioneering 
techniques of Pogler in 1948(55) and subsequently some principles of 
cryobiology have emerged, which if observed should result in 
consistent retention of function even in long-term storage. It is 
important to recognise that there is variation in cryopreservation 
technique between tissues . and even for the same tissue between 
species, to ensure optimum storage.
5.6.2 Principles of Cryopreservation
Rapid reduction of temperature towards 4°C can result in cell 
death. This "thermal shock" has not been fully explained(56) but 
its effect can be demonstrated by lysis of cells at 0°C in a 
hypertonic solution which at 37°C causes minimal lysis. Gradual 
reduction of temperature over a few minutes is satisfactory. It is 
suggested that thermal shock may be a membrane effect since leakage 
of ions and cytoplasmic enzymes has been noted(57). Long-term 
storage requires sub-zero temperature but progressive rapid cooling 
results in formation of ice crystals. Freezing rate was established 
as a critical factor in successful cryopreservation by extensive 
experimentation58). As the temperature falls ice formation 
progresses through the extracellular fluid with a resultant 
increase in osmolarity. The cells then lose water, as it moves to 
the relatively hyperosmolar extracellular compartment, and undergo a
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degree of shrinkage. The cell membrane remains, at least for a 
time, a barrier to the simultaneous development of intracellular 
ice(59). If the rate of freezing is sufficiently rapid, 
intracellular ice does develop with associated increase in 
osmolarity of intracellular fluid which limits the movement of water 
out of the cell, resulting in little shrinkage. Rapid freezing 
therefore is advantageous for morphological examination of cells but 
the cells are likely to be functionally dead on thawing(58).
Cell mechanisms slow down on cooling but are not arrested, except at
low temperatures, and this happens in an uncoordinated way.
Metabolic changes such as cessation of sodium pump(60), enzyme 
systems and phase changes of membrane lipids occur as well as 
increased solute concentration and pH change(62).
Slow cooling on the other hand can result in a lethal degree of cell 
shrinkage. The extent to which water leaves the cell on the 
formation of extracellular ice depends on the properties of the cell 
membrane. Mature granulocytes, for example, are notoriously hard to
preserve in the frozen state, possibly due to the high level of
membrane permeability. As the temperature slowly drops the cell1s 
environment becomes more hostile due to (a) direct contact with ice,
(b) increased contact with increasing concentration of solutes whose 
water has formed ice(63), and (c) injury related to the degree of 
shrinkage^). Direct contact with ice may of itself induce little 
damage (65), but it is considered that increased concentration of 
extra cellular solutes have a major role to play, either by a direct 
effect (e.g. pH) or by exacerbating shrinkage by osmotic mechanisms, 
but which has the greater influence remains controversial.
There are therefore risks related to rapid rate freezing (largely- 
resulting from intracellular ice formation) and slow rate freezing 
(due to direct solute toxicity and/or osmotic shrinkage of the cell) 
which make them unsuitable for storing bone marrow in a viable 
state. Tissues also vary in susceptibility to injury from rapid or 
slow freezing. In general terms a cell with intracellular ice will 
be dead after thawing whereas a shrunken cell without intracellular 
ice can be functional after thawing.
Intermediate freezing rates which avoid these extremes can permit a 
degree of survival for a limited variety of cells (e.g. red cells), 
but the key development for bone marrow cryopreservation has been 
the use of cryoprotectant agents.
5.6.3 Cryoprotective Agents
Cryoprotective agents have their effect in different ways but have 
the one crucial characteristic of water solubility in common, but 
only agents that are non-toxic to cells can be considered.
Although thermal shock occurs when cells are rapidly cooled to 0°C, 
cryoprotectants can prevent this(66). At temperatures above 0°C 
most cryoprotectants are directly toxic to the cells so undue 
exposure at this temperature must be avoided - either before 
freezing or at time of thawing.
In general, cryoprotectants are assumed to work by restricting the 
formation of extracellular ice (which is not itself harmful) thus 
leaving the cells less exposed to high electrolyte concentration
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(67*68). The importance of cell penetration with reduced 
shrinkage(69) and prevention of intracellular ice formation is 
debated since a degree of shrinkage is acceptable and several 
cryoprotectants of I high molecular weight work efficiently yet are 
unable to penetrate the cell. Penetrating cryoprotectants may 
protect by limiting shrinkage whereas the mechanism of the 
protection afforded by non-penetrating agents raise the possibility 
of a membrane effect(69,70).
The mechanism may be more subtle, in that the cryoprotectant may 
control extracellular ice formation such that damaging extracellular 
concentrations of electrolyte are not formed(67)* but there is some 
increase in extra-cellular osmolarity which removes intracellular 
water thus restricting the risk of intracellular ice formation. 
Such a mechanism could explain how cells pre-frozen, say to -20°C, 
at a controlled imtermediate rate can then survive immediate 
transfer into liquid nitrogen (-196°) with the associated rapid 
freezing. The temperature to which any cells must be "pre-frozen” 
is dictated by the concentration of the cryoprotectant. At higher 
cryoprotectant concentrations a lower rpre-freeze1 temperature is 
required for the solute concentration, which is required for optimum 
cell shrinkage to be achieved. In this respect shrinkage of the 
cell is temperature dependent. In addition, direct solute toxicity 
to the cell is reduced at lower temperatures. It is therefore 
desirable to utilise the highest concentration of cryoprotectant 
that is not itself directly toxic to the cells. Cryoprotectant 
toxicity can be reduced by addition to the marrow suspension at low 
temperature, e.g. l|°C and preferably with minimal time exposure of 
the cells to cryoprotectant in liquid phase.
Despite attempting to segregate the important components of cryo­
preservation, it is crucial to recognise their interdependence. For
example, although slower freezing, which prevents intracellular ice 
or undue electrolyte concentrations, is possible by increasing cryo­
protectant concentration, these relationships may change as 
individual variables are altered.
Although protein concentration is another potential variable,
relatively little systematic study of its importance has been
done(71). While bulk marrow contains sufficient plasma, stem cell 
rich fractions [MNC], require plasma to be added - usually in the 
form of autologous plasma.
5.6.J| Choice of Cryoprotectant
Glycerol and Dimethylsulphoxide (DMSO) are cell penetrating 
cryoprotectants. Glycerol is well-known for red cell preservation. 
It is characterised by slow penetration of the cell and therefore 
requires cell contact for some time prior to freezing(72.73). DMSO 
penetrates rapidly and therefore is more convenient. Each has an 
optimum range of concentration (10—12% for Glycerol:5-1256 for DMSO), 
the precise concentration used depends on the cooling rate 
employed. There is abundant evidence that both glycerol and 
DMSO (7*1,75,76,77) successfully protect haemopoietic stem cells.
Polyvinylpyrolidone (PVP) and Hydroxyethyl starch are examples of 
effective protectants (70,77,78) which do not penetrate the cell and 
may exert their effect on the cell membrane. They have been 
infrequently used for haematological stem cells.
The choice between DMSO and glycerol is not yet obvious. In some 
rodent experiments glycerol was found to be superior to DMSO(79,80) 
and vice versa. In lethally irradiated dogs and monkeys they were 
equally effective. There is some evidence to suggest that the 
combination of glycerol and PVP is better than either agent 
alone(81,82).
Probably because of its convenience, DMSO is most widely used in 
human bone marrow cryobiology. Glycerol has the disadvantage that a 
dilution step is probably desirable before re-infusion, to avoid 
toxicity, which.is not necessary with DMSO(83).
5.6.5 Conditions of Thawing
Such evidence as is available suggests that rapid thawing retains 
viability better than a slow thaw process(78,84,85). This is most 
obvious when the freezing rate has been rapid so that intracellular 
ice has formed. Indeed, slow thawing of cells resulting in some 
intracellular ice formation, may result in apparent growth of the ice 
particles within the cell (an effect known as recrystallisation). 
Although there has been evidence to link the size of the ice 
crystals to cell injury and membrane defects have been demonstrated 
adjacent to the ice crystals, an alternative mechanism of injury is 
the change in electrolyte, and therefore osmotic concentrations, as 
the ice melts. Although rapid thawing appears to be appropriate for 
certain cells including bone marrow, there are tissues, e.g. embryos 
or red cells stored in higher concentrations of cryoprotectants, 
where retarding the thawing to the extent that some intracellular 
ice formation takes place, improves survival.
5.6.6 Cryopreservation of Bone Marrow
A cooling rate of 1-2°C per min seems acceptable for bone marrow 
cells in the presence of *\0% DMSO. As the temperature falls, the 
nidus of extracellular ice grows and the salt (NaCl) concentration 
in the remaining liquid progressively rises, till at -21°C it 
achieves a concentration of 5.2 mol/1 when the remaining solution 
solidifies. This is the "eutectic point". At this stage the 
osmotic gradient removes water from the cell with resulting 
shrinkage. As the sample undergoes phase change the "latent heat of 
fusion" is generated. A temperature rise of more than 2°C 
associated with this results in damage, and, with the controlled 
rate freezer, increased liquid nitrogen is delivered to the chamber 
to contain the temperature rise. The duration of this phase change 
may influence viability(86,87)» it being desirable to overcome this 
within 1-2 mins. However, its duration may not be so important if 
the cells have reached this stage with optimum freezing. There may 
be temperature variations throughout the volume of marrow being 
frozen, so prior concentration of the marrow to reduce volume would 
be advantageous, facilitating more even freezing through the 
sample. Similarly the thickness of the sample must be controlled to 
ensure that cold penetration is as even as possible.
The rate of freezing after the fheat of fusion1 phase has also been 
shown to affect viability. A continuing slow rate (1°C/min) 
resulted in about twice the number of viable CFU-GM colonies 
recovered than faster rates (up to 9°C/min) - an observation 
recently corroborated by Gorin(88). An accelerated rate of freezing
at this stage can occur inadvertently if the cooling system 
over-reacts to the latent heat of fusion. This "third slope of 
freezing" is indicated by line A2 in the diagram.
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Figure 5.6 Over Reaction of Automated Freezing - The "Third 
Slope of Freezing".
In this representation, Line A represents the temperature 
of the marrow sample. In response to the temperature rise 
of the heat of fusion, the machine pumps in extra liquid 
nitrogen to lower the temperature with the potential 
substantial reduction in chamber temperaturb (Line B). 
this results in an acceleration of the freezing rate (Line 
A2 ) compared with the ideal - Line C.
A high concentration of cells may result in clumping after thawing - 
probably due to cell lysis of differentiated granulocytes. This can 
be curtailed by limiting the concentration of cells and/or including 
DNAase in the freezing solution. The preparation of marrow as a 
stem cell rich fraction (MNC), with the removal of mature 
granulocytes, has largely eliminated this problem in our practice.
Cell concentration has seldom been studied and may be relatively 
unimportant in unfractionated marrow till high concentrations are 
reached (>5 x 10? cells/ml) when troublesome clumping can occur. 
But such a risk may be reduced when mononuclear fractions are 
prepared.
5.6.7 Post-Thawing Handling
Surprisingly little is known about the optimum handling of cells 
which have been thawed. Although viable by such tests as dye 
exclusion, little information exists to indicate sensitivity to 
osmotic or mechanical stresses.
In the practical use of bone marrow in vivo the option exists of 
removing the cryoprotectant by step-wise dilution and washing prior 
to infusion. This has the advantage of removing the cryoprotectant 
(DMSO) which otherwise has to be excreted by the patient via the 
lungs which can be unpleasant for patients and staff for 24-36 
hours. We have previously reported toxicity in a patient receiving 
autologous marrow containing a large volume of cryoprotectant(89)• 
These are however relatively minor problems because the production 
of a low volume stem cell-rich fraction results in much smaller
amounts of DMSO reaching the patient. Where in vitro step-wise 
dilution is performed the presence of protein in the diluent 
reduces trauma and some workers have demonstrated improved recovery 
as measured by in vitro culture assay compared with rapid thaw 
techniques(90). Assessment of this component of the whole process 
by such assays is difficult because cryoprotectant becomes diluted 
out in the culture suspension which is plated in the petri dish for 
assay.
If slow step-wise dilution is preferred then this is better carried 
put at 0°C to avoid direct toxicity of the cryoprotectant to the 
cells but a rapid dilution results in improved survival if carried 
out at room temperature at 37°C. Improved viability as measured by 
CFU-GM assay was demonstrated by employing a dilution technique, but 
manipulation of the thawed marrow may introduce a risk of bacterial 
contamination and prompt infusion into the patient most probably 
results in suitable dilution in vivo.
5.6.8 Duration of storage
The very low temperature storage of liquid nitrogen (-196°C) appears 
to retain constant viability, probably for several years(91). Where 
higher temperatures are used, such as in the vapour phase, viability 
and function, as measured by reconstitution of a lethally irradiate 
animal, deteriorates after a few weeks or several months(74,92). 
Such deterioration may be masked by storing a large number of cells 
such that the minimum number of cells to ensure reconstitution still 
remain, so it may be a more important factor than generally realised 
as present.
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Liquid phase storage (-196°C) is also likely to offer more secure 
and stable conditions. Vapour phase storage may be liable to 
fluctuations due to periodic opening of the storage container.
Concern has been expressed about the effects of background radiation 
on these cells which are incapable of activating cellular repair 
mechanisms(93). Such as is known about this risk in long-term 
storage does not suggest that this need be a serious worry.
Many clinical studies have been done in man over recent years which 
purport to validate the technique of cryopreservation employed. In 
the majority of these studies, high dose chemotherapy protocols were 
used which were not ablative, and it is therefore quite possible 
that haematological recovery was due to endogenous recovery in the 
patient. Protocols using total body irradiation are less common. 
Although irreversible damage to normal marrow is assumed to occur at 
radiation doses of 500-600 cGy(94), recovery from larger doses is 
known with prolonged supportive care(95). The recent demonstration 
of mixed haemopoietic chimerism following doses in excess of 1000 
cGy confirms that true marrow ablation is not easily achieved(96). 
Despite these reservations, several studies confirm in man the 
suitability of cryopreservation techniques, based on the principles 
outlined above, to retain marrow viability(97,98).
In the light of these aspects of cryobiology we adopted methodology 
of preparing and freezing marrow for autologous transplantation.
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Figure 5.7 Cryopreservation of Mononuclear Cell Fraction
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5.6,9 Method of Cryopreservation
The bulk bone marrow is processed to prepare a stem cell rich 
fraction as described. The volume is noted and the preparation kept 
on ice. An equal volume of DMSO made up as a 20^ solution in the 
patients* autologous plasma, and pre-chilled to 4°C, is added, 
giving a final concentration of 10$.
The bag is transferred to a haemofreeze bag (Gambro Ltd), fixed in 
an aluminium envelope in the freezing chamber of a controlled rate 
freezer (R201 Planer Ltd) in which the rate of freezing can be 
preset (figure 5.7). Pilot tubes (Sterlin Ltd) are usually frozen 
for subsequent in vitro assessment.
The selected programme holds the chamber and contents at +4°C for 10 
mins, then reduces at 2°C/min. to -5°C and thereafter at 1°C/min to 
-40°C and thereafter at 10°C/min to -160°C whereupon the bag is 
removed from its metal envelope and rapidly transferred to the 
liquid nitrogen storage container, where it is stored in the liquid 
phase (-196°C).
The basis on which the automatic freezer operates is that a chamber 
thermocouple located adjacent to the sample measures the sample 
temperature in the immediate environment and regulates the flow of
nitrogen into the freezing chamber in an effort to keep the
temperature in the immediate environment as close as possible to
that of the pre-set programme. The serial temperature recordings of
a typical cryopreservation are shown in figure 5.8. The pre-set 
programme (line A) and the chamber thermocouple (line B) are
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identical. Line C is an additional thermocouple inside a test 
aliquot of marrow suspension. A temperature rise at around -10°C is 
observed - the eutectic point of this sample. Eventually the sample 
temperature (line C) catches up with the prescribed programme. This 
is, however, not optimum freezing and raises the question of how 
best to compensate for the heat generated at the eutectic point. 
The chamber thermocouple (line B) set at the base of the freezing 
chamber is not capable of detecting the temperature rise in the 
sample.
Fig 5.8 Temperature Recordings of a Fully Automated 
Cyropreservation Programme.
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In theory, it is possible to compensate for this by using a separate 
thermocouple located in a pilot sample to control the nitrogen
response. This would more rapidly respond by increasing nitrogen 
flow. A number of experimental runs were undertaken to measure the 
temperature response of a programme conducted in this way. A
representative chart is shown in figure 5.9. As expected, the
initial sample temperature rise, line D, in an attempt to follow the 
pre-set programme (line A) increases the nitrogen flow with a
substantial drop in chamber temperature (line B). The sample is 
over-corrected (line C) and there is substantial disparity between 
the temperature in the sample (line D) and the pre-set programme, 
before it returns to the desired protocol. This is the "third 
slope" of freezing referred to in figure 5.6.
Fig 5.9 Sample Temperature Controlled Cyropreservation Programme
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It was concluded from these experiments that relying on the 
automatic machine response would not be sufficiently precise. With 
each freezing run, an aliquot sample is used to record sample
temperature and the temperature observed constantly till the
|
eutectic point is reached, whereupon the nitrogen pump is manually 
activated to compensate. When compensation is complete the 
programme can continue automatically. A typical freezing procedure 
following this method is illustrated in figure 5.10. This results 
in a much more satisfactory freezing run when compared with the 
pre-set programme.
Fig 5.10 Cryopreservation Programme with Manual Override.
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Using a pilot ampoule of the marrow sample is the most that in 
practice can be done to record the events in the sample itself. It 
is clearly desirable that there is minimal variation of freezing 
throughout the marrow specimen, due to variable sample thicknesses. 
For this reason, the marrow bag is clamped in a metal envelope to 
maintain a uniform sample thickness of 4-8 mm.
Another potential variable is whether the eutectic point is 
substantially affected by the cell concentration of the bone 
marrow. In figure 5.11 the relationship of eutectic point - which 
for most runs occurred , in our experience at -12°C to -13°C - and 
cell concentration, is shown for eighteen procedures.
Fig 5.11 Variation in the Eutectic Point with Sample Cell 
Concentration
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Although there was some variation in the eutectic point, this did 
not correlate to the cell concentration of the sample. In view of 
the decision to incorporate a manual override into the programme the 
position of the eutectic point is not crucial.
5.6.10 In Vitro Assessment of Cryopreservation Programme
Prior to cryopreservation aliquots of marrow, including the 
cryoprotectant, were assayed for CFU-GM and BFU-E. DMSO is toxic to 
these cultures at high concentration but to obtain the desired cell 
concentration for plating dilution was required which eliminated 
DMSO toxicity. At variable periods, from days to several months, 
cryopreserved aliquots were thawed, diluted as appropriate, and 
re-assayed. No systematic study of the effect of duration of 
storage on recovery was undertaken, but there did not seem to be 
detectable deterioration with time. When the recoveries are 
expressed as a percentage of the 1 fresh* sample, it is observed 
that adequate recovery of CFU-GM (98£: range 10-282) and 
BFU-E(70£: range 22-117) is obtained. Similar recoveries on 
megakaryocyte colonies (CFU-Mega) were noted in our laboratory*.
5.6.11 In Vivo Assessment
As with other manipulations in vivo regeneration of haemopoiesis in 
the patient given ablative chemo-radiotherapy is the acid test. 
Neutrophil regeneration is illustrated in a group of 30 patients in 
figure 5.12. All patients received an ablative treatment involving
* Mr A Lamb as part of MSc Thesis.
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total body irradiation. The controls are 13 recipients of fresh, 
unmanipulated allogeneic marrow. These are compared with 17 
patients receiving cryopreserved autologous marrow. While the 
regeneration of the autologous cryopreserved marrow is slower 
(median to 500 neutrophils 27 days for the cryopreserved group 
versus 15 days for the fresh group: and to 1000 neutrophils 36 days 
versus 19 days), it provides adequate evidence to confirm that the 
cryopreservation technique is satisfactory and, as will be seen 
below, is not different from the recovery pattern seen using 
autologous non-cryopreserved autologous marrow.
Fig 5.12 Neutrophil Regeneration following Cryopreserved Bone 
Marrow.
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Fig 5.12 continued
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5.7 LIQUID STORAGE OF BONE MARROW
Cryopreservation involves considerable expertise and sophisticated 
equipment to be used with confidence. Short-term storage in liquid 
state at l|°C is considerably simpler but the duration of safe 
storage is not known. For high dose protocols, which can be 
administered and metabolised within hours, short-term storage in the 
liquid state has been reported to accelerate haemopoietic 
recovery(99).
In vitro assays (CFU-GM) monitoring of storage in Ithe liquid state 
show variable results when stored at il°C of between 91% at' H days 
(100), to iJ0$ at 2*1 hours(101). In the former study there was
little decline over the first 9 days of storage. Similarly, in 
vitro results may depend on the temperature of storage in the liquid 
state, 25°C was initially stated to be better but some comparisons 
between 1}°C, 10°C and 20°C over 1} days had recoveries of CFU-GM of 
68%, 58% and 26% and at 7 days of 21$, *13$ and 16$ respectively, 
suggesting 10°C as the appropriate temperature(101). A clinical 
study of high-dose chemotherapy followed by autologous marrow stored 
at 10°C suggested prompt haemopoietic recovery(102) - but the
protocol used would not be regarded now as more than intensive 
treatment. It is perhaps of relevance to the resurgence of interest 
in using peripheral blood stem cells that poor recovery (6$) of 
CFU-GM derived from peripheral blood was noted following storage at 
4°C for days(100).
The use of non-frozen bone marrow clinically is bedevilled by the 
fact that none of the studies mentioned involved ablative 
treatment. Indeed, by present standards, the chemotherapy did not 
require autologous marrow for recovery. The comparison by McElwain 
et al(99) of the neutrophil recovery following high-dose Melphalan 
showed more rapid regeneration in the group receiving marrow 
infusion, but it is noteworthy that the control group reconstituted 
satisfactorily with only a few days delay.
Liquid storage may be able to retain some pre-granulocyte cells 
which store poorly in the frozen state, which are capable of acting 
as a granulocyte transfusion, while endogenous. recovery of bone 
marrow in the patient is responsible for sustained recovery. So the 
duration of storage in liquid culture which retains the capacity to 
repopulate an ablated patient is untested as long as there is
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uncertainty about the ablative potential of the intensive regime 
given.
It is not known whether liquid storage at the temperatures 
mentioned, or cryopreservation selectively kills clonogenic 
leukaemic cells. There is however some experimental evidence of 
poorer survival of leukaemic cells at higher temperatures, 
suggesting an alternative method of purging the autograft(103).
As previously stated, in vitro assays serve only as a guide to the 
viability of the CFU-S equivalent cell in man.. No in vitro data has 
previously been available of BFU-E storage in liquid state.
We conducted in vitro studies over 3 days of CFU-GM and BFU-E 
recovery (table 5.5). It is apparent that a degree of viability 
remains for up to 72 hours. These studies were the prelude to two 
clinical studies involving high-dose chemotherapy or 
chemo-radiotherapy using autologous marrow which had been stored at 
4°C as whole marrow, or, in a few cases, as a mononuclear fraction.
Table 5.5 Survival of Marrow Stem Cells at 4°C
0 hrs 2*1 hrs 48 hrs 72 hrs
CFU-GM 100 84 ± 10.3 
(n=22)
81.5 * 14.5 
(n=14)
37 t  8.5 
(n=9)
BFU-E 100 83 ± 9.3 
(n=6)
45 ± 12.3 
(n=6)
28 £ 7.5 
(n=11)
Mean £  S.D
Results expressed as a percentage of growth obtained when 
assayed immediately (time = 0 hrs)
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In the first study initiated in 1981(10*1), 27 patients with small 
cell carcinoma of lung received high-dose Cyclophosphamide 
180-200 mg/kg in two doses 12 hours apart with reinfusion of 
autologous marrow 22 hours later which had been stored for 36 hours. 
All patients had previously received standard combination 
chemotherapy ("CHOP" Protocol)*. Half received a fprimingf dose of 
Cyclophosphamide (500 mgs) to reduce non-myeloid toxicity seven days 
before the high-dose treatment. All patients were given 
2-mercaptoethanol-sulphonate sodium [Mesnum](105) to prevent 
Cyclophosphamide induced urotoxicity. In these patients prior 
chemotherapy reduced the number of CFU-GM obtained per 10^ ficoll 
separated marrow cells compared with an untreated control group [4.4 
range 1-13 vs 15.*1 range 5-28, p = <0.01 Wilcoxon^ rank sum]. A 
cell dose of 2.4 x 10®/kg was harvested (range 1.2 - 4.9 x 10^/kg).
Prompt neutrophil and platelet regeneration occurred suggesting 36 
hours storage resulted in sufficient viable cells to ensure 
recovery. The cell doses were relatively large for autograft 
requirements which could have masked cell losses that might have been 
critical at lower cell doses.
Subsequently a patient received the same high-dose protocol without 
bone marrow. Her haematological recovery pattern was not different, 
calling into question the contribution of the autograft to the 
regeneration pattern. It appeared therefore that cyclophosphamide
* CHOP Protocol Cyclophosphamide 750 mg/m2 I.V. day 1
Adriamycin 50 mgs/m2 I.V. day 1 
Vincristine (Oncovin) 1.4 mgs/m2 day 1 
Prednisolone 25 mgs qid oral day 1-5
given in these doses is not ablative as suggested by others(106), so 
our initial conclusions regarding the storage protocol were not 
secure. There was little evidence for improved survival in these 
patients and the protocol has been discontinued(107).
Subsequently, 12 patients with Acute Myeloid Leukaemia received 
ablative treatment of Cyclophosphamide and TBI with infusion of 
autologous bone marrow stored at *J°C for 5*1 hours.
The pattern of regeneration is shown in figure 5.13, where it is 
compared with the regeneration seen in ablated patients receiving 
fresh or cryopreserved marrow. Adequate neutrophil recovery was 
demonstrated, corroborating for the first time, that liquid storage 
at *l°C for up to 5*1 hours, is compatible with retention of 
sufficient viability to permit recovery from an ablative protocol.
Figure 5.13 Neutrophil Regeneration with Marrow given fresh, 
cryopreserved or stored in liquid phase (*1°C)
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Figure 5.13 continued
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5.8 METHODS for CFU-GM and BFU-E ASSAY
The methods adopted to assess the viability of bone marrow in vitro, 
using the erythroid precursor (BFU-E) and granulocyte-macrophage 
precursor (CFU-GM) have been mentioned. These techniques are 
described below.
5.8.1 Preparation of Cell Suspension
Cells are separated over a ficoii-metrizoate gradient 
(S.G. 1.077 -  0.001 g/ml) at ilOOG for 30 mins. The cells are 
removed from the interface and washed in Hanks Balanced Salt 
Solution (Gibco) at 100G for 15 mins, and again following 
resuspension in Iscovefs Modification of Dulbecco's Medium 
(IMDM) (Gibco). The cell pellet was resuspended to a final cell 
concentration of 1 x lO^/ml. One ml of cell suspension was added
to each assay 35 mm diameter culture plate (Flow Laboratories), 
immobilized in 0.855 methylcellulose.
5.8.2 Culture Additives
CFU-GM
Assay
BFU-E
Assay
5% PHA-LCM
5 x 10”5m  2-Mercapto-
ethanol
2055 foetal bovine serum
155 bovine serum albumin 
(fraction V: Sigma Ltd)
\ /
2 u/ml erythropoietin 
(Connaught, Step III)
5 x 10”5m  2-Mercapto- 
ethanol
2 055 foetal bovine serum
1J5 bovine serum albumin 
(fraction V: Sigma Ltd)
These methods are based on the techniques of Iscove for BFU-E(108) 
and the preparation of PHA-LCM is the method of Wu(109)> in which 
peripheral blood lymphocytes [usually from a single haemochromatotic 
patient undergoing venesection were stimulated with the mitogen 
phytohaemaglutinin(PHA)].
5.8.3 Incubation Conditions
The assay plates are set up in triplicate and incubated at 37°C in a 
5% CO2 humidified atmosphere for 10 days (CFU-GM) or 10-14 
days(BFU-E).
5.8.4 Colony Enumeration
Colonies are defined as aggregates of greater than 40 cells and are 
counted as the total per plate and the result expressed as
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colonies/105(CFU-GM) or /10**(BFU-E) cells plated.
The colonies are readily recognised by the trained eye and are 
viewed on an inverted microscope at x*10 magnification. The colony 
morphology is illustrated in figures 5.1*1 and 5.15.
Fig 5.1*1 Microscopic Appearances of a Granulocyte-Macrophage 
Colony(CFU-GM)
* + ' * -O' ■> .
Figure 5.15 Microscopic Appearances of an Erythroid "Burst" (BFU-E)
5.9 COMMENTS ON TECHNIQUES OF MARROW MANIPULATION AND STORAGE
Local experience of over two hundred and fifty bone marrow harvests 
has confirmed that this procedure presents no risk to the donor with 
minimal sequelae. Procurement of our arbitrarily defined cell doses 
was always obtained, even in patients recently treated with 
intensive chemotherapy. Sufficient marrow was usually obtained by 
two operators in 30-40 minutes. Concentration of the.harvest to a 
mononuclear fraction is now routine, and such a manipulation has 
been satisfactorily demonstrated not to be detrimental to the 
repopulative potential of bone marrow when given to ablated 
patients. In vitro evidence, with its acknowledged limitations, and 
in vivo regeneration has confirmed that storage of bone marrow at 
4°C for up to 54 hours, or cryopreserved in 10% DMSO at -196°C 
results in adequate haemopoietic recovery in ablated patients. The 
preparation of a mononuclear cell concentrate of bone marrow has 
greatly facilitated the freezing method, and simplified the 
administration to the patient. As well as being economical in its 
use of low temperature storage capacity, it, as will be discussed in 
Chapter 9, is a necessary preliminary step preceding ex vivo 
treatment of the bone marrow.
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CHAPTER 6
CLINICAL RESULTS OF AUTOLOGOUS 
BONE MARROW TRANSPLANTATION IN 
ACUTE MYELOID LEUKAEMIA
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6.1 PATIENT DETAILS AND PREPARATION
Twenty-five patients with Acute Myeloid Leukaemia in first remission 
who were under 55 years of age or under HO years and lacked a 
suitable HLA-matched donor for allograft were offered ablative 
treatment with autologous bone marrow transplantation as final 
consolidation treatment of their disease. Patients who received 
treatment from the time of diagnosis at The Royal Infirmary were not 
selected in any way, but three additional patients within this 
institution declined the treatment, two of whom have subsequently 
died of their disease. Ten of the twenty-five patients had their 
initial chemotherapy at other hospitals and it is not possible to 
know whether there was a selection bias in their referral pattern. 
A 10-year old boy who received all his treatment, including 
autograft, at The Royal Hospital for Sick Children is included in 
this series.
6.1.1 Patient Details
The characteristics of the study patients are shown in Table 6.1 and 
include 13 females and 12 males with a median age of 38 (range 
15-53). Ten patients were not considered for allograft because they 
were older than ^0 years of age and a donor was not sought, and 15 
who were suitable for allograft on age criteria, had no suitable 
donor. The diagnosis of acute myeloid leukaemia was fulfilled in 
all cases by the criteria of having >30% of bone marrow cellularity 
comprising blast cells. In almost all cases the blast population 
exceeded 00%, and in 2*1/25 cases the myeloid nature of the blast 
population was corroborated by, at least, positive sudan black 
cytochemical reaction. The morphological subdivision (FAB subtype)
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was allocated by the diagnosing Haematologist according to the 
originally described criteria (1), the distribution of cases was 
M1=8; M2=8; M3=3; M4=6; M5=0. This distribution is proportionately 
in approximate agreement with the subtype distribution found in an 
AML population. For example, the Medical Research Council AML8 
Trial entry of 1573 patients comprised 5155 of M1 and M2; 5% M3; 
2555 MM; and M5.
Satisfactory cytogenetics were available at diagnosis on 17/25 
cases. Of these seventeen, five showed karyotypic abnormality - the 
details of which are shown in Table 6.2. Three patients had an 
antecedent haematological abnormality, two of whom had a normal 
karyotype. No patient presented with a blast cell count in excess 
of 20 x 109/1 or CNS disease.
6.1.2 Chemotherapy Prior to The Autograft
Because this was a phase I experience, and initial treatment was 
undertaken in different hospitals, no initial effort was made to 
standardise the type or duration of chemotherapy which these 
patients received in the pre-autograft interval. In the event the 
induction chemotherapy was very similar in all patients comprising a 
three drug protocol, (Daunorubicin 50mg/mg2 i.v., Cytosine 
Arabinoside 100mgs/m2 by i.v. bolus and Thioguanine 100mgs/m2 
oral). There was variation in the number of doses of Daunorubicin 
(one, two or three doses) per induction pulse. Although the 
cytosine and thioguanine were almost invariably given 12-hourly, 
some patients received 5 days, some 7 and a few 10 days of these 
drugs. Subsequent experience in the literature does not indicate
Table 6.2 Nature of Cytogenetic Abnormalities
Patient UPN Cytogenetic] Abnormality
00*1 1:14 translocation
007 1:4 Translocation
018 —C, +D, +E, —2G
023 7q f
-=
r
CMO hyperdiploidy: deletion of long arm 7
that there is a substantial or consistent difference in remission 
rate achieved by such variables, although more induction pulses of 5 
days may be required to achieve remission than of 10 day pulses (2).
Consolidation/maintenance usually involved Cytosine Arabinoside 
70-80 mg/m^ 12-hourly i.v. or s.c. and Thioguanine 100 mgs/m^ 
12-hourly orally for 5 days with or without intravenous Daunorubicin 
50 mg/m^ on Day 1. There was some variation in the drugs used in 
consolidation with some referring physicians substituting Etoposide, 
Amsacrine or omitting Thioguanine at this stage. There appeared to 
be little qualitative difference between the nature of the treatment 
given to the patients but, as indicated in Table 6.1, there was 
notable variation in the number of pulses given to individual
patients. From 1-4 induction pulses were required to achieve 
remission and between 3 and 14 post-remission pulses were given, the 
latter had the important associated consequence that there was 
considerable variation in the time that each patient spent in 
remission before the autograft, the possible implications of which 
will be discussed later. The median duration of remission 
pre-autograft was 22 weeks (range 16-90). The median time interval 
from initiation of induction chemotherapy and the achievement of 
remission was 50 days (range 28-210). The total number of pulses of 
chemotherapy given before the autograft was 8, (range 5-17) and the 
time interval from initiation of chemotherapy and autograft was 34 
weeks (range 22-96).
6.1.3 Marrow Harvesting
In the first 13 consecutive patients the protocol (protocol A) 
involved single fraction total body irradiation and it was possible 
to avoid cryopreservation and store the bone marrow at 4°C for 54 
hours as whole marrow, as described in Chapter 5. In these patients 
therefore, the autograft was obtained immediately before the ablative 
treatment. In the subsequent 12 patients, whose ablative approach 
(protocol B) incorporated fractionated irradiation, the autograft 
was cryopreserved. This allowed more flexibility in the timing of 
marrow harvesting but in all patients this was done immediately 
before the last chemotherapy pulse. All patients had a back-up 
marrow taken earlier in remission, which was cryopreserved to be 
used in the event of accidental damage to the autograft designated 
for use, graft failure, or as an option for use in the event of 
post-autograft relapse. On no occasion has use of the back-up
marrow been needed because of accidental damage, but in one patient 
(UPN020) it was given to improve graft function.
Although a minimum nucleated cell yield of 1 x 10®/kg was 
arbitrarily set, the doses obtained ranged from 0.98-5.0 x 10®/kg 
(median 1.91) and the volumes from 642-1390 mis (median 960 mis). 
In patients who received protocol B (UPN014 - UPN025) a mononuclear 
cell concentrate (MNC) was prepared, resulting in a cell dose of 
0.21-0.69 x 10®/kg (data shown later; table 6.11).
6.1.4 Ablative Treatment
As discussed in Chapter 4, the first 13 patients received 
Cyclophosphamide and single fraction TBI at a low dose rate with 
autologous marrow stored at 4°C for 54 hrs (Protocol A). The 
subsequent 12 patients received melphalan and fractionated TBI with 
cryopreserved marrow (Protocol B). The reasons for this change were 
discussed previously. Although nausea and vomiting was usual in all 
patients receiving both treatments, this was less obvious in the 
fractionated irradiation group. Parotid gland swelling was usual in 
the first few hours following single fraction TBI, but rarely 
noticed in the subsequent patients. Overall, the protocols were 
well tolerated with no obvious increased toxicity in the older 
patients.
6.2 PATTERN OF INFECTION
Four conditions adopted by the supportive care protocol in these 
patients may influence the pattern of infection seen; (i) all
222
patients were nursed in laminar air flow conditions with reverse 
barrier nursing; (ii) they received non-absorbable antibiotics to 
decontaminate the bowel; (iii) all patients had an indwelling atrial 
catheter for venous access; (iv) patients who were seronegative 
(titre < *1: if) to cytomegalovirus, received blood products from 
seronegative blood donors.
In these patients the vast majority of infectious episodes occurred 
in the ;first four weeks post-transplant, during the neutropenic 
period. The main indicator of infection was the development of a 
pyrexia, but routine monitoring also documented a significant 
urinary tract infection in one apyrexial patient.
The experience in the twenty-five patients is set out in Table 6.3* 
Twenty-two (88?) developed a significant pyrexia necessitating the 
introduction of broad spectrum intravenous antibiotics in line with 
the principles outlined in Chapter 4. Two patients remained 
apyrexial throughout with no positive bacterial isolates. The third 
patient (UPN022), referred to above, developed a urinary tract 
infection due to Klebsiella which was regarded as significant, and 
treated with the appropriate oral antibiotic.
In nineteen of the twenty-two pyrexial incidents positive 
bacteriology was obtained, thought to be significant, but in only 
ten of these was the isolate from a blood culture. The frequency of 
infecting organism in these nineteen patients is shown in Table 6.^, 
but it is recognised that some of these isolates may not be the 
direct cause of the pyrexial incident.
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Coagulase negative staphylococcus was the commonest isolate - 
occurring in twelve patients. In seven of those patients the only 
isolate was from Hickman line, from three peripheral venous blood, 
and in two from both isolates. It is probable, though not certain, 
that the isolates from Hickman line were significant.
Table 6.4 Bacterial Isolates in AML Patients
Infective Organism
}
No of Isolates
Coagulase Negative Staphylococcus
Streptococcus Sanguis/Mitis 3
oL Haemolytic 2
Faecalis 2
£  Haemolytic 1
Pneumoniae 1
Klebsiella 2
Proteus 1
E Coli 1
27
The traditional isolates in neutropenic patients are gram negative 
bacilli, probably from endogenous bowel flora. These occurred 
relatively rarely in these patients, an observation that is probably 
attributable to the oral non-absorbable antibiotics given to 
decontaminate the bowel.
The emergence of coagulase negative staphylococcus as the most 
frequent infecting organism is not surprising, and is widely 
reported in other series, where it is attributed to the use of
22 7
indwelling catheters, which are assumed to permit access of skin 
flora, or skin flora are introduced at the time of catheter 
insertion. As will be discussed in more detail below, the 
administration of prophylactic intravenous vancomycin at the time of 
catheter insertion may reduce the infection rate.
6.2.1 Response to Empirical Antibiotics
The duration of the study has seen changes in the particular 
antibiotics used as part of the unit policy for the empirical 
treatment of pyrexia in neutropenic patients, but the principles 
have, however, not changed. All patients received an aminoglycoside 
(Gentamicin, Netilmicin or Amikacin) and Urideopenicillin 
(Ticarcillin, Mezlocillin, Pipercillin or Ciprofloxacillin). 
Vancomycin was introduced either empirically if no response - as 
judged by temperature lysis - by *18 hours, or if a coagulase 
negative staphylococcus was isolated and it was thought necessary to 
add the third antibiotic based on the clinical condition of the 
patient. All of the twenty-two pyrexial patients responded 
satisfactorily to this approach with complete resolution of 
temperature within 72-96 hours. No patients developed documented 
fungal infection.
Late bacterial infections in these patients have been unusual. Two 
patients developed pneumonia (UPN006, UPN021) which resolved with 
broad spectrum antibiotics without the causative organism being 
found. All patients received Cotrimoxazole for six months to 
prevent pneumocystis carinii infection.
6.2.2 Viral Infections
The sequence of viral infections following allograft is 
characteristic, with most patients who were seropositive to herpes 
simplex type I virus (HSVI) reactivating infection in the oropharnyx 
in the first three weeks. Reactivation or secondary infection of 
cytomegalovirus is most likely to occur one to four months with 
herpes zoster typically occurring later(3).
i
Mucositis was relatively common in these patients in the first two 
weeks, either due to HSVI infection or as a direct consequence of 
radiation treatment. In this respect, the patients who received 
fractionated TBI appeared to be considerably less troubled by this 
symptom. Eight patients excreted HSVI from the oropharynx. These 
did not necessarily correspond to the patients who were most 
symptomatic. Symptomatic patients tended to receive intravenous 
acyclovir empirically to provide pain relief, on the grounds of the 
probability of viral aetiology.
Thirteen patients showed seroconversion to HSVI, of whom six had 
virus isolated, so a total of fifteen patients produced evidence 
suggestive of HSVI infection. This largely corresponds to the 
experience of others in allograft(il), but evidence for such a 
pattern has also been reported for patients receiving chemotherapy 
for leukaemia(5).
Seroconversion to cytomegalovirus occurred in three patients without 
evidence of virus excretion, while CMV was isolated in two further 
patients from routine throat or urine swabs. Pneumonitis 
attributable to CMV did not occur in these patients.
Herpes Zoster in a single dermatome occurred in three patients 
within the first nine months, but settled rapidly following prompt 
treatment with acyclovir.
One patient (UPN002) died of pneumonitis having already relapsed. 
Post-mortem isolates from lung grew adenovirus which was thought to 
be the aetiological agent. Adenovirus was not found in any other 
patient in this series.
6.2.3 Hickman Catheters as a means of Venous Access
All patients had a double or single lumen atrial (Hickman) catheter 
to facilitate venous access. As well as greatly assisting in the 
management of these patients without the stress, and potential 
infective risk of repeated venepuncture, such an approach carries a 
risk as a source of infection. With the widespread use of such an 
approach in immunosuppressed patients there has been a substantial 
increase in documented infections due to staphylococcus epidermis 
which is frequently multiply resistant to antibiotics, but is 
sensitive to Vancomycin (6). On occasion, persistent pyrexia will 
necessitate catheter removal. The patients in the autograft 
programme formed part of a larger study group which has been 
examined to delineate (a) the factors associated with the 
development of infection, and (b) the effect of the use of 
intravenous vancomycin given prophylactically oh the day of catheter 
insertion, on catheter related sepsis (CRS) and catheter lifespan.
Included in this survey were 17 of the autograft patients and 28 
recipients of allogeneic transplants. Fourteen patients, 9
allografts and 5 autografts, received Vancomycin (500 mg in 50 mis 
of normal saline over 30 minutes) the night before catheter 
insertion, and on three occasions at 6-hourly intervals on the day 
of catheter insertion. These patients were not randomised but they 
happened or not to receive Vancomycin depending on the preference of 
referring centre or the medical attendants preference.
The catheter care was undertaken by the nursing staff, which 
included the withdrawal of venous samples and fluid and drug 
administration. The skin exit site was cleaned daily and a sterile 
occlusive dressing applied. Patients were instructed in catheter 
management while in hospital and were usually able to care for the 
catheters after discharge. When Hickman catheters were no longer 
necessary, or became infected, they were removed by simple traction, 
but some double lumen catheters required surgical removal under 
local anaesthesia.
All patients in this study had the same approach taken to infection 
control outlined in Chapter *1. They were nursed in laminar airflow 
beds and received oral non-absorbable antibiotics to reduce gut 
flora during their period of neutropenia. Blood cultures were taken 
when the temperature was greater than 38°C or when clinically 
indicated. All patients with documented or suspected infection were 
treated with broad spectrum antibiotics; an aminoglycoside, a 
ureidopenicillin and Vancomycin which were continued until the 
neutrophil count recovered to 500 x 10^ per litre. Other 
antibiotics were added or substituted when indicated by culture. 
Amphotericin and/or acyclovir were added to the treatment of those 
patients with documented or suspected fungal and/or viral
infection. Granulocyte transfusions were not administered. Where 
the septicaemia did not resolve with antibiotic therapy and 
catheter-related sepsis was suspected, the Hickman line was removed.
CRS was defined as either those patients with exit site or skin 
tunnel infection associated with the development or erythema, 
tenderness, induration and/or purulence or those patients with fever 
and positive blood cultures and a positive culture for the same 
organism at the catheter exit site. Septicaemia unrelated to the
catheter was defined as fever and positive blood cultures with no
evidence of skin tunnel or exit site infection either clinically or 
bacteriologically. Only the first catheter inserted prior to the 
conditioning chemoradiotherapy was evaluated.
The mean age of the *15 patients (28 male/17 female) was 28.5 years 
(range, 17-5*0. The median duration of catheterisation for the *15 
patients was 50 days (range, 7-37*1 days). Catheter life in patients 
receiving autografts was a median of 96 days (range 17-37*0, which 
was significantly longer than the allograft group - median *13 days 
(range 7-365), p=<0.05.
Nine of the patients died with the original catheter in-situ at a 
mean of 110.2 days. None of these deaths was catheter-related, but 
were due to post-transplant complications such as interstitial
pneumonitis (H), graft-versus-host disease (3), non-engraftment (1) 
or relapse of leukaemia (1). Three catheters were removed because 
of thrombosis. Two catheters were removed accidentally. Sixteen 
catheters were removed electively because they were no longer
required.
Of the 20 patients in whom CRS was diagnosed, seven of these 
catheters had evidence of local infection at the exit site or skin 
tunnel while 13 catheters also had positive blood cultures. Five of 
these patients responded to antibiotic therapy and eventually had 
their catheters removed electively. The remaining fifteen catheters 
were removed because CRS did not respond to antibiotic therapy.
A variety of pathogens were isolated during episodes of both 
catheter and non-catheter infection (Table 6.5). Staphylococcus 
epidermidis was the predominant organism isolated in catheter- 
related septicaemia (10 of 13 isolates, 77%) and was also a common 
organism in catheter-unrelated septicaemia (5 of 18 isolates, 2 & % ) . 
Other organisms isolated in catheter-related septicaemia were 
Staphylococcus aureus and diphtheroids. Gram-negative organisms 
were an uncommon isolate, accounting for a small proportion of all 
bacteriologically proven septicaemia (6 of 31 isolates, 1 9 % ) . The 
commonest pathogen causing catheter-unrelated septicaemia was Strep 
viridans (7 of 18 isolates, 39$).
The risk factors associated with the removal of these catheters are 
shown in Table 6 .6 . Neutropenia or thrombocytopenia on the day of 
catheter insertion, a diagnosis of aplastic anaemia, allogeneic bone 
marrow transplant, double lumen catheters and intravenous nutrition 
were found to have no significant effect on CRS. Only the 
prophylactic administration of Vancomycin on the day of catheter 
insertion significantly reduced the number of catheters removed for 
infection (p = 0.023).
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Table 6.6 The Risk Factors Associated with Hickman Catheter Removal 
for Infection
RISK FACTOR FACTQR PRESENT FACTOR ABSENT P VALUE
(Fisher1s exact test)
Neutropenia on 
day of HC insertion 2/6 13/39 1.0
Thrombocytopenia on 
day of HC insertion ; 5/9 10/36 0.24
Aplastic Anaemia 4/6 11/39 0.17
Allogeneic BMT 10/28 5/17 0.92
Double Lumen HC 10/23 5/22 0.25
Prophylactic Vancomycin 1/14 14/31 0.023*
Parenteral Nutrition 1/6 14/39 0.87
* Statistically significant (Mann Whitney Test)
CRS rates for the Vancomycin and No-Vancomycin groups are shown in 
Table 6.7. There was a significant increase in the mean duration of 
catheter life in the group which received prophylactic Vancomycin at 
the time of catheter insertion (p<0.02), and episodes of CRS per 100 
catheter days were over three and a half times more common in the 
group which did not receive prophylactic vancomycin. The incidence 
of CRS within 30 days of catheter insertion was reduced in the group 
which received prophylactic Vancomycin(Table 6.7), although this was 
not statistically significant, (p = 0.2).
Table 6.7 Hickman Catheter Related Sepsis: The Influence of
Vancomycin Prophylaxis
No Vancomycin Vancomycin
Total catheter no 31
Total catheter days 
(range)
2*178
(7-37*1)
2265
(20-365)
Mean duration of 
catheter insertion 80 + 97 162 + 107*
Total CRS 16
CRS per 100 days 0.65 0.18
CRS before 30 days 9 1**
* P<0.02 (Mann Whitney) ** P = 0.2 (Fisher*s exact test)
6.2*3.1 Comments on the use of Hickman Catheters.
In our experience the Hickman catheter has proven a useful method
for gaining prolonged venous access in patients undergoing bone
marrow transplantation(7,8). Although patient acceptability is 
excellent, the catheter is not without risk. Serious haemorrhage at
the time of catheter insertion did not occur in our series but this
may reflect the fact that the majority of patients had a normal 
platelet count at the time of catheter insertion, and that 
prophylactic platelet transfusions were given to thrombocytopenic 
patients. The 6 ,5 % incidence of catheter thrombosis in our series 
was lower than has been previously reported(9), and may be related
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to the duration of thrombocytopenia in the post-transplant period.
In the marrow transplant patient the overall incidence of 
septicaemia in the first 30 days is reported to be *J25&, and does not 
appear to have significantly increased with the introduction of 
long-term indwelling central venous catheters(8). Nonetheless in a 
recent review of Hickman catheters in patients with malignancies a 
catheter sepsis rate of 13% was reported(6 ). When bacteraemia is 
such a common complication in this patient population it may be 
difficult to determine whether the catheter is implicated as a 
source of infection. Catheter sepsis may be obvious where there is 
an exit site or tunnel infection but may not be apparent when there 
is bacteraemia alone. In this study it is conceivable that the 
catheter has been incorrectly implicated as the source of infection 
in those patients who had no obvious local signs of sepsis.
Staphylococcus epidermidis has been increasingly implicated in CRS, 
the 77$ incidence in the present study is slightly more than that 
found in a recent review where it was responsible for 5*155 of all 
catheter infections(6). The combination of the Hickman catheter 
allowing transcutaneous spread of infection, profound 
immunosuppression and the intrinsic antibiotic resistance of 
staphylococcus epidermidis may have contributed to the emergence of 
this pathogen. The polyester Dacron cuff situated on the 
extravascular subcutaneous segment of the catheter induces 
fibroblastic proliferation. This may result in a physical barrier 
which prevents migration of both commensal and pathogenic orgamisms 
along the catheter tract from the exit site to the intravascular 
segment.
Attempts at minimising Hickman catheter sepsis have included the use 
of prophylactic granulocyte transfusions(10) and laminar flow 
isolation(11) although the use of experienced nurses specialised in 
catheter management have minimised the incidence of infections(12). 
Perioperative antibiotics may be of benefit in reducing CRS and are 
used routinely in some centres prior to catheter insertion(13).
It is well recognised that skin preparation with antiseptic agents 
will not remove all skin bacteria. This is reflated to the
distribution of the skin flora, many of which are localised in the 
hair follicles(1*l). By the administration of an antibiotic at the 
time of catheter insertion, the potential colonisation of the
catheter may be reduced. In this experience, a number of patients
were given Vancomycin as a prophylactic agent because of its 
activity against normal skin commensals (10055 of S. epidermidis in 
Glasgow Royal Infirmary are sensitive to Vancomycin). The
administration of Vancomycin to this group of patients was 
associated with a significant increase in catheter life and a 
significant reduction in the number of catheters removed for 
infection. The only other factor to significantly increase the 
duration of catheter life was autologous marrow transplantation and 
this is possibly related to the increased post-transplant 
immunosuppression associated with allogeneic marrow transplantation.
The explanation behind this beneficial effect of prophylactic 
Vancomycin remains unclear. There was no difference in the 
incidence of documented septicaemia or positive exit site swabs 
between the two groups. It is possible that prophylactic Vancomycin 
prevents early infection in the skin tunnel and allows tissue
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ingrowth into the cuff before the skin tunnel distal to the cuff 
becomes colonised with bacteria. Even if this theory were correct, 
it is unlikely that prophylactic Vancomycin would reduce the 
incidence of intraluminal spread of infection which is associated 
with manipulation of the catheter system(15). Furthermore, the 
incidence of early catheter infection was not significantly reduced, 
although it is conceivable that the administration of Vancomycin has 
a long-term effect on skin commensal organisms.
In a controlled trial assessing the value of prophylactically 
administered Vancomycin at the time of catheter insertion in 
surgical patients receiving intravenous nutrition, there was no 
reduction in the incidence of CRS(16), although it has been shown 
that CRS is more likely to occur in those patients who are 
immunosuppressed at the time of catheter insertion(17)• 
Prophylactic Vancomycin may therefore have a role in the prevention 
of CRS in the immunocompromised patient who is more susceptible to 
infection with "commensal” skin organisms.
Hickman catheters allow reliable long-term venous access with low 
complication and infection rates. There was no mortality or 
long-term morbidity associated with catheter use in these patients. 
This study suggests that CRS in marrow transplant patients may be 
reduced by the administration of Vancomycin at the time of catheter 
insertion, but these results require to be confirmed by a randomised 
prospective study.
6.2.11 Influence of Provision of CMV Negative Blood Products
As part of a wider study, all patients who had an autologous graft - 
including the patients with AML - who were CMV seronegative, 
received blood products exclusively from seronegative donors. 
Seropositive patients received unscreened products. The rationale 
of such an initiative was discussed in Chapter i!.
This study was intended to determine the extent of the CMV infection 
and pneumonitis in both allografts and autografts, and whether the 
provision of seronegative blood products to the seronegative 
patients was beneficial.
Seventy-one consecutive adult patients undergoing bone marrow 
transplantation have been studied. Thirty-nine received allogeneic 
marrow (5 aplastic anaemia: 3*1 haematological malignancy) and 32 
received autologous marrow for acute leukaemia.
Serological status of each patient to cytomegalovirus (CMV) was 
determined by the anti-complement immuno-fluorescence test 
(ACIF)(18). Patients whose titre was less than 1sl| were designated 
CMV seronegative and thereafter received blood products from a pool 
of community donors who were CMV seronegative. Current CMV status 
of each donor was rechecked immediately after donation. 
Seropositive patients received unscreened products from community 
donors.
Thirty-seven patients, 22 allografts and 15 autografts, were found 
to be seronegative and 3*1 patients, 17 allografts and 17 autografts,
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seropositive. The distribution of patients by age, diagnosis, 
conditioning protocol and graft-versus-host prophylaxis was similar 
in both groups (Table 6 .8). All of the allograft patients received 
bone ;marrow HLA fully match, MLC non-reactive sibling donors.
Of the 22 seronegative allograft recipients 6 received marrow from a 
seropositive donor whereas, of the 17 seropositive recipients, 10 
received bone marrow from seropositive donors.
Table 6.8 Characteristics of 71 patients under evaluation of the 
role of CMV Negative Blood Products
Seronegative
Recipients
Seropositive
Recipients
ALLOGRAFT AUTOGRAFT ALLOGRAFT AUTOGRAFT
Patient no. 22 15 17 17
Age - mean 
- range
21
(13-37)
27
(18-i»3)
27 38
(15-38) (19-54)
Diagnosis - leukaemia 
- aplastic
- anaemia
19
3
15
0
15
2
17
0
Conditioning - cyclo-
phosphamide+TBI 19
- cyclophosphamide alone 3
- melphalan+TBI 0
4
0
11
15
2
0
7
0
10
GVHD Prophylaxis
- cyclosporin A
- T cell depletion
9
13
7
10
Donor CMV status
- seronegative
- seropositive
16
6
7
10
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Post-transplant, all patients were monitored for evidence of CMV 
infection - the criteria of which were isolation of virus grown in 
culture, a four-fold increase in CMV serology, or both. Routine 
culture of throat and urine and serology was undertaken every j 1-i| 
weeks post-transplant for 150 days. The minimum follow-up in these 
patients is 150 days.
Interstitial pneumonitis was characterised by tachypnoea, hypoxia, 
fever and pulmonary infiltration on chest x-ray. Definitive 
diagnosis was attempted by fibroptic bronchoscopy and bronchial 
lavage, with culture and direct immuno-fluorescence. All patients 
received oral cotrimoxazole to prevent pneumocystis carinii 
infection.
Table 6.9 Incidence of cytomegalovirus infection, interstitial 
pneumonitis, and graft-versus-host disease
seronegative
recipients
seropositive
recipients
ALLOGRAFT AUTOGRAFT ALLOGRAFT AUTOGRAFT
Patient no 22 15 16 17
CMV INFECTION 0 0 10 3
Interstitial pneumonitis
- CMV
- idiopathic
0
0
0
0
3
1
0
0
Acute GVHD 
Grade I-II 
Grade III-IV
ij
1
3
3
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Of the 71 patients in the study, one patient - a seropositive 
allograft recipient - died within 40 days due to non-engraftment and 
acute renal failure without evidence of CMV infection. Of the 70 
evaluable patients (Table 6.9), no seronegative patients showed 
evidence of viral infection or pneumonitis. Three of seventeen 
seropositive autografts excreted virus (1855) but did not develop 
pneumonitis. Ten of 16 seropositive allografts fulfilled our 
criteria of infection (6*1%), four (2 5 % ) developed pneumonitis (3 CMV 
and 1 idiopathic).
The incidence of acute graft-versus-host disease (GVHD) grades I-II 
did not differ between the allogeneic groups. Although three 
seropositive patients developed grade III-IV, GVHD versus one of the 
seronegative group, this was not statistically significant.
The blood product requirement did not differ between the groups and 
the seronegative patients received exclusively negative products 
(Table 6.10).
Table 6.10 Red cell and platelet donations required during the 
first 90 days post-transplant
seronegative 
blood products
unscreened 
blood products
ALLOGRAFT AUTOGRAFT ALLOGRAFT AUTOGRAFT
Red cells 19 19 33 18
Platelets 134 114 133 119
6.2.4.1 Comments on the Use of Screened Blood Products
Cytomegalovirus pneumonitis is an important complication of 
allogeneic bone marrow transplantation, occurring in 10-15/5 of 
cases, but it seldom responds to treatment. The extent of the 
problem in autologous transplants has not previously been clearly 
defined. On review of a larger number of autografts who had similar 
conditioning protocols, pneumonitis of all aetiologies was 
unusual(19). The apparent difference may be related to differences 
in the degree of immunosuppression and speed of immune 
reconstitution.
It is assumed that CMV infection originates from latent infection in 
the host or that it is a result of primary infection most probably 
transferred by blood products or possibly allogeneic bone marrow 
cells. Primary infection from other sources is considered unlikely.
Seronegativity as measured by current techniques is taken to 
indicate absence of latent virus, so the likely source bf infection 
is blood products or bone marrow cells. Our finding that provision 
of products which are seronegative results in low rates of infection 
and pneumonitis supports that contention. Seronegative patients who 
receive products from unscreened donors have an increased incidence 
of CMV infection. Only three of our donors were seropositive and 
did not transfer infection, but this is insufficient data to exclude 
donor status as a relevant factor, although recent studies suggest 
that it may be(20).
No patient in this study received granulocyte transfusion. In
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previous studies granulocytes from positive donors result in higher 
infection rate even in seronegative recipients(21).
The demonstration that the same strain -of virus was found in 
infections post-transplant as was present pre-transplant(22) 
suggests that reactivation of latent virus is the likely mechanism 
of infection in seropositive patients. Screened products in these 
patients have little effect on the incidence of infection. Such a 
subgroup would appear to be at high risk and alternative strategies, 
such as high titre immunoglobulin or anti-viral agents are currently 
under evaluation. There is no evidence to suggest that 
immunoglobulin would be an effective alternative or addition to 
screened blood products(21), despite some indication of 
effectiveness when used alone(23,2*1,25).
This experience in seventy-one patients suggests that provision of 
seronegative blood products is an important contribution to the 
supportive care of seronegative recipients of allogeneic bone marrow 
transplants, but because the incidence of infection and pneumonitis 
in the autografts is so low the considerable logistic effort 
necessary to obtain such products for these patients is probably not 
justified.
6.3 HAEMAT0L06ICAL REGENERATION
One of the concerns at the time of the introduction of these studies 
was whether bone marrow, which had previously been subjected to 
intensive chemotherapy, would be capable of full regeneration, and 
sustained haemopoiesis. Within this series the patients received a
variable amount of chemotherapy, and had various periods of delay 
pre-autograft so it is possible to examine these and other 
questions.
6.3.1 Neutrophil Regeneration
All 25 patients showed evidence of neutrophil regeneration. It is 
probable that a proportion of the neutrophils which reappear are 
derived from the committed myeloid precursors transfused with the 
autograft - the equivalent of the CFU-GM population. These may be 
relevant, particularly to early neutrophil regeneration, whereas 
sustained recovery to levels in excess of 1 x 10^/1 may derive from 
the pluripotent stem cell compartment.
A peripheral neutrophil count of 1 x 10^/1 was taken as indicative 
of successful engraftment. Few patients, either allografts or 
autografts, fail to sustain their counts thereafter, whereas it is 
not infrequent that lower levels may be reached without any 
subsequent improvement.
Of the 24 patients evaluable (patient UPN024 excluded), 4 
regenerated in relapse and failed to achieve 1 x 10^/1 neutrophils, 
and one (UPN020) has had a persistently hypoeellular bone marrow and 
achieved 1 x 10^/1 neutrophils for the first time 7 months 
post-autograft. Nineteen patients were therefore evaluable in whom 
to assess the kinetics of neutrophil recovery.
A control group of allograft recipients, who received identical 
ablative treatment, did not develop graft-versus- host disease, and
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whose marrow was not manipulated to remove T cells ex-vivo, was used 
for comparison. The autograft patients regenerated more slowly 
(Figure 6.1). The median time for the allografts to achieve
1 x 1()9/1 was 19 days (range 12-32) compared; with the autografts 33' 
days (range 22-59).
Figure 6.1 Neutrophil Regeneration of Autografted Marrow in AML
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If the autograft group receiving marrow stored at 1}°C (protocol A) 
is compared with those receiving cryopreserved marrow (protocol B) 
no important differences are seen (Figure 6.2). It should be noted 
that the curve representing the cryopreservation group in this 
diagram includes patient UPN020 referred to above.
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Figure 6.2 Comparison of Neutrophil Regeneration: Protocol A vs
Protocol B
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When all 2*1 patients who are available for scrutiny, and the 
patterns of neutrophil regeneration of patients who have relapsed is 
compared with those who survive in remission a difference (6^ *56 vs 
100?) can be seen(figure 6.3), but this is largely explained by the 
1} patients who regenerated in relapse. If these early relapsers are 
excluded and the 7 patients who subsequently relapsed between 4 and 
11 months is compared with the long-term disease-free survivors, no 
differences are observed (Figure 6.4).
The fact that some autograft patients remained relatively 
neutropenic for a longer period than is usual with allografted 
patients did not result in a higher incidence of infection or 
pyrexial incidents in the 2-5 weeks post-transplant.
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Figure 6.3 Neutrophil Regeneration: Relapsers vs Non-Relapsers
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Figure 6.4 Neutrophil Regeneration: Non-Relapsers vs Late Relapsers
100-i
90-
80-
70-
60-
50-
40-
30-
20-
10 -
o*n
J--H1
9-— 6
— r~ 
10
9— 6
i
i-Wi
96
1
t
u6
9— -6
1
•4
 -----   Non-relapsers(n:12)
9— -0 Late relapsersCn:7)
I I o I'"* I "1"
15 20 25 30 35
— r~ 
40
» ■!---- r*
45 . 50 55 60
OAYS POST AUTOGRAFT
249
6.3.2 Platelet Regeneration
Delayed recovery of platelet count is regularly observed following 
allogeneic grafts despite evidence in the peripheral blood and bone 
marrow of erythroid and myeloid engraftment and regeneration. This 
is usually associated with megakaryocyte engraftment in the bone 
marrow although the precise cause of failure of platelet 
regeneration is often ill-defined. There is a well recognised 
association with GVHD but the phenomenon is also seen in the absence 
of clinically obvious GVHD, but could nevertheless be a 
manifestation of subclinical GVHD.
In this series of autograft patients persistent thrombocytopenia was 
unexpectedly frequent. In only one patient (UPN020) could this be 
attributed to poor graft function characterised by a hypoplastic 
marrow, persisting neutropenia and thrombocytopenia which 
necessitated several weeks of outpatient blood product support. 
Four patients regenerated in relapse and never recovered to a 
platelet count of greater than 20 x lO^/l. If these five patients 
and the early death (UPN02H) are excluded, platelet regeneration is 
still considerably delayed. The kinetics of recovery to a level of 
50 and 100 x 10^/1 are shown in Figure 6.5 and 6.6. In Figure 6.5 a 
control group of allogeneic patients are compared. These patients 
all had HLA fully matched donors, received identical ablative 
treatment, did not develop clinical evidence of GVHD and all 
received grafts which were not manipulated ex vivo to remove T 
cells. It is noteworthy that all the allograft patients rapidly 
recovered to 50 x 10^/1 within a median time of l| weeks but the 
median time to achieve this level in the autograft group was 20
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Figure 6,5 Kinetics of Platelet Regeneration to 50 x 10^/1 in 
Autograft for AML vs Allograft
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weeks, and only 64/f had achieved a count of 100 x 109/1 by 2 years 
post-graft (Figure 6.6).
Of these 19 patients, 11 received Cyclophosphamide and single 
fraction TBI with 1}°C stored bone marrow (Protocol A), and 8 
received Melphalan and fractionated TBI with cryopreserved marrow 
(Protocol E), but there were no important differences between these 
subgroups in regeneration kinetics to 50 or 100 x 109/1 platelet
counts (Fig 6.7 and 6.8). ;
Figure 6.7 Platelet Regeneration to 50 x 10^/1 in Evaluable
Patients: Protocol A vs Protocol B
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Seven of the 19 patients relapsed later between tj and 11 months.
But, if the regeneration patterns between these later relapsers and 
the non-relapsers are compared to a level of 50 x 10^/1 no
difference is apparent (Fig 6.9) but fewer patients who relapsed 
late achieved a platelet count of 100 x 109/1 than did the 
non-relapsing subgroup vs 82%) (Fig 6.10). While failure of
platelet regeneration was more frequent in the patients who 
subsequently relapsed this may simply be interpreted to mean that 
they were not permitted sufficient time to achieve these platelet
levels before relapse intervened, rather than indicate a direct, and 
possibly predictive, relationship to eventual relapse. It should be 
noted that the recovery of platelets in the non-relapsers, now 
followed for a minimum of 15 months, was slow and therefore
persistent thrombocytopenia is not necessarily indicative of
eventual relapse since approximately half the long-term remitters 
failed to achieve a count of 100 x 10^/1 by 12 months 
post-autograft.
Figure 6.9 Platelet Regeneration to 50 x 109/1: Relapsers vs
Non-Relapsers
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Figure 6.10 Platelet Regeneration to 100 x 10^/1: Relapsers vs
Non-Relapsers
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These differences are not explained on the basis of quantitative or 
qualitative variations in pre-autograft chemotherapy or the cell 
dose given. As will be illustrated later, delayed platelet 
regeneration is not j seen in the majority of patients autografted 
with an identical ablative protocol for acute lymphoblastic 
leukaemia. Since the majority of that group of patients were in 
second remission, they were at least as heavily treated as the AML 
patients. Platelet antibodies were not detected in any of these 
patients. f
Despite persistent thrombocytopenia, it was not our policy to 
administer platelet support, except in the patient (UPN020), 
previously referred to with poor engraftment. This conservative 
approach resulted in no untoward clinical consequences.
6.3.3 Days Spent in Hospital
A consideration for patients contemplating this form of treatment is 
the duration of hospitalisation. This is important from a health 
care resource point of view, and is included along with other 
individual patient details concerning the marrow harvest and 
haematological regeneration (table 6.11). The median number of days 
to elapse before discharge from hospital after the graft was 
31 (range 20-56). The minimum criteria set for achieving discharge 
was usually a neutrophil count of 1 x 10^/1, good mobility and food 
intake. In practice, some patients left hospital before the 
neutrophil target had been achieved.
Ta
bl
e 
6.
11
 
Gr
af
t 
Ch
ar
ac
te
ri
st
ic
s/
Bl
oo
d 
Pr
od
uc
t 
Su
pp
or
t/
Ha
em
at
ol
og
ic
al
 
Re
ge
ne
ra
ti
on
 
of
 
Au
to
gr
af
t 
Pa
ti
en
ts
255
0)
-p
•H
(X W 
CO >» 
O Cd 
ffi Q
o CO O
•H i—i O *—
-P -H o CO
Cd .C T—ft f t  A  H
d) O NG ft cn co
0) -P o o f»
bO 3 O  T~ cd *—
d> 0) in •a x—« 2 /\ X w
rH
cd
o
•H
bO o x—
O co o cn
H 4-5 T—
o d) A  r-1 ✓“S
4-5 H s CO
cd d> cn
s -P o d)
d> cd o t- d)
cd r—1 in £ o
ffi PU / \  X in
O -P
3
•oo
ft(ft
•Oo
oH
cq cn
<D bO 
co j *  
O v. 
Q  COoO T-
2
2 X
d)(0 bo 
O X
o \
CO 
iH O  
r-1 r “ 
0)U K
.H
s
£ d) 
O S 
ft 3
ft r-l
0} O
s >
2a.
2
co
4-5
G
2
VO
CM
CM
co
o
m
t-
CM
O
CO
CO
CO
o
CO CM
CM
CO
CO
CO
cn 
CM
CO
CO
CO
in
CM
C7\
VO
CM
CO
CM
CM
ov
43"
OV
CM
<d
2
VO
43-
CM
OV
CO
VO
CO
o
fc-
CM
4=T
vo
in
o
in
in
VO
43-
43-
OV
CM
CO
CO
fc-
CM
CO
CM
O
VO
O
cn
co
vo
CM
«aj
2
43-
CM
O
VO
CO VO
CM
CO
CO CO
CM
CM
in co
CO
t-
CO CO
CM
cn in
co
cn
in
coo
o
cn
co
o
xr-
fc-
in
t-
o
COo
o
CO
C“-
o
CM
cn
o
vocn
in
c-
CM
oo
CMoo
CO
oo
o
o
ino
o
voo
o
oo
COo
o
cn
o
o
Ta
bl
e 
6,
11
 
Gr
af
t 
Ch
ar
ac
te
ri
st
ic
s 
Co
nt
in
ue
d
256
a)
p•Hcx co 
co t>> 
o co
o CO O
•H rH O CM
P •H O cn
a) .G
G (X /S rH
<u O s
G G OV 03
0) -p O O >>
bO o o T— cd •=r
<D a) in •O «—
K / \ X
i—i
cd
o
•H 5
bO o
O CO o
rH p r —
o 0) A rH
p *—i N co
cd o OV X
S p O CD0) cd O x— 0)
cd rH in £ <S
EC P-i / \ X
CO
Po
3
•ao
g
PU
TJo
oH
03
P
•H
G
ED
a> bo
03 X  
O 'N. 
QCO 
O 
O  'r -
ES
2 X
d)
03 bO 
O .X 
Q \
CO 
•H O  
rH t—
Q)
a x
■—i
a
5 0)
o s 
g oP-t i—i(0 o 
s  >
a,
o
ov
CM
•=r
m CM
vo
in
CM
cn
o
CM
c-
cn
co
CM «
in
co
<0
<
s
<c
o
CO
CM
fr-
CM
Ov
in
o
•=r
ov
co
■=r
v o
CM
CM
o
CM
.=r
cn
c n
vo
CM
vo
in
v o
■=T
fc-
O
OV
OV
in
co
c n
vo
t-
t-
cn
o
ov
CM
cn
vo
CM
in
in
CM
o
in
<0
o
cn
CM
co
t-
co
o v
v o
CO
OV
VO
VO -=r
CM
if
c n
ov
v o
.=r
c n
cn
o
CM
c n
c n
CM in
ov
c n
ov
cn
CM
v o
o
CM
Ov
O
i n
Ov
o
cn
ov
in
c-
o
o
cn
co
o
co
ov
o
in
o
o
co
o
o
CM
o
cn
x—
O
■=r
o
inX—
o
VO
o
t-
o
CO «— 
o
Ta
bl
e 
6.
11
 
Gr
af
t 
Ch
ar
ac
te
ri
st
ic
s 
Co
nc
lu
de
d
257
co
4-1
•H
O. CO 
CO >» 
O 01 
EC O
£
O CO o
•H rH o C O
-P •H o •=T
cd .£
£ a A  rH<D o
£ £ O N co
d) 4-1 o  o >»
50 £ o  *- cd <—
d) d) in T) C O
PS 53 /V X
rH
cd
o
•H
50 o
O CO O <d
H 4-1X— 55
o 0) /\ rH4-1 rH S (0
cd d) ON .X
S 4-1 o d)0) cd O  T- .d)
cd rH in ;s «a*
as cu /\ X 55
CO
d) r ^ in
CO rH CO CM
■P 0) P x—
O 4-1 *H
£  Cd £
TJ H  D
O v r
£
CU
co
•o  4->
O *rt
O O  £
rH CQ O in
CQ «  w
Q) bO
n .x o \
QOO
oO T -
s
S  X
0)
CO bO 
O  .X 
Q  ^  
co 
rH O  
H  1 0
O X
rH
s
5 d) 
o  S  
£  £  
fc* H
cd O 
S  >
aPh
o
in
in
co
in
in K
CO
-=T
ON
CO
<
o
o
CO
in
co
co
in
in
co
o
co
co
o
c—
<d
<C
<Jj
s :
<d
o
-=T
O
in
<4S
fc-r^
<d
«3J
m
cm
CM
CM
O
CM
CM
•=r
CM
CM
CM
ON
CM CO
o
CO
o
CO CM
o
V
CO
Q.
cd
rH
d>
«
a
•H
•O
0)4^
cd
£
d)
£0)50
0)
PS
PS
PS
VO
4T
t-
CM
CO
VO
CO
CO
c—
CO vo
t -
CM
CM
in
vo
ON
o
ON
VO
CM
C O
c -
CM
•sr
vo
VO
-=r
t -
o
ON
o
ON
•o
<D
>
d>
•H
.£
O
cd
-p
o
a
«aj
S£
ON
o
o
CM
O
CM
O
CM
CM
O
C O
CM
O
-=r
CM
O
in
CM
o
6.3»*1 Pattern of Megakaryocyte Stimulatory Activity Post-Transplant
Relatively little is known about the humoral regulation of 
megakaryocytopoiesis, although a megakaryocyte growth factor has 
recently been characterised(26). As with other in vitro assays of 
the Committed1 stem cell compartment, there is an optimum source of 
stimulatory activity for the Megakaryocyte Colony Assay (CFU-Mega).
The plasma of post-transplant patients is a rich source of this 
activity and is the source of the stimulatory activity used
routinely for this colony assay. The method and morphology of these
colonies are outlined in Figures 6.11 and 6.12. Since it was known 
that this stimulatory activity normally diminishes to zero over the 
subsequent 3 or 4 weeks post-transplant, we* decided to study the 
pattern of its activity on an unselected group of transplant 
patients (allogeneic and autologous) and correlate its activity with 
other parameters of platelet regeneration.
Seventeen patients were evaluated, 9 autografts and 8 allografts.
Six of the 9 autografts were patients in the AML autograft protocol 
and 3 had ALL. Of the 8 allograft recipients 5 had myeloid 
leukaemia and 3 had ALL. Plasma samples were taken immediately
pre-transplant and on post-transplant days 5,10,20,30 and 35. The 
heparinised samples were centrifuged (2000 rpm for 10 minutes) 
within 30 minutes of collection, the supernatant plasma was filtered 
(0.22 um) and stored at -20°C.
* The megakaryocyte Colony Assay and the technical work in these 
experiments was carried out by Mr Alistair Lamb F.I.L.M.S. as part 
of an MSc Thesis.
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Figure 6.11 Method of CFU-Mega Assay
Culture additives:- 1 x 10^ separated
mononuclear cells
Iscove’s Modified Dulbecco’s Medium 
(IMDM) containing
- 30^ heparinised (15 units/ml) 
stimulatory (or test) plasma
- 5 x 10"5m mercaptoethanol ) 1 ml
5% PHA conditioned medium
i
0.9/S methylcellulose /
Bone marrow cells are separated as described in section
5.8.1 and, as before, the PHA conditioned medium is 
prepared as described in section 5.8.2. This method was 
described by Messner(27).
Morphology of CFU-Mega in Vitro
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Figure 6.12 Characterisation of CFU-Mega Colony
(a) The Cells comprising the in Vitro Colony plucked off and 
stained with Wrightfs Stain and viewed at x1000 
magnification, clearly have the morphological 
characteristics of Megakaryocytes.
(b) Cells removed from an in Vitro Colony, incubated with 
the monoclonal antibody J15 which recognises the 
glycoprotein Ilb-IIIa complex on the megakaryocyte 
membrane(28). Following incubation, the suspension is 
treated with FITC labelled goat-anti-mouse and viewed at 
x1000 magnification by Fluorescent microscopy.
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6.3^*1 Assay of Stimulatory Activity
Test plasma samples were set up as the source of megakaryocyte 
stimulatory activity in the CFU-Mega Assay. On each occasion a 
plasma of known stimulatory potential is set up in parallel. Normal 
donor bone marrow is used as the target cell population for each 
assay and the colony numbers produced by the test plasma were 
compared with those produced by the rreference1 plasma. The result 
is expressed for the test plasma as a percentage of the activity of 
the reference plasma:
no. colonies x 1q5 cells generated by test plasma
x 100
no. colonies x 10^ cells generated by reference plasma
When the stimulatory activity, post-transplant, is plotted and 
compared with the platelet regeneration and the presence of 
megakaryocytes in the bone marrow, 4 patterns of response are 
observed.
The first pattern was shown by 6 patients, designated Group 1, and 
represents what could be regarded as the prototype of a normal 
sequence of events (Figure 6.13a). The megakaryocyte stimulatory 
activity is initially high on Day 5 at 87$ of reference plasma 
levels and progressively declines until it is undetectable by Day 
35. This activity is inversely related to the pattern of platelet 
regeneration which recovers towards normal within 35 days. 
Megakaryocytes are present in the bone marrow.
The second pattern (figure 6.13b) has only been seen in 2 patients 
(Group 2) whose day 5 stimulatory activity is 68$ but falls off
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progressively as in group 1, but these patients have remained 
thrombocytopenic with platelets recovery to 50 x 10^/1 not taking 
place till 22 and 39 weeks post-graft. Marrow megakaryocytes 
however are readily apparent. I
In Group 3 (5 patients - figure 6.13c) initially normal stimulation 
activity is apparent, but persists at day 35; thrombocytopenia 
persists, but only occasional megakaryocytes are present in bone 
marrow. j
In Group (1} patients - figure 6.13d), stimulatory activity is 
initially subnormal but diminishes to an undetectable level on day 
35, thrombocytopenia persists and megakaryocytes are scanty on 
marrow examination.
6.3.4.2 Clinical Relevance of Patterns of Response
Clinical details of the individual patients in these studies are 
shown in table 6.12. There is little relationship between these 
subgroup patterns and conditioning protocol or diagnostic category 
although 3 of the 5 ALL patients are in group 1.
Group 2 patients characteristically show megakaryocyte hyperplasia 
with thrombocytopenia suggestive of peripheral platelet consumption 
or destruction. Using the techniques for platelet antibody 
detection available locally, none of the 17 patients showed platelet 
antibodies.
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Group 3 patients are characterised by persistent CFU-Mega 
stimulatory activity. An inverse relationship between activity and 
megakaryocyte numbers in the bone marrow has been reported(29), and 
it is of interest thatj 3 of these 5 patients had poor graft function 
and were the only 3 of the 17 patients to receive a top-up marrow 
infusion.
In group *1 stimulatory activity on day 5 was suboptimal but became 
undetectable, as with the other groups. There were however few 
megakaryocytes in the bone marrow and persistent thrombocytopenia. 
All of these *1 patients relapsed within 5 months of transplant.
If the relationship to relapse is examined, all the early relapses 
have occurred in group *1. Two later relapses (at 12 and 13 months) 
were seen in group 1 and none in the other groups.
Failure to regenerate a normal platelet count has been observed in 
*1/6 patients who eventually relapsed but, since 6 of 13 long-term 
survivors of autograft had poor platelet regeneration, 
thrombocytopenia itself is not a useful indicator of outcome, as 
previously discussed.
There was no correlation between the presence of absence of 
megakaryocytes in the bone marrow, and relapse. Both Group 3 and *1 
had relatively few megakaryocytes in the bone marrow but the 
relapses were confined to Group *| (0/5 in group 3 vs in group 
*1). The only way of distinguishing these groups is that the 
megakaryocyte stimulatory activity in Group *1 on day +5 was less 
than that of the other subgroups. Whether this finding will be a 
reliable predictor of subsequent relapse, and, if so, the nature of
270
the underlying mechanism, are both matters of continuing study.
6.4 IMMUNE RECONSTITUTION
i
Suppression of cellular and humoral immunity following allogeneic 
bone marrow transplantation has been widely reported and a notable 
feature is its prolongation for a considerable period after the 
peripheral lymphocyte count has returned to normal levels. As 
previously mentioned, the pace of reconstitution is delayed, and the 
suppression more marked in patients with graft-versus-host disease 
(30). Disturbances in lymphocyte subpopulations have been 
demonstrated in such patients by Fc receptor analysis (31) 
heteroantisenum (32) biochemical analysis (33) and more routinely in 
recent years by commercially available monoclonal antibodies 
(3^ 35,36) all showing an excess of subpopulations with suppressor 
and cytotoxic activity in vitro. Whether these changes are a 
consequence of the ablative treatment with subsequent regeneration, 
subclinical graft-versus-host inter-reactions, or a specific feature 
of allogeneic compared with autologous recovery is not fully known. 
It was at one stage suggested that such disturbances were predictive 
for the development of GVHD (32).
Similar patterns of suppression of cellular and humoral immunity 
have been demonstrated follow syngeneic (37) and in a few cases of 
autologous bone marrow transplantation where high dose chemotherapy 
was used (38), and this too persisted after normal levels of 
circulating lymphocytes had been achieved.
This autograft study, together with information drawn from some of
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our allograft patients, offered the opportunity to make direct 
observations and comparisons of the pattern and pace of T-subset and 
humoral immunity regeneration as a limited assessment of immune 
reconstitution.
The 10 allografted patients included in this study received HLA 
matched allogeneic grafts from sibling donors following ablative 
treatment with Cyclophosphamide and TBI, either as a single fraction 
(950 cGy) or fractionated (6 x 200 cGy). The primary diagnosis was 
AML or ALL and graft-versus-host prophylaxis was either Methotrexate 
or Cyclosporin A.
Lymphocyte subpopulations were identified on ficoll-hypaque 
separated peripheral blood mononuclear cells by antigen expression 
detected by indirect immunofluorescence observed by microscopic or 
flow-cytometric techniques. Commercially available monoclonal 
antibodies were used for pan-T (CD3/OKT3) helper-inducer subset 
(CD^/OKT*!) and suppressor-cytotoxic subset (CD8/OKT8) (Ortho 
Diagnostics Inc). Results were derived from 500 cell differential 
counts, or, in the case of flow-cytometry orders of magnitude more, 
with all samples being examined in duplicate.
6.M.1 Recovery of T Subsets following Ablative Treatment
Fifteen autograft patients were available for analysis over a 
12-month period. Although they received different ablative 
protocols (protocols A and B), there were no differences between 
these groups, so all autograft patients were examined together.
6.4.1.1 Changes in Percentage of Subgroups
Both the autograft and allograft patients had normal percentages of 
all 3 subtypes before transplant. Both transplant groups had lower 
helper subset (CD4) but this was not significantly different from 
controls.
A control population of 11 healthy volunteers was used for 
comparison. Re-examination of patients was undertaken 20 weeks 
post-graft because, for most patients, this represents the period of 
most obvious change from the pre-graft profile (Figure 6.1*1).
Figure 6.14 Change in Percentage of T Cell Subsets in Allografts 
and Autografts following Transplantation
CD3 CD4 CD8
90-
pre
80- post
70-
posti- 60- pre
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40-
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30-
20-
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n: controls a: autografts b: allografts mean* s.d.
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Allograft patients have a significantly lower percentage of T cells 
(CD3 positive cells) compared with the autografts (46.1 i 11.7 vs 
68 i 7.7: p=<0.001) who are not significantly different from
pregraft levels. Both groups have significantly lower proportions 
of helper cells (CD4 positive) than normal and are significantly 
reduced from their own pre-transplant levels in each case [Auto
20.2 ± 5.6 vs 210.1 ± 12.5 (p=<0.001): Alio 19 ± 7.8 vs 41.3
± 8.2 (p=<0.001)]. Although there was a trend in both groups to 
have an increased proportion of suppressor cells (CD8 positive), 
this did not achieve levels of statistical significance.
If calculated in absolute numbers of T cell subtypes, the 
considerable variation between patients obscures any consistent 
trend (Figure 6.15) except perhaps a slight but non-significant 
increase in suppressor cell (CD8) numbers. If examined on an 
individual patient basis and expressed as a helper/suppressor ratio, 
there is a clear reduction in ratio following transplant in both
Figure 6.15 Changes in Absolute T Subset Numbers in Allograft and 
Autograft following Transplantation
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groups resulting from the combined effect of a reduction in the 
proportion of helper cells (CD^ I) and an increase in suppressor cells 
(CD8), although the former is the more substantial effect. There 
are no significant differences between the 2 transplant types in 
reversion of the ratio to greater than unity, but there is some 
suggestion that the pace of autograft recovery may be slightly 
quicker than the allografts in the 12 month follow-up illustrated in 
Figure 6.16.
Figure 6.16 Change in the Helper/Suppressor Ratios in Allografts 
and Autografts following Transplantation
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Humoral immunity within the limited definition of serum immuno­
globulin levels of IgG, IgA and IgM was measured for 2 years in the 
AML autograft patients and 12 control allograft patients who avoided 
significant GVHD. For reasons which are unclear, the levels 
maintained by the autografts were higher than the allografts, and 
tended ta be at the lower limit of the normal range pre-autograft,
and remained so during the 2 year follow-up. At no time, however, 
were the differences between the transplant types significant. The 
ablative treatment made little impact on immunoglobulin 
levels(figure 6.17).
Figure 6.17 Serial Changes in Immunoglobulin Levels in Allografts 
and Autografts following Transplantation
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Figure 6.17 Continued
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The substantial alteration in the numbers of T cells expressing 
helper or suppressor phenotype have been described following 
allograft by several groups (39, 40, 41). The most important effect 
is a persistent reduction in helper cells (CD4 positive) with a 
relative increase in suppressor cells (CD8 positive). The resultant 
inversion of the helper/ suppressor ratio was initially thought to 
be a consequence of graft-versus-host disease (42) or implicated in 
its cause (32). These autograft patients have demonstrated no 
detectable difference in the pattern seen in an allograft 
population, receiving identical ablative treatment and thus strongly 
suggest that the charges consistently observed are unrelated to GVHD 
but are rather the physiological responses to ablative treatment.
AutograftS^
6-
5-
4-
3-
2 -
Allografts
MONTHS POST TRANSPLANT
While such changes are consistent with the increased susceptibility 
of transplant patient to infectious complications, they do not 
explain the apparent greater intensity of immunosuppression in the 
allografts. More subtle testing of immune function demonstrates the 
profound complexity of events in immune reconstitution following 
transplant (43) but relatively little such detailed information is 
yet available in autologous transplantation.
6.5 PULMONARY CONSEQUENCES ?
The observations made in Chapter 2 concerning the multifactorial 
causes of pneumonitis in allogeneic transplantation, and the 
deductions made from that information, suggested that pneumonitis 
would not be a serious risk in autologous transplantation. In this 
series two patients developed pulmonary symptoms with radiological 
changes. A 53 year old man (AUT.004) had already relapsed before 
developing progressive tachypnoea with falling PO2 and bilateral 
infiltration of the lung fields. Over three days his pulmonary 
function progressively deteriorated despite assisted ventilation. 
At post-mortem adenovirus was grown from the lung biopsy which was 
considered to be the causative agent. A second patient (AUT.008) 
developed increasing exercise intolerance over two weeks and 
presented with a mild pyrexial, unilateral chest signs and reduced 
PO2 . Pulmonary function did not deteriorate but trans-bronchial 
lung biopsy and broncheo-alveolar-lavage specimens did not isolate a 
pathogen. This patient made a full recovery following the 
administration of broad spectrum antibiotics. In the remainder of 
this series and in a further twenty autograft patients, given an 
ablative chemo-radiotherapy protocol, no cases of pneumonitis have
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occurred. Our experience of one case in an autograft experience of 
forty-five patients endorses the prediction that this complication 
would be of low incidence in autologous transplantation. The 
prognosis of the single patient who did develop pneumonitis was 
already poor due to relapse of his leukaemia.
6.5.1 Subclinical Effects on Pulmonary Function
As well as overt pneumonitis, subclinical changes in lung function 
may be expected following chemo-radiotherapy. Assessment of the 
autograft series offered base-line measurements which could be 
attributed to the conditioning protocol without a significant 
contribution from other factors such as graft-versus-host-disease, 
profound immunosuppression, and post-graft immunosuppressive 
therapy.
Alterations in pulmonary function have been described on serial 
assessments in allograft patients. Some of these defects have been 
progressive. It is not clear whether these changes are due to the 
ablative treatment per se, or a manifestation of graft-versus-host 
disease.
Three clinical studies have previously been reported. Dupledge and 
colleagues ( M )  at The Royal Marsden Hospital made serial 
observations on allograft recipients, all of whom received
Cyclophosphamide and TBI. Minor defects were apparent 
pre-transplant, possibly explained by previous chemotherapy, 
infection, or leukaemia infiltration. The latter explanation is 
less plausible since no differences were noted between patients in
relapse or remission. Serial observations carried out over 12 
months showed no change in lung volumes but a reduction of around 
205S in diffusion capacity (DlCO) which tended to recover at about 9 
months. Separate analysis in younger patients (<18|yrs) revealed a 
similar reduction in lung volumes and FEV.J to that seen in diffusion 
capacity for the whole group. Of particular interest was that 17 
patients with mild skin GVHD showed no differences in pulmonary 
function to those without GVHD. In 5 patients with severe GVHD 
there was severe reduction in diffusion capacity.
In the first of his two studies from Seattle, Springmeyer(*l5) 
observed 81 patients over a 2 year period. As a group they also 
showed a mild reduction in predicted diffusion capacity 
pre-transplant. A possible insult to the lungs is fat embolisation 
from the infused marrow - while this may have occurred in these 
patients, pulmonary function testing only detected minor changes 
reduction in lung volumes). Unlike the Marsden series, serial 
testing showed no evidence of sequential change. There was no 
difference between patients receiving radiation (leukaemias) or not 
(aplastics). Consistent changes were not apparent in those patients 
with GVHD. The development of pneumonitis was however associated 
with a restrictive defect with reduced diffusion capacity which 
usually pre-dated the clinical syndrome by 2-3 weeks. Such an 
observation, however, is not a useful predictor of pneumonitis since 
there was a subgroup of patients with a 20£ reduction in diffusion 
capacity who remained symptom free.
The possibility of long-term pulmonary problems has been raised by 
Springmeyersf study of patients over a *1 year period (*J6). Patients
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were assessed at 3 months (the customary time of departure from 
Seattle) and thereafter annually. Thirty-nine patients completed 4 
years of follow-up, 18 of whom were leukaemics who received 
irradiation. Restrictive changes (reduced TLC and VC) were noted at 
12 months, but these changes were unrelated to the presence of GVHD 
or inclusion of TBI in the protocol. Most changes were mild 
(<20$ reduction), occurred in 15$ of cases, and were not 
progressive. More severe changes were noted in those patients who 
had recovered from pneumonitis. Obstructive Changes (reduced FEV<j) 
were also observed, most cases having less than 30-^0$ reduction 
from pre-transplant measurements. These changes were unrelated to 
the presence or absence of GVHD, previous pneumonitis or TBI. Of 
some concern is the observation that a higher proportion of patients 
showed abnormality with time, for example, 18$ at one year and 26$ 
at i] years.
6.5.2 Sequential Changes in Pulmonary function: Comparison of Four 
Cytoreductive Protocols
Serial pulmonary function tests have been performed on more than 
seventy patients treated for haematological malignancy, with 
allogeneic or autologous bone marrow transplantation. These 
patients were similar in terms of disease status, age and prior 
chemotherapy but received four different chemo-radiotherapy 
protocols and, for allografts, post-graft GVHD prophylaxis. This 
provided an opportunity to examine the subclinical effects of these 
different chemo-radiotherapy on pulmonary function. Since the 
intention was to delineate differences between allogeneic and
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autologous transplants, patients who had complications such as GVHD 
or pneumonitis were excluded from the study.
On this basis, 40 patients wbre followed. All had serial data for 
the first 12 months post-transplant. Several have had subsequent 
follow-up for 3-5 years but the data is less complete. The first 
group (designated Group I) comprised 5 recipients of allogeneic 
transplants. All were conditioned with Cyclophosphamide 60mg/kg x 2 
and TBI (6 x 200cGy) with lung shielding restricting the lung dose 
to 1100cGy. They all received Cyclosporin A as GVHD prophylaxis. 
Group II comprised 10 allograft recipients, conditioned with 
Cyclophosphamide 60 mg/kg x 2 and TBI (7 x 200cGy) with lung 
shielding at 1100cGy. T cell depletion of the allografted marrow 
was the only GVHD prophylaxis in this group. Group III comprised 14 
autograft recipients who received Melphalan 110-120 mg/m2 and 
TBI (6 x 200cGy) with lung shielding at 1100cGy, as myelo-ablation, 
and in Group IV were 11 autograft recipients whose ablative protocol 
was Cyclophosphamide 60 mgs/m2 and TBI (950cGy) as a single fraction 
at a dose rate of 5.5cGy/min with lung dose limited to 800cGy. 
These groups primarily reflect the evolution of the TBI approach 
used at this centre as we have moved from single fraction at low 
dose rate to fractionated schedules with higher total dosage.
6.5.3 Tests of Pulmonary Function
Lung volumes were measured by Vital Capacity (VC) and Residual Lung 
Volume (RLV) and Total Lung Capacity (TLC) by spirometric techniques 
(47) and an assessment of dynamic movement of air volume by the 
Forced Expiratory Volume in One Second (FEV<|). Such tests detect
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air trapping as would occur in airways obstruction and reduced lung 
elasticity as would be found in pulmonary fibrosis. Gas transfer 
(Diffusion capacity) was measured by a single breath technique on a 
standard respirameter (47). The tests depend on patient compliance 
and avoidance of significant anaemia during testing. These patients 
were all fit enough to co-operate with the testings and had no more 
than minor degrees of anaemia, for which correction was made in 
calculating the test result. For each patient test results were 
expressed as a percentage? of predicted values set out in standard 
reference tables(47). The results are presented in the subsequent 
sections as the actual values pre-transplant but subsequent serial 
values are expressed as percentages of the individual patients* pre­
transplant value. Statistical analysis of serial changes were 
carried out using the Student*s T Test for paired data. The p value 
on the tables indicate the significance of any change from 
pretransplant values.
6.5.4 Diffusion Capacity
The patients can only produce a valid result in this test if they 
have normal haemoglobin levels, and can sustain inspiration for at 
least 10 seconds. Only a few patients who could not satisfy these 
criteria were excluded from study.
In the four groups of patients, the patients in Group IV (single 
fraction TBI autografts) had a significantly greater diffusion 
capacity pre-transplant than the other three groups (Table 6.13). 
The reason for the minor difference seen is unclear, but they may on 
average have been further away from remission induction chemotherapy
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than the other groups, but they did not have less chemotherapy
overall than the other groups before transplant.
In all groups a significant deterioration in diffusion capacity 
developed during this period. In Group I (TBI 6 x 200 allografts) 
there was no significant change until 6 months when a 30$ reduction 
was observed. Subsequent observations at 9 and 12 months also
showed significant reductions from pre-transplant observations but 
there was some recovery. Only four patients in this group were
available for observation during the second or third years but in 
all but one, recovery to greater than 9055 had occurred by.month 2H. 
The fourth patient persists at 70-75/5 of pre-transplant values H2
months later.
In the allograft recipients of 7 x 200 TBI (group II) a small but
significant reduction was observed at one and three months, but
there were no significant reductions from 6 months on.
The autograft groups also showed significant reductions. Group III 
(6 x 200 TBI) showed changes at 1,3, and 6 months with the maximum 
mean reduction of 18$ at 3 months, but recovery by 9 months. The
single fraction TBI group (Group IV) had significant reductions on 
every observation being maximal at 35$ at months 6 and 9. Of seven 
group IV patients observed in years 2 and 3, five have persisted in 
the 70-80$ range and two have recovered to >90$ pre-transplant
observations.
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6.5.5 Forced Expiratory Volume in One Second (FEVj)
There were no significant differences in the pre-transplant values 
between the four groups. Serial observation within the groups 
expressed as a percentage of the pre-transplant value show few 
significant changes in any group over the first year (table 6.1*0. 
Significant increases were recorded at month 1 and 3 in Group II and 
a significant reduction at 6 and 9 months was noted in group IV. 
These reductions of 75.8  £  17.3 and 88.5 £ 15.7,  at 6 and 12 months, 
were significantly greater than in the 6 x 200 TBI autograft group 
at the same time (95 .8  £ 13.7:  P=0.01 and 1 1 0 . £  5 .5 :  p =0 .0 1 ) .  .
6.5.6 Static Lung Volumes
There was surprisingly little change in the static lung volumes. 
There were no significant differences between the four groups in 
Vital Capacity, Total Lung Capacity, Residual Volume and Total Lung 
Capacity on pre-transplant assessments. No changes in Vital 
Capacity or Total Lung Capacity (tables 6.15 and 6.16) were seen in 
any of the three fractionated protocols. Significant reductions, 
however, were noted from 1-6 months (Vital Capacity) and 3-9 months 
(Total Lung Capacity) in the single fraction TBI autografts (Group 
IV), but these changes disappear by 12-15 months. The reduction of 
2055 and 11# respectively were similar to those noted in Depledge’s 
single fraction allograft patients.
Although sporadic changes in Residual Volumes were noted in all 
three fractionated groups, the percentage changes were relatively
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minor (Table 6.17). The consistent and moderately more pronounced 
(20/6 reduction) was noted between one and 6 months in the single 
fraction group, but had recovered by 12 months.
Scrutiny of individual patients followed for 3-5 years has shown no 
important late changes develop. The two patients mentioned earlier 
who developed pulmonary problems exhibited volume reductions of 
*10-50$ at the time of the incident. The second patient made a full 
clinical recovery but at *1 years has a 30-*10$ reduction in lung 
volumes.
6.5.7 Discussion of Changes in Respiratory Function
There are a number of reasons why pulmonary function may be 
adversely affected following allogeneic transplantation for 
leukaemic patients. Among these are the possibility of leukaemia 
infiltration, pre-existing damage to the lungs caused by 
anti-leukaemic chemotherapy, cyclophosphamide and/or irradiation in 
the ablative protocol, fat micro-embolisation at the time of marrow 
infusion, graft-versus-host disease or infection post-transplant.
Although some anti-leukaemic drugs have well documented lung 
toxicity, the only drug of relevance in these patients is 
thioguanine where there has been a reported association with 
interstitial pneumonitis (*48). Cyclophosphamide in high dose can 
result in late fibrosis, but, early interstitial pneumonitis usually 
resolves when the drug is discontinued (*49). Little is known about 
the subclinical consequences of Cyclophosphamide given alone at the 
dose level which these patients received. Although post-transplant
Methotrexate is associated with a higher incidence of pneumonitis 
(50,51), this is not a simple relationship, as discussed earlier, 
and in any event none of the patients under study received 
post-graft Methotrexate.
The possible short term consequences of fat microemboli lodging in 
the lungs immediately after marrow infusion has been specifically 
examined by Springmeyer (i|5) who found these to be minimal. the 
majority of our patients received the bone marrow as a mononuclear 
cell (MNC) fraction, which is fat free. Pneumonitis is more likely 
to occur in association with GVHD and, as previously discussed, is 
progressively more likely with the severer grades of GVHD. 
Allograft patients with significant GVHD were excluded from the 
groups of patients in this study.
In these groups of patients there has been the opportunity to study 
four different conditioning protocols when the effects of GVHD and 
pneumonitis have been excluded. It is crucial to recognise that the 
patients were asymptomatic at the times of testing. With each 
grouping the consequences were generally consistent, providing some 
reassurance that the changes seen were due to the ablative 
treatment. Groups I and II both received 6 x 200cGy TBI, thus 
allowed observations to be made directly between allografts (Group 
I) and autografts (Group II).
Although significant reductions in diffusion capacity were seen in 
the autograft patients, they were much less profound and occurred 
earlier than the significant changes seen in the allografts, and had 
shown complete recovery within the first year post-transplant.
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While this observation suggests that there may be additional factors 
affecting an allografted patientfs lungs (e.g. subclinical GVHD) 
definitive proof would require prospective study. One reason why 
these differences should be interpreted with caution is that the 
clanges in the allografts receiving Cyclophosphamide and 7 x 200cGy 
TBI (Group II) are less marked than in Group I. The latter group 
had lung shielding at the same level (1100cGy) but it may be 
important that they were all given T depleted marrow which 
effectively prevents5 GVHD in 7355 of patients (Chapter 9) whereas 
Group I patients received Cyclosporin. If the difference between 
Group III and Group I is real, it may be accounted for by the use of 
Melphalan rather than Cyclophosphamide with the TBI.
The most profound changes occurred in Group IV patients - autografts 
receiving' single fraction TBI with lung shielding at 800cGy. This 
group is the most similar to the allograft patients reported from 
The Royal Marsden Hospital who were allografts who received single 
fraction TBI to the same total dose at a lower dose rate 
(2.5cGy/min) compared with our 5.5cGy/min) without lung shielding, 
they also had significant reductions in diffusion capacity and were 
the only subgroup to show consistent reduction in lung volumes, but 
none of these changes persisted in asymptomatic patients with 
complete recovery, usually noted by one year.
6.5.8 Conclusions on Changes in Pulmonary Function
In conclusion, these data clearly indicate that in asymptomatic 
patients all the protocols used, result in significant deterioration 
in measureable lung function. There is some but not a substantial
difference between allografts and autografts given similar 
chemo-radiotherapeutic protocols. Many of the changes seen are 
transient. None of the changes was symptomatically noticeable and 
observation of some of these patients between 3 and 5 years later 
show no evidence of progressive deterioration. This evidence 
supports the view that fractionation of TBI has a sparing effect on 
the lung. It was not possible to use serial lung function tests to 
predict which patients would develop clinically apparent lung 
changes - although there were only two patients in this category.
6.6 PATIENT OUTCOME
One patient (UPN 024) died two weeks after marrow reinfusion. His 
death occurred as a sudden event, having experienced no particular 
problem in the previous few days. Post-mortem was not carried out 
but it was concluded that death was due to myocardial infarction or 
a massive cerebral vascular accident.
An 18 year old girl (UPN 011) developed progressive haemorrhagic 
cystitis requiring substantial blood product support. Eventually 
she underwent total cystectomy with re-implantation of her ureters 
into colon. This was surprisingly well tolerated, but unfortunately 
she regenerated in relapse shortly afterwards. This experience 
occurred despite the use of mesnum. No viral isolates were grown 
from her urine. This experience was a factor in my decision to 
substitute melphalan for cyclophamide in our ablative protocol in 
subsequent patients.
294
In all other patients the protocols were well tolerated, all 
surviving patients have normal performance scores.
Patient UPN 004 was noted, 25 months post-autograft, I to have 
atypical mononuclear cells on routine examination of his peripheral 
blood. He was asymptomatic with otherwise normal peripheral blood 
parameters and bone marrow examination confirmed continuing 
remission. Serological examination revealed a CMV titre rise from 
1:4 to 1:256. Although no virus was cultured from throat, urine or 
buffycoat it was assumed that this incident was due to cytomegalo­
virus infection. He remained clinically well but developed 
progressive thrombocytopenia, but not neutropenia, which persisted 
for 11 months. Anticipating relapse several marrow aspirates and 
biopsies were performed but there was never any suggestion of 
relapse, although cellularity was concluded to be in the low/normal 
range. Eventually he required intermittent platelet support for 
haemorrhagic incidents and 35 months post-autograft he died suddenly 
at home of what appeared to be a cerebral haemorrhage. No 
post-mortem was carried out.
6.6.1 Leukaemia Free Survival
Of the 24 evaluable patients, 11 have relapsed between 2 and 11 
months post-autograft. Of these relapses, 5 occurred before or at 
the time of haematological regeneration. Of the remaining 13 
patients followed for a minimum of 15 months, with a median 
follow-up period of 35 months (range 15-64 months), no relapses have 
occurred.
The predicted probability of surviving in these 25 patients is 50% 
at 5 years (figure 6.18) with a probability of remaining in 
remission of 5^%» The proximity of these two figures reflects the 
low incidence of procedural related mortality. Comparison of this 
data with the syngeneic data (figure 3.1), to which is identical, 
suggests that it is probable that the risk of relapse resulting from 
contamination of the graft by residual leukaemia is therefore 
small. As previously argued, the use of unpurged marrow is not a 
major limitation to successful autograft in first remission.
Figure 6.18 Survival and Leukaemia Free Survival (LFS) in Patients 
Undergoing Autologous Bone Marrow Transplantation for 
AML in First Remission
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When the prospect of remaining leukaemia free is examined for 
patients receiving protocol A (Cyclophosphamide + TBI with 4°C 
stored marrow) and those receiving protocol B (Melphalan + 
fractionated TBI with cryopreserved bone marrow) no difference is
observed: 5*1$ vs 55$ (figure 6.19) - in this analysis the two
non-leukaemic deaths were censored at the time of death. The 
follow-up in the protocol B patients is shorter (median 21 mo.) than 
those in protocol A (median 46 mo.).
As a rule, survival after relapse is very poor. Subsequent
chemotherapy, where attempted, has always been poorly tolerated, 
resulting in early death. The one exception in this series has been 
patient UPN 015 who relapsed 11 months post-autograft but was 
successfully given standard chemotherapy and remains in complete
Figure 6.19 Prospect of Remaining Leukaemia Free Following
Autologous Bone Marrow Transplantation for AML:
Comparison of Melphalan TBI and Cyclophosphamide TBI
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remission off all treatment 24 months later. It seems probable that 
only the patients who relapse beyond 6-8 months should be considered 
for further chemotherapy.
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6,6.2 Factors Affecting the Prospects of Surviving Leukaemia Free
Of the 25 patients 7 had cytogenetic abnormalities or a period of 
myelodysplasia prior to the diagnosis, both of which could be 
considered as adverse factors. The actuarial survival of this 
subgroup was not inferior to the total group at 57 .^
I have previously illustrated that haemopoietic regeneration 
post-graft - although incomplete - was, with the exception of those 
patients who regenerated with leukaemia, not predictive of 
subsequent outcome. Similarly, factors such as FAB subtype, age or 
Ablative Protocol do not identify particularly good prognosis 
subsets of patients. Such observations are relatively crude on the 
small number of patients available.
At the time of autograft these patients had previously received a 
variable amount of prior chemotherapy and there was therefore a 
considerable difference between patients in remission prior to the 
autograft. Nine of 2*1 evaluable patients received the autograft 
within 26 weeks of achieving remission whereas 15 were autografted 
beyond this time. The survival (and leukaemia-free) probabilities 
were 335S and 65% respectively. The simplest explanation of this 
finding is that the patients who received a late (>26 wks) autograft 
were a selected group in that they had already survived through the 
period of remission where the risk of relapse was greatest. This 
argument will surface again when the international data is reviewed 
(Chapter 8). An alternative explanation would be that these 
patients were also those who received more post-remission 
cytoreductive chemotherapy. For patients in this series who
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received less than five pulses of post-remission chemotherapy the 
survival was 3355 compared with 6735 for those recipients of more than 
four pulses. Based on the concepts of cytoreduction outlined in 
figure 1.1 it could be argued that bytoreduction chemotherapy prior 
to the autograft would be of value because it would reduce the
possible contamination in the harvested bone marrow and it will 
present the patient to the ablative treatment with less tumour
bulk. It is not possible at present to distinguish whether the 
advantage gained by pre-autdgraft delay is due to additional 
chemotherapy, or selection out of the patients with the responsive 
disease.
Many would argue the latter to be the more plausible explanation, 
referring to the lack of evidence that consolidation chemotherapy 
has a major impact on outcome. But, as argued in Chapter 1, the 
inability to demonstrate benefit from one phase of treatment does 
not necessarily mean that it will not have a synergistic role to 
play when combined with an additional effective modality such as 
ablative chemo-radiotherapy. When these studies were initiated the 
importance of the duration of remission and therapy pre-autograft 
was not considered as an important factor - the major concern was
whether autologous bone marrow, in heavily treated leukaemic
patients, would sustain prolonged haemopoietic recovery. Once this 
point was resolved, patients were autografted earlier in remission. 
There was no indication that haemopoietic recovery was poorer in 
patients who were autugrafted closer to remission induction 
therapy. In recent years, as induction and post-induction 
chemotherapy has become more intensive, morphological definition of 
remission has become less straightforward because myelopoiesis tends
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to be more primitive (or left-shifted) in the recovery phase. 
Retrospective examination of the marrow smears of these patients at 
time of autograft was carried out by experienced Haematologist 
colleagues. All marrows were concluded to be in morphological 
remission although doubts were expressed in a few cases, but there 
was no correlation between the "unequivocal remissions" and 
"doubtful remissions" in the subsequent pattern of relapse. As 
early intensive treatment of AML continues to be part of most 
treatment approaches, it is comforting to have other criteria of 
remission, such as full haemopoietic regeneration, as confirmatory 
evidence. There may, therefore, be some benefit in this respect of 
a pre-autograft delay to corroborate remission.
During the period of this study, three patients who fulfilled the 
requirements for autograft declined the treatment. One remains in 
remission at four years while the other two have died of their 
disease. Only one patient relapsed while waiting for autograft but 
this is an unreliable figure because there may have been additional 
patients treated in other hospitals who may have relapsed before 
referral.
The question arises as to whether successful outcome is only 
achieved in patients with responsive disease. As indicated above, 
crude indicators such as antecedent dysplasia or cytogenetic 
abnormality had no predictive value in these patients. Another 
indicator of responsiveness might be the time taken to enter 
complete remission (CR). This has not been specifically looked at 
in large chemotherapy studies in AML, but in the 8th MRC Trial the 
number of pulses taken to enter complete remission was not a
predictor of long-term outcome(52). If these autograft patients are 
segregated into those who achieved remission before or after 50 
days, survival was 73$ in the 12 achieving remission in <50 days. 
Fifty days iwas chosen because it would mean that patients who were 
induced with 5 day pulses would probably have completed two courses 
and the more recent patients would have recovered from a 10 day 
course. Initial responsiveness, as measured by the number of 
courses required to achieve remission, shows the same trend. The 12 
patients who entered CR with £ or less courses had a superior 
long-term survival than those 12 patients requiring more than 2 
courses (65% vs i\2%).
From what has been said it would seem likely that the best outcome 
will be achieved for patients who enter remission promptly and who 
have the autograft delayed till 26 weeks, and the poorest outcome 
seen in patients who are slow to remit and proceed to autograft at 
an early stage.
In this group of patients, 8 entered remission in <50 days and were 
autograft within 26 weeks and the survival was 6355:7 entered 
remission in >50 days and were autografted within 26 weeks with a 
survival of *10$:7 entered remission in >50 days and were autografted 
beyond 26 weeks with a survival of kz% and 8 entered remission in 
<50 days and were autografted beyond 26 weeks with a 10055 survival.
6,6.3 Relationship of Marrow Growth in Long Term Bone Marrow 
Culture and Clinical Outcome
A long-term marrow culture technique has been described in the mouse 
by Dexter(52). When marrow cells in liquid suspension containing 
horse serum and hydrocortisone are incubated an adherent layer forms 
on the flask surface which supports proliferation of pluripotent and 
committed stem cells for several weeks or months. The stromal layer 
contains many cellular elements with varying phenotypes, e.g. 
endothelial-like cells, reticular cells, macrophages and fat cells. 
In the mouse system this layer generates cells which are released 
into the supernatant which, when grown in clonogenic assay, in
semi-solid media can be shown to be BFU-E, CFU-GM, CFU-GEMM and
CFU-S. This system has been a valuable prototype of the marrow 
microenvironment. A similar system has been developed for man(53) 
but it is usually much more restricted both in its longevity (it
usually dies off in 8-10 weeks) and cell type. Usually the
supernatant cell population are only committed granulocyte- 
macrophage precursors(CFU-GM).
This assay system is capable of detecting a cell population which 
are probably derived from a more primitive level of cell hierarchy 
than the committed colony forming cells (CFU-GM, BFU-E, CFU-GEMM 
etc) and as such may better reflect the pluripotent stem cell 
population. Techniques which can remove all committed colony 
forming cells, as measured by CFU-GM population, do not eradicate 
the repopulative ability of bone marrow infused into ablated 
recipients (5*1,55) as will be discussed in Chapter 9. Growth can, 
however, be demonstrated in Long Term Bone Marrow Culture.
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The technique is described in Figure 6.20. When flasks are 
inoculated with a standard number of cells, e.g. 20 x 10^ an 
adherent, stromal layer will form on the floor of the flask. The 
supernatant medium is changed weekly and! the cellular component of 
the supernatant is available for examination. These cells are 
generated from, or following interaction with, the stromal layer and 
in humans are restricted to the granulocyte lineage (CFU-GM), which 
are set up in the standard assay in semi-solid medium.
Leukaemic haemopoiesis grows poorly in this system(56) so it was 
considered that normal growth might indicate a healthy marrow, and 
therefore such an assay may be a useful indicator of outcome of 
autologous bone marrow transplantation.
In this autograft series *} patients* haemopoietic regeneration was 
accompanied by leukaemic relapse. A further 7 patients regenerated 
adequate neutrophil numbers but relapsed within 11 months. In this 
latter group the pace of neutrophil regeneration was not 
distinguishable from that of patients who became long term 
survivors. Although the data is not presented, there was no overall 
impression of any correlation between performance in CFU-GM Assay 
and leukaemia free survival. The data is not readily assessable 
because over the years the assay technique has been continuously 
modified, so direct comparisons between patients cannot be made.
Long Term Bone Marrow Culture (LTBMC) has been performed on frozen 
aliquots of the autograft on twelve of the patients in the series. 
A control range was established using marrow obtained from normal
Figure 6*20 Method of Long Term Bone Marrow Culture
Long. Term Bone Marrow Culture ( LTBMC)
BM^-Buffy Coat 1(20 x 106)
McCoys
FBS
HS
Hydrocortis
7 1
cAdd an equivalent volume of fresh mediuiRemove 1/2 the supernatant weeklyAssay for CFC-GM
The culture flasks are routinely inoculated with 20 x 10^ viable
medium including Foetal Bovine Serum and hydrocortisone to a total 
volume of 10 mis per 25cm2 capacity siliconised flask (Nunclon, 
Gibco). The flask is initially incubated for one week at 37°C in 5% 
CO2 humidified atmosphere, and then transferred to 33°C in a 5% CO2 
humidified atmosphere. At weekly intervals, half the supernatant 
containing non-adherent cells is removed, to be replaced by an equal 
volume of medium. Cell counts and CFO-GM assay are performed on the 
supernatant which has been removed.
* 500 mis of Supplemented McCoy’s 5A: McCoy’s 5A medium (Gibco); 
Penicillin/Streptomycin 7.2 mis; L-glutamine 7 .2 mis, MEM Amino 
Acids 5.8 mis; MEM non-essential amino acids 2.9 mis; MEM Vitamins
7.2 mis; Na pyruvate 7 . 2  mis; NaHCOg 7.5% Solution 7.2 mis; 
Hydrocortisone (1 mg/1 ml in Horse Serum (Gibed) 12.5 mis and Foetal 
Bovine Serum (Gibco) 12.5 mis.
cells. The suspension medium comprises supplemented McCoy’s 5A*
donors. In each case 20 x 10^ viable cells were incubated into each 
assay flask.
In normal donors generation of CFU-GM continued in all cases beyond 
5 weeks and in some out to 8 weeks. Six patients, who have remained 
leukaemia-free, sustained growth in all cases for 5 weeks but the 
culture tended to die off by the 7th week. Supernatant CFU-GM 
growth was quantitated weekly and, although significantly fewer 
CFU-GMs 5 were generated at week 2 compared with controls, the 
differences on the other weeks were not significant till weeks 6 and 
7 (figure 6.21).
Six patients who relapsed (3 regenerated with relapse and 3 relapsed 
later) showed a different pattern of growth. In general, there was 
on each occasion, a lower number of CFU-GM regenerated but this was 
not usually significantly different from the non-relapsing patients, 
but it was usually significantly lower than that generated by normal 
marrow. A noticeable feature was that none of these patients 
exhibited growth for more than H weeks. Where poor growth was 
found, aliquots were set up on two or three further occasions to 
confirm the finding.
While the data is presented in numerical form in Figure 6.21, the 
most obvious difference seen microscopically is the rapid decline 
exhibited by the relapse group. These culture studies were carried 
out without knowledge of the clinical outcome.
Although the number of patients completely examined is so far small, 
this data suggests that persistent poor growth in LTBMC may predict
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Figure 6.21 Growth of Bone Marrow in Long Term Culture: Comparison 
of Normals, Relapsers and Non-Relapsers after
Autologous Bone Marrow Transplant
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The significant figures shown refer to comparison between test group 
(relapsers or non-relapsers) and control marrows.
Statistical analysis by the Students* T test.
relapse. No apparent differences were seen between the performance 
in culture of marrows from patients who regenerated in relapse or 
who relapsed later, although the numbers of patients is very small 
for such an observation to be conclusive. Even patients who survive 
well do not have sustained growth compared with untreated normal 
marrow donors. This observation is consistent with there being a 
reduction in the stem cell pool, due to previous chemotherapy. This 
does not appear to be an adequate explanation for the poorer growth 
seen in the patients who subsequently relapse. No method exists to 
determine whether these patients, despite morphological appearances, 
were not in true remission. These may represent a subgroup of 
patients who are in morphological remission but whose haematopoiesis 
is the clonal progeny of the original leukaemia, as suggested by 
analysis of remissions with X-linked markers (57,58).
6.7 COMMENTS and CONCLUSIONS
In the discussion of the rationale of autograft in AML, I suggested 
that the procedural related morbidity and mortality would be low but 
that, because of the lack of a graft-versus-leukaeraia-effect and a 
protective effect of graft-versus-host disease, which may be 
separate mechanisms, a higher relapse rate would be expected. The 
prolonged observation of this series confirms that prediction and 
confirms that this approach can be safely applied to older patients.
Although infections occurred during the early neutropenic phase, 
these were not more difficult to treat than those which occur during 
remission induction chemotherapy. Pneumonitis was not an important 
problem. Late complications or infections were exceptional. Four
of five patients who survive for more than four years have developed 
early cataract, two of which have come to successful surgery. This 
high incidence is consistent with that now predicted for allograft 
recipients conditioned with single fraction TBI and is predicted to 
be much less common in the recent cohort who received fractionated 
TBI.
The overall leukaemia free survival is satisfactory and is identical 
to the limited international data on syngeneic transplants for AML 
in first remission. Not only is the relapse incidence similar to 
twins but the lack of relapse beyond 12 months is a pattern also 
seen with twins - but, in both situations the database is small. If 
such an observation holds as more patients are observed, this does 
suggest an effect not seen with chemotherapy protocols who tend to 
have a continuous risk of relapse. The disadvantage of relapses 
occurring early is that there is little room for therapeutic 
manoeuvre, and it is noteworthy that the only patient who was 
successfully re-treated was the patient who relapsed late (11 
months) after transplant. No other patient benefited from 
subsequent treatment.
It was particularly perplexing to observe regeneration with relapse 
in i| patients, who were, by all morphological criteria, in bona fide 
remissions. A number of explanations for this, including the 
possibility of a "clonal" remission, have been mentioned. 
Identification of this subgroup is of paramount importance, and the 
preliminary data from Long Term Bone Marrow Culture is encouraging 
in this respect. Clearly, autograft is inappropriate in these 
patients who perhaps in the future, would be candidates for matched 
unrelated donor transplants.
The similarity between these results and the syngeneic data suggests 
that if there is contamination of the autograft it is not clinically 
important. The high relapse rate in twins compared with allogeneic 
transplantation confirms that a priority remains improvement of 
leukaemia eradication in the patient. To this end we have now 
adopted a higher TBI dose of 1i|lJ0cGy which is also well tolerated. 
There are clearly many options available for improving myelo- 
ablation, of which increasing the TBI is only one. A higher dose 
TBI schedule has not been found to be effective in relapsed patients 
in Seattle(59), but there is little or no data available on patients 
transplanted in remission. Examination of the effect of higher dose 
schedules of TBI on toxicity and leukaemia relapse in allogeneic 
transplantation is limiting on the one hand because there are a 
number of additional mechanisms of damage to the lung occurring 
concurrently and since the relapse rate for allografts in remission 
is relatively low large numbers of patients would be required to 
show important differences. Autograft patients offer less 
restrictions in these respects and offer considerable 
radiobiological interest for the design of better TBI-based 
protocols.
Reference has been made to the possibility of selection occurring 
because of pre-autograft delay. What treatment is given to the 
patient during this time can be expected to be of major importance 
in the design of future protocols. On the basic principles 
discussed in Chapter 1, post-remission cytoreductive treatment would 
be theoretically logical, and should preferably be standardised for 
all patients.
The data presented here, with follow-up between 15 and 62 months, 
suggest that autologous bone marrow transplantation has an important 
role in the management of AML. The optimum timing, myelo-ablative 
protocol and pre-autograft chemotherapy remain to be defined. Such 
issues would seem of higher priority for controlled clinical trial 
than the need to develop and test techniques aimed at eradicating 
minimal residual disease from the autograft.
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CHAPTER 7
IMPACT OF ABLATIVE TREATMENT ON REMISSION 
DURATION IN AML
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7.1. INTRODUCTION
The limited ability of chemotherapy to maintain remission in AML has 
been highlighted in Chapter 1. The current results achieved by 
allogeneic BMT were alluded to and represented a major stepping 
stone towards the introduction of the autograft approach. My own 
results and the international experience of autograft apparently 
produce an almost identical pattern of survival to the international 
data of allograft. Some reservations about the autograft results 
have been described - particularly the possibility that patients are 
selected because of pre-autograft delay - but this is also a 
legitimate criticism of the allograft experience. Data has been 
cited from the EBMT database to indicate that performing allograft 
early or late did not affect outcome in terms of survival(1), but no 
analysis concerning the relationship between pre-allograft interval 
and risk of relapse has been done. Based on results presented, it 
is not clear whether all patients with AML in remission should 
automatically be offered an allograft as the preferred option, 
knowing that some of the allograft survivors will suffer significant 
morbidity from non-fatal immunobiological complications, which will 
not occur in autograft. One of the advantages of autograft is that 
it can safely be offered to older patients who are not normally 
considered for allograft on grounds of age, but it is by no means 
clear what the cut off age for allograft should be, in view of 
improvements in allograft technique.
Since 1981, it has been my policy to offer ablative treatment to all 
patients with AML in first remission, under 55 years of age. Those 
under l|0 years receive allogeneic bone marrow if a suitable donor
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exists, and all other patients will receive autograft. The policy 
is summarised in Figure 7.1. In order to assess the impact of such 
an approach, the outcome is compared with that in a previous 
consecutive series of patients treated in Glasgow Royal Infirmary 
between 1976 and 1981 with chemotherapy alone.
Fig 7.1 Treatment Policy for AML in First Remission Patients Under 
55 Years
Induction/Consolidation
Chemotherapy
/ \
Under HO years No donor
with donor under 55 years
I I
ALLOGRAFT AUTOGRAFT
7.2. PATIENT POPULATIONS
7.2.1. Transplant Group
Details of the 25 patients receiving autologous BMT were described 
in the previous chapter. During this period 15 patients have 
received an allograft from an HLA identical sibling donor and their 
characteristics are included in Table 7.1. They received slightly 
differing ablative protocols and GVHD prophylaxis as the allograft 
programme evolved, these are detailed in Table 7.2.
Table 7.1. Patient Characteristics
Allograft Autograft Chemotherapy
number 15 25
M:F 8:7 12:13 21:19
mean age 
(range)
26.5 yrs 
(2-51)
38
(15-53)
43
(18-6 0)
median remission 
pre-BMT
2.5 mo. 5 mo. 3 mo.
Table 7.2. Treatment Protocol of Allograft Patients
Age/Sex Fab Conditioning Protocol GVHD
Prevention
1 14m M1 Cyclo + TBI 1000 cGy) MTX
2 17F M2 n n 6 x 200 cGy) MTX
3 15F Mil it it 6 x 200 cGy) CSA
4 18F M2 n tt 6 x 200 cGy) McAb
5 15F M4 tt it 6 200 cGy) n
6 2M M1 it it 4 x 200 cGy) n
7 7M M2 tt n 6 x 200 cGy) it
8 23M M3 it n 7 x 200 cGy) it
9 37M M2 it n 7 x 200 cGy) n
10 33F M5 n it 7 x 200 cGy) n
11 35M M2 it n 7 x 200 cGy) it
12 20M M1 it it 7 x 200 cGy) it
13 37F M2 n it 7 x 200 cGy) n
14 25M M5 n tt 7 x 200 cGy) it
15 51M M1 n tt 7 x 200 cGy) tt
MTX: Methotrexate CSA: Cyclosporin
McAb: T Cell Depletion
7.2.2 Chemotherapy Patients
Of 135 patients presenting with AML from 1976-1981, 85 entered
complete remission. In order to impose a similar ! selection bias of 
these patients as may apply in the transplant group, only patients 
who were under 60 years, and had been in complete remission for 3 
months were included in the comparative group. Details of the 40 
patients who fulfilled these criteria are shown in Table 7.1.
}
7.2.3 Details of Chemotherapy
All patients received a similar remission-induction protocol 
comprising a combination of Daunorubicin (40 mg/m2), Cytosine 
Arabinoside (100 mg/m2) intravenously and Thioguanine (100 mg/m2) 
orally in pulses of 5-10 days duration. Consolidation usually
involved the same drugs but at reduced doses per pulse and those who 
continued on maintenance received Thioguanine orally and 
subcutaneous Cytosine in 5-day pulses at monthly intervals.
7.3 CLINICAL RESULTS
Twelve of the 15 allografted patients remain alive 4 months to 7 
years post-graft. Two early deaths due to procedural complications 
occurred (1 pneumonitis: 1 cerebral haemorrhage). One girl had
persistent eye symptoms due to lack of tear formation as a sequelae 
of chronic GVHD and eventually died in complete remission of 
overwhelming pneumococcal septicaemia 35 months post-transplant. 
All other patients have normal performance status and have an 
actuarial survival of 72$ with a prospect of remaining free of
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leukaemia of 80^ which is displayed with the autograft survival and 
leukaemia-free survival in Figure 7.2.
Fig 7*2 Survival and Leukaemia Free Survival Following Allograft 
and Autograft
100 i-ttO-------*8
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Of the 110 patients in the chemotherapy group, 39 relapsed and 38 
died directly or indirectly as a result. One patient remains 
disease-free and one is in a prolonged second remission. The actual 
survival has been 9% at 5 years.
When the survival of the group transplanted with allogeneic or 
autologous marrow, following ablative treatment, is compared with 
the chemotherapy group (Fig 7.3), the overall outcome for the trans­
planted group (58?) is significantly better than the chemo- therapy 
group ( 9%) P = <001 (log Rank Test), suggesting this an ablative 
approach has had a major impact on treatment of this disease, but 
recognising that this was not a controlled trial comparison.
Fig 7.3 Comparison of Ablative Treatment with Conventional 
Chemotherapy
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7.4. COMMENTS ON THE IMPACT OF ABLATIVE THERAPY
Data compiled in the International Transplant Registry till 1985 
indicates that 45-5056 of patients allografted in first remission for 
AML will survive. Single centre series do not suggest that results 
appear to be improving over the years within the individual centres, 
so our good results may merely reflect the relatively small 
numbers. It will be of interest to see in the next few years 
whether other centres who can employ both effective T depletion 
(i.e. avoidance of GVHD and rejection) and CMV-negative blood 
products in their allogeneic programmes can improve the overall 
survival in AML by eroding the non-leukaemic causes of death. This
may be balanced by an increased relapse rate resulting from 
T depletion. Our own data indicate that if a patient has a donor, 
in particular if the patient is CMV seronegative, allograft should 
be offered and the question of autograft not be raised. It remains 
unclear whether the allograft age limit could be raised because of 
T depletion.
Experience with chemotherapy overall and in this selected 
comparative subgroup in particular has been disappointing, but not 
substantially different from other studies, and the data strongly 
suggests that the strategy adopted since 1981 represents a genuine 
improvement.
On examining the patients* charts, it is difficult to accept that 
the anti-leukaemic gain could be accounted for by differences in 
chemotherapy prior to the autograft. There have been changes in 
supportive care in this centre over the last 10 years, but it is 
difficult to see how these could influence the outcome in patients 
who have been in remission for 3 months and therefore are almost 
exclusively outpatients, and in whom the cause of death has always 
been disease recurrence.
CHAPTER 8
INTERNATIONAL EXPERIENCE of 
AUTOLOGOUS BONE MARROW TRANSPLANTATION 
in ACUTE MYELOID LEUKAEMIA
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8.1 INTRODUCTION
Subsequent to the initiation of the autologous transplant programme 
in Glasgow, a number of centres have adopted such an approach. Some! 
of the published series have used different protocols which deserve 
separate comment. Autologous transplantation for acute leukaemia 
has been investigated more extensively in Europe than in the United 
States and most of this experience has been collected by the 
Autologous Working Party of the European Group for Bone Marrow 
Transplantation (EBMT) as a database for scrutiny. All this data is 
anecdotal, but nevertheless may be a source of information to assist 
in the design of the next stage of development - the controlled 
clinical trials - which are at the preliminary stages in a number of 
countries.
No individual centre’s series is large enough to draw conclusions 
about factors which may affect the outcome of autologous 
transplantation in AML, or confirm or refute some of the 
observations made in Chapter 6 . These aspects may be of major 
importance in designing the autograft arm of future comparative 
clinical studies, which alone will ultimately define the place of 
autograft in AML. An analysis of all known patients who received an 
autograft in first remission before November 1986 and updated to 
February 1988, with a minimum follow-up of 16 months will be 
presented. In chapter 4, arguments were set out which formed the 
basis of our local protocol which has been largely vindicated by the 
results presented. As will become evident, other groups have used 
different approaches which will be critically reviewed.
8.2 TRANSPLANTATION in FIRST COMPLETE REMISSION
Three other groups have used a TBI based ablative protocol similar 
to Protocol A used in Glasgow with no efforts being made to remove 
residual leukaemia from the autograft. These series (1,2,3) 
comprise relatively small numbers of patients with similar results 
to those presented in chapter 6, and are therefore not discussed-in 
detail, but form part of the analysis presented later. Four groups 
have concentrated on high dose polychemotherapy rather than TBI as 
the ’ablative’ protocol and are worthy of separate scrutiny.
8.2.1 High Dose Melphalan
Melphalan is an alkylating agent whose dose is limited by bone 
marrow and gut toxicity, but in conventional dose has little proven 
efficacy in AML. Much has been learned about its toxicity in high 
dose intravenous infusions (180-240 mg/m2) with or without 
autologous marrow rescue in solid tumours. The Marsden Group 
substituted Melphalan 110 mg/m2 for Cyclophosphamide in an ablative 
protocol for allogeneic transplantation for AML in first remission. 
They report a reduced relapse rate in the Melphalan cohort but this 
has not yet become statistically superior (4).
The first evidence that high dose Melphalan (140 mg/m2) was an 
effective agent in AML, was provided by the Marseilles Group(5,6) 
who used that dose for the treatment of relapsed patients, who then 
received autologous bone marrow stored during first remission. Of 
16 patients treated, 11 entered a complete remission (6935). Three 
patients died 2-4 months, after autograft, of hepatitis (1) and two
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relapsed. Seven patients underwent a second autograft as 
consolidation of second remission with a second dose of Melphalan 
1H0 mg/m2. Two patients died of infection, *1 relpased 8-60 months 
later and one patient continues in remission beyond 5 years.
Thirteen subsequent patients received a single autograft following 
Melphalan as consolidation of first remission. Only two remained 
leukaemia free 6 and 9 months later. Eleven further patients 
received a double autograft, as fof* the relapse patients, in first 
remission. There was one procedural death, and 6 relapses, leaving 
*1 patients in unmaintained remission 5-*l2 months after the second 
autograft. These clinical studies demonstrate that Melphalan has an 
anti-leukaemic effect, but such an approach does not appear to be 
superior to the other approaches used.
8.2.2 High Dose Polychemotherapy - The TACC Protocol
One of the preliminary series examining the use of autograft in AML 
was reported by the Besancon Group(7). They chose to use a high 
dose chemotherapy schedule, without TBI, given the eponym TACC 
(Table 8.1). They favoured this approach, having gained experience 
of its use in relapsed patients where it achieved complete 
remissions in 10 of 11 patients. As with other studies, these 
remissions were not durable, but were of sufficient length (*1.5-15 
months: median 9 .7 months) to provide encouragement that this
approach would be justified in first remission. A second unique 
feature of this series was that the bone marrow was treated ex-vivo 
with a stable activated cyclophosphamide derivative (Asta-Z-7557). 
Such techniques of ex-vivo treatment will be discussed in detail in 
Chapter 9.
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Table 8.1 The TACC Protocol (Besancon)
- 6-Thioguanine 400 mgs/m2/day, day -6 to -2
- Cytosine-Arabinoside 400 mgs/m2/day by continuous intravenous 
infusion, day -6 to -2
- CCNU 400 mgs/m2, day -5
- Cyclophosphamide 45 mg/kg/day, day -5 to -2 
(later modified to 60 mg/kg/day on days - 3 and -2)
>
In the published series of 25 patients, 2 of whom received cyclo­
phosphamide and TBI ablation and 23 the TACC protocol, 5 patients 
died of procedural related causes (3 cardiac failure: 2 infection). 
The protocol was given in modified form to some patients to reduce 
cardiotoxicity. At time of publication only 4 patients were beyond 
12 months post autograft, 4 had relapsed but 8 were in unmaintained 
remission. Follow-up of this study as part of the analysis below, 
two and a half years after initial publication, reveals that 7 of 
the original 25 patients are alive in continuous remission. 
Although there may be differences between these patients and the
Glasgow series, for example, in the period of time that the patients
were in remission pre-autograft (Besancon median 144 days, range 
61-361 days: Glasgow median 179 days, range 95-655 days) it appears 
that the TACC protocol is less effective than a TBI based approach. 
This is perhaps emphasised when it is considered that 2 of the 7 
patients remaining alive in the Besancon series were the two
exceptions who received cyclophosphamide and TBI. Unfortunately the 
considerable effort which was put into the efforts to eliminate
residual leukaemic cells was fruitless, being overwhelmed by the 
inability of the protocol to eradicate the disease from the patient.
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8.2.3 The BAVC Protocol (Rome)
An Italian study is underway comparing conventional Cyclophosphamide 
+ TBI against a high dose chemotherapy protocol developed in Rome, 
designated BAVC (table 8.2). This combination had proved effective 
in relapsed disease(8) and seemed worthy of examination in first 
remission. In a consecutive series of 30 patients with a maximum 
follow-up of 30 months, one patient died early with pulmonary 
thromboembolism, 7 have relapsed and 22 ;(73?0 continue in remission 
with a median follow-up of 9 months. These results are encouraging 
but the follow-up is too short to indicate superiority over any 
other protocol(9). An update to February 1988 is included in the 
review below.
Table 8.2 The BAVC Protocol (Rome)
- BCNU 800 mgs/m2 3 days
- Cytosine-Arabinoside 300 mgs/m2 3 days
- Etoposide (VP-16) 150 mgs/m2 3 days
- m-AMSA 150 mgs/m2 3 days
i| The Double Autograft Approach
The concept of a double autograft was originated at University 
College Hospital, London (UCH Protocol). Following a high dose 
chemotherapy in first remission, accompanied by autograft of 
remission marrow, it is argued that a second harvest of regenerated 
marrow will benefit from the preferential regeneration of normal
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haemopoietic cells, thus reducing the possibility of contamination 
by residual leukaemia. The nin vivo" purging of the patient and 
graft present the patient to a second round of high dose 
chemotherapy supported by infusion of the second marrow harvest.
The chemotherapy used is shown in table 8.3. It is noticeable that 
the individual doses given are less than in the other chemotherapy 
protocols already discussed, and it is not known whether this 
regimen crucially requires autologous stem cell rescue. This is 
perhaps rather an academic point since curtailment of the duration 
of cytopenia in the patient minimises the associated risks. It is 
noticeable that the median times taken to regenerate 0.5 x 10^/1  
neutrophils and 50 x 10^/1 platelets after the first autograft were 
21 and 27 days and after the second autograft 27 and 42 days 
respectively. Although haemopoietic regeneration was significantly 
slower following the second autograft, this equivalent to, or in the 
case of platelets, superior to the Glasgow data using TBI.
Table 8.3 The UCH Protocol
Cyclophosphamide 1.5g/m2 days -5,-^,-3
Adriamycin 50 mgs/m2 day -5
BCNU 300 mgs/m2 day -5
Cytosine-Arabinoside 100 mgs/m2 b.d. days -5 to -2
Thioguanine 100 mgs/m2 b.d. days -5 to -2
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In an earlier report(10) 16 patients had been entered into this
study, one patient died during the pancytopenic phase due to an 
intracerebral haemmorrhage. For a number of reasons, such as 
relapse, delayed haematological recovery, refusal Or other toxicity, 
only 6 patients underwent the second graft. These patients remain 
in remission 2.5-6 years after autograft and are probably cured. In 
a more recent follow-up(11) 27 patients have entered the protocol; 
the projected disease free survival is 61J5 with a median follow-up 
of 18 months. Only 11 have had a second autdgraft, none at the time 
of the update had relapsed - but 2 subsequently have. Superficially 
this data is prima facie evidence to support double autograft using 
the UCH protocol as the optimum intensification approach. However, 
the patients who reached the autograft stage are almost certainly 
highly selected, both because they have avoided relapse, and also 
because they have superior haemopoietic reconstitution following the 
first autograft and are considered suitable for a second procedure. 
This latter characteristic may reflect my own observations of growth 
in Long Term Bone Marrow Culture (figure 6.21), being indicative of 
a good outcome - this may be the curable cohort.
The inability of all patients to complete the protocol makes overall 
interpretation difficult, and, that being the case, incorporation of 
this approach into a comparative prospective trial will be 
complicated.
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8.3 EUROPEAN EXPERIENCE of AUTOGRAFT in AML
Apart from the Groups just referred to, several centres have 
investigated autologous bone marrow transplantation for AML. This 
data has been collected under the auspices of the European Group for 
Bone Marrow Transplantation. I have conducted an analysis of the 
data on 32iJ cases whose autograft was performed no later than 
November 1986, and the outcome updated in mid-February 1988, 
ensuring that the series has a minimum follow-up of 15 months.
8.11 AUTOLOGOUS BONE MARROW TRANSPLANTATION in FIRST REMISSION
The characteristics of 263 patients receiving ABMT in first 
remission are shown in table 8 • 4 • It can be noted that the age 
range of 1-62 includes 120 patients who would be excluded from most 
allograft programmes, and several patients beyond 50 years of age.
Table 8.4 Autograft for AML in First Remission: Patient Details
263
135 male, 128 female 
1-62 years (median 31)
M 1=60: M2=89: M3=18: MH=61: 
M5=32: M6=3
Duration of Remission Pre-ABMT : 16—694 days (median 1^3)
Date of ABMT : 12 August f80 to 22 Oct *86
Updated : 20 February 1988
Follow-Up Period : 16-90 months (median 33)
Total Number 
Sex distribution 
Age range 
FAB distribution
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The median follow-up of all patients is 33 months with a range of 
16-90 months. There was a considerable variation in the duration of 
remission before the autograft but the median was 143 days (range 
16-69^ days) j
The details of the induction chemotherapy and the institutions* 
remission rates are unknown. All patients are assumed to have 
post-remission consolidation chemotherapy but the details are not 
known. As will be discussed later, there was considerable variation 
in the time taken to enter complete remission which consequently 
also means a considerable variation in the amount of chemotherapy 
received in that phase. From the arguments set out in Chapter 1, 
such factors may be important, but are outwith this database.
The treatment schedules used to 1 ablate* the patient can be grouped 
into nine protocols which are detailed in table 8.5. One hundred 
and forty-six patients received a TBI based schedule, either 
standard Cyclophosphamide (60 mgs/kg x 2) with single fraction 
TBI (schedule 1) or fractionated TBI (schedule 2) or another drug, 
usually Melphalan with either single fraction (schedule 3) or 
fractionated (schedule 4) TBI. One hundred and seventeen patients 
received a chemotherapy based protocol following the TACC protocol 
(schedule 5 ) which includes 4 patients receiving the 
Busulphan/Cyclophosphamide protocol (12), high dose Melphalan with 
single or double autografts (schedule 6), the UCH Protocol of which 
8 had double grafts (schedule 7 ) or the BAVC regimen (schedule 8). 
A few patients had other schedules such as high dose cytosine- 
arabinoside. Eighty of the 263 patients had treatment of the 
autograft ex vivo with, in virtually all cases, a Cyclophosphamide
derivative. Although some attention will be given to the use of ex 
vivo manipulation ("purging") of the bone marrow in these patients, 
a detailed discussion of this subject is given in Chapter 9 .
Table 8.5 Ablative Schedules for AML in First Remission
Schedule Total Non-Purged Purged
51) Cyclo + TBI 96 67 29
2) Cyclo + fTBI 27 18 9
3) Other chemo + TBI 2 0 2
4) Other chemo + fTBI 21 11 10
5) TACC (or Bu/Gy) 33 9 24
6) Melphalan 21(7)* 21 0
7) UCH Protocol 23(8)* 23 0
8) BAVC 34 28 6
9) Other 6 6 _0
263 183 80
* as double autografts
8.4.1 Methods of Data Analysis
The database has been analysed on a Honeywell XP microcomputer using 
the BDMP Statistical Package for Survival Functions. The survival 
curves represent survival distribution . by the product limit of 
Kaplan and Meier(13). Differences between these survival
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distributions are tested for statistical significance by the method 
of Mantel(1l|) which tends to give greater weight to early 
observations to detect differences, and the generalised Wilcoxon 
test proposed by Breslow(15) which is more sensitive to late 
events. Although *pf values are considered from both tests, the 
latter is considered more suitable for this analysis so the 
significance levels indicated are from the generalised Wilcoxon 
Test.
8.11.2 Results of Autograft in First Remission
The data has been analysed in an effort to determine (a) whether any 
particular protocol is superior and therefore can be reommended for 
future comparative trials, (b) the overall and procedural related 
mortality rate, (c) whether any late events occur - thus indicating 
the period of follow-up necessary in a comparative clinical trial 
which is required to show differences in outcome; (d) whether there 
is any requirement to 1 purge1 the bone marrow ex vivo and (e) 
whether individual factors such as age, sex, FAB subtype, 
pre-autograft delay or time taken to enter remission, influence 
outcome as independent variables.
8.11.3 Overall Survival and Probability of Remaining Leukaemia Free
The overall survival in the 263 patients and relapse-free 
probability are shown in figure 12.1, which indicates that i|7$ of 
all patients survive event free with an expectation of being 
leukaemia free of 57$. It can therefore be confirmed from this 
large database that the death rate from non-leukaemic causes is
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acceptably low at 5$* which compares favourably to that seen with 
conventional post-remission chemotherapy. Only 6 events, *1 of which 
were relapses, occurred after 2*1 months, so since the median 
follow-up of these patients is 33 months, there is little likelihood 
of a substantial change in the position of the plateau. Most of the 
relapses occur within 12 months with few relapses beyond 2*1 months. 
Half of the relapses are recorded within the first 5 months 
confirming the Glasgow experience, that there are a group of 
patients who relapse unexpectedly early after the autograft. The 
most critical assessment of outcome is to look at event free 
survival, i.e. the occurrence of death or relapse. The plateau on 
that basis is at H7% from 32 months. The reason that this is 
slightly less than the survival probability is that although some 
patients have relapsed, they continue in a subsequent prolonged 
remission.
Figure 8.1 ABMT in First Remisision: European Study(n=263)
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8.4.4 Comparison of Ablative Schedules
If the three schedules (nos 1,2 and 4) are compared, no significant 
differences in leukaemia free probability are observed (schedule 
1:63?> schedule 2 :51 % and schedule 4:5855), therefore all TBI 
protocols are taken together for subsequent analysis. The 
probability of remaining leukaemia free for all TBI patients 
compared with all chemotherapy patients is 6155 and 52% respectively 
(figure 8.2) which is not significantly different. The overall 
respective survivals are 5455 and 50?.
When the four main chemotherapy schedules are compared (figure 8.3) 
it is immediately obvious that the DCH and BAVC at 64? relapse free 
probability are significantly superior to Melphalan (33?) or TACC
(36?) (p=0 .02).
Figure 8.2 First Remission Leukaemia Free Survival: TBI vs
Chemotherapy Ablation
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Figure 8.3 First Remission: Comparison of Chemotherapy Protocols
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As shown in table 8.5, fifty of the TBI patients and 30 of the 
chemotherapy patients received purged bone marrow in an effort to 
reduce the relapse rate. If these patients are there excluded from 
analysis a more accurate comparison can be made of the three most 
promising protocols. These data show no significant difference 
between TBI(57$), UCH(64$) and BAVC(55$) in relapse free probability 
(figure 8.4). It Is of interest to note that removal of the 
recipients of purged marrow from the TBI and BAVC groups results in 
a small reduction in relapse free probability from the 61$ and 64$ 
respectively shown in figures 8.2 and 8.3, suggesting a beneficial 
effect of the purging technique. Although the UCH protocol contains 
8 patients who received a double autograft who have a relapse free 
probability of 81$, this protocol Is compared as a single schedule 
because some of the reasons for patients not receiving a second 
graft are themselves a limitation of the practical use of this 
approach in a comparative trial(11).
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Figure 8.4 First Remission: Comparison of TBI with UCH and BAVC
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8.4.5 The Influence of Ex Vivo Purging of The Autograft
The background and methodology of ex vivo treatment of bone marrow 
("purging") will be discussed in the next chapter, but, since 80 of 
these first remission patients received purged marrow, some 
observations can be made at this stage. Within the chemotherapy 
group 6 of the 34 BAVC group had purged marrow, of whom all remain 
in remission but the number is too small to reach any conclusion. 
Twenty-four of the 33 patients receiving the TACC protocol had
purged marrow but the overall outcome of this group has already been 
demonstrated to be relatively poor, probably indicating a failure to
effectively ablate the patients. For these reasons no valid
information on the effect of purging can be derived from the
chemotherapy patients.
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When the patients treated only on TBI schedules are compared on the 
basis of receiving unpurged (n=96) or purged marrow (n=50), a 
significantly improved prospect of remaining leukaemia free is seen 
in the purged group (7 7% ) compared with the unpurged group (5350, 
p=0.026 (figure 8.5). Since pharmacological purging may prolong the 
duration of cytopenia post-graft, or disadvantage the patient in 
other ways, account must be taken of the comparative event free 
survival which will include any differences in non-leukaemic causes 
of death. The difference remains, with an advantage for the purged 
group (6330 over the unpurged group (H5%) (figure 8.6), but this is 
no longer significant (p=0.11). Most of the purged patients are 
from Gorin1 s Group in Paris, who tailor the dose of in vitro agent 
to the individual patient - an approach about which I have some 
reservations, based on our own pre-clinical studies - which will be 
discussed in the next chapter.
Figure 8.5 First Remission: Effect of Purging with TBI Protocols
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Figure 8.6 First Remission: Effect of Purging with TBI on Event Free 
Survival
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8.1J.6 Other Factors Affecting Outcome
A number of other factors have been examined to see whether they 
influence outcome on a univariant analysis.
8.4.6.1 Age and Sex
Age and Sex have no effect, with patients over 50 years experiencing 
no lower a prospect of remaining leukaemia free or surviving event 
free.
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8.11.6.2 Pre-Autograft Delay
I suggested that outcome in the Glasgow patients was influenced by 
the pre-autograft delay in remission. ;The implication of this was 
either that the patients in the study were selected and did well 
because they had a lower probability of relapse the longer they 
remained in remission, or that these patients received more 
consolidation chemotherapy which might, in theory, improve the 
prospects of remaining leukaemia; free. The distribution of the 
pre-autograft delay in these patients is shown in figure 8.7(a). If 
all patients are stratified into five groups - less than 2 mo.; 2—4 
mo.; 4—6 mo.; 6-9 mo.; 9-12 mo.; and greater than 12 mo, the effect 
on relapse rate is shown in figure 8.7(b). It is clear that 
pre-autograft delay has no effect on outcome until beyond 12 months, 
when a substantial proportion may be claimed to be already cured by 
chemotherapy. The implications of this observation for the design
Figure 8.7 Distribution of Pre-Autograft Delay and Effect on Outcome 
(a) Variation in Pre-Autograft Delay
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(b) Effect of Pre-autograft delay on relapse free outcome.
100
> 1 2  MO 83%
80-
p NS
<2M 0
60-
UJ 2 - 4  MOiiiccu.
6 -1 2  MO 4 - 6  MOucoa.
<_i
20-
8 16 24 32 40 48 56 64 72 80 88 96
MONTHS POST-ABMT
of a comparative clinical trial will be discussed later. When the
data was examined within the TBI or Chemotherapy subgroups and at
different time outpoints, no differences could be found up to 12
months.
8.4.6.3 Duration of Diagnosis to Remission Interval
The Glasgow series of patients also suggested that these patients 
who achieved remission promptly had an improved prospect of
remaining leukaemia free. A simplistic interpretation of this
observation is that these were the subgroup of patients with the 
most responsive disease. This factor has been examined in all
patients, and in subgroups, and has not been found to be
influential. When various outpoints are examined, no correlation
with leukaemia free survival is observed (table 8.6). It is of
interest to note that even patients who have taken a considerable
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time to enter remission, and may therefore be considered poor risk 
cases, do not have a poorer prospect of survival post-autograft. 
This may reflect the possibility that disease resistance is 
compensated jfor by more chemotherapy.
Table 8.6 The Influence of Time Taken to Enter Remission on the 
Probability of Remaining Leukaemia Free Post Autograft
Diagnosis to 
Remission Interval
(days) <35 36-i»5 46-55 56-65 66-75 76-85 86-95 95+
? Probability of
Continuous Remission 50 51 53 76 77 67 55 58
In the Glasgow data all patients who entered remission within 50 days 
and had an autograft beyond 6 months remain alive and in complete 
remission. This relationship has been examined(table 8.7), and although 
some general benefit is seen in the patients autografted beyond 6 
months, this .is neither statistically significant nor related to the 
diagnosis-to-remission interval.
Table 8.7 Influence of Diagnosis-to-Remission and Pre-Autograft 
Intervals on Leukaemia Free Probability
Pre-Autograft
Delay
Time to
Remission(days)
Less than 
6 months
More than 
6 months
<55 55? 75?
56-75 53? 65?
76-100 59? 80?
100+ 60? 67?
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8.4.6.4 The FAB Subtype
FAB Subgroup has not been found to relate to long term survival on 
chemotherapy with the possible exception of the M3 subgroup, who 
some would feel has a sufficiently good prognosis that they should 
not be subjected to a transplant. Similarly, there are reports that 
patients with an M4 or M5 subtype are poor risk for allograft 
because of an increased relapse probability(16). The distribution 
of FAB subtype in these patients was shown in table 8.4, and the 
influence of the prospects of remaining in remission are shown in 
figure 8.8.
Overall, the FAB subgroup has a significance in two respects. The 
M3 subgroup have a significantly better outlook (73?) than other
Figure 8.8 ABMT in First Remission: Influence of FAB Subtype
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groups, while the M4 subgroup (30?) fare significantly worse, but 
the M5 (67?) subgroup have a good prospect of remaining in 
remission. these differences are statistically significant 
(p=0.0^9) but, if re-examined within the TBI subgroup, only the same 
differential trend remains (data not shown) but the differences are 
no longer significant, possibly because the numbers in each subgroup 
are now small. The interest in looking at TBI separately arises 
from the reports of increased extramedullary relapses in Mil subtypes 
noted on conventional schedules(17) which might have beerf 
compensated by an increased ability of TBI to treat sanctuary sites 
- no such benefit can be identified.
8.4.5 Survival After Relapse
Since in the Glasgow series, it was our general experience that 
survival after relapse was very poor, with one exception who 
continues in a subsequent remission of over 30 months, the prospects 
of useful durations of survival after relapse was examined. The 
results confirm, figure 8.9, that the expected survival following 
TBI is poor(6?) but that a significantly improved outcome(12?) is 
seen for patients given chemotherapy ablation (p=0.000*1). The 
precise treatment given to these patients is not known, but this may 
represent an unexpected, albeit small, advantage for chemotherapy 
ablation. Prolonged follow-up of these exceptional patients is 
required.
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Figure 8.9 Survival After Relapse: TBI vs Chemotherapy
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8.5 AUTOLOGOUS BONE MARROW TRANSPLANTATION In SECOND REMISSION
Sixty-one patients have to be autografted In second remission, the 
characteristics of whom are shown in table 8.8. The minimum 
follow-up of these patients is 15.5 months with a group median of 3*1 
months.
Table 8.8 Details of Patients Autografted in Second Remission
Total Number
Sex
Age
ABMT date
Updated
Follow-Up
61
i|0 male; 21 female 
1-50 Years(median 28 years) 
27 June 1981 - 8 Nov 1986 
20 Feb 1988
15.5-82 mo. (median 3^1 mo.)
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The treatment schedules in these patients is more limited and is
shown in table 8.9. Thirty-eight patients received unpurged marrow
and in 23 purging was undertaken with a Cyclophosphamide derative.
Table 8.9 Treatment Schedules for Autologous Bone Marrow
Transplantation in Second Remission
Schedule Total Non-Purged Purged
1) Cyclo + TBI 33 18 15
2) TACC or Bu/Gy 11 3 8
3) UCH Protocol 5 5 . 0
1|) BAVC 9 9 0
5) Other 3 3 0
8.5.1 Results of Autograft in Second Remission
The probability of remaining leukaemia free in these 61 patients, 
shown in figure 8.10, is k6% with a plateau of survival forming at 
2k months. Eleven patients are beyond this point with the longest 
survivor at M  months. Overall survival and event free survival are 
k3%.
When the patients are divided into those treated with a TBI schedule 
or with chemotherapy, there appears to be a survival advantage for 
the latter group as shown in figure 8.11, but this difference just 
fails to achieve statistical significance(p=0.07). Within the
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chemotherapy patient group there is no significant difference 
between those receiving purged(iJ5/0 or non-purged marrow(53£).
Figure 8,10 ABMT in Second Remission: European Study(n=6l)
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Figure 8,11 Autograft Survival in Second Remission: 
Chemotherapy Protocols
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The results of autograft in second remission are encouraging, and 
comparison of probability of remaining in remission and overall 
event free survival is not significantly inferior to the results of 
the first remission patients. It should be borne in mind, however, i 
that the follow-up is relatively short and therefore the outcome 
could deteriorate substantially with time. As will be emphasised in 
the next chapter, an important determinant of outcome in second 
remission is usually the duration of first remission. Since 
information concerning duration of first remission is not knownj it 
is not valid to exclude the possibility that it is only those 
patients who have had prolonged remission who are doing well, or 
indeed that the whole second remission group may have selected 
itself in a similar way.
8.6 THE IMPLICATIONS of THE INTERNATIONAL DATA REVIEW
These data have a number of Important advantages. First, they 
represent a number of patients sufficiently large to perform 
statistical analysis in an attempt to glean guidance for future 
protocol design. Second, the duration of minimum follow-up is 
sufficiently long to give reasonable confidence that the results 
seen will not change substantially with the passage of time. Third, 
the recent follow-up means that the data is uniquely current.
Like all registry data, there will be important heterogeneity 
between patients even apparently treated in the same way. It is 
also not possible to exclude patient selection in data reporting 
from the Centres or indeed in the pattern of patient referral to 
individual centres. Nevertheless, some tentative observations can
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be made from these results.
(1) the predicted low procedural related mortality has been 
corroborated in a large group of patients.
(ii) the leukaemia free probability of around 50% has been 
confirmed in a patient population up to 60 years of age.
(iii) Ablation with total Body Irradiation remains the gold-standard 
of treatment, but this can be matched by the UCH Protocol in a 
smaller number of patients and the BAVC Regimen also in a 
smaller number of patients whose follow-up is also shorter. 
BAVC Chemotherapy could hold the important advantage of being 
more generally available than TBI - but more prolonged 
follow-up is required before this can become the recommended 
schedule. The overall results of the UCH Protocol are 
sustained by the subgroup who received a double autograft. 
Since there is clear biological selection of those patients 
who receive a second autograft, it is difficult to know how a 
clinical trial using this protocol could be interpreted.
(iv) Since the procedural related mortality is low. there may be 
room to intensify the schedules already in use. It is likely 
that non-myeloid toxicity will limit the development of 
chemotherapy schedules, but there may be considerable scope 
for increasing the TBI.
(v) Techniques of ex vivo purging appear to offer the prospect of 
improved anti-leukaemic effect. This therefore implies that, 
contrary to what has been suggested earlier, lower rates of 
relapse are possible with autograft than what has been 
observed in the twin data, and part of the reason for relapse 
after autograft is contamination of the graft* The overall 
survival of the recipients of purged marrow is not
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significantly better than the unpurged group.
(vi) There are no consistent clues In relation to selection of good 
or bad risk patients with respect to pre-graft interval or 
diagnosis-to-remission interval. The observation of similar ! 
survival with differing delays up to 12 months could be used 
as an argument to perform the autograft early In remission 
thereby minimising the risk of relapse pre-transplant. The 
impressive outcome of double autograft seen with the UCH 
protocol, but not with Melphalan, could also be interpreted to 
support the value of pre-autograft cytoreduction to the 
eventual outcome.
The somewhat unexpected observation that the outcome is not 
influenced by a prolonged diagnosis-to-remission interval, is 
surprising but indicates that, considering such patients as 
high-risk, is at present unjustified.
(vii) Although the follow-up is shorter, the outcome for second 
remission is surprisingly hopeful. While the chemotherapy 
treated patients have a superior outlook than TBI treated 
patients, this is not significantly so. In this respect it is 
notable that only 2 of 9 BAVC treated patients have relapsed. 
Unpurged marrow is not worse than purged marrow in this 
setting.
If the observation that the overall outcome is not significantly 
worse in second remission than in first holds up with time, there is 
a strong argument to advocate reserving autograft exclusively for 
second remission, since a proportion of patients (20-3055) can be 
cured with conventional chemotherapy, and unnecessarily undergo 
transplantation.
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CHAPTER 9
REMOVAL OF SELECTED CELL POPULATIONS 
FROM BONE MARROW - "PURGING"
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9.1 INTRODUCTION
Clinical studies of autograft in AML using unpurged marrow, have 
already indicated that; about half the patients relapse, usually 
within the first year. It is currently impossible to say whether 
relapse originated from endogenous cells which survived Ablative1 
treatment in the patient, or from residual disease which may have 
been in the autograft itself. As previously discussed, the apparent 
increase in relapse rate in syngeneic transplants compared with 
allogeneic grafts (particularly with chronic GVHD) suggests that a 
graft-versus-leukaemia-effect may contribute to the encouraging 
anti-leukaemic effect of allograft. The relapse rate in autograft 
is indistinguishable from that found in twins - an observation which 
has two implications, (i) residual clongenic disease in the 
autograft, if present, may not threaten clinical outcome. I argued 
in Chapter 3 that residual disease in the graft may be minimal,
(ii) it will be extraordinarily difficult to measure in vivo the 
value of any purging technique, because of the large numbers of 
patients required. Nevertheless, improved results of autograft in 
the future in acute leukaemia may depend on techniques which can 
successfully remove ("Purge") contaminating cells.
It is crucial to recognise that sophisticated techniques of in vitro 
purging are futile if the ablative or cytoreductive protocol fails 
to eradicate endogenous disease in the patient. Similarly, any 
technique must avoid damage to the graft which could prevent 
sustained haemopoietic reconstitution, or renders the bone marrow 
more susceptible to damage during storage.
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9.2 PRACTICALITIES OF PURGING
Purging techniques can be potentially useful clinically if they 
effectively remove unwanted cells (normal or malignant) without 
damaging the repopulative potential of bone marrow, a property which 
is difficult to measure in humans by in vitro techniques. The 
limitations of committed stem cell assays have been discussed 
previously - but they do serve as a guide. They are useful in that 
if growth is apparent the marrow is probably viable, but if absent 
does not necessarily result in failure of regeneration - an 
observation highlighted by some of the clinical studies of purging 
to be described. The categories of techniques available for purging 
are outlined in Table 9.1.
Table 9.1 Techniques of Purging Bone Marrow
1) Density Separation - Density Gradient
- Centrifugal Elutriation
2) Immunological - Opsonisation
(Monoclonal Antibody) - Complement
Toxin (e.g. Ricin)
- Immunomagnetic
3) Physical/Chemical - Pharmacological Agent
(l| HC: VP-16: Synergy)
- Merocyanine
Selective Culture
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9.3 SEPARATION BY DENSITY
Bone marrow of human and other species can be separated by density
gradient techniques to isolate a stem cell rich fraction(1).
Further precision can be introduced by counterflow centrifugation - 
elutriation, a technique which separates on a combination of size, 
mass and density of individual cells. In experiments on dogs, two 
CFU-GM enriched fractions could be obtained by this technique but 
only one could effectively protect lethally irradiated hosts. This 
could indicate that CFU-GM subgroups, of different density exist, 
but do not necessarily serve as an accurate indicator of the
pluripotent stem cells which cannot directly be measured(2). A 
major limitation of this technique is the requirement to process
large numbers of bone marrow cells, but this can be overcome by 
alteration in rotor design(3).
The question of whether physical differences exist between 
clonogenic leukaemia cells and normal pluripotent cells remains 
open.
Clinical experience in man is limited. As part of his studies of 
autograft in relapsed acute leukaemias, Dicke processed the bone 
marrow over a discontinuous albumin gradient(4). This appeared to 
have little effect. Since almost all patients in his study 
relapsed, albumin gradient purging has not been continued. However, 
as discussed elsewhere, it is probable that the relapses in his 
study originated from remaining cells in the patient, and so the 
role of such techniques in man remains unassessed.
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It is of interest to note that counterflow centrifugation- 
elutriation seems capable of making a useful contribution towards 
eliminating T cells from an allogeneic graft with observed 
reductions in graft-versus-host disease (5).
9.*J IMMUNOLOGICAL PURGING
Due to hybridoma technology production of specific antibody 
(monoclonal) in bulk has generated extensive investigation of 
immunologically based techniques for removing selected cell 
populations. Since in vivo use of monoclonal antibody is still 
problematical due to cross reactivity with host tissues, e.g. kidney 
tubules in the case of the common ALL antibody (CALLA), most 
activity has centred around uses of antibody in vitro.
9.^.1 Technical Aspects Of Immunological Purging In Vitro Using 
Monoclonal Antibody
It is almost a prerequisite for any purging technique that some 
concentration of marrow occurs, ideally to the extent of preparation 
of a Mononuclear Concentrate [MNC]. As well as saving reagents - an 
important consideration in itself - such conditions may improve the 
reproducibility of the technique by starting with as homogenous a 
cell population as possible, free from contaminating red cells.
Antibody specificity can be exploited in a number of ways, 
i) direct opsonisation with subsequent in vivo removal by the hosts1 
reticuloendothelial system. This approach, largely tried to deplete 
bone of normal T cells to prevent graft-versus-host disease, appears
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of limited use either because of shedding of antibody or 
inefficiency of the Reticulo-Endothelial System following its recent 
exposure to ablative preparative chemo-radiotherapy(6,7).
(ii) complement mediated lysis. |Use of complement has become the 
standard method of inducing cell lysis in vitro, having been adopted 
to remove normal T cells from allografts to prevent GVHD, and 
leukaemic cells from autografts.
The antibodies chosen require to have certain properties to be 
effective in such a system. As well as being directed against the 
appropriate antigen, they must bind complement. Many of the mouse 
monoclonal antibodies used as diagnostic agents bind complement 
poorly or not at all, but IgM antibodies fix rabbit complement 
well. IgG antibody subgroups IgG 2A, IgG 2B and IgG 3 have variable 
binding but IgG 1 combines poorly with rabbit complement(8). Few 
appropriate antibodies bind human complement. The requirement in 
most cases for rabbit complement is troublesome in that there may be 
considerable interbatch variation in lytic ability or damage to 
haemopoietic precursors. Batches must therefore be scrupulously 
pre-tested. Optimum lysis may require more than one round of 
complement. Similarly, cell concentration may affect degree of 
lysis but it appears that a cell count of <2 x 10? cells/ml is 
required(9).
Cocktails of antibodies may be more effective with lysis resulting 
in a i|-6 log kill being possible( 10,11). The use of two antibodies 
to the same epitope can increase lysis further in some systems(12).
(iii) Monoclonal antibody linkage to target cells can be exploited 
in other ways. Coupling to the toxin Ricin can directly kill the
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target cell without damaging marrow(13,14). Initial clinical 
studies in allogeneic and autologous transplantation have been 
reported, with some preliminary evidence of clinical 
effectiveness(15,16).
Cobalt colloid is paramagnetic and can bind immunoglobulin. If the 
immunoglobulin is goat anti-mouse then it in turn can bind cells 
coated with mouse monoclonal antibody and the complex removed with 
an5 electromagnet(17). Magnetic microspheres coated with monoclonal
antibody is an alternative method, and is effective in removing 
neuroblastoma cells for example, with a 3-4 log removal of antibody 
positive cells being possible. The technique is relatively simple 
and can be applied to bulk marrow without the need for sophisticated 
equipment(18). A few clinical studies are underway with this 
technique. The immunomagnetic techniques, because of their 
simplicity and encouraging in vitro effectiveness, are likely to be 
more widely used in future clinical allograft and autograft studies.
9.4.2 T Cell Depletion Of Allogeneic Bone Marrow To Prevent Graft 
Versus Host Disease
The most widely depletion/purging technique used in recent years has 
been T cell removal from allogeneic marrow to prevent 
graft-versus-host disease. In this context useful information can 
be gained to suggest whether this approach in general can be used on 
bulk marrow, without detriment to engraftment and with the 
convenience of a short-term clinical end point, to demonstrate 
effectiveness. It has the additional advantage that the technique 
is measurable in the laboratory, which is not readily the case for
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many of the techniques used to remove leukaemic cells from 
autologous marrow.
As discussed in Chapter 2, Graft-versus-host disease has been a 
major problem in allogeneic transplantation. As well as being an 
important direct cause of death, it is a major risk factor for CMV 
pneumonitis and contributes to complications resulting from 
immuno-suppression. There is in addition considerable morbidity 
associated with non-fatal GVHD or its preventative treatment with 
drugs such as methotrexate and/or cyclosporin. It remains difficult 
to treat disease which is more extensive than skin involvement, at 
present, and it is still debatable whether traditional prophylactic 
measures (methotrexate or cyclosporin) are effective.
There seems little doubt that the effector cells are the T cells in 
the allograft. Animal experiments demonstrate that T cell removal 
from the graft prevents GVHD(19) so it is therefore a reasonable 
proposition that selective in vitro removal of these cells may 
reduce GVHD in man and thereby directly and indirectly reduce 
procedural related mortality and morbidity.
9.4.2.1 Clinical Studies of T-Depletion to Prevent GVHD
Based on apparent effectiveness in animal systems, the Royal 
Free (London) and Minnesota groups undertook preliminary pilot 
uncontrolled studies using the commercially available pan-T 
monoclonal antibody 0KT3, incubating it with the allograft, and 
relying on the reticuloendothelial system of the host to remove the 
opsonised T cells. There are a number of technical reasons why this
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was unlikely to be successful and the clinical results were not 
convincing that such a simple approach would work(6,7).
Subsequent clinical studies have used one or more monoclonal 
antibodies directed against post-thymic T cells with the addition of 
complement in vitro to ensure lysis, rather than opsonisation, of T 
cells prior to administration to the patient. The antibodies used 
have almost all necessitated the use of rabbit complement. There 
seems little doubt from these studies that clinically significant 
GVHD (> Grade II) can be prevented(20,21), but most studies have 
been associated with an unexpected incidence of graft 
failure (22,23,2*0.
In 198*1 I introduced T cell depletion to our allograft transplant 
programme using monoclonal antibodies, kindly provided by Professor 
Janossy (Royal Free Hospital, London), to prevent GVHD in patients 
undergoing allograft for haematological malignancy. This data 
represents the technical prototype for all immunological purging 
methods which we have employed, including removal of residual 
leukaemia cells from patients with Acute Lymphoblastic Leukaemia, 
which will be referred to below.
9. *1.2.2 Patient Population
This approach has been applied in 35 allografts with various 
haematological malignancies - the majority of whom were adults - and 
therefore a group at high risk of GVHD. The details of these 
patients are shown on Table 9.2. Patients were subdivided into two 
groups. Group I was the first 8 consecutive patients who received a
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conditioning protocol of standard cyclophosphamide 60 mgs/kg on Days 
-*l and -5 and fractionated TBI (6 x 200 cGy). One of these 
patients, a 2-year old boy, received reduced TBI (*J x 200 cGy) 
because of anxiety about the long-term effects of radiation. Group 
II comprises 27 subsequent patients who received cyclophosphamide as 
for Group I but an increased TBI protocol comprising 7 x 200 cGy. 
In all patients the TBI was administered by our standard technique 
(described in Chapter *1) with lung shielding to 1100 cGy.
Table 9.2 Characteristics of Patients Receiving T Depleted 
Allogeneic Bone Marrow Grafts
Group I Group II
Number 8 27
Age 13.1 yrs 22.8 yrs
(2-21) (*1-*J2)
Sex M:F 7:1 16:11
Disease/Status
AML CR1 2 6
AML CR2 0 1
Rel. 0 2
ALL CR1 1 i\
ALL CR2 3 10
Rel. 0 1
CML Ch.Ph 2 1
Other 0 2
Group I received 6 x 200 cGy of TBI: Group II received 7 x 200 cGy 
of TBI
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9.^.2,3 Laboratory Technique of T-Depletion
Bulk bone marrow was removed from the donor and prepared as a mono­
nuclear cell fraction (MNC) as described in detail in Chapter 5. The 
stem cell rich fraction was then incubated with the monoclonal 
antibodies RFT8 (CD8) and MBG6 (CD6) (Table 9.3) at room temperature 
for 30 minutes. Baby rabbit complement was then added in a volume 
equal to that of the MNC (mononuclear cell fraction) and the 
suspension incubated at 37°C for 30 minutes. Baby rabbit complement 
was obtained from a commercial supplier (Pelfreeze Ltd). Suitable 
batches were defined in Professor Janossy's Lab, by in vitro testing 
of cytotoxicity against target T with MBG6 + RFT8 (or leukaemic) 
cells, without any in vitro toxicity against normal marrow precursors 
CFU-GM, BFU-E and CFU-GEMM(25). The cell suspension was then washed 
in the cell washer in 500 mis of Hanks Balanced Salt Solution (Gibco 
Ltd) and concentrated. A second round of complement was incubated 
for 30 minutes at 37°C» as before, and then washed in Hanks balanced 
salt solution (Gibco Ltd/BRL) containing 185 mg/1 Na+ and 200 ml/1 
Mg++ and then in a 2.5$ Human Plasma Protein Solution (Scottish 
National Blood Transfusion Service). The final product was infused 
into the patient within 3 hours.
Table 9.3 Characteristics of Monoclonal Antibodies for Ex Vivo T Cell 
Depletion of Allogeneic Bone Marrow
MGB6 CD6 IgM Equivalent to 0KT3 but binds to a
different epitope. Binds to >93% 
of mature T lymphocytes(26)
RFT8 CD8 IgM Recognises 32KD antigen on T Cells
of Suppressor/Cytotoxic Type(27)
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9.*1.2.11 Evaluation of the Technique
Aliquots of bone marrow were evaluated before, during and after the 
procedure for T cell,! CFU-GM and BFU-E composition. T cells were 
enumerated using fluorescent microscopy. Aliquots of 1 x 10^ cells 
were washed in phosphate buffered saline (PBS) and incubated with 
fluorescence conjugated goat anti-mouse immunoglobulin for 10 
minutes. Five hundred cells were counted. In order to confirm that 
the remaining dells showing membrane fluorescence, although not 
lysed, were not viable the preparation was counterstained by adding 
10 ul of ethidium bromide. Dead cells were identified by nuclear 
uptake of the stain (showing red)(28).
9. *1.2.5 Engraftment Criteria
Satisfactory engraftment was defined as peripheral blood neutrophils 
reaching 1 x 10^/1 for a minimum of three consecutive days. 
Platelet engraftment was arbitrary selected as the day when the 
count reached 50 x 109/1.
9.**.2.6 In Vitro Results
The quality of T cell depletion was satisfactory ranging from >95 to 
>99/6» with 33 of 35 patients being >98$ depleted. The absolute 
number of T cells infused was 0.03 - 2.*42 x 10^/kg. The 
consequences of the procedures on in vitro parameters are shown in 
Table 9.*l, The T cell reduction was one log with one round of 
complement, and an approximately equivalent further log reduction 
after the second round of complement. All but two patients received
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less than 1 x 108 T cells/kg with the majority receiving 
substantially less (median 0.09: range 0.03 - 2.42 x 10^/kg). Of 
the absolute loss of nucleated cells, about 25$ can be accounted for 
by T cell lysis, the remainder and the CFU-GM loss presumably 
occurred during the washing procedures in a non-specific way, but 
this was not directly measured.
Table 9.4 In Vitro Consequences of T Cell Depletion (n=35)
Total T Cells 
x 108
T Cells Dose 
x 106/kg
Nucleated 
Cell Recovery
cf
CFU-GM 
x 105
Pre- 7.54* 17.8 100 46.3
±  2.92 ±  11.4 + 36.8
After 1st 0.76 1.85
Complement i 0.75 i 2.04
After 2nd 0.10 0.36 20.7 23.9
Complement i+ o • i 0.55
CO•
-=r
+1 +  22.1
* Mean ± S.D.
The use of ethidium bromide counterstaining is shown in Figure 9.1 
which shows the preparation after the addition of one round of
i
complement, with cells showing membrane fluorescence with RFT8 but 
no ethidium counterstaining, indicating that these are viable 
cells(28). After the second round of complement, membrane staining 
cells are confirmed to be dead by uptake of the counterstain. The 
degree of depletion is deduced by a 500 cell differential count of
i
viable'membrane fluorescent positive cells.
371
Although less sensitive than direct microscopy, the procedure can be 
examined by fluorescent flow cytometry as illustrated in figures 9.2 
■which show the population of RFT8 +ve cells in the gate (Plate A) 
before treatment with complement, after one (Plate B) and two 
(Plate C) rounds of complement. The ethidium staining cells which 
are also RFT8 +ve show in the gate as a separate population of RFT8 
+ve cells which do not take up the counterstain. VJhile flow 
cytometry is probably less accurate than direct microscopy, it can 
count a large cell number.
Fig 9.1 Fluorescent Microscopy Assessment of T Cell Depletion
Plate A
Typical appearances after the first 
round of complement showing surface 
positivity (RFT8/MBG6) on two cells.
The upper cell is counter-staining 
with ethidium bromide, and is non- 
viable; the lower cell has no 
counterstain and is viable.
372
Figure 9.1 (continued)
Plate B
A final preparation showing two 
non-viable cells after a second round 
of complement.
lip*
A 500 cell count is done with the microscope shutters admitting 
white light. The same field is then searched for fluorescence 
staining cells and the result expressed as positive cells per 500 
nucleated cells, from which the absolute numbers can be calculated.
Vo
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Fig 9.2 Detection of T Cell Depletion by Flow Cytometry
Plate A. The mononuclear cell fraction contains 22Jf RFT8/MGB6 
positive cells which are shown as the population in box A, which 
show higher levels of fluorescence. In the figure the x-axis shows 
increasing amounts of fluorescence per cell: and the y-axis is cell 
volume. The accompanying digital print-out (not shown) of 5000 
cells indicate that 1117 (22%) are in gate A and therefore T cells. 
Flow cytometry is carried out on a Becton and; Dickinson Cell 
Analyser. The antibody (RFT8/MBG6) coated cells are illuminated by 
attachment to a rabbit-anti-mouse FITC conjugate (Dako Ltd) with an 
excitation wavelength of 488 nm and an emmision wavelength of 516 nm 
which is selectively detected by suitable filters.
t
- “ - \ mm
• ‘ ' ‘ Gate A
6 . *r.*« - . - ; "5
FITC
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Figure 9.2(continued)
Plate B.
The appearances of the analysis change after the first round of 
complement. The X-axis is again increasing FITC (517 nm) but the 
X-axis is increasing levels of ethidium bromide. The cells in gate 
A are again RFT8/MBG6 positive; the cells in gate B are unstained 
and the cells in gate C are RFT8/MBG6 and ethidium bromide 
positive. Double staining of individual cells is possible because 
ethidium bromide has an excitation wavelength of 488 nm but can be 
specifically detected because of its emission frequency of 605 nm, 
which can be detected by suitable filters.
This technique readily illustrates remaining viable T cells (gate A) 
but a larger proportion of non-viable T cells (gate C).
t
Eg
t5
!E+*
uj
I
1st.Complement
Gate B Gate C
.
Gate A
FITC
375
Figure 9.2(continued)
Plate C. The appearances after the second round of complement, 
showing that the majority of RFT8 positive cells are now appearing 
in gate C with a few viable T cells remaining in gate A.
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9.4.2.7 Engraftment
The kinetics of engraftment of neutrophils are shown in Figure 9.3, 
the data is expressed as the percentage of patients achieving 
1 x 109 neutrophils/1 with time.
It is apparent that some patients failed to achieve adequate 
engraftment. A total of six patients had graft failure. In two 
there was no Evidence of a neutrophil increment, and in four there 
was an initial rise in neutrophils but this was not sustained with 
loss of graft occurring within 28 days. Attempts were made to
Fig 9.3 Neutrophil Regeneration in Patients Receiving T Depleted 
Allogeneic Bone Marrow.
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regraft these patients with (n=3) or without (n=2) additional 
conditioning. One of these patients, the two year old boy who had 
been given a reduced dose of TBI (4 x 200 cGy) rejected his sister fs 
marrow but regenerated autologous haemopoiesis, confirmed by 
cytogenetics, and remains well 32 months post-graft. All other 
graft failures died.
Non-engraftment was apparent in five of the first eight patients 
(Group I). At that time careful comparisons’ were made of in vitro 
data, and the depletion technique with the Royal Free and other 
collaborating groups who had four graft failures in *18 patients. 
There was no detectable difference in the graft characteristics in 
the different centres - but the major difference was concluded to be 
a different irradiation technique (750 cGy single fraction rapid 
dose rate in the Royal Free vs 6 x 200 cGy fractionated over 3 days 
in Glasgow)(29).
Having changed the radiation dose for the subsequent twenty-seven 
patients to 7 x 200 cGy over three and a half days, all but one 
patient engrafted. One additional patient did not achieve 1000 
neutrophils till day +112 but has sustained engraftment which are 
100? (cytogenetically documented) donor origin.
The rationale of increasing the conditioning TBI will be discussed 
below but, to ascertain whether there were differences in the graft 
characteristics between the first eight patients (Group I) and the 
Group II patients, the in vitro data is compared (Table 9.5). It is 
apparent that there is no significant difference between the graft 
characteristics of the two groups.
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Similarly, when the in vitro graft characteristics of the patients 
who successfully grafted are compared with those who had graft 
failures, no significant differences emerge (Table 9.6>. It is 
interesting to note that, if anything, the patients who failed to! 
graft received more T cells (0.57 - 0.81 x 10^/kg) than the
successful grafts (0.19 ± 0.22 x 10^/kg), but this difference was 
not significant(Studentfs T Test).
When the pace of haemopoietic regeneration of the T depleted 
patients who grafted successfully is compared with an historical 
group of patients who received unmodified marrow, receiving alter­
native GVHD prophylaxis, but who did not develop GVHD (Figure 9.4),
Figure 9.4 Haematological Regeneration of Neutrophils and Platelets 
in Recipients of T Depleted Allografts who Grafted 
Successfully.
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there are no differences in platelet regeneration, but neutrophil 
recovery to 1 x 10^/1 is slower [T depletion: median 29 days (range 
15-116): Control median 19 days (range 12-33) P=<0.001].
9.4.2,8 Development of Graft versus Host Disease
The main aim of the technique is to eliminate graft-versus-host 
disease as the important biological endpoint. As shown in the 
preceding data, there is substantial (2 logs) but not complete kill 
of phenotypic T cells. It may also be that less mature T cells have 
not been removed.
Acute Graft versus Host Disease: Of the 29 patients who have
engrafted, all have been observed for >70 days to be fully evaluable
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for acute GVHD. As an approximate comparison, they are compared 
with 35 previous patients treated in Glasgow for similar 
haematological disorders, of whom 3*1 are evaluable. The stage of 
GVHD is based 'on established criteria(30).
Eight of the 29 (2750 T depleted patients developed acute GVHD 
restricted to skin and none developed stage III or IV disease 
(Table 9.7). Twenty-one (73$) had no evidence of acute GVHD. All 
skin GVHD responded rapidly to treatment. Seven of 3*1 historical 
patients developed stage I or II disease (21$) and eight Stage III 
or IV disease (24$) and nineteen of 34 (56$) had no GVHD. As well 
as eliminating serious GVHD it appeared on subjective assessment 
that the skin disease was milder and more responsive to treatment. 
There is little doubt that there was a substantial reduction in the 
overall toxicity in the T depleted group during the transplant.
Table 9 .7 Incidence of Acute Graft versus Host Disease in 
Recipients of T depleted Bone Marrow.
At Risk Nil Grade I or II III or IV
Historical Controls 34 19(56$) 7(21$) 8(24$)
T Depletion 29 21(73/0 8(27$) 0
Historical controls comprised 15 children and 19 adults who received 
Methotrexate (n=l4) or Cyclosporin and Methylprednisolone (n=20) as 
GVHD prophylaxis.
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Although there was a tendency for the patients who developed GVHD to 
have received a higher fdosef of T cells compared with those without 
GVHD (0.57 ± 0.111 vs 0.15 ± 0.22 x 106/kg) the difference was not 
significant[Student's T Test],
9. *1.2.9 Conclusions on T depletion to Prevent GVHD
The technique with the particular antibodies used is capable of 
effecting a 2 log depletion on the population of T cells which 
constitute around 20-25? of the cells in the Mononuclear Cell 
concentrate, but a few cells remain.
Although some patients unexpectedly failed to engraft it does not 
appear that this is due to toxicity of the in vitro procedure but 
may be attributable to host factors. A rejection rate of around 20? 
has been observed using other methods of T depletion (22,23,21}). It 
is probable that haemopoietic engraftment depends on adequate 
immunosuppression of the host which is traditionally achieved by the 
preparative protocol of cyclophosphamide and TBI. But, an 
additional immunosuppressive effect may be mediated by donor 
lymphocytes in the graft. There is evidence in experimental systems 
which supports this concept since the presence of T cells enabled 
engraftment from non-identical donors, an effect which was abrogated 
by Cyclosporin (31). Removal of this mechanism by T depletion 
probably is capable of tipping the balance in favour of rejection of 
the graft.
The rationale for increasing the TBI was based largely on the 
developmental data from Thomas who established the traditional dose
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of TBI widely used in allogeneic transplantation as a result of a 
series of dose escalation experiments aimed at achieving a dose
which would reliably ensure stable engraftment(32,33). This 
traditional dose was adopted for this reason rather than because it 
was known to have a useful anti-leukaemic effect. It seemed
possible that an extra fraction of TBI (with appropriate lung 
shielding to 1100 cGy) would be sufficient to consistently achieve 
engraftment in the T depleted setting, without increasing toxicity.
It has been suggested elsewhere that GVHD may be anti-leukaemic and 
its eradication may therefore result in a higher relapse rate in. 
AML. This appears to happen in chronic myeloid leukaemia(3*1) - 
although these patients also received post-graft cyclosporin - but 
the evidence in AML is equivocal in favour(35) and against(36,37) 
such a consequence. In this respect there may be different 
consequences for different diseases and there may be qualitative 
differences between techniques currently used by different groups.
Part of the rationale for choosing to add an extra fraction of TBI, 
was to augment the anti-leukaemic effect which might be anticipated 
in the absence of GVHD. This was achieved without increased 
toxicity. Of the 13 first remission cases in this series who have
been followed for a minimum of 9 months (range 9-36 months), 3 have
relapsed. All three were at relatively high risk of relapse being a 
poor risk ALL, a FkB-MH AML and a secondary AML respectively. The 
actuarial risk of relapse is 27%, When combined with the 38 first 
remission patients, receiving T depleted allografts at The Royal 
Free Hospital, London, with the same monoclonal antibody technique 
where the actuarial relapse rate is 12£ (Prentice H G, personal
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communication) there is little evidence so far to suggest that there 
will be a higher relapse rate using these antibodies, than the 
international norm.
9.4.2.10 Comments on Immunological Purging Technique
This data, and the general experience of immunological methods of T 
cell removal to prevent GVHD, confirm that the techniques are 
effective as judged by the observation that significant GVHD is
prevented. Within the restrictions of in vitro assessment little
damage is done to the viability of the graft with these antibodies. 
While there have been graft failures, and the precise reason was not 
initially clear, this is currently attributed to disruption of the 
complex interactions between host and donor which permits 
engraftment rather than to damage to the graft by the in vitro
processing.
Whether such a technique is thorough enough if transferred to the 
setting of leukaemia cell removal is an open question at present. 
The advantage of the T depletion technique is that it is measurable 
in vitro. Since the starting position is equivalent to 2056
contamination with target cells - equal to relapse in the leukaemia 
setting - a 2 log kill is measurable by currently available 
techniques.
As will be indicated below, residual disease in leukaemia is not 
easily measurable by current techniques even before the purging 
process.
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Clearly several T cells are returned to the patient after purging, 
but this is compatible with the desired clinical effect. In 
leukaemia, such a level of contamination may be unacceptable, and 
therefore a more stringent technique Required.
9.4.3 Immunological Purging in Acute Lymphoblastic Leukaemia
Since ALL probably does not originate in a multipotent haemopoietic 
stem cell and expresses differentiation antigens which theoretically 
offer targets for monoclonal antibodies which are not expressed on 
progenitor cells, it represents an attractive setting in which to 
employ immunologically based techniques.
9**1.3.1 Selection of Monoclonal Antibodies
T cell differentiation within the'thymus results in the progressive 
expression of antigens(38,39) as- indicated in table 9 .8 . 
Pre-thymocytes or bone marrow derived cells are Tdt, 0KT6, 
transferrin receptor and CD7 positive(40).
Figure 9 .5 Immunophenotype of Maturing T Cells
Ear ly
Thymocyte
Mature  T Cel l
(suppressor)
CD7 rn 8
CD7 J ? 2 L C D 8 jT CD3
,r- C D S X - X  /
CD3
L a t e
Thymocyte  (helper )
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Physiological expression of antigens related to differentiation 
within B cell lineage is not so clearly known, the observations 
being confused by expressions occurring due to activation or 
possibly different subsets of B cells. Data derived from membrane 
phenotype on B cell lymphoproliferative disorders and immunoglobulin 
gene rearrangement( 1) leads to a working proposition of expression 
related to differentiation from which a logical specification of 
antibody for purging could be selected.
i
Most acute T cell leukaemias are derived from thymocyte or 
pre-thymocyte precursors, i.e. Tdt+; T10+; CD7+ cells(42,38,43,44).
Common ALL (Calla/J5 or CD 10 +ve) is within the B cell lineage as 
corroborated by immunoglobulin rearrangement studies(45). What 
proportion of 'null* ALL is in early B lineage is unknown; such 
tumours do not yet show immunoglobulin gene rearrangement, and so 
cannot be proven to be with the B cell lineage(46).
In addition to selecting antibody of the appropriate phenotype, it 
must be established that they do not cross-react with marrow stem 
cells. As mentioned in Chapter 5 , the only available methodology of 
the CFU-GM:CFU-GEMM and BFU-E assays. Long Term Bone Marrow Culture 
may demonstrate an earlier stem cell population which survives even 
after immunological or chemical destruction of committed stem 
cells. This may develop into a clinically meaningful assay in this 
context.
The argument for using a mixture of antibodies is strong. In the 
first place, expression of antigen between individual cases of the
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same disease may vary. It is known that phenotypic expression on 
relapse may be different than that observed at diagnosis. Perhaps a 
more serious problem which is common to all antibody based 
techniques is the possibility that the clonogenic leukaemia cells - 
which would be responsible for recurrent disease - do not express 
the antigens present on the blast cells. A reliable leukaemia cell 
clonogenic assay is required in human ALL to clarify this point(47) 
in individual cases.
9 . 3 . 2  Clinical Considerations for Autografting in ALL
Defining the clinical context in which autograft may be useful in 
ALL is much more complex than in AML. It shares with that disease 
the numerical advantage of providing a therapeutic option to 
patients without donors but who merit transplant, and since most 
suffering from this disease are under 60 yrs, has the potential to 
make a substantial impact on the disease as a whole. In children, 
conventional chemotherapy may be capable of curing 60-7055 of 
cases(i|8 ). That is not to say that a strategy of early 
intensification alone (i.e. autograft or allograft) might not result 
in further improvement or at least an equivalent outcome, in which 
case the long-term consequences of treatment will then be a decisive 
issue. For patients who relapse from first line chemotherapy - 
despite obtaining a further remission, the prospect of cure is 
remote. Allogeneic transplant is usually reserved for those who 
fail conventional chemotherapy when it appears to offer the best 
possibility of cure(li9,50,51,52), but even that is now questioned 
with improving second line chemotherapy(53). About 30-^0? of 
patients allografted at this stage will survive but there is a
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predicted relapse rate of around 50%, A higher relapse rate in 
autograft could be expected in view of the demonstrable GVL effect 
in this disease, associated with graft-versus-host disease referred 
to previously, which would be lostCS1!).
The limited antileukaemic effect achieved in allograft suggests that 
a high relapse rate can be expected following autograft at this 
stage, due to failure to eradicate the disease in the patient.
>
Assessment of benefit in any individual will be difficult but 
clearly any treatment which can produce a second remission which is 
longer than the first can claim to be advantageous, (so called 
"inversion"). It has recently been emphasised that there is 
considerable heterogeneity of prognosis in any group of ALL in 
second remission(55). Clearly patients who relapsed on treatment 
have a poor prognosis compared with those who enjoyed a long first 
remission and relapsed when off therapy. This should be borne in 
mind when assessing any clinical result or constructing a controlled 
trial in this disease. It is also perfectly possible that the 
’ablativef protocol itself, without purging, may produce significant 
benefit. Several groups now employ autograft in ALL with purging 
only but one study currently assess the contribution of unpurged 
autograft (Proctor, 1987, Personal Communication).
In allogeneic BMT in ALL, there is concern about the high relapse 
rate following transplant in second remission. This has given 
impetus to defining subgroups who can be predicted at diagnosis to 
respond poorly to conventional chemotherapy and offer alternative 
treatments such as BMT as first line treatment. Similar criteria
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can legitimately be applied to the use of autograft for those 
without donors.
Some criteria are generally accepted, e;g. presenting blast cell 
count >50,000 x 10^/1(56,57):B cell leukaemia(58): Philadelphia
positive ALL(59): CNS disease at presentation. To this I have added 
all adult ALL irrespective of other criteria with the current 
exception of teenage females(60,6l,62). Patients who have not 
entered remission on marrow assessment by Day 28 may do badly and 
justify a graft as first line treatment once remission has been 
achieved. These criteria will not be universally accepted as 
indications for transplant, particularly as (a) new chemotherapy 
protocols are under evaluation(63,6*0 and (b) there is limited long 
term follow-up, even in allograft, to indicate that patients who are 
considered fpoor risk1 for chemotherapy are not also poor risk for 
transplantation, but the initial results in the IBMTR experience are 
encouraging(65).
9.4.3*3 Clinical Studies In ALL
Clinical studies published so far almost exclusively concern second 
remission. None is a randomised study and, although in some cases 
encouraging, do not yet establish autograft as advantageous. Since 
none of the studies has been done with unpurged marrow, the 
usefulness of purging techniques remains unanswered.
The Boston group studied patients, paediatric and adult, with non-T 
ALL in second or subsequent remission(66). As cytoreductive 
treatment they added VM-26 (200 mgs/m2 x 2) and 5 days of Cytosine
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Arabinoside (500 mgs/m2/2*l hrs) to standard Cyclophosphamide and TBI 
(6 x 200 cGy). In vitro purging was undertaken with J5 (cALLA) and 
gp26, an antibody which reacts with 68$ of cALLA negative non-T 
cells. In vitro assays CFU-GM, CFU-GEMM and BFU-E indicated little 
reactivity of these antibodies with marrow precursors. 
Haematological reconstitution, although consistently achieved, but 
was delayed - 1000 neutrophils on median day lJ3 (range 16-78) and 
platelets >25,000 median day 50 (range 16-103).
Of 3^ 1 patients entered into the study, 12 died from toxicity in 
complete remission and 10 patients have relapsed. The relapse cells 
were cALLA positive as before. All relapses occurred within 8 
months of ABMT, seven within 3 months, and all occurred in the bone 
marrow. Twelve patients remain in complete remission H months to 5 
years post graft. The actuarial prediction of survival at 5 years 
is 30$.
In a series of 23 patients in second or greater remission of ALL the 
Minnesota group purged bone marrow with a combination of BA-1, BA-2, 
BA-3 monoclonal antibodies and baby rabbit complement(67). The 
cytoreductive protocol was cyclophosphamide and fractionated TBI. 
Engraftment kinetics were not different from similar patients 
receiving allografts, indicating that regeneration was not 
compromised. Sixteen patients relapsed, one died of infection and 
six remain disease free at 16-38 months. It is not stated whether 
these six patients have now achieved durations of remission longer 
than their previous one, i.e. have inverted. It is therefore not 
possible to draw any conclusions as to the effectiveness of the 
purging technique from this study.
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These clinical studies in ALL demonstrate that leukaemia specific 
antibodies and complement treatment in vitro does not prevent 
haematological regeneration, but it is not possible to be sure of 
any clinical advantage to the patient, the remaining problem being 
eradication of disease in the patient.
In the data collected by Gorin on behalf of the EBMT Autograft 
Working Party, 112 patients were autografted in CR2 and 117 in 
CR1(68). The cytoreductive protocol varies and depends on centre 
preference. Approximately 70^ of all cases had some attempt at 
purging although there was variation in technique - and probably the 
quality of purging. Cytoreductive protocol differed, 2055 did not 
have TBI(Table 9.8).
There is a trend for patients receiving fractionated TBI to have a 
superior prospect of remaining leukaemia free and a significant 
advantage has emerged for those receiving monoclonal purged marrow. 
No benefit is apparent for patients whose marrow was 
pharmacologically treated in vitro.
Table 9,8 Autologous Bone Marrow Transplantation for Acute 
Lymphoblastic Leukaemia - European Survey*
Autograft in ALL, EBMT Review 1987 = First Remission
Disease-Free Survival (3 yrs)
Number Purged Non-Purged Purged Non-Purged Overall
117 82 35 5855 3055 *1255
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Table 9.8(continued)
Autograft in ALL, EBMT Review 1987 = Second Remission
Disease-Free Survival (3 yrs)
Number Purged Non-Purged Purged Non-Purged Overall
112 84 28 38$ 27$ 35$
* From Gorin et al(68)
9.4.3.4 Autologous BMT for Acute Lymphoblastic Leukaemia in Glasgow
To date eighteen patients have received an autograft for ALL in
first or second remission. The intention is to offer all patients
with known leukaemia cell phenotype autograft following high-dose 
chemo-radiotherapy with appropriately immunologically purged bone 
marrow. For patients whose immunological phenotype is not known - a 
situation which may arise for technical reasons, because of referral 
from sources where immune phenotyping was limited, and in the 
occasional case whose initial overt disease predated the 
availability of phenotyping - unpurged marrow is used.
Table 9.9 Autograft for ALL in First Remission: Glasgow Criteria
Adults (>15 yrs): All cases in CR under 60 yrs.
Children: B cell
Philadelphia Positive
Presenting Blast Count >50,000 x 10^/1
8=14 translocation
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Patients in second and subsequent remission are accepted, where 
autograft is regarded as a salvage procedure. A suitable end point 
of benefit for these patients will be "inversion” of the patient’s 
remission, i.e. achievement of a longer remission than the previous 
one.
Certain clinical parameters have been adopted as entry criteria to 
the study in first remission. This approach is offered to "poor 
prognosis" subgroups of patients, which - as locally agreed - are 
listed in Table 9 .9, together with all patients who have failed 
chemotherapy and are in second remission.
9.*1.3.5 Antibodies for In Vitro Manipulation
Cases with a T cell phenotype were treated with RFT2 (CD7 ) the 
characteristics of which are outlined in Table 9.10. Common (cALLA 
positive) and Null ALL are treated with RFAL3*.
The technique is identical to that already described for T depletion 
of allograft, involving two rounds of baby rabbit complement. 
Autologous plasma can be used as a source of complement for RFAL3 
but it is more convenient to persist with the baby rabbit material.
The laboratory results of the procedure are documented in 
Table 9.11. There was acceptable loss of BFU-E and CFU-GM. It
*Kindly supplied by Professor George Janossy, Department of 
Immunology, Royal Free Hospital, London.
was not possible to assay pre- and post- treatment samples for the 
target cell population to measure lysis in the individual cases. 
Since these cases were accepted as being in remission, phenotypic 
detection of minimal disease was beyond the level of detection of 
our technique. Specialised techniques have been described by others 
which suggest an ability to detect residual leukaemia at logs, 
i.e. 1 in 1000 cells(28).
TABLE 9.10 Antibodies used for In Vitro Purging in ALL
RFAL-3 CD10 IgM Rabbit and human
(c-ALLA) complement
RFT2 CD7 IgG 2 rabbit complement
30 day old rabbit complement used at 33% final dilution stored at 
-70°C. Colony forming units not affected(69).
Table 9.11 Purging of ALL in Vitro: Cell Loss
Antibody % MNC % CFU-GM % BFU-E
28.3* ± 11.5 56.2 t 26.3 53.1 * 1*1.2
20.9 £ 3.^ 62.2 i 25.1 62.9 * 26.H
* mean £ 1 standard deviation
Results expressed as % of value observed before incubation with 
monoclonal antibody.
RFAL3
RFT2
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9. *1.3 *6 Patient Characteristics
Eighteen patients with Acute Lymphoblastic Leukaemia in first or 
second remission have undergone this protocol. Of the seven adults, 
five were in first remission and fulfilled the criteria set out in 
Table 9 .9 . Due to unavailability of monoclonal antibody or lack of 
convincing phenotype at diagnosis, three of these patients received 
nunpurgedn marrow.
Of the eleven second remission patients, ten received purged 
marrow. The duration of first remission ranged from four to 
fifty-six months and six relapsed on maintenance therapy. 
Individual patient details are given in tables 9.12 and 9.13.
The cytoreductive protocol was either Melphalan 110 mg/m^ and 
fractionated TBI(6 x 200 cGy) for the adults or Cytosine 2g/m2 bd 
for 3 days, Cyclophosphamide 120 mgs/kg over 2 days and TBI(6 x 200 
cGy) for the children. Males received an additional *100 cGy 
irradiation to the testicles.
9.4.3.7 Haemopoietic Reconstitution
Neutrophil regeneration in the first thirteen patients is shown in 
Figure 9.6 where it is compared with the pattern seen in the AML 
patients described earlier, showing there to be no difference. 
Since there was no detectable difference between first and second 
remission, or the recipients of purged or non-purged marrow, the 
data is pooled. Platelet regeneration is illustrated for thirteen 
patients with ALL who did not relapse in the first *1 months
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post-graft. Platelet recovery is very similar to that seen in 
uncomplicated allografts (data not shown) and is compared (Figure 
9.6) with the kinetics of 13 of the 25 AML recipients of autografts 
discussed earlier, who have remained in remission with a minimum of 
15 months follow-up. This emphasises the point of an apparent
difference in platelet regeneration, the reason for which is 
unexplained. Since the majority of the ALL patients are in second 
remission, it seems unlikely that the difference is explained by the 
amount of previous chemotherapy received.
Figure 9.6 Haemopoietic Regeneration following Autograft for ALL in 
First and Second Remission
NEUTROPHIL REGENERATION PQST-ABMT
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Figure 9.6 (continued)
PLATELET REGENERATION OF LEUKAEMIA-FREE SURVIVORS
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9.^.3.8 Clinical Results
Prior to and during these studies, patients who met the criteria for 
transplant and had an HLA matched donor underwent allogeneic graft 
in much the same way as has happened in Glasgow for patients with 
AML. A total of 25 patients underwent allograft in second remission 
and 10 in first remission.
The overall survival of each subgroup is shown in figure 9.7 and 
9.8.
In first remission, where a total of only 15 patients have been 
transplanted, there is no apparent difference between autograft
Fig
Fig g
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J.7 Comparison of Outcome of Autologous and Allogeneic 
Transplant in ALL in First Remission
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and allograft, in overall survival. The one autograft patient who 
has relapsed survives in a second remission following further 
chemotherapy including a second autograft. Both approaches are 
encouraging at this preliminary stage.
Of the 37 patients transplanted in second remission, 25 had an 
allogeneic graft, of whom only 6 survived. Of the 12 evaluable 
autograft patients, 7 survive - although with shorter follow-up. 
The heterogeneity of ALL patients in second remission has previously 
been mentioned, and therfore makes even early interpretation of 
these data suspect when presented as a crude survival - which, at 
face value, could be called upon to question the justification for 
offering an allograft rather than an autograft to patients in second 
remission.
A more useful way to evaluate the second remission data is to plot 
the comparison of the duration of first remission against second 
remission. In these circumstances a more relevant influence of 
transplant can be observed. When this is done (figure 9.9) only 3 
of the 23 allografted patients have, so far, had a therapeutic 
"gain", but one has died of her disease. Of the remaining 23 
patients charted, only 3 have any prospect of gain but they require 
to remain in remission for a further 110-1*10 weeks. Two thirds of 
the allograft patients who died, succumbed to causes other than 
leukaemia.
Of the 11 autograft patients charted (figure 9.10), only 2 so far 
have had a therapeutic gain, of whom one has died of his disease. 
Six of the remaining 9 patients have a prospect of gain but require
4U4
to remain in remission for between *10 and 200 weeks.
Figure 9 .9 Therapeutic Gain for ALL Patients in Second Remission 
receiving Allogeneic Transplants
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Figure 9.10 Therapeutic Gain for ALL Patients i n . Second Remission 
receiving Autologous Transplants
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Long-term follow-up of ALL patients is clearly required to establish 
the efficacy of such an approach. Even if eventually proven to be 
superior, this will not necessarily establish that the in vitro 
purging was an essential component. Some (n=H) of these patients 
received unpurged marrow, of whom one has relapsed compared with 3 
of 14 who received purged marrow.
*Some of these patients were under the care of Dr I Hann at The 
Royal Hospital for Sick Children, Glasgow, to whom the author is 
grateful for permission to include follow-up data.
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9.4.1! Prospects for Immunological Purging in AML
The most widely recognised classification of AML is the *FABf 
subdivision based on morphological appearances(70), which now 
results in seven categories(71). There are only minor prognostic 
implications in this subdivision(72,73). Immunophenotyping studies 
have suggested similar heterogeneity of blast cells in this 
disease(711,75). In an analysis of 70 patients, 62 expressed myeloid 
antigens which are recognisable in normal myeloid maturation, which 
allowed subdivision into l| groups with phenotypes equivalent to that 
of CFU-GM, myeloblast, promyelocyte and promonocyte. These 
subdivisions approximately correspond to the subgroup defined by 
morphology but there were some disparities indicating that membrane 
differentiation did not always correlate with morphology. There 
were differences between the subgroups in remission rates suggesting 
that this type of immunophenotyping which has been contributory in 
ALL, may be helpful in AML.
There are no leukaemic specific antigens on AML blasts, which are 
exploitable for a purging technique. The phenotype of the blast 
cells which constitute the bulk of detectable disease may be 
irrelevant, in that they may be the maximally differentiated 
(therefore with limited proliferative potential) progeny of 
clonogenic leukaemic cells which are analogous to the normal 
clonogenic cells which sustain haemopoiesis.
In subsequent studies, clonogenic leukaemic cells were divided into 
3 subgroups by immunophenotyping(76). One group were la, My9 
positive, second group la, My9 and PM-81 and the third group la,
4 U/
My9, PM-81 and AML-2-23 positive. The proportion of cases in each 
group was approximately equal and on phenotype characteristics are 
the equivalent of the CFU-Mix (la, My9) Day 1l| CFU-C (la, My9, PM81) 
and Day 7 CFU-C (la, My9, PM81, AML-2-23). This heterogeneity of 
phenotype of CFU-L is confirmed in other studies(77,78). This data 
may indicate that AML stem cells originate from cells equivalent to 
different stages of maturation. A proportion may be close to the 
multipotent stem cell (la, My9 positive) while others from a later 
stage within the myeloid lineage. It could be that the artificial 
conditions of culture result in an arbitrary division, being 
permissive for some cells which may only constitute a subset of the 
stem cell population.
Some reassurance on this point is provided by Lowenberg's Group(79) 
who did not find that variation in the in vitro culture conditions 
affected phenotype expression, but as well as absolute differences 
in antigen expression, they also noted heterogeneity of antigen 
density.
The initial conclusions concerning immunological characteristics of 
AML are (i) there is heterogeneity of antigen expression on the 
blast cell population; (ii) clonogenic leukaemic cells (CFU-L) often 
have a different phenotype than the blast cell within the same 
patient; (iii) there is diversity within the CFU-L phenotype between 
patients, both qualitatively and quantitatively, in antigen 
expression. In general, clonogenic cells express antigens 
associated with normal clonogenic cells and some preliminary 
studies also suggest that those CFU-L with the more immature 
phenotype have greater proliferative potential. There is
408
evidence from these observations to suggest that some clonogenic 
cells in AML originate at the level of the pluripotent stem cell 
which others may derive from a later cell within the myeloid 
lineage.
Other evidence supports this concept. Using the X-linked marker 
G-6-PD(Glucose-6-Phosphate Dehydrogenase) the Seattle group have 
been able to study the iso-enzyme pattern of patients who are 
constitutionally heterozygous(80), i.e. their cells should express 
type A and type B enzyme in a fixed ratio, who have AML. In
approximately a third of cases they were able to demonstrate that
the leukaemic cells were of a single isoenzyme type but that
morphologically uninvolved lines (e.g erythroid/megakaryocytes) also 
exhibited the same clonal enzyme, whereas normal haemopoiesis would 
be expected to show an equal expression of type A or type B enzymes, 
or more accurately, the A:B ratio which the patient constitutionally 
expresses in non haemopoietic cells. Studies of AML with this
system have recently been paralleled by gene probing techniques of 
an other X-linked gene HPRT(Hypoxanthine Phosphoribosyl 
Transferase)(81). These data suggest that some cases at least of 
AML originate at the level of the pluripotent stem cell. It is 
difficult to envisage a technique which is capable of selectively 
removing these cells. For cases which are lineage restricted 
defined either by X-linked gene probe analysis or immunophenotype of 
clonogenic leukaemia cells, it may theoretically be possible to 
employ immunological purging techniques.
"Multipotent" disease carries the la, My9 positive phenotype, both 
of which are expressed on CFU-GM, BFU-E and CFU-GEMM. However, the
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CFU-S in the mouse is la negative and transplanted marrow which was 
treated with HLA-DR antibody and complement was capable of 
haemopoietic regeneration(82,83). In humans, la-treated marrow has 
been grown satisfactorily in long-term culture(8i|). In an initial 
report, two patients regenerated following ablative treatment, when 
the autologous marrow had been treated in vitro with anti-la and 
complement(85). While such information may offer some 
encouragement, even for multipotent disease, the X-linked 
information still suggests that the pluripotent stem cell is 
involved in a proportion of AML cases. It appears that this cell is 
la negative but it is similarly possible that a proportion of AML 
may similarly be la negative. Preliminary clinical studies in 9 
patients(86) have been commenced with carefully selected antibodies, 
giving a spectrum of reactivity against myeloid differentiation. 
The patients were beyond first remission and therefore at high risk 
of recurrence. The results are too preliminary to suggest any 
benefit from the purging procedure, but haemopoietic regeneration 
has been unimpaired. Just as with the pharmacological techniques to 
be discussed, in vitro measurement of purging efficiency is 
currently impossible and any benefit will require to be measured 
clinically. The problems relating to clinical assessment of purging 
in AML have been discussed.
9.5 PHYSICAL METHODS OF PURGING - MEROCYANINE 5*10
A novel approach, with potential application as a purging method, is 
the exploitation of differences in cell membranes of leukaemic and 
normal marrow precursor cells. Differences in membrane 
phospholipase digests have been noted between chronic myeloid
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leukaemia and normal cells(87). Although considerable technical 
difficulties exist, it is conceivable that these differences could 
be detected by optical probes. Merocyanine 540 is an amphipathic
fluorescent dye developed by Eastman-Kodak as a sensitizing agent
for photographic emulsions. It has been shown to react 
preferentially with circulating leukaemic cells(88). In the 
presence of serum it reacts strongly with leukaemic cells 
irrespective of lineage, and poorly with normal cells, and is 
J claimed to be capable of detecting one reactive cell in 1000 normal 
cells(89). The mechanism of this selective binding is unknown but 
it appears to be independent of cell cycle.
Exposure of a merocyanine bound cell to light results in lysis, 
although lysis may not be immediate. Mouse bone marrow incubated 
with merocyanine and then exposed to light were incapable of forming 
colonies(90). However, colonies could be grown from treated cells
provided they were not exposed to light. It is postulated that
toxic photoproducts are produced on exposure to light and the 
membrane is irreparably damaged. The relative sensitivity of 
haemopoietic cells to this process has been studied in the mouse and 
human by in vitro colony forming assays and suggest that the more 
primitive precursors are the least photosensitive. Numerous 
leukaemia and solid tumour cell lines have been tested in vitro and 
even lines resistant to chemotherapy are photosensitive.
Experimental in vivo studies in the L1210 leukaemia model have been 
successful, in that leukaemia/normal marrow suspensions injected 
into ablated recipients regenerate normal haemopoiesis without 
clinical evidence of leukaemia(91). Recipient animals were
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subsequently successfully used as donors. This interesting approach 
has not yet been brought into clinical practice.
9.6 PHARMACOLOGICAL TECHNIQUES OF PURGING
Because of the difficulties in developing immunologically based 
techniques for purging AML cells, activity has been focussed on 
pharmacological methods. The hope of this approach is that stem 
cells responsible for haemopoietic reconstitution may preferentially 
survive drug treatment in sufficient numbers whereas the leukaemic 
population will be destroyed. That this may be true continues to be 
hotly debated even among advocates of purging. There are numerous 
drawbacks in assessing this approach at the preclinical level. As 
will be discussed, committed colony forming units from normal marrow 
can be eliminated by these methods of in vitro treatment, yet this 
has not prevented haemopoietic reconstitution in vivo, thus 
highlighting the technical limitations of how damage to normal 
marrow elements can be measured in vitro. Similarly, most 
conclusions regarding leukaemia eradication have been derived from 
clonogenic assays of cell lines derived from animal or human 
sources, which may be irrelevant to an individual patient.
9.6.1 Agents For Pharmacological Purging - Cyclophosphamide 
Derivatives
Cyclophosphamide requires metabolic activation by the P1I50 mixed 
function oxidase system of the liver before becoming cytotoxic(92). 
Jj-hydroxy-cyclophosphamide and phosphoramide mustard are the active 
metabolites. The metabolic activation pathway of cyclophosphamide 
is shown in Figure 9.11.
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i|-Hydroxycyclophosphamide is unstable and difficult to isolate, but 
Ij-Hydroperoxycyclophosphamide (4—HC) is more stable and can be 
prepared in crystalline form and appears to have the same actions in 
vitro. At neutral pH it has a half-life of 90 mins but the compound 
is rapidly reduced on entering the cell to H-hydroxycylophosphamide.
Figure 9.11. Metabolic Activation of Cyclophosphamide
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Mafosfamide [Asta-Z-7557] is an activated cyclophosphamide 
metabolite [H-Sulphoethylthiocyclophosphamide - prepared by 
Asta-Werke] which decomposes in aqueous solution to
lJ-hydroxycyclophosphamide(93). Its in vitro properties against
leukaemia cells and marrow precursors appear very similar to 
4-HC(9l|).
Cyclophosphamide or its metabolites might not appear to be the 
obvious ehoice of drug to concentrate on as a purging agent in AML. 
Clinical experience of very large doses (14G) are not ablative to 
the stem cell(95), and may therefore have similarly limited effect 
against clonogenic leukaemia cells. It is not acknowledged to be 
particularly effective as a single agent for AML in man. Cellular 
sensitivity to cyclophosphamide has been postulated to be due to
increased cellular levels of aldehyde dehydrogenase which breaks 
down l| hydroxycyclophosphamide to the inactive form carboxy-
cyclophosphamide(96). This protective mechanism can be by-passed by 
use of a cytotoxic metabolite, such as methy 1-cyclophosphamide 
because the 1} methyl-subgroup is not a substrate for the enzyme, or 
by phosphamide mustard which is beyond aldehyde dehydrogenase in the 
metabolic sequence. These analogues are indeed more toxic to the 
marrow than cyclophosphamide(97). The enzyme content of cell lines 
derived from more differentiated leukaemias have lower levels of 
enzyme than less differentiated lines - a difference which 
correlates with observed responsiveness to cyclophosphamide(96).
Based on these considerations Sharkis(98) chose to investigate the 
efficacy of ^-hydroxypercyclophosphamide in the Brown-Norway
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rat model of acute myeloid leukaemia - the characteristics of which 
have been reviewed but some of which are similar to promyelocytic 
leukaemia in man(99).
In this model system rats were rescued from fatal aplasia (total 
body irradiation) by injection of syngeneic bone marrow. When the 
injected marrow was contaminated by leukaemic cells the recipients 
survived aplasia but a few days later died of leukaemia. As these 
contaminated marrow mixtures were treated; with increasing doses of 
4—HC progressively more animals survived aplasia and did not develop 
leukaemia. This provides convincing evidence of the effectiveness 
of in vitro purging, particularly as it is claimed that a single 
cell is capable of causing leukaemia in this model (Santos, 198H, 
personal communication). While this result is impressive, it should 
be noted that the model system was selected because of its 
particular in vivo sensitivity to cyclophosphamide, unlike most 
human myeloid leukaemias.
This study, however, is the major reason why several groups have 
continued to develop pharmacological approaches to purging in man.
9.6.2 Pre-clinical In Vitro Studies Using Cyclophosphamide 
Metabolites
In a study of clonogenic leukaemic cells in vitro derived from the 
Brown Norway AML model and normal rat precursors, Hagenbeck(100) 
demonstrated clearly increased sensitivity in the leukaemic 
population, very much in keeping with the results reported in vivo.
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In comparative in vitro experiments between normal human precursors 
(CFU-GM and BFU-E) and leukaemic colonies obtained from de novo 
cases of human leukaemia(101) or from an HL60 leukaemia line(102)
there appeared to be little differential sensitivity.! Subsequent
studies using leukaemia colonies derived from newly diagnosed 
patients continued to support the view that there was little 
evidence of preferential sensitivity between leukaemia cells and 
CFU-GM or BFU-E. In addition there was considerable variation in 
leukaemia cell responsiveness between patients. It appears that the 
in vitro dose required to eliminate leukaemic cells will also
eradicate most of the CFU-GM population.
In subsequent clinical studies it became clear that elimination of 
CFU-GM did not prevent - but probably delayed - haemopoietic 
recovery in the patient. Long term culture techniques have recently 
demonstrated however that precursor cells remain viable and capable 
of setting down stromal layers and producing CFU-GMs.
A detailed in vitro study demonstrates that BFU-E, CFU-GM and
CFU-GEMM are all relatively sensitive to in vitro incubation of 
cyclophosphamide metabolites, but precursor cells capable of 
establishing long-term culture and fibroblast colonies are more 
resilient - withstanding concentrations up to 300 umol/1 of 
4-HC(103).
From the pre-clinical in vitro studies a number of important general 
points emerge related to measurement and technique of in vitro 
purging with cyclophosphamide metabolites:
(i) Normal marrow clonogenic cells CFU-GM, BFU-E, CFU-GEMM
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(ii)
(iii)
(iv)
(v)
(vi)
(vii)
may be no more resistant to purging agents than 
clonogenic leukaemic cells, but precursor cells 
reponsible for establishing long term marrow culture may 
be. I
Individuals1 leukaemic blasts vary in sensitivity in 
vitro making choice of a standardised dose for all 
patients questionable.
Pharmacological agents may increase the susceptibility 
of normal marrow cells to cryopreservation injury.
There may be individual variation in dose responsiveness 
to pharmacological purging (with cyclophosphamide) 
suggesting a requirement to pre-test individual patients 
CFU-GM or BFU-E in order to select the most appropriate 
purging dose.
It is not known whether there is substantial individual 
variation as measured by long term culture or whether 
this is variable in any individual with time.
It is not known whether an individual’s clonogenic 
leukaemia cells tested at diagnosis are of a different 
sensitivity to those assumed to be the target during 
remission.
Incubation conditions such as cell count, mixture 
haematocrit, temperature and duration of incubation, may 
result in major changes in sensitivity, and require to 
be determined within each investigator’s technique(10*1).
417
9.6.3 Etoposide (VP-16-213)
Etoposide is a semi-synthetic derivative of podophyllotoxin which is 
an extract of the roots of the plant, Podophyllum peltatum, which 
has had known medicinal value as an emetic for more than a century. 
It is related to a similar derivative Teniposide (VM-26) (Figure
9.12). Both these agents have an antileukaemic effect in
man(105,106). The major dose limiting consideration is
myelosuppression. Its mechanism of action is by inhibition of DNA
synthesis by causing DNA strand breakage(107). As such, it is cell 
cycle and phase specific (S and G2 phases) (108). Since it is 
stable, available and does not require metabolic activation, it has 
been suggested as a suitable purging agent.
Fig 9.12 Structure of Etoposide and Teniposide (VM-26)
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In studies of CFU-GM responsiveness, Herve suggests(109) that, while 
there is a linear dose response with ASTA-Z, the effect obtained 
with VP-16 plateaus at 70 ug in a 30 min. incubation at 37°C, In 
long-term culture conditions ASTA-Z treated marrow (50 ug) shows 
evidence of CFU-GM recovery towards normal whereas VP-16 (50 ug) 
does not, suggesting that it is more toxic to primitive stem cells. 
There appeared to be little difference in responsiveness of 
leukaemic colonies (HL-60 cells) between the two agents. 
Coibanu(110) found the agent effective against a number of leukaemia 
and Hodgkinfs cell lines but noted recovery in long-term culture 
assays of normal marrow cells.
In vivo studies have been reported by Stiff(111) using the C57BL/6 
mouse and its syngeneic lymphoid tumour EL-4. Initial studies 
indicated that 15$ of CFU-GMs survived incubation with 40 ug/ml. No 
clonogenic cells were detected above 20 ug/ml. The in vivo results 
using TBI to ablate recipient animals resulted in leukaemia-free 
survival if the contaminating leukaemic population was limited to
3-4$. Purging could not eradicate tumour if the mixture has 30-40$ 
contamination, which is an unlikely challenge in a clinical setting.
9.6.4 Bleomycin
Bleomycin is virtually untested in haematological malignancies, but 
is not cycle specific in its action. Studies in the BN rat(112) by 
Yeager indicated a familiar dose response of normal CFU-GM. 
Prevention of leukaemia was not complete even at levels of 1000 
mU/ml which destroyed 98$ of CFU-GM.
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9.6,5 In Vitro Synergy
In an extension of the studies of Bleomycin in the Brown Norway rat 
leukaemia model the sequential treatment j of cells with Bleomycin 
(1000 mU/ml) followed by 4-HC 12 ug/ml was capable of preventing 
recurrent disease, where each drug separately was ineffective. 
Other preliminary studies of two agent purging also suggest an 
additive effect offering potentially limitless combination to be 
experimentally assessed in the futuhe. Similarly, evidence is now 
available to suggest that a combination of pharmacological (4-HC) 
and immunological (Monoclonal antibody and complement) may be more 
effective than each modality alone.
While normal colony forming assays have been demonstrated in this 
work to have limited value in predicting the repopulative potential 
of the treated marrow, which is perhaps better indicated by recently 
described long-term culture techniques, it is quite unknown whether 
the same may not be true also for the leukaemic population. It is 
conceivable that viable leukaemic cells remain which could be 
Cursed1 along till they eventually become capable of detection in 
the clonogenic assay. The leukaemic colony assay is unsuccessful in 
a substantial proportion of cases - it may be that those cases 
capable of establishing a leukaemia colony assay are selecting 
themselves and may be unrepresentative of the leukaemic cells which 
will kill the patient. Most in vitro assays require a minimum 
number of cells to grow. It is conceivable that the in vitro 
purging is merely reducing their number below the threshold required 
to register in the assay, without achieving complete leukaemia cell 
eradication.
420
9.6.6 Laboratory Studies Of Pharmacological Purging
With a view to introducing pharmacological treatment of bone marrow 
ex vivo into clinical practice, a number of preclinical studies have 
been undertaken. Since the ultimate aim of these studies was the 
treatment of bulk marrow prepared as a mononuclear cell concentrate 
[MNC] only aliquots of marrow prepared in this way for allogeneic or 
autologous transplantation were used for these preclinical studies. 
Although this approach took longer, conclusions concerning the 
variables and practical difficulties of treating bulk marrow are 
likely to be different from those derived from experience using 
samples obtained from diagnostic aspirates.
9.6.6.1 In Vitro Treatment of Stem Cell Fraction (MNC) with 
ASTA-Z-7557
When these pre-clinical studies were initiated, Cyclophosphamide 
derivatives were the only agents available for evaluation. This 
data concerns the use of the stable derivative ASTA-Z-7557 
(Mafosamide).
(i)Stability of Reconstituted ASTA-Z-7557
ASTA-Z-7557 once reconstituted in solution may deteriorate 
prior to incubation with bone marrow cells, thus losing 
cytolytic activity. To examine this point ASTA-Z was 
reconstituted and left on the bench. At various time 
intervals stock solution was set up under standard 
incubation conditions at a dose of 2.5 ug/10?
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mononuclear cells. The recovery of CFU-GMs expressed as a 
percentage of untreated mononuclear cells did not vary 
significantly (Figure 9.13).
Fig 9.13 The effect of Dissolution Time of ASTA.Z.7557 on Cytotoxic 
Activity
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(ii) Duration of in vitro incubation: In order to determine
the optimum duration of incubation a number of time course 
studies were undertaken, which are summarised on 
Fig 9.1*1. The maximum of CFU-GM kill was achieved after 
60 mins incubation at 37°C. There was only minor 
difference in kill achieved between 30 and 60 minutes.
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(iii) Choice of incubation dose of ASTA-Z-7557. Dose responses 
were carried out on 21 bone marrows from MNCs of several 
individuals. Incubations were undertaken at 37°C for 60 
mins. CFU-GM assay was undertaken in triplicate for each 
dose and the mean value expressed as a percentage of the 
mean of the triplicate CFU-GMs grown when incubated in 
solutions containing no drug. Figure 9.15 shows the 
overall dose response curve obtained in these studies. At 
an incubation mixture of 12.5 ug/10? cells the CFU-GMs 
from every sample was destroyed at a dose of 10 ug/107 
cells 90^ were destroyed. The results show the mean and
one standard error of the group at all dose points.
»
Within this general dose dependent effect there, was 
considerable variation between individuals.
ASTA Z 7557 WITH HUMAN MONONUCLEAR CELLS 
ON CFU-GM RECOVERY .
(Dose = 2.5pg ASTA Z 7557/107cells)
Figure 9.15. Dose Effect of ASTA-Z on CFU-Gm Colonies in 21 
Individuals
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From this data it could be concluded that a standard dose, for 
example, of 5.0 ug/IO? cells would be sufficient to destroy 60% of 
CFO-GMs.
Because of differences of responsiveness between individual marrows 
the choice of a standard dose for universal treatment will result in 
a wide range of CFU-GM kill. For example, from each individual 
dose-response curve the concentration of ASTA Z required to kill 50% 
(Fig 9.16) and 90^ (Fig 9.17) is shown. A selected dose of 4 ug/10? 
cells will only optimally kill (pre-set at 50% kill) in 4 cases 
while 6 will be under treated and 11 will be over-treated. If the 
desired kill is 90% (Fig 9.14) again a wide range of dosage is
required and a standard dose of, say 9 ug/IO? cells will only kill 
in ij cases optimally, overtreat 9 and undertreat 8. The accuracy of 
the CFU-GM count diminishes considerably at a level of 90J6 kill 
because of the small numbers of colonies available to count. This 
is reflected in a wider range within any triplicate (of which the 
mean is charted) than at lower doses where more colonies survive for 
counting. In the experiments illustrated the bone marrow was taken 
as an aliquot from bulk marrow harvest from normals (Closed circles) 
or leukaemics in remission (open circles). There was no difference 
in responsiveness between these groups. The ranking of 
responsiveness was not the same in the two levels of kill, i.e. the 
most sensitive at 50% kill were not necessarily the most sensitive 
at 90? kill.
Fig 9.16. Individual ASTA-Z Dose required to kill 50% CFU-GM
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Fig 9.17. Individual ASTA-Z Dose required to kill 90? CFD-GH 
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Individual variation in response has been observed by Gorin*s 
group(113) who suggest that selection of the dose should depend on a 
dose response previously performed on the individual*s marrow. In 5 
patients double marrow harvests with MNC preparation was undertaken 
so it was possible to examine reproducibility of dose response in 
these individuals. The results in 4 patients are shown in Fig 9.18 
where for each individual, curve 1 is the first marrow and curve 2 
the response of the second. There are clearly substantial 
differences in each case. The dose-selection would be undertaken on 
the data available from curve 1. If a 50? kill was required, the 
doses selected for patients A,B,C and D would be respectively 5,6, 
4, and 5.5 ug/10? cells of the MNC. This would have resulted in an 
actual kill of 80?, 95?, 60?, 95? respectively in these patients, 
based on the second individual dose response.
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Figure 9.18 Comparison of Dose Response in Individuals at Different
Times
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From these results it appears that it is extremely difficult to 
predict accurately the consequences of any selected dose, suggesting 
a real possibility of eradicating CFU-GM. As implied elsewhere, 
this may not mean that the repopulative .ability of the marrow is 
irreparably damaged.
(iv) Susceptibility of ASTA treated cells to Cryo injury
Some anecdotal information suggested that pharmacological 
treatment predisposes cells to unexpected degrees of 
cryo-injury. All clinical protocols envisaged would 
require cryopreservation of bone marrow.
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We have previously found that controlled rate freezing at 1°/C/rain 
to -1|0°C followed by a rapid freeze to -196°C results in acceptable 
preservation of marrow function when assessed by CFU-GM recovery and 
haemopoietic regeneration in the patient. ;
To examine the effect of purging on storage by cryopreservation 
samples of MNC fraction were exposed to a range of doses of ASTA-Z. 
Following incubation, half the sample at each dosage was used for a 
"fresh" CFU-GM Assay. The remaining half was frozen by the standard 
technique, thawed and set up in CFU-GM Assay. Comparisons were made 
between untreated samples which were assayed fresh and after 
cryopreservation to determine the loss inherent in cryopreservation 
in these experiments. There was a loss of 5—755 of CFU-GM 
attributable to the cryopreservation technique.
The results in dose responses of 5 individual marrows examined are 
illustrated in Fig 9.19. At each dose level the ASTA + 
Cryopreserved and cryopreserved untreated samples are expressed as a 
percentage of the result with no drug in the system. The charts 
show in each case the differences (either plus or minus) between the 
ASTA + cryo and cryo only percentages. In patient numbers 1, 2, 3 
and 5 additional CFU-GM loss was noted but this has tended to be 
less marked at higher doses.At a dose of 7 .5 ug/107 cells losses are 
-255, -5$, -3%t -1255. In patient i| recovery was superior in the 
pre-treat aliquots. The risk of increased damage to bone marrow by 
cryo-injury, as measured by CFU-GM, by pretreatment in vitro, seems 
to be of minor importance.
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Figure 9.19 Effect of Cryopreservation on Colony Recovery (CFU-GM) 
following In Vitro Pharmacological Treatment
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The results are expressed as the difference in percentage recovery 
obtained, compared with an unfrozen aliquot, for the cryo only 
sample and the cryo+ treatment sample. The percentages shown are 
the differences (+ or -) of the results obtained for the. cryo+ 
treatment sample compared with the cryo only sample.
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9.6.6.2 Summary of Preclinical Studies:
(i) ASTA-Z-7557 appears to be stable, once reconstituted, to carry 
out incubation without concern about drug deterioration.
(ii) Maximal in vitro effect is achieved by a 60 minute incubation.
(iii) Pharmacological treatment results in a minor additional loss 
of CFO-GM during cryopreservation and thawing.
(iv) Dose selection is complicated by variable responsiveness 
between individuals and in the same individual tested on two 
occasions.
9.6.7 Clinical Studies of Pharmacological Purging
The innovative studies which brought pharmacological purging into 
clinical practice have been undertaken in Baltimore. In an initial 
series of 30 patients, with a spectrum of haematological 
malignancies, autologous marrow was treated with an increasing 
concentration of l}-Hydroperoxycyclophosphamide (H-HC). At an in 
vitro dose of 80 ug/mls CFU-GMs were completely inhibited. All but 
one patient whose marrow was treated at 100 ug/mls had full 
haematological regeneration but at doses of 120 ug/ml graft failures 
occurred(11H). These phase one studies established two important 
points; (i) bone marrow in which treatment has inhibited all CFU-GM 
is still capable of full haematological regeneration, and (ii) the 
maximum tolerable in vitro dose is 100 ug/ml under their stated 
laboratory conditions.
The next problem for the Baltimore group was how to establish that 
the in vitro purging was effective. At the initiation of their
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studies the experience of using unpurged marrow was not available 
but, in any event, they argued that second remission AML would be an 
appropriate setting in which to conduct the initial clinical 
studies. Where allogeneic transplants have been undertaken in 
second remission, the actuarial risk of relapse is 50-6055, even with 
the benefit of the postulated graft-versus-leukaemia effect, and
without the risk of contaminating residual disease in the graft.
Twenty-five patients 5 with AML in second (n=20) or third (n=5) 
remissions received a preparative protocol comprising Busulphan 
mgs/kg/day for 1} days followed by Cyclophosphamide 50 mgs/kg/day for 
1} days, which is the Baltimore groupTs preferred cytoreductive 
protocol for allogeneic graft. They then received an autologous 
graft which contained a fairly high nucleated cell count (1.6 - 5.0 
x 10®/kg) which had been treated with 100 ug/ml (two cases at 80
ug/ml, one at 60 ug/ml) of 4—HC in most cases.
Haemopoietic reconstitution was, as expected, delayed(115). For 
comparison time taken to 500 neutrophils x 10^/1 of these patients 
is compared with my own first remission unpurged group(Fig 9.20). 
Five patients died of infection, four within the first 25 days and 
one at 6 months due to persisting hypoplasia. Nine of the twenty at 
risk patients have relapsed in a minimum follow-up of 230 days - no 
relapses have been observed beyond 320 days, giving an actuarial 
survival of 4355. This result is similar to results achieved in the 
general experience of allograft in second remission. The outcome in 
second remission is heavily influenced by whether the patient 
relapses on treatment and the duration of first remission. Any 
strategy which results in a current remission longer than the
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previous one can legitimately claim to have favourably influenced 
outcome. This measurement is useful for assessing early results in 
second remission. Of the eleven patients in continuing remission 
five are in current remissions longer than the previous one. All of 
the nine patients who relapsed had shorter remissions following 
autograft than the previous remission.
Figure 9.20 Regeneration of Neutrophils using Purged Marrow
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The probability of regenerating neutrophils to 500, in 
patients where the autograft was treated with H-HC (Baltimore 
data n=25) compared with 32 patients (Glasgow data) receiving 
unpurged autologous cryopreserved marrow.
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These studies offer encouragement for patients in second remission 
who do not have donors, but do they demonstrate the value of in 
vitro purging? In the multicentre data from Europe no advantage of 
using purging in second remission was detectable when the majority 
of purging was by the ASTA-Z-7557 method. This experience however 
may be prejudiced by the use of inadequate ablative procedures. It 
certainly does not appear to confer any improved prospect of 
leukaemia free survival. It would be of interest to study the 
effect of purging techniques in second remission with best available 
ablative protocols for example Busulphan/Cyclophosphamide or the 
BAVC regimen.
Of the two single centre studies carried out in first remission, 
some lessons can be learned, the Besancon Group used ASTA-Z-7557 at 
various doses per nucleated cell count, but unfortunately used the 
TACC protocol as ablation, which was clearly incapable of leukaemia 
eradication in most patients. Gorin (116) on the otherhand elected 
to use conventional Cyclophosphamide and TBI while tailoring the 
ASTA-Z-7557 dose to that required to eradicate 95$ of each 
individual CFU-GM. This was achieved by a dose response study on an 
aspirate taken a few weeks before autograft. Our data presented 
earlier challenges the accuracy of this approach. In a previous 
report on the EBMT data(88), the first remission survival curves of 
purged and non-purged autografts were superimposable. However, in 
the data analysis presented in Chapter 8, the importance of taking 
into account the ablative protocol has been recognised. It is now 
possible to show a significantly improved prospect of remaining 
leukaemia free in the purged group when the ablative protocol 
included TBI, but there is as yet no clear advantage in overall 
event-free survival.
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9.7 PURGING BY MARROW CULTURE IN VITRO
Experimental studies showed that murine bone marrow maintained in a 
Dexter type culture system(117), which has already been referred to 
in Chapter 6, are capable of reconstituting ablated mice(H8). this
system is not conducive to leukaemic haemopoiesis(119), thus
offering a further potential technique of selective removal of 
leukaemic precursors from normal marrow. Such an approach has been 
applied to human autograft with initial success(120), although the 
bone marrow was only sustained for 10 days in culture, which in 
initial studies was sufficient to eliminate leukaemic haemopoiesis 
carrying a genetic marker. The problems involved in scaling up to
the number of cells required to provide an adequate graft have been
overcome, with clear demonstration that haemopoietic recovery - 
albeit slowly - takes place. This approach probably represents at 
present the most rational approach to purging in AML but, since 
current clinical studies have been undertaken in first remission, it 
will be unlikely that - for reasons already discussed - the 
potential advantage of such an approach will be measurable in 
clinical practice, in first remission.
9.8 SUMMARY AND COMMENTS
A wide body of opinion supports the view that purging is not a pre­
requisite for a successful outcome following autograft for AML in 
first remission. This is clearly true, based on the evidence 
presented in chapters 6 and 8, when compared with the results of 
syngeneic transplantation. The syngeneic data is not extensive and 
may not be sufficiently solid to justify outright rejection of a
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future role for purging in this setting.
A variety of purging techniques are available, some of which have 
been discussed. Immunological approaches are attractive principally 
because of the availability of suitable monoclonal antibodies. They 
can be exploited in a number of ways to enhance the degree of log 
kill, and there is little doubt that further technical refinements 
will take place. The clinical effectiveness of ex vivo purging has 
been clearly demonstrated by the prevention of Graft-versus-host 
disease following T-cell depletion of allogeneic marrows. A number 
of studies in ALL are underway with antibodies that have appeared 
highly effective at leukaemia cell lysis in pre-clinical studies. 
There is no evidence and no current clinical trial which will 
directly address the question of purging versus non-purging in ALL. 
We and others have preliminary experience which confirms that the in 
vitro technique does not prejudice haemopoietic reconstitution in 
the ablated patient. The initial clinical experience is encouraging 
and superior to other published studies of a similar size - but such 
results may be achievable without the need to purge.
AML presents considerable difficulty from an immunological point of 
view. Not only is there considerable heterogeneity in blast cell 
phenotype but frequently differences have been noted, qualitatively 
and quantitatively, between clonogenic leukaemic cells and their 
blast cell progeny. Such antibodies as are expressed are not 
specific to leukaemic cells - so, in the meantime, selective 
leukaemic cell removal is not a practical proposition.
The alternative of pharmacological approaches have been extensively 
discussed. It is not easy to conceive of the possibility that 
leukaemic cells will be inherently more susceptible to this approach 
than normal stem cells. Much in vitro experimental data supports 
this reservation. The impressive paradox is the experimental data 
in the Brown Norway Rat Model. This has sustained considerable 
efforts by a few groups to pursue this approach, but there are many 
technical difficulties in the application of this approach. These 
relate mainly to the difficulties in measuring a successful end 
point of the antileukaemic effect in vitro, the lack of an adequate 
assay of human haemopoietic stem cells, and the considerable
individual variation in responsiveness. In vitro culture, 
conceptually, is much more attractive. Longer follow-up on more 
patients of the Manchester technique is awaited with interest. To 
date there is no evidence to suggest that purging is beneficial 
clinically. All clinical results achieved so far can be achieved 
with unpurged bone marrow. The priority remains the eradication of 
the disease from the patient.
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CHAPTER 10
DEVELOPMENT OF A LEUKAEMIA AUTOGRAFT 
MODEL IN THE RAT
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10.1 BACKGROUND
The basis of the widespread interest in pharmacological techniques 
of 1purging1 autologous marrow are the experiments of the Baltimore 
Group in the Brown Norway Leukaemia Model system(1). There are 
limitations to its usefulness because it is a syngeneic system, 
selected because of its extreme sensitivity to cyclophosphamide. It 
is, however, a myeloid leukaemia - apparently equivalent to acute 
promyelocytic leukaemia in man - with kinetic characteristics 
believed to be more equivalent to human disease(2).
Demonstration of the principles of in vitro treatment in other 
animal models in vivo would be helpful per se and may facilitate 
evaluation of other agents and techniques of selective removal of 
leukaemic cells. With this aim in view a chemically induced non—  
lymphoid leukaemia in the Long-Evans rat has been adapted. The 
leukaemia has a number of interesting features, several of which are 
briefly summarised in Chapter 12, which have been investigated by 
the author in recent years.
10.2 DEVELOPMENT OF THE MODEL SYSTEM - IN VIVO.
The emphasis of the system was intended to be in vivo. There were 
two objectives: (i) To establish a suitable myelo-ablative protocol 
with successful autologous rescue in the Long-Evans rat which was 
capable of detecting damage to the repopulative potential of the 
marrow which was reflected in the subsequent survival of the host in 
vivo; (ii) an in vivo "bioassay" for the detection of minimal 
residual disease in the graft capable of producing detectable 
disease in the host.
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10.3 MIEL0-ABLATI0N WITH AUTOLOGOUS MARROW RESCUE
10.3.1 Procurement and Administration of Autologous Marrow
A technique of obtaining autologous marrow from the rat was 
devised. Under brief ether anaesthesia a bone marrow needle was 
introduced to the femoral shaft through the femoral condyle with the 
knee flexed. It is not necessary to create an incision in the 
skin. The technique is graphically illustrated in Figure 10.1. 
Powerful suction through a 20 ml syringe, which has been flushed in 
heparinised tissue culture medium, is applied as the needle is 
withdrawn from the femoral shaft. A plug of marrow can thereby be 
obtained. The syringe is flushed on a few occasions with 
heparinised tissue culture medium (2 mis) and the marrow suspension 
deposited in a bijou for storage or in vitro treatment. The stored 
or treated bone marrow was routinely returned to the same rat by 
tail vein injection. The technique was found to be suitable for 
rats age 6 weeks or greater, since the femurs of younger animals 
tended to be too small or fragile. By this means sufficient cell 
numbers could be obtained, usually from one femur, to ensure an 
adequate individual marrow dose. The bone marrow suspension was 
routinely stored for 2*1 hours, in tissue culture medium, at 4°C, 
before reinfusion after the myelo-ablative treatment. For 
reinfusion the cell concentration was adjusted to ensure adequate 
cell numbers per 1 ml which was arbitrarily set as the standard 
reinfusion volume.
454
Fig 10.1 Bone Marrow Procurement from the Rat.
10.3.2 Myelo-ablative Protocol
The requirements of the myelo-ablative protocol are that, in the 
absence of marrow rescue, all animals will die, but when adequate 
doses of marrow are reinfused all animals should recover, thus 
providing a sensitive system in which to assay in vivo for damage to 
the marrow caused by the in vitro treatment.
10.3.3 Total Body Irradiation
For the purposes of this model, a protocol with a known 
antileukaemic effect is not necessary. Total body irradiation is 
the traditional technique of marrow ablation used in experimental 
animals, but, in a series of preliminary studies, almost all animals 
given a single fraction dose of 800 cGy, died within a few days of 
acute toxicity before infused marrow could influence the situation. 
Only with a progressive reduction in radiation dose did a few 
survivors emerge. Absence of early death was only consistently 
avoided at doses of 500 cGy, which may not be reliably ablative to 
the bone marrow, therefore haemopoietic recovery of rats receiving 
autologous marrow could not conclusively be attributed to the 
autograft. The reason for the early death in these rats was not 
investigated further. For these, and logistic reasons, irradiation 
was abandoned.
10.3.11 Busulphan
Because of its radiomimetic effects, busulphan was investigated as 
an alternative to TBI. A suitable preparation for intraperitoneal
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injection was made up by dissolving busulphan powder in 1 ml of DMSO 
(dimethyl- sulphoxide) and mixing this in 9 mis of arachis oil.
A preliminary series of experiments were conducted to establish the 
lethal dose of busulphan. Rats aged 6-8 weeks were injected 
intraperitoneally with a range of busulphan doses calculated on the 
basis of recipients1 body weight. The volume injected was usually 
less than 1 ml through a 25G needle with the rats under a brief 
5 ether anaesthesia.
The results of these experiments are summarised in Figure 10.2. It 
became clear that Busulphan at a dose of 30 mg/kg was always fatal 
to rats of this age within 1*1-16 days. A few animals survived lower 
doses. A dose of 30 mg/kg was thereafter adopted as the potential 
ablative dose.
Figure 10.2 Survival of Rats Given Intraperitoneal Busulphan.
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Post-mortem examination of the animals dying from the busulphan dose 
suggested that death was probably a consequence of marrow failure. 
A number of animals had pulmonary exudates, suggesting infection, 
but the survival was not influenced when experiments were conducted 
in which half the animals received routine antibiotics (framycetin) 
in their drinking water.
10.3.5 Anatomical And Haematological Consequences Of Busulphan: The 
Influence Of Autologous Marrow Rescue
In order to determine what the consequences of this dose of (30 
mg/kg) busulphan were on these rats, and the influence of 
intravenous marrow Rescue1, groups of weaned littermates were used, 
aged 6-8 weeks, in a number of experiments.
Half the animals had autologous marrow removed as described above. 
This group and the remaining intact animals then received busulphan 
(30 mg/kg i.p.). Twenty-four hours after the busulphan dose the 
autologous group received reinfusion of their own marrow adjusted to 
a cell dose of 2.0 x 10®/kg. The day of busulphan administration 
was designated Day 0.
Cohorts from the Busulphan + ABMT, and Busulphan only groups were 
electively sacrificed on experimental days +2, +5» +7> +9> +12, +15 
and +21 and peripheral blood, bone marrow, liver, spleen, adrenal 
and thymus examined. Contemporary animals, not receiving busulphan 
were sacrificed on each occasion to provide control data. Each 
value represents a mean of at least 8 test animals with one standard 
deviation. The normal ranges are the mean t standard deviation of
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at least 8 untreated control littermates. Statistical differences 
were derived by the application of the Student*s ft* Test.
10.3-5.1 Haematology
Up to 1.0 mis of blood was obtained under ether anaesthesia by 
cardiac puncture before each animal was sacrificed and haemoglobin 
and total white cell count measured by standard automated techniques 
on a Coulter M5 30.
A normal haemoglobin range of 14.3+1.02 g/dl (mean ± S.D.) and 
total white count of 11.08 ± 3.99 x 10^/1 was established from the 
cumulative control results. In the animals receiving busulphan 
without marrow rescue a significant anaemia, compared with controls, 
developed on day 9 and 12 (p=<0.001) (Figure 10.3a). Although the 
Busulphan only group were more anaemic than the autograft group by 
Day 9, the difference was only significant on Day 12 (p=<0.001). By 
Day 15 all the busulphan only group had died, as was expected, from 
the data previously presented (Figure 10.2). The Busulphan plus 
autograft only became significantly anaemic compared with controls 
on Day 12 (p=<0.001) and recovered by Day 15.
A similar pattern emerged for total white count(Figure 10.3b). Both 
groups became significantly leucopenic by Day 2 (p=<0.001) with the 
busulphan only group being significantly more so, compared with the 
autograft group, on days 7,9 and 12 (p=<0.001). By day 12 the 
autograft group had recovered to control levels with an overshoot to 
levels which were significantly greater than controls on day 15 
(p=<0.005) and day 21 (p=<0.01).
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Fig 10.3 Changes in Haemoglobin and White Count following 
Busulphan (30 mg/kg) + Autologous Marrow.
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10,3.5.2 Bone Marrow Cellularity
Marrow cellularity was assessed in two ways. One femur was excised 
and the ends removed, the bone marrow was detached from the 
periosteal surface by coring with a fine wire, the detached marrow 
was avulsed into a small volume of tissue culture fluid by blowing 
through a pasteur pipette. The cell suspension was disaggregated by 
serial passage through a 25 gauge needle and the cellularity 
expressed a total nucleated count per femur. In another cohort of 
animals the other femur was deposited in Bouinfs solution for four 
days and a longitudinal section prepared and stained by haematoxylin 
and eosin for histological examination.
Busulphan had a dramatic effect on marrow cellularity such that by 
day 2 there was an 80-90? reduction in marrow counts (figure 10.4). 
The degree of hypoplasia was not influenced by autologous marrow 
until after day 12 when there were no surviving animals in the
busulphan only group. By day 15 marrow cell counts had recovered to 
normal levels in the autograft group.
Serial histological examination was in broad agreement with the
sequence of events indicated by the bone marrow counts (Figure
10.5). By Day 2, there is a substantial reduction in marrow
cellularity with apparent sparing of megakaryocytes. Complete 
aplasia is apparent by Day 5. Early regeneration is apparent in the 
autograft group on Day 9 in the periosteal area, which is seen to a 
lesser extent in the busulphan only group. In the autograft group a 
few nucleated cells can also be seen more centrally adjacent to the 
fat spaces.
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Fig 10,4 Effect of Busulphan + Autologous Marrow on the Femoral 
Marrow Nucleated Cell Count
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Obvious differences between the two groups are seen by Day 12 with 
cellular proliferation at the periosteal in the autografts with 
nests of haemopoiesis further into the medulla whereas the busulphan 
only group remain severely hypoplastic. The failure to obtain any 
indication of this difference in the marrow counts on Day 12 is 
probably explained by failure of the flushing technique to avulse 
cells from the bone margin.
By Days 15 and 21, when only the animals who received autologous 
bone marrow survived, the histological appearances of the marrow are 
indistinguishable from control animals.
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10.3.5.3 Changes in Organ Weight
The organ weights are expressed as a percentage of total body 
weight. There: was little change in the adrenail or liver weights 
following busulphan. In the Long-Evans rat early death following a 
leukaemogenic dose of carcinogen, is often due to adrenal 
haemorrhage characterised by an increase in adrenal weight and 
mid-zone haemorrhage on histological examination(3) - no such 
changes were seen following Busulphan.
Fig 10.6 Change in Adrenal and Liver Weights following Busulphan 
+ Autologous Marrow.
a) Adrenal
.05-
h  .04-
normal
< .02-
0 5 10 15 20 25
DAYS AFTER BUSULPHAN
467
b) Liver
7-|
6 -
normal
ABMT
Busulphan Only
£2-
5 10 150 20 25
DAYS AFTER BUSULPHAN
The pattern of cell destruction and repopulation seen in the bone 
marrow is reflected in the spleen weights (figure 10.7a) which 
significantly diminish by day 2(p=<0.001) but recover to normal 
levels in the autograft group by day 12 which does not occur in the 
busulphan only group. Similar rapid destruction of the thymus 
occurs (Figure 10.7b) with no evidence of recovery in Busulphan 
group at time of death. Autologous marrow permits sufficient 
survival time for a degree of thymic regeneration, but this has 
still not returned to normal by the end of the experiment on day 
21(p=<0.001).
Fig 10,7 Changes in Spleen and Thymus following Busulphan 
Autologous Bone Marrow
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The influence of autologous marrow on restoration of haemopoiesis 
following a lethal dose of busulphan is clearly demonstrated in 
these experiments, suggesting the potential to rescue animals from 
ablative treatment in vivo.
10.3.6 Survival of Rats receiving Busulphan with Autologous Bone 
Marrow.
In a further? series of experiments bone marrow was removed for 
experimental animals in the usual way. They, and intact control 
littermates, received busulphan 30 mg/kg I.P. (designated Day 0). 
Twenty-four hours later the autologous marrow was reinfused and the 
animals examined daily till death or for 60 days. In these and 
subsequent experiments it became clear that no events occurred 
beyond 30 days, which in the presentation of the data was taken as 
the endpoint. Control littermates received busulphan only.
The result (Figure 10.8) clearly indicates the effectiveness of 
autologous marrow infusion in rescuing animals from busulphan. It 
is not surprising that some rats continue to die early, during the 
aplastic phase, before the infused marrow could influence the 
situation.
While clearly demonstrating the effectiveness of marrow infusion, 
these animals received a variable amount of bone marrow (cells/kg) 
depending on what was harvested. For the purpose of determining the 
influence of marrow dose on survival, the survival was examined for 
subgroups who received >2.0 x 10®/kg: 1.0-2.0 x 10®/kg and <1.0 x 
10®/kg. Optimum recovery is achieved when the infused dose is
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>2.0 x 10®/kg (Figure 10.9)» but further cut-off points at higher 
doses did not result in improved survival(data not shown).
Fig 10.8 The Effect I of Intravenous Autologous Bone Marrow on 
Survival of Rats Treated with a Lethal Dose of Busulphan
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Fig 10.9 The Influence of the Number of Bone Marrow Cells Injected 
on Survival of Busulphan Treated Rats.
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For effective use of this autograft system therefore three criteria 
were derived:-
(i) Rats aged 6-8 weeks
(ii) Busulphan 30 mg/kg by intraperitoneal injection
(iii) Infusion of a standard dose of 2.0 x 10® autologous 
marrow cells per kilogram, stored at 4°C and given 24 hours 
after the busulphan.
10.4 IN VIVO DETECTION OF RESIDUAL LEUKAEMIA CELL CONTAMINATION OF 
BONE MARROW.
In order to measure the effect of in vitro treatment a sensitive 
assay for the detection of the remaining leukaemic cells in a bone 
marrow suspension is required. Since recurrence in the host animal 
is the relevant parameter, an in vivo Tbioassayf was preferable to 
an in vitro assay, although both will be used.
As will be described in Chapter 12, cell lines from primary 
leukaemias induced by serial doses of dimethylbenz(a)anthracene in 
the Long-Evans rat, were established and maintained in liquid 
culture. A useful characteristic of the model is that injection of 
a suspension of these cells subcutaneously will produce a local 
tumour, usually within two weeks, which is readily detectable by 
palpation and inspection(as illustrated in Figure 10.10).
This feature of the model was adapted to mimic a normal marrow 
contaminated by residual leukaemia. To normal rat marrow cells were 
added leukaemic cells in the desired ratio, e.g. 15S leukaemic cell 
contamination. This would represent, in subsequent assessment of
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Fig 10.10 Development of Subcutaneous Tumours Following Injection of 
Leukaemic Cells
Day 11
Day 15
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1*40 160
purging techniques, a "remission" marrow. What had to be determined
was the absolute number of leukaemic cells present in the inoculum
required to produce a measurable tumour in vivo.
Normal rat marrow was obtained from several rats which were 
sacrificed, femurs removed and cored and bone marrow expelled by 
blowing air through the femur via a pasteur pipette. The marrow 
cells were suspended in tissue culture medium and disaggregated by 
several passages through 25-18G needles. To the suspension was
added leukaemic cells taken from liquid culture, such that the
leukaemic contamination of the final suspension was ]%. Volumes of 
this cell suspension were prepared for injection into young rats, 
which contained escalating numbers of leukaemic cells per inoculum, 
always in a ration of to normal cells.
Unweaned litters were used as host animals. Babes aged 10-20 days 
each received a subcutaneous inoculum of the 1% contaminated marrow 
suspension, but they were divided into groups who received 
increasing doses of leukaemic cells. The babes were observed for 30 
days for the development of subcutaneous tumour. In these 
experiments the range of leukaemic cell dose injected ranged from 
10*1 to 106. The development of tumour in these babes is indicated 
in Figure 10.11.
There is a relationship between leukaemia cell dose and the 
incidence and time taken to develop a palpable tumour. This is 
illustrated in figure 10.12 which shows a linear relationship 
between the cell number in the inoculum and the median time of 
tumour development latent period). The straight line relationship
suggests that the cell kinetics is not influenced by a cell number 
effect, i.e. is not showing grompertzian type kinetics. The data
suggest that the cell doubling time is less than 2*1 hours.
Figure 10.11 Relationship between Inoculum Cell Dose and Tumour 
Development
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The relationship between the cell number in the inoculum, and the 
percentage take is also shown in figure 10.13, which shows 
reasonable linearity at cell numbers of 1 x 10^ and greater but, as 
expected, less accuracy at lower cell numbers. The TD50* this 
system is approximately 1 x 10^ cells.
#Tumour cell dose required to produce tumours in 50% of recipients.
Fig 10.12 Relationship Between Injected Cell Number and latent 
Period to Develop Tumours.
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Fig 10.13 Relationship Between Injected Cell Number and the 
Percentage of Animals which Developed Tumour (Tumour
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It is important to note that as the absolute number of leukaemic 
cells were reduced, the incidence of tumour was reduced and the time 
till appearance delayed but it is crucial to notice that even when 
the calculated dose in the inoculum was 10 cells, ^5% of animals 
developed tumour(Fig 10.11).
This transplantable leukaemia represents a very reliable bioassay 
system for the detection of very low numbers of residual leukaemic 
cdlls. Of the cells maintained in liquid culture, 30-40^ are 
usually clonogenic, as defined by formation of colonies in 
clonogenic assay (see Chapter 12) The data suggest that, if as few 
as 5-6 clonogenic cells remain in the inoculum, H0% of recipient 
babes will develop tumours within 30 days. Prolonged follow-up (i| 
months) did not detect further tumour formation in the groups in 
whom it had not already developed by Day +30.
10.5 SUMMARY OF IN VIVO MODEL SYSTEM.
A model system has been developed which appears capable on the one 
hand of detecting damage to the integrity of normal haemopoietic 
precursors required to rescue animals from an ablative dose of 
Busulphan, and on the other, of detecting very small numbers of 
contaminating leukaemic cells in bone marrow suspensions 
contaminated by as few as 1:100 leukaemia cells. The test animal 
which receives autologous marrow must, in this system, be different 
from the animal which receives the leukaemic cell inoculum. This is 
because babes older than 21 days generally do not reliably engraft 
with the leukaemic cell inoculum. This is probably an immune 
phenomenon, since we have observed tumour takes in animals whose
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thymus has been rendered atrophic by a single dose of 7,12,DMBA. 
Animals of that age are too small to satisfactorily aspirate marrow, 
as the femur is too fragile.
The in vivo model system is illustrated in Figure 10.14.
Fig 10.14 Autologous Bone Marrow Transplant Model in the Rat.
AUTOLOGOUS BMT RAT MODEL
Busulphan 30mg/kg
Survivor
Aplasia
In Vitro Treatment j 
ug/1Q7cells j
Tumour
5x10 cells BM
0.5x10 ELB cells
10.6 IN VITRO MONITORING OF THE SYSTEM
Although the in vivo consequences of manipulation of the bone marrow 
are the crucial factor, the system can be monitored by in vitro 
assays.
10.6.1 In Vitro Monitoring of Repopulative Ability of Rat Bone 
Marrow
Bone marrow precursor assay CFU-GM (described in detail in Chapter 5 
for human marrow) has been simply adopted for rat bone marrow. Even 
using human conditioned medium, colonies of similar morphology 
(Figure 10.15) are grown in methylcellulose, which are of 
granulocytic origin. Similarly, preliminary studies indicate that a 
long-term culture system, using the same technique described for 
human marrow (Section 6), can be established if necessary if, as in 
humans, CFU-GM, is insufficiently precise to reflect the repop­
ulative potential of bone marrow.
Fig 10.15 Morphology of Rat CFU-GM
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10.6.2 Clonogenic Assay for Leukaemia Cells.
The- responsiveness of clonogenic cells to treatment can be monitored 
in vitro by a clonogenic assay. Cells taken from liquid culture;can 
be plated on a methocell semi-solid medium and incubated in a COg 
atmosphere for 5 days, by which time colonies are detectable by 
microscopic examination. The technique is summarised in Figure 
10.16. The colonies (Figure 10.17) can be quantitated per 103 cells 
plated. The effect of in vitro treatment can therefore be 
quantitated by this clonogenic assay.
10.16 Rat Leukaemia Clonogenic Assay - Method
Medium/Cell Mixture
- 2 A %  Methylcellulose (MC)
- Foetal Bovine Serum (FBS) 0.6 ml
1.2 ml
- Dulbecco*s Modified Eagle1s 
Medium (DMEM) 0.55 ml
- Cell Suspension (48 x 103/ml) 0.05 ml
2 .M0 ml
1 ml 1 ml
Incubate at 37°C in a 5% CO2 Humidified Atmosphere 
Count Colonies (fig 10.17) °n day 5 .
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10.17 Rat Leukaemia Clonogenic Assay - Morphology
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CHAPTER 11
PHARMACOLOGICAL PURGING in THE RAT 
AUTOLOGOUS TRANSPLANT MODEL
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The autologous bone marrow transplant model which was developed has 
been described. This model offers considerable scope to evaluate 
differing techniques aimed at eradicating minimal residual disease 
from bone marrow suspensions. Immunological ^techniques await the 
development of a suitable monoclonal antibody, which is currently 
under development. Although the list of potentially useful pharma­
cological agents is long, particularly if used in vitro in 
combination, two agents have so far been evaluated - the Cyclo­
phosphamide derivative Ifosphamide (ASTA-7557) and Etoposide 
(VP-16).
11.1 IFOSPHAMIDE (ASTA-7557)
As previously discussed, this drug has attracted most attention as a 
useful agent in this context, with evidence for and against its 
ability to preferentially eradicate leukaemic cells compared with 
bone marrow committed precursors (e.g CFU-GM). This data has almost 
exclusively been obtained from the responses of experimental 
leukaemic cell lines against normal rodent marrow or cell lines 
derived from human leukaemias (e.g. HL60) admixed with normal human 
bone marrow cells. The measureable endpoints in these in vitro 
studies is the number of colonies produced in a semi-solid clono­
genic assay system. With exception of the Brown Norway Model there 
is little or no in vivo evidence to support any of these data. 
Extrapolations based solely on a clonogenic assay are potentially 
suspect for a number of reasons. The ability to observe a colony 
may depend on there being a minimal number of viable cells plated. 
It may be that a number of viable clonogens survive but the absolute 
number falls below that required for any particular system. The
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plating efficiency therefore must be capable of detecting all 
clonogens. As will be illustrated in Chapter 12, the clonogenic 
assay developed for this model system is highly efficient with a 
capability of detecting as few as cells/10^ in the inoculum. In 
the absence of such efficiency it will be necessary to add several 
fold extra cells to the plate to ensure an observable endpoint is 
available. A useful feature of this model is the opportunity to 
compare in vitro prediction with in vivo outcome.
The development of the Cyclophosphamide derivative used in the Brown 
Norway System (il-hydroperoxycyclophosphamide) was the result of a 
considerable pharmacological effort, but this drug was chosen 
because that leukaemia was particularly sensitive in vivo to 
Cyclophosphamide. Its sensitivity may be related to the fact that 
this has the morphological characteristics of a well differentiated 
myeloid (promyelocytic) leukaemia. Differentiated cells have higher 
levels of aldehyde dehydrogenase which is correlated with response 
to Cyclophosphamide. The leukaemia model which is described shows 
little evidence of differentiation, although it can be induced to in 
vitro to exhibit features of erythroid differentiation.
11.1.1 Effect on In Vitro Incubation of Rat Bone Marrow on 
Repopulative Potential Following Ablative Therapy
In Vitro incubation was carried out on all occasions under standard 
conditions. Celis were exposed at stated microgramme concentrations 
(ug/ml) at a cell concentration of 1 x 10? cells/ml and incubated at 
37°C in a waterbath with occasional shaking for one hour.
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Intravenous administration to ablated rats was undertaken
immediately ensuring a standard nucleated cell dose of 2 x 10®
cells/kg of receipt rats body weight. For in vitro assays the
incubated! mixture was diluted and plated at the standard
concentration of 1 x 10® cells/assay plate.
11.1.2 Dose Effect of ASTA-Z-7557 on In Vitro Colony Growth (CFU-GM)
A series of normal rat bone marrow suspensions dose response curves 
were derived. The results were in each individual case expressed as 
the percentage of colony number grown in the control plates (Oug/ml 
of ASTA-Z-7557). All assays were performed in triplicate and a mean 
used for subsequent calculation. The results were reproducible 
between individual rats (figure 11.1) with residual colony growth 
still detectable at a dose level of 12.5ug/10? cells. The dose 
required to inhibit 50% growth (TD50) approximately 3.5-*l.0ug/1o7 
cells.
Figure 11.1 Dose Response of Rat CFU-GM Incubated with Asta-Z-7557
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11.1.3 Survival of Rats Given ASTA-Z-7557 Treated Marrow Autografts 
Following Ablative Treatment
In several groups of experiments a number of littermates were 
divided into groups whose autologous bone marrow wa3 treated at 
different doses (1.0ug-20ug) of ASTA-Z-7557 per 10? marrow cells 
under the stated conditions. Rats aged 6-8 weeks were used, each 
receiving an ablative dose (30mg/kg) of Busulphan I.P. immediately 
after marrow removal.
The survival of these groups of rats is shown in figure 11.2. 
Control (untreated marrow) animals were used in each experiment with 
the usual survival in excess of 85£ (data not shown). The survival 
of each dose group is expressed as a corrected observation i.e. 
adjusting the result on the assumption that the untreated autograft 
group had a ^0Q% survival. A clear linear relationship to dose is 
noted with a TD50 at 10 ug. The in vitro CFU-GM dose response 
(figure 11.1) suggested that only 6% of CFU-GM survive this dosage.
100
Figure 11.2 Survival of Rats Following Ablation with Autologous Bone 
Marrow Incubated in Vitro with ASTA-Z-7557
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Two interpretations can be put on this apparent anomaly. The 
minimum number of CFU-GMs required for graft take is not known in 
this system. Although only 6% of available colonies achieve the 
TD501 this may still represent an adequate total number of; cells to 
secure engraftment. As has become clear in the clinical experience 
of pharmacological purging in man, the CFU-GM may be an 
insufficiently sensitive assay to predict haemopoietic repopulative 
potential of bone marrow.
11.1.1} Effect of Incubation with ASTA-Z-7557 on Clonogenic 
Leukaemia Cells
Leukaemic cells taken from liquid suspension culture were incubated 
in the standard conditions at a series of doses per 10? cells of 
ASTA-Z-7557. After the 60 minutes the cells were washed and set up 
in the clonogenic assay (section 10.6.2). Although a dose response 
is observed, colonies can still be observed at incubation doses of 
30ug/10? cells (figure 11.3)• This was corroborated by at least
Figure 11.3 Effect of ASTA-Z on Clonogenic Leukaemia Cells in Vitro
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eight similar experiments with cultures being set up in triplicate 
at each dose level. The apparent inability of ASTA-Z to eradicate 
all clonogens was confirmed when cells were returned to liquid 
culture after incubation with the drug, and [examined 7-10 days later 
when clones were readily detectable.
11.1.5 Elimination of Residual Leukaemia by In Vitro Treatment 
with ASTA-Z-7557
Normal rat bone marrow was contaminated with leukaemic cells in a 
ratio 99:1(normal:leukaemic) and incubated in vitro with ASTA-Z in 
the conditions stated above. Immediately following incubation, rats 
7-18 days old were injected with a cell suspension (0.2 mis) which
Figure 11.4 Development of Tumours: Influence of in vitro purging
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contained 5 x 10^ leukaemia cells (as a \% contaminant of bone 
marrow). These animals were then observed for. 50 days and the date 
of appearance of palpable tumour recorded (figure 11.ll). These data 
indicate that doses of 4.0ug and;beyond are effective in eradication 
of residual leukaemia cells. In these experiments no tumours 
occurred beyond 30 days.
When the percentage tumour 1 takes1 is correlated with purging dose 
(figure 11.5) it can be seen that a dose of 2.75ug results in 50% 
takes. Previously (figure 10.13) the correlation between cell dose 
of the inoculum and tumour takes indicated that about 1 x 1 0 ^  cells 
were required for 50% takes in this model. In these experiments 50% 
takes were observed with a treated inoculum of 5 x 101* cells 
indicating that a purging dose of 2.75ug has resulted in a 2 log 
leukaemia cell kill.
Figure 11.5 Relationship Between Tumour Takes and Purging Dose of 
ASTA-Z at 1% Leukaemic Cell Contamination
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A typical experimental observation of effective purging is shown in 
the two groups of rats in figure 11.6 which are controls compared 
with treatment with 5ug/10? cells on day 18 after inoculation.
Figure 11.6 Prevention of Subcutaneous Tumour Formation following 
Incubation of The Inoculum with ASTA-Z-7557
A contamination of 1$ was chosen because it might represent a bone 
marrow in remission. In order to determine whether this agent was 
as effective at higher levels of contamination these series of
experiments were repeated where the leukaemic cell contamination in 
the inoculum was 10$. This was achieved by a reduction in normal
bone marrow cells in the mixture leaving the same absolute number of
leukaemic cells in the inoculum (5 x 10^) to ensure a high level of 
tumour take if these cells remain viable. The results shown in 
figure 11.7a and 11.7b indicate that a very different pattern of
response occurs with little impact being made until the dose is 
increased to beyond 20ug/10? cells.
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Superficially this data bears out what would be expected to happen, 
namely that the outcome would be more favourable with minimal 
residual disease. However, the absolute amount of disease in the 1$ 
and 10$ inoculum was the same, which implies that the non-leukaemic
Figure 11.7 Development of Tumours: Influence of In Vitro Purging 
with ASTA-Z-7557 at 10$ Contamination 
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cellular component was also influential. In the circumstance where 
5 x 10^ leukaemic cells are mixed with 5 x 10^ normal cells, ASTA-Z 
is more effective than when they are mixed with 5 x 10^ cells. The 
incubation dose was added per 10? cells present so the former 
mixture would have ten times as much drug in the mixture, on the 
assumption that each cell would then be uniformly dosed i This does 
not appear to be the case. The observed differences could be 
explained by preferential uptake of ASTA-Z in leukaemic cells
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Figure 11.7(b) 15-50ug incubation dose
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relative to normal bone marrow cells, thus the dose for leukaemic 
cell in the 1% mixture would be several fold higher. This 
distribution may vary with different pharmacological agents.
11.1.6 Conditional Cure Rates for ASTA-Z-7557 •
The animals can only be cured at dose levels which are sufficient to 
eradicate residual tumour yet spare marrow repopulative ability. 
Since each of these conditions in this model was worked out as a 
separate experiment, it is not immediately apparent what the optimum 
dose for in vitro treatment would be. At the low end of the dose 
range there will be a high probability of stem cell survival but a
i-
high chance of tumour development and vice versa at higher .doses. 
If the percentage risk of survival is multiplied by the percentage
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probability of being tumour free, then a "conditional" survival at 
each dose level can be devised. The optimum dose will then emerge 
for that level of contamination.
j
From the data in figures 11.2 and 11.3 the conditional survival with 
1* contamination is displayed (figure 11.8). At this level the 
maximum conditional survival is about 63* and can be achieved with 
an incubation dose of H-6ug. Using data derived from that displayed 
in figures 11.7a and 11.7b a conditional cure for 10* contamination 
is also shown(figure 11.9), hut at this level cure rate is low(9*).
11.2 VP-16-213CETOPOSIDE)
This alkylating agent does not require metabolic activation and is 
therefore a candidate for in vitro pharmacological purging. As 
discussed earlier, it has - unlike cyclophosphamide - reported 
activity even as a single agent in acute non-lymphoid leukaemias in 
man.
11.2.1 In Vitro Sensitivity of Clonogenic Leukaemic Cells to 
Incubation with VP-16 (Etoposide)
The conditions of in vitro incubation are as described above. At 
low dosage, e.g.2ug/107 cells, 98* of clonogens have been 
destroyed(figure 11.10). No growth is observed at higher incubation 
dosage - an observation confirmed when residual treated cells are 
nurtured in liquid culture for 7t 10 days and then replated. In this 
liquid assay, an opportunity is provided for viable or non-cycling 
cells to recover and become detectable in the clonogenic assay. No 
late growth was seen with doses of Hug or more.
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Figure 11.10 Response of Clonogenic Leukaemia Cells to Incubation 
with VP-16
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11.2.2 In Vivo Tumour Formation Following Incubation with VP-16
In a series of experiments the standard inoculum of 5 x 101* 
leukaemic cells comprised a 1$ or 10$ contamination of normal marrow 
cells, and was incubated at 37°C for one hour with various 
concentrations of VP-16 (etoposide).
At 1$ contamination few tumours occurred at dosage of 5ug/107 cells 
but at 3ug all animals developed tumour(figure 11.11). This in vivo 
result is in broad agreement with the results of the clonogenic 
assay dose response.
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Figure 11.11 Effect of In Vitro Purging with VP-16 213 on Tumour 
Incidence: at 1$ Contamination
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At contamination levels of 10JG a somewhat similar dose response is 
observed when tumour development is displayed although the 
relationship to dose is linear (figure 11.12). A few late tumours 
developed at the 5.0ug dose, but 65% of animals receiving the 
inoculum treated at 2.Oug developed tumour. The 50% tumour take 
(TD50) occurs at a dose of 2 .9ug, which means that an approximate 
3 log leukaemia cell kill has been achieved by VP-16. This is 
little different from the TD50 at \% contamination which is 3.5ug or 
an approximate 3 .5 log kill (figure 11.13). It is not obvious why 
there should be such a steep slope to the dose response curve for 
the \% contamination between the 3 and i|ug doses.
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Figure 11.12 Effect of In Vitro Purging with VP-16 213 on Tumour 
Incidence: at 10f Contamination
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11.2.3 Survival of Rats given Ablative Treatment and Autologous 
Marrow Incubated In Vitro with VP-16 (Etoposide)
In a series of experiments autologous bone marrow was incubated at 
different dose levels, and returned to the host animals which had 
been ablated with Busulphan 30mg/kg. The outcome of these 
experiments is shown in figure 11.14. At a dose of 5.0ug only 1255 
of animals survived whereas at a dose of 2.0ug 52£ of animals 
survived. An in vitro dose response of rat CFO-GM was not 
undertaken for VP-16.
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11.14 Survival of Rats following Ablative Treatment and 
Autologous Marrow Treated with VP-16-213
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11.2.4 Conditional Cures following In Vitro Incubation with VP-16
By multiplying the observed survival with the tumour free survival 
for each dose and both levels of contamination a conditional cure
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can be calculated, as before. These are displayed in figure 11.15. 
VP-16 differs from ASTA-Z-7557 in that the conditional cure is not 
substantially affected by the degree of leukaemic cell 
contamination. The conditional cures achieved with VP-16 are 
inferior to those achieved with ASTA Z, being a maximum of 20$ for 
10$ contaminations achieved by a dose of 2ug or a maximum of 17$ for 
1$ contaminations achieved by a dose of i|ug.
11.3 DISCUSSION OF PHARMACOLOGICAL AGENTS FOR IN VITRO PURGING IN 
THE RAT MODEL SYSTEM
In this system VP-16 provides little selective advantage of killing 
leukaemic cells while sparing the cell populations required to 
regenerate haemopoiesis, and therefore is of limited value in this 
system.
These data suggest, however, that ASTA-Z-7557 is in this context a 
more useful agent, with the property of eradicating a proportion of 
clonogens at doses where normal marrow precursors can be spared. 
This drug is only effective at low levels of contamination, e.g. 1$ 
and virtually ineffective at higher levels (e.g. 10$).
The limited sensitivity of these leukaemic cells to ASTA-Z as seen 
in vivo at 10$ contamination is in approximate agreement to the 
outcome of the dose response of in vitro clonogenic cells, which 
indicate that a few clones appear even after incubation doses of 
50ug.
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Synergy experiments using a small dose of VP-16 (e.g. 0.5 or 1.0ug) 
together with a suboptimal dose (e.g. of ASTA-Z-7557) may offer some 
chance of improvement in conditional survival, but are not yet 
concluded.
In vitro dose responses of clonogenic leukaemic cells to these two 
agents were approximately accurate in that they could predict that 
VP-16 was capable of eradicating clonogens at a given dose. This 
dose was similar to that required in the in vivo system. The 
clonogenic assay predicted that even at doses of 30ug it was not 
possible to eradicate residual disease. The reliability of this 
assay in predicting in vivo outcome is probably directly related to 
the ability of the system to detect the presence of very few 
clonogens.
CHAPTER 12
CHARACTERISTICS OF THE RAT LEUKAEMIA 
USED IN THE AUTOGRAFT MODEL
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12.1 INDUCTION AND DIAGNOSIS OF LEUKAEMIA IN THE LONG-EVANS RAT
In 1966 Huggins and Sugiayama described a method of inducing 
leukaemia in rats of the Long-Evans strain by the serial 
administration of the polycyclic aromatic hydrocarbon 7,12,Dimethy1- 
benz(a)anthracene (DMBA)(1). The sister compound 7*8,12 
Trimethylbenz(a)anthracene (TMBA) is equally effective(2). 
Leukaemia can be induced within a short time (less than 100 days) in 
virtually all animals by a series of oral (10 mgs) or intravenous 
administrations (30mg/kg) at biweekly intervals, for a minimum of 
four doses.
The diagnosis is most easily made by histological examination of 
liver, obtained by open biopsy under brief ether anaesthesia, 
commencing two weeks after the last dose of carcinogen, and repeated 
at 1^1 day intervals. The earliest evidence of leukaemia cell 
induction is deposition of aggregates of basophilic cells in the 
liver sinusoids. Over subsequent days and weeks extensive 
infiltration of liver and, frequently, spleen takes place which are 
readily palpable clinically(Figure 12.1). As a late event 
associated with extensive marrow infiltration, pancytopenia 
develops, the animal undergoes substantial weight loss, and abnormal 
cells circulate in the peripheral blood. As a pre-terminal event 
animals adopt a haunched posture attributed to "leukaemic 
osteopathy"(3) and have a reduced body temperature. Female rats 
lose the normal periodicity of the oestrus cycle as the disease 
progresses, and few animals survive more than a month once the 
diagnosis has been established. A minority of animals develop a 
leucocytosis, but this can readily be detected in a small volume of
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Figure 12.1 Diagnosis of Leukaemia in the Rat
A Earliest evidence of leukaemia in sinusoids of the liver (x *10 
magnification)
B Sinusoidal Infiltration with Leukaemic Cells (x 1000 magni 
fication)
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blood (0.1ml), obtained by cardiac puncture, by a micro-micro- 
haematocrit technique. This method uses glass capillary tubes 
(Kimble Products Ltd) which are thinner than the normal haematocrit 
tube, having an external diameter of 0.7-1.Omm and a wall thickness 
of 0.2mm. Standard tubes of 75mm are used in a microhaematocrit 
centrifuge under standard conditions (5,000 rpm for 5 mins) . The 
thin tube wall permits visualisation of the layers of the cellular 
elements of the blood (figure 12.2), under these circumstances a 
reduced haematocrit, expansion of the buffycoat with leukaemic 
cells, and a reduction in thickness of the platelet layer. By using 
a micrometer eyepiece the layers can be measured to produce a 
correlation with the cell counts obtained by conventional counting 
techniques.
Figure 12.2 Detection of Leukaemia in Peripheral Blood
NORMAL LEUKAEMIA
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12.2 HISTOLOGICAL AND CYTOCHEMICAL CHARACTERISTICS OF THE RAT 
LEUKAEMIA
Bird described the histological distribution of advanced leukaemia 
in these animals in spleen, thymus, lymphoid tissues and bone 
marrow(3 , 5 ) .  Heavily infiltrated tissue showed reversal of the 
Malate Dehydrogenase (MDH) to Lactate Dehydrogenase (LDH) ratio in 
affected tissue, and that there were increased amounts of LDH 
isoenzyme 5, with reduced MDH levels, all consistent with increased 
anaerobic glycolysis - one of the earliest described characteristics 
of neoplastic cells(6).
I have examined material for more than *J0 consecutive new cases, 
using cytochemical stains (Periodic Schiff(PAS); Sudan Black; Acid 
and Alkaline Phosphotase) to which no reactivity has been observed. 
The morphological characteristics of a collection of leukaemic cells 
(figure 12.3), suggest the appearances of early erythroid lineage 
but there is no objective evidence to confirm such lineage 
commitment.
Figure 12.3 Leukaemic Cells in Peripheral Blood in Advanced 
Leukaemia
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12.3 INDUCTION OF DIFFERENTIATION
Under appropriate conditions in vitro, incubation with agents 
capable of induction of differentiation such as 1J6-1.5$ 
Dimethylsulphoxide (DMSO) or Hexamethylenebisacetamide (3mM) (HMBA) 
are capable of achieving erythroid differentiation^) as illustrated 
in figure 12.4. We have no experience of the use of agents more 
usually associated with induction of myeloid differentiation. Such 
evidences support the subjective impression that this is a leukaemia 
of early erythroid lineage.
Figure 12.4 Induction of Differentiation by Incubation with 
DMS0(1.5$)
Cells in Liquid Suspension Following Incubation with 
DMSO
A. Reduction in Cell Volume 
with pink discoloration 
(haemoglobinisation) of 
cytoplasm
B. Benzidine Positivity (for 
Haemoglobin)
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12.4 CYTOGENETIC CHANGES OCCURRING DURING LEUKAEMOGENESIS AND IN 
LEUKAEMIC CELLS
Non-random chromosome changes have been described in the leukaemic 
cells in more than 50% of rats bearing primary leukaemia(8,9) . The 
most common abnormality was a trisomy of the largest telocentric 
chromosome. In some cases this was associated with a trisomy of the 
sixth megacentric chromosome. In a small number of cases both 
abnormalities are found. Typical karyotypes are illustrated in 
figure 12.5. The regular involvement of the largest telocentric 
chromosome is consistent with the dose-dependent aberrations of this
Figure 12.5 Karyotypic Changes in Leukaemic Cells
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B) Trisomy of C1 in conjunction with Trisomy of A6
chromosome induced by a single dose of DMBA(10). The incidence of 
the chromosome breaks seen within hours of DMBA administration is 
increased by rendering the recipient rats anaemic, and reduced by 
keeping them polycythaemic(11). The induced anaemia and 
polycythaemia respectively increase and reduce the incidence of 
leukaemia suggesting that the short-term chromosomes aberrations 
observed are integral to the leukaemogenic process. An association 
of karyotypic abnormalities with the clinical pattern of disease has 
been demonstrated, providing additional information that karyotypic 
changes are likely to be causal(12,13).
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12.5 HORMONE DEPENDENCE OF PRIMARY LEUKAEMIA
One of the more remarkable observations in this model is its 
resolution in 5055 of cases following hypophysectomy. This 
observation was first made by Huggins(m) who had for a long time 
been aware that hypophysectomy in the rat results in an important 
degree of anaemia(15). These results have been confirmed on a 
number of occasions in Huggins* lab(l6) including an experiment 
5which I jointly conducted, summarised in table 12.1. The reason for 
this remarkable effect has not yet been fully explained. Thyroid 
hormone deficiency, achieved by surgical thyroidectomy, or thyroxine 
excess, achieved by daily administration of thyroxine, was found not 
to affect animals with established leukaemia(17).
Table 12.1 The Effect of Hypophysectomy on Primary Leukaemia:
- 10 day Results
25
9 (3655)
4 (1656)
12 ( W )
Leukaemia was induced with l| or 5 bi-weekly 
intravenous doses of 7,12,DMBA (35mg/kg). Hypo­
physectomy was performed by the parapharyngeal 
route, within one week of an unequivocally 
diagnostic liver biopsy. Assessment was made on 
repeat liver biopsy performed 10 days after 
hypophysectomy.
Total
Progressive Disease 
Partial Response 
Complete Response
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12.5.1 Influences on Induction of Leukaemia
Single doses of DMBA, cause random breakages within 48 hours to host 
cell chromosomes. These effects are accentuated in circumstances of 
increased erythropoietic drive, such as induced anaemia or 
administration of erythropoietin, and reduced in the polycythaemic 
state(11). A significantly higher incidence of leukaemia was noted 
in anaemic animals than controls, while polycythaemic animals had a 
significantly reduced incidence Compared with controls. Where 33/39 
anaemic animals developed leukaemia, only 1/14 polycythaemics became 
leukaemic(11).
Prolactin excess or blockade does not influence leukaemogenesis(18) 
but in hypophysectomised animals, in which tumour induction is known 
to be difficult(19,20), the implantation of pituitary homografts 
under the renal capsule restored effective leukaemogenesis(21). 
Prolactin or Growth Hormone Supplementation in hypophysectomised 
rats results in leukaemia, an effect which was not influenced by 
adreno-ovariectomy(21), while hypothyroid - but not hyperthyroid - 
rats, have a reduced incidence and delayed appearance of 
leukaemia(17). These latter experiments were inhibited by a high 
rate of early death due to aplastic anaemia. It is normal for a few 
animals (<15£) to die from the consequences of aplasia during 
induction, but the hypothyroid rats were extremely sensitive to the 
established dose protocol of DMBA.
In 1978 Huggins and Fukunishi(22) demonstrated that adrenal 
haemorrhages found in Sprague Dawley rats given DMBA, could be 
prevented by the oral administration of the Azo Dye, Sudan III
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(7.5 mgs). Subsequently Deda and Huggins found(23) that this 
compound, given before each dose of DMBA completely prevented 
leukaemogenesis. In pilot (unpublished) experiments I confirmed 
that prior administration of Sudan III protects thyroldectomised 
rats from both aplasia and leukaemia following serial 
administrations of DMBA. We have postulated that an explanation of 
this effect is that a series of metabolising enzymes of DMBA are 
selectively induced by Sudan III within the mixed function oxidase 
system of the liver, which are stereospecific, and result in altered 
metabolism of the DMBA(24). Like most aromatic hydrocarbons DMBA is 
not itself directly carcinogenic and requires metabolic activation 
to the ultimate carcinogen. In this respect the 3,4 diol 1,2 oxide 
is the favoured contender(25).
In figure 12.6 the metabolites of DMBA measured by High Performance 
Liquid Chromatography(HPLC) obtained from liver following DMBA 
administration to control or Sudan III treated rats can be seen to 
differ. In the Sudan III (protected) animals no 3-4 diol is found, 
suggesting a possible explanation for the protective effect observed 
in vivo(26).
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Figure 12.6 DMBA Metabolites found in control and Sudan III 
Pre-treated Rats following intravenous DMBA
0.01T
E 254
0-1- 
0.0 1t
E 254
0.01T
. DMBA-3.4-diot
DMBA-8.9-diol
DMBA- 
10,11-diolDMBA-5,6-diolE 254
TIME (mins)
The distribution of DMBA dihydrodiols in rat livers after 
intravenous injection of DMBA (30mg/kg) measured by HPLC. 
Figure shows the elutriation profiles of the dihydrodiol 
fractions obtained from the livers of control rats (A) and 
rats pre-treated with Sudan III (7.5 mgs orally)(B). 
Reference dihydrodiols are shown(C).
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12.6 ESTABLISHMENT OF A CELL LINE FROM PRIMARY LEUKAEMIA
We have established a cell line from a case of primary leukaemia 
induced by four intravenous doses of DMBA (30mg/kg) given at 14 day 
intervals. Diagnosis of leukaemia was established by liver biopsy, 
and the animal allowed to develop progressive disease when it was 
sacrificed. The spleen was removed under aseptic conditions and 
dissected into 1-2mm sections with scissors and then forcibly 
disaggregated through needles. Debris was removed by washing in 
tissue culture medium followed by centrifugation. The cells were 
resuspended in supplemented tissue culture medium for a few days to 
ensure sterility and then plated (1 x 103/ml) in semi-solid media 
(as described in section 10.6.2). Individual colonies were removed 
after 5 days and deposited in liquid suspensions of culture medium 
in flat bottom flasks in a humidified 5% CO2 atmosphere at 37°C.
After a few days in liquid culture, cells were again plated in 
semi-solid media as above. Individual colonies were removed and 
perpetuated in liquid culture, from which cells could be removed and 
frozen down. It was found possible to establish cell lines from a 
number of primary colonies, but the experiments described in 
chapters 10 and 11 used exclusively a single line.
12.6.1 Growth of Cell Lines in Liquid Culture
By a process of trial and error the culture medium which sustained 
optimum growth was derived, the constituents of which are listed in 
table 12.2.
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The liquid suspension is routinely sustained in 25ml flat bottomed 
flasks(Nunclon) containing 10mls of medium with an initial cell 
concentration of 5 x 1 o V m l .  Eight mis of the media is replaced two 
or three times per week. Under these circumstances the cell 
concentration is maintained at around 1 x 105/ml, with a doubling 
time of 12-14 hours. Cells used for in vivo administration or in 
vitro clonogenic assay are taken from this liquid culture system.
Table 12.2 Culture Medium for Optimum Cell Growth5
1 Earlefs Balanced Salts Solution 750ml
2 MEM Amino Acids (50x) 4 0ml
3 MEM Non-Essential Amino Acids (100x) 20ml
4 MEM Vitamin Solution (100x) 20ml
5 MEM Sodium Pyruvate (100x) 20ml
6 Penicillin/Streptomycin 20ml
7 Sodium Bicarbonate (7.555) 20ml
8 L-glutamine 10ml
9 Foetal Bovine Serum 100ml
Items 1-7 can be satisfactorily stored at 4°C for 
one month, but items 8 and 9 must be prepared
immediately prior to use. Items 1-8 obtained
from Gibco Laboratories and Item 9 from Flow 
Laboratories.
12.6.2 Transplantability of Leukaemia
Cell suspensions from the spleen, bone marrow, or blood of advanced
cases of primary leukaemia are capable of establishing leukaemia(l)
when injected into young rats aged less than 21 days old.
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Administration can be intravenous, intraperitoneal or subcutaneous.
r
Failure of tumour take becomes more common as the age of the 
recipient increases. The relationship between tumour take and 
inoculum cell dose and evolution of palpable tumours has already 
been illustrated in chapter 10, for subcutaneous administration 
which was preferentially adopted for this model system.
12.6.3 Sensitivity of the In Vitro Clonogenic Assay
The clonogenic assay used in the experimental autograft model is 
identical to that originally used to clone the primary leukaemia 
from liquid culture. The plating efficiency has remained remarkably 
consistent, with 35— 5^56 of the cells plated resulting in colony 
formation. In a 35mm culture plate, 1 x 103 cells are routinely 
plated, resulting in the formation of 350-H00 colonies per plate.
In order to determine the ability of this system to detect small 
numbers of colony forming cells, several experiments were 
undertaken, whereby serial dilutions of cell suspensions were plated 
under standard conditions, and the number of colonies per plate 
counted 5 days later. The results of these dilution assays (figure 
12.7) indicate that this in vitro system is capable of detecting as 
few as H remaining clonogenic cells - thus making it sufficiently 
sensitive for the in vitro detection of residual disease which may 
remain following a purging technique.
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Figure 12.7 Relationship between Number of Cells Plated and Colony 
Growth in Vitro
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12.7 LEUKAEMIA MODEL SUMMARY
This chemically induced leukaemia in the rat has many interesting 
features worthy of further study. This model was chosen for 
modification into an autograft model because of the author’s 
familiarity with it and the fact that it was non-lymphoid and 
therefore more representative of the problems presented for purging 
techniques in acute myeloid leukaemia in man.
We do not yet know whether a leukaemia specific monoclonal antibody 
can be raised against this leukaemia which could be exploited for 
immunologically mediated techniques of purging. This is the subject 
of current work. The model offers an additional and unique 
potential for purging by induction of differentiation which, in our 
hands, terminates the ability of these cells to proliferate in 
vitro.
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Data presented here and in chapter 10 indicate that the system, both
in vitro and in vivo, is capable of detecting a very small number of
residual leukaemic cells and therefore is well suited to measuring
the effectiveness of any purging technique.
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CHAPTER 13
FINAL COMMENTARY
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The traditionally based principles of cytoreduction by pulsed 
chemotherapy using more than one drug has improved the control of 
acute myeloid leukaemia clinically. As supportive care has improved
so has the rate of complete remission. It is less clear what is the 
best course of action post-remission induction. There seems little 
evidence to suggest value in continuous maintenance over a number of 
months or years. Even with rigorous chemotherapy in the immediate 
weeks after remission has been administered, the majority of
patients will die of their disease. It may not however be justified
to discard all current chemotherapeutic approaches when introducing 
newer forms of post-remission treatment such as ablative
chemoradiotherapy, since they may be improved by prior maximal 
cytoreduction.
Allogeneic bone marrow transplantation has the potential to cure the 
majority of patients for whom that option exists. To date the 
international data suggest that, although only J45—5055 are surviving 
long-term, the probability of being cured is about 80$. The reasons 
for the 30$ mortality were discussed, with some of the possible 
improvements which could be made to avoid such complications. 
Pneumonitis has historically been associated with a 10-12$ mortality 
in the international experience but attention to radiobiological 
principles, and prevention of Graft-versus-host disease, should 
substantially reduce these complications.
Prevention of Graft Versus Host disease has been an elusive goal for 
a number of years, but in vitro T cell depletion of the allograft 
can achieve this, as data presented here has clearly indicated. The 
potential disadvantages of this methodology have been illustrated
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and extensively discussed. It is reassuring that the change in TBI 
schedule which was introduced - and reported for the first time in 
this data - has reliably prevented rejection. Whether relapses will 
be more common remains to be seen. It may well emerge that there Is 
a subtle relationship between conditioning protocol, leukaemia type, 
and the particular monoclonal antibodies used which will be decisive 
in this area.
> It has become clear that with careful attention to detail and
adjustment of the elements of supportive care, allogeneic 
transplantation survival may, as suggested by local experience 
(Chapter 7) become equivalent to leukaemia free survival.
These important improvements to allograft technique, however, will 
only result in cure for more patients with the disease.
Restrictions based on age and donor availability will eliminate
approximately 9055 of those with the disease from this outstandingly 
effective antileukaemic treatment. Expansion of the donor pool is 
one way to help younger patients come to transplant, but the use of 
extended family members who are other than virtually fully matched 
is disappointing, except in the situation of a one in six HLA 
mismatch where clinical results are emerging as equivalent to those 
of a full match, but will still only be an option for 10% more of 
the younger patients. More recently, there is some preliminary 
evidence to suggest that phenotypically matched but unrelated
transplants may become consistently successful - thus far there Is 
very little data in AML.
Autologous bone marrow transplant was introduced on the basis that a
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substantial component of the antileukaemic effect was due to 
cytoreduction. Although an immuno-regulatory mechanism may be 
important, it was argued that this would be compensated for by 
reduced procedural related morbidity and mortality. Pneumonitis was 
predicted to represent a minor risk and the additional avoidance of 
GVHD and immunosuppression would make this a suitable approach for 
older patients. At the time of commencing these clinical studies, 
autograft for relapsed leukaemia had been reported, but this could 
be expected from the allograft data available at that time to be 
unsuccessful due to a high relapse rate. Subsequent experience has 
confirmed this prediction. It was felt important to undertake the 
autograft in first remission using a chemo-radiotherapy based 
cytoreductive protocol which was the gold-standard of the allograft 
experience.
The results presented vindicate the decisions made with survivals as 
good as or superior to any other treatment modality with little 
procedural morbidity or mortality. Subsequent analysis of the 
international experience suggests that a TBI based protocol was the 
correct approach. We are not justified in concluding that the 
chosen cytoreduction is yet optimum - indeed, there may be 
considerable scope to increase the TBI. Our present cohort of 
autografted patients are receiving a total of 1M0 cGy without 
toxicity. Although it has been suggested in some quarters that 
autograft should be the preferred option to allograft, there is no 
data to support such a view. Our data does not support such an 
approach, but the combined approach for patients under 55 years, as 
outlined in Chapter 7, seems the most advisable at the present time 
with an overall prospect for cure predicted to be in excess of 60% •
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A valid criticism of all transplant data is that the patients were 
already selected to be at low risk of relapse because they had been 
in remission for a number of weeks prior to the graft. Our own data 
j- although not conducted as a controlled study - and many studies of 
chemotherapy, continue to demonstrate that the cure rate for 
patients who have been in complete remission remains small.
The influence of pre-autograft delay has been highlighted in Glasgow 
but was not confirmed in the International Data. The possibility of 
selection of patients is the possible explanation for this effect 
but it may reflect the amount of pre-autograft chemotherapy, and 
therefore cytoreduction, pre-autograft. The influence of 
pre-autograft cytoreduction was particularly illustrated by the UCH 
double autograft approach which was discussed. The important point 
with that data is that a single autograft failed to cure one group 
of patients but few relapses have occurred after a second graft. 
Clearly again, there were a number of reasons why the second group 
got to' the second graft which may constitute selection. For many 
centres the double autograft is not logistically possible but 
nevertheless it would be wise to regard the pre-autograft 
chemotherapy, including probably induction treatment as having an 
influence over autograft outcome, despite the fact that it is not 
capable alone of curing more than a few cases in the absence of 
autologous transplantation.
In trying to assemble evidence for a clear advantage for these 
autograft data from the published results of chemotherapy, two 
important features can be cited.
527
First, it is important to note that even patients in the 
International review who received the autograft within 2 months of 
achieving remission had a 6*1$ prospect of survival. This subgroup 
is likely to contain the patients at highest risk of early relapse
so the observation of equivalent survival to. other groups is
relevant. Those who argue that because autografts are frequently 
delayed till several weeks into remission, and because the relapse 
rate, with conventional treatment, in the first few months is
around 5$ per month, there is no demonstrable ; evidence that 
autograft can achieve anything not already seen with conventional 
chemotherapy, must pay attention to this subset of patients. Even 
if we accepted for reasons of comparison that all this group were 
autografted at 2 months, rather than within 2 months, then they 
would have survived a relapse risk of 10$ so’ the frealT outcome 
would not be 6*1$, but 58$(6*1$ of 90$), which is well in excess of 
published chemotherapy results, particularly for an adult 
population. A second feature of the autograft data to date is the 
apparent appearance of a plateau of relapse free survival beyond 2*1 
months. A sustained period free of relapses is not a feature of
conventional chemotherapy protocols.
Improved chemotherapy must remain a priority if for no other reason 
that that there are many cases currently considered too old for 
autologous bone marrow transplantation. As improvements take place, 
some patients who are curable by chemotherapy will therefore be 
transplanted unnecessarily. In the near future It may be possible 
to use prognostic factors such as cytogenetic markers to predict 
patients who will do well with conventional treatment. At present 
there is no unequivocal data in this area.
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Recent allograft data from Seattle and the International Registry 
suggests that 3055 of patients can be cured if transplanted in 
untreated first relapse or second remission. This has stimulated 
debate, which will become more crucial as and when chemotherapy 
improves, as to whether patients with donors should only be given 
conventional therapy and transplanted only if they relapse. This 
strategy has the merit of not unnecessarily transplanted "cured" 
patients but may, if followed on a national basis, present 
considerable logistic difficulties. Some transplant centres, such 
as our own, would have ethical difficulty in delaying an allograft 
when our data predicts a 78$ prospect of surviving. Clearly the 
role of autologous versus allogeneic transplant versus chemotherapy 
for remission maintenance requires to be evaluated in a major 
prospective randomised trial. Such a study is about to commence 
under the auspices of the Medical Research Council. An additional 
feature of this trial will be the randomisation to receive a late 
autograft for the patients who relapse from chemotherapy, giving an 
opportunity to test the concept described above, and given 
encouragement by the results described of autograft in second 
remission in Chapter 8.
Some factors have been suggested as useful in predicting the outcome 
of autologous bone marrow transplantation. Growth of remission bone 
marrow in Long Term Bone Marrow Culture may have prognostic 
significance for autograft but its relationship to outcome of 
chemotherapy is unknown. The analysis of the clonality of 
remissions by X-linked gene probe analysis in heterozygous females 
will be increasingly undertaken. One may postulate that 1 clonal * 
remissions should not be subjected to autograft. When such data is
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collected, and assuming minimal progress with chemotherapy alone, 
one could conceive of a strategy being decided thus: (a) patients
with matched donors will receive an allograft (b) patients with 
non-clonal remissions who sustain growth in Long Term bone Marrow 
Culture will receive an autograft and (c) patients with poor growth, 
or clonal remissions will receive an allograft from a 
phenotypically, but not genotypically identical, donor.
It has been argued from a number of points of view that an ^ inability 
to purge minimal residual disease from remission bone marrow is not 
a major factor in clinical outcome. Part of the argument is 
mathematical, predicting that the harvesting, freezing, thawing and 
seeding of a number of clonogeneic cells so small as to be minor 
compared with what remains in the patient. The importance of 
optimum pre-autograft cytoreduction is obvious. The crucial
clinical data which provides a yardstick is the outcome of syngeneic 
transplant In AML which I presented in an updated form in Chapter 
3. This is perhaps the clearest data in AML to support the argument
that there Is a clinically important allogeneic or
graft-versus-leukaemia effect in AML, illustrating, as it does, 
twice the relapse rate of allogeneic transplantation. The marked 
similarity of the unpurged autologous and syngeneic data is my major 
argument for suggesting that prospective clinical studies of purging 
versus non-purging are not a pressing clinical issue in first 
remission. Such studies will be restricted to the relatively small 
number of centres capable of undertaking such techniques. It is
doubtful whether sufficient numbers could be accrued to undertake 
such a clinical trial.
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In vitro purging clearly is an effective technique as demonstrated 
by the data concerning T depletion to prevent GVHD. But such 
methods may not be capable of eradicating the much lower levels of 
contamination assumed to be present in remission marrow. 
Immunologically based purging techniques are more logical for ALL 
where appropriate monoclonal antibodies exist. The encouraging 
clinical data of such an approach presented here, confirms the 
repopulative ability of marrow treated in this way but does not 
establish the need for purging in this disease. Multicentre data, 
collected under the auspices of the European Group for Bone Marrow 
Transplantation (EBMT) suggest a trend in favour of those patients 
with ALL who received purged marrow compared with those receiving 
unmanipulated marrow. A major problem in ALL is the inability of 
ablative chemo- radiotherapy to eradicate the disease from the 
patient, which may sweep away any advantage provided by 
sophisticated purging techniques.
Pharmacological purging for AML has little conceptual logic, but is 
sustained by the experimental data in the Brown Norway Rat Model and 
a few enthusiastic advocates. Clinically, as mentioned above, it 
will be almost impossible to demonstrate a benefit in first 
remission studies. Pure in vitro comparisons are probably too 
artificial to be relevant, and in vitro assessment of purging 
efficiency is not currently possible. Clinical studies of purging 
versus non-purging are statistically practicable in second remission 
and such multicentre studies currently proposed.
The pre-clinical data presented here raises serious questions about 
the criteria to be set for optimum purging with pharmacological
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agents and the consistency of effect that can be achieved in 
individual patients and between patients.
Outright rejection of in vitro purging is unjustified because the 
syngeneic data upon which so much of the counter argument is based 
is only available on a relatively few patients and reservations 
about its solidity have been expressed already. The experimental 
model system which we have devised and which is described here is 
sensitive, on the one hand to damage to the repopulative capacity;of 
the treated bone marrow in vivo, and on the other, is capable of 
detecting very small number of residual clonogenic leukaemic cells. 
This system would appear well suited to evaluate the relative 
efficiency of different purging techniques and of immediate 
interest, combinations of pharmacological agents. Such 
experimentation may be a valuable contribution to improving 
autografting techniques.
At the present moment the results of autologous transplantation in 
acute myeloid leukaemia achieved in this and subsequent series have 
generated widespread international interest. Important prospective 
clinical studies are at the preliminary stages but many aspects 
require thoughtful evaluation, probably in a number of clinical 
studies, before the precise role of autologous bone marrow in AML, 
if any, can be established.
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